COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2026 December 31
(Fiscal Year Ending-Month and Day)

SEC Form 20-ISA - Definitive Information Statement
(FORM TYPE)

_____
(Period Ended Date)

_____
(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any)

ASIA PACIFIC MEDICAL CENTER-ILOILO, INC.
(Formerly: Allied Care Experts Medical Center Iloilo, Inc.)

2026 Annual Stockholders' Meeting
Definitive Information Statement

Table of Contents

Marked and Unmarked Notice of 2026 Annual Stockholders' Meeting	4
Affidavit of Publication	10
Marked and Unmarked Proxy Form	12
Checklist	16
Information Required in Information Statement	
A. General Information	
1. Date, Time, Place of Meeting of Security Holders	21
2. Dissenters' Right of Appraisal	21
3. Interest of Certain Persons in or Opposition to Matters to be Acted Upon	22
B. Control and Compensation Information	
4. Voting Securities and Principal Holders Thereof	22
5. Directors and Executive Officers	28
6. Compensation of Directors and Executive Officers	36
7. Independent Public Accountants	37
8. Compensation Plans	39
C. Issuance and Exchange Of Securities	
9. Authorization or Issuance of Securities	39
10. Modification or Exchange of Securities	39
11. Financial and Other Information	39

12. Merger, Consolidation, Acquisition and Similar Matters	40
13. Acquisition/Disposition of Property	40
14. Restatement of Accounts	40
D. OTHER MATTERS	
15. Action with Respect to Reports	40
16. Matters Not Required to be Submitted	40
17. Amendment of Charter, By laws or Other Documents	40
18. Other Proposed Actions	42
19. Voting Procedures	52
20. Participation of Shareholder by Remote Communication	53
ANNEXES	
Annex A - Requirements and Procedure for Electronic Voting in Absentia and Participation by Remote Communication	55
Annex B - 2025 Board of Directors and Executive Officers Profile	58
Annex C - Final List of Nominees for Election to the 2026 Board of Directors	76
Annex C1 - 2026 Board of Director Candidates Profile	77
Annex D - Certificate of Qualification of Johanna Marie B. Bermudo-Belgira	90
Annex D1 - Certificate of Qualification of Nathalie Ann F. Deebuque	93
Annex D2 - Certificate of Qualification of Lorna C. Silverio	96
Annex D3 - Certification of Ferjenel G. Biron	97
Annex D4 - Certification of Rolex T. Suplico	98
Annex D5 - Certification of Lemuel T. Fernandez	99
Annex E - Engagement Proposal of Berces-Ocampo, Mendoza and Associates	100
Annex E1 - Pre-Approval Policy in the Engagement of External Auditor	102
Annex E2 - Profile Berces-Ocampo, Mendoza and Associates	110
Annex E3- 2025 Audited Financial Statement	120

Annex F - Minutes of the Annual Stockholders' Meeting on 18 June 2025	195
Annex G- Marked and Unmarked Management Report	233
Annex H - Material Information on 2026 Stockholders	264
Annex I - 2025 Board Attendance Report	266
Annex J - 2025 Board Appraisal/Performance	274
Annex K - 2025 Board Compensation Report	278
Annex L - Certification on Disclosure of Directors' Self-Dealing and Related Party Transactions	280
Annex M- 1st Quarter 2026	281
Annex N - Secretary's Certificate	434
Annex O- Proof of Payment	436

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

ASIA PACIFIC MEDICAL CENTER ILOILO

NOTICE OF REGULAR MEETING OF STOCKHOLDERS
June 18, 2026

The 2026 Regular Meeting of the Stockholders of Asia Pacific Medical Center-Iloilo, Inc. (formerly known as Allied Care Experts (ACE) Medical Center – Iloilo, Inc.) will be held on **18 June 2026** at **9:00 a.m.**

The meeting will be conducted via remote communication thru a **Zoom Conference**.

Though there is no physical venue, the Chairman will preside over the meeting at the principal office, **Asia Pacific Medical Center Hospital Building, Brgy. Ungka, Jaro, Iloilo City**.

Agenda of the Meeting is as follows:

1. Call to Order
2. Certification of Notice and Quorum
3. Approval of the Minutes of the Regular Stockholders' Meeting held on 18 June 2025
4. Presentation of the Annual Report and Approval of the Audited Financial Statements for the year ended 31 December 2025 and action thereon
5. Open Forum
6. Ratification and Approval of the previous acts and resolutions of the Board of Directors and Corporate Officers
7. Amendment of the Articles of Incorporation
   Art. III - Principal Office of the Corporation
   Art. VII - Authorized Capital Stock of the Corporation
8. Amendment of the By-laws
   Art. VI - Office
9. Appointment of External Auditor for the current year
10. Election of 2026 Board of Directors
11. Other Matters
12. Adjourment

Only stockholders of record as of **31 May 2026** are entitled to notice and to vote at this meeting.

The Company will not hold a physical meeting and will instead conduct the meeting via Zoom webinar. Stockholders can therefore only attend and participate in the meeting by remote communication. Stockholders also have the option to vote in absentia or appoint the Chairman as proxy.

Stockholders who intend to attend by remote communication shall inform the Company by email to **corpsec@apmciloilo.com** on or before **16 June 2026** subject to the procedure set in the Information Statement which will be posted in the Company's website **www.apmc-iloilo.com**.

In the same website, stockholders may access the following: (a) Management Report; (b) SEC Form 17A; (c) Minutes of the Meeting on 18 June 2025 and (d) Proxy Form for Attendance at Meeting and other meeting documents required under Section 49 of the Revised Corporation Code.

The link for the Zoom webinar will be sent to the email address of the stockholders who registered to attend via remote communication.

To those who would opt to participate by voting through the Chairman as proxy, the deadline for submission of proxies will be at **5:00 pm** of **11 June 2026**. Those who are unable to join the meeting via remote communication but wish to vote on items in the agenda may appoint the Chairman as proxy with specific voting instructions which will be duly counted. Proxies can be submitted to the Office of the Corporate Secretary or via email to the aforementioned address. For individual stockholders, the submission must be accompanied by a copy of a government issued ID as proof of identification. For corporations, the submission must be accompanied by a certification from its Corporate Secretary stating the corporate officer's authority to represent and sign on behalf of the corporation. Kindly submit to the Office of the Corporate Secretary the original signed and notarized documents within thirty (30) days from the conduct of the Annual Stockholders' Meeting.

During the meeting, the Company shall entertain questions and comments after the presentation of the Annual Report. Questions which were not answered during the meeting shall be forwarded to the Office of the Corporate Secretary for the appropriate response via email.

For ASM-related queries, email to **corpsec@apmciloilo.com** or contact the Office of the Corporate Secretary at **(033) 3215748** and **09292703169**. For shareholding concerns, please contact the Investor Relations Office at **(033) 3215748** and **09292703169** or via email directly to **apmciloilo.investment@gmail.com**.

sgd. THERESE MARIE A. GERAFIL
Corporate Secretary

ASIA PACIFIC MEDICAL CENTER ILOILO

EXPLANATION OF AGENDA ITEMS

Call to Order

The Chairman will formally open the meeting at approximately 9:00 o'clock in the morning.

Certification of notice and quorum (and rules of conduct and procedures)

The Corporate Secretary will certify that written notice for the meeting was duly sent to stockholders and that a quorum exists for the transaction of business.

Pursuant to Section 57 and 23 of the Revised Corporation Code which allow voting in Absentia by the stockholders, the Corporation has set up an online voting portal which may be accessed by the stockholders to register and vote at the matters of the meeting in absentia. A stockholder who votes in absentia shall be deemed present for purposes of quorum.

Stockholders may participate in the meeting by remote communication. Stockholders who intend to attend by remote communication who have not registered to vote in absentia shall inform the Company by email to **corpsec@apmciloilo.com** on or before **16 June 2026,** subject to the procedure set in the Information Statement which will be posted in the Company's website or register in the online voting portal within the period prescribed.

Approval of the Minutes of the Regular Stockholders Meeting held on 18 June 2025

A resolution approving the Minutes of the Previous Stockholders' Meeting held last 18 June 2025 will be presented. The Minutes of the Meeting is available at the company website www.apmc-iloilo.com.

Presentation of the Annual Report and Audited Financial Statement

Presentation of the Annual Report contains the Chairman's Message, President's Management Report and the 2025 Audited Financial Statements will be posted in the Company's website.

The Audited Financial Statements (AFS) as of 31 December 2025 will be presented to the stockholders for their approval. The AFS will be included in the Information Statement to be sent to the stockholders at least fifteen (15) business days prior to the meeting and will also be set forth in the Annual Report. The Audit Committee has recommended to the Board the approval of the AFS, and the Board had approved the same on 11 May 2026.

A Resolution noting the report and approving the Audited Financial Statements will be presented to the stockholders for approval by the affirmative vote of the stockholders representing at least a majority of the outstanding capital stock present at the meeting.

Open Forum

The Investor Relations Officer will read the questions and comments of stockholders which will be answered by the concerned officers. Questions and comments not taken up shall be forwarded to the Office of the Corporate Secretary, and will be addressed via email.

Ratification and Approval of All the Acts and Proceedings of the Board of Directors and Corporate Officers

The acts of the Board and its Committees were those adopted since the annual stockholders' meeting on 18 June 2025 until the date of meeting. They include the approval of agreements, appointments, bank transactions and other matters covered by disclosures to the Securities and Exchange Commission.

The acts of the officers were those taken to implement the resolution of the Board or its Committees or in the general conduct of business.

A resolution on this agenda item will be presented to the stockholders for approval by the vote of the stockholders representing at least a majority of the outstanding capital stock present at the meeting.

Amendment of the Articles of Incorporation

In its regular Board Meeting held last 28 September 2025 and 07 April 2026, the Board of Directors of Asia Pacific Medical Center (APMC) - Iloilo, Inc., with requisite quorum present and acting by majority vote, resolved to approve the amendments to the Corporation's Articles of Incorporation, specifically Articles III and VII.

1. A resolution approving the amendment to **Article III** of the Corporation's **Articles of Incorporation** will be presented for approval by the affirmative vote of the stockholders representing at least two-thirds (2/3) of the outstanding capital stock of the Corporation.

From	To
That the place where the principal office of the Corporation is located at Brgy. Ungka I, Jaro, Iloilo City, 5001.	That the place where the principal office of the Corporation is located at **Brgy. Ungka, Jaro, Iloilo City, 5000.**

2. A resolution approving the amendment to **Article VII** of the Corporation's **Articles of Incorporation** will be presented for approval by the affirmative vote of the stockholders representing at least two-thirds (2/3) of the outstanding capital stock of the Corporation.

From	To
That the authorized capital stock of the Corporation is TWO HUNDRED FORTY MILLION PESOS (P 240,000,000), Philippine Currency, and said capital stock is divided into two hundred forty thousand (240,000) shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) TWO HUNDRED THIRTY NINE THOUSAND FOUR HUNDRED (239,400) COMMON shares with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx	That the authorized capital stock of the Corporation is **FOUR HUNDRED EIGHTY MILLION PESOS (P 480,000,000)**, Philippine Currency, and said capital stock is divided into **four hundred eighty thousand (480,000)** shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) **FOUR HUNDRED SEVENTY NINE THOUSAND FOUR HUNDRED (479,400) COMMON shares** with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx

Amendment of the By-laws

In its regular Board Meeting held last 28 October 2025, the Board of Directors of Asia Pacific Medical Center (APMC) - Iloilo, Inc., with requisite quorum present and acting by majority vote, resolved to approve the amendment of Article VI of the Corporation's by-laws.

1. A resolution approving the amendment to **Section I, Article VI** of the Corporation's By-Laws will be presented for approval by the affirmative vote of the stockholders representing at least a majority of the outstanding capital stock.

From	To
Section 1. The office of the corporation shall be located in Brgy. Ungka I, Jaro, Iloilo City, 5000. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.	**Section 1.** The office of the corporation shall be located in **Brgy. Ungka, Jaro, Iloilo City, 5000**. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.

Appointment of External Auditor and Fixing of its Remuneration

The Board, through its Audit Committee, will endorse to the stockholders the appointment of Berces-Ocampo, Mendoza and Associates (BMA), as the external auditor for the current year as well as its proposed remuneration. The external auditor conducts an independent verification of the Company's financial statements and provides an objective assurance on the accuracy of its financial statements.

The profile of Berces-Ocampo, Mendoza and Associates (BMA), will be provided in the Information Statement.

A resolution for the appointment of the external auditor and for the approval of its remuneration will be presented to the stockholders for adoption by the affirmative vote of stockholders representing a majority of the outstanding capital stock present at the meeting.

Election of the Board of Directors

The Corporate Governance Committee of the Board had evaluated and determined that the Fifteen (15) nominees to the Board, including the nominees for independent directors, have all the necessary qualifications to serve as directors and the expertise and competence, individually and collectively, to enable the Board to fulfill its roles and responsibilities and manage the Company to achieve its objectives.

The profiles of the candidates to the Board of Directors will be provided in the Information Statement. A resolution on the election of the top twelve (12) nominees for Directors and three (3) Independent Directors who will garner the highest votes will be presented to and approved by the stockholders representing at least a majority of the outstanding capital stock present at the meeting.

Consideration of Such Other Business as May Properly Come Before the Meeting

The stockholders may raise such other matters or issues that may be properly taken up during the meeting.

Manila Standard

PHILIPPINE MANILA STANDARD PUBLISHING, INC.

AFFIDAVIT OF PUBLICATION

I, Mario R. Policarpio Jr., Chief Accountant of Manila Standard, with office address at 6th Floor Universal Re Building, 106 Paseo de Roxas, Makati City, hereby depose and state that:

Manila Standard is a newspaper of general circulation and is distributed nationwide;

Manila Standard at the same time, publishes its online version through its website https://manilastandard.net;

Manila Standard is qualified to publish all kinds of judicial notices.

Manila Standard published on

MAY 24 & 25, 2026

a Notice:

ASIA PACIFIC MEDICAL CENTER-ILOILO, INC.

RE: NOTICE OF REGULAR MEETING OF STOCKHOLDERS

IN WITNESS WHEREOF, I hereby affix my signature this 25TH day of MAY 2026 in Makati City.

[redacted]

MARIO R. POLICARPIO JR.
Authorized Signatory

SUBSCRIBED AND SWORN to before me this 25TH day of MAY, 2026 in Makati City, affiant exhibiting to me his SSS No. 33-0476897-7.

[redacted]

ATTY. RAYMOND A. RAMOS
COMMISSION NO. M-229
NOTARY PUBLIC FOR MAKATI CITY
UNTIL DECEMBER 31, 2026
2364 ANGONO STREET
BARANGAY PORLACION 1210, MAKATI CITY
SC Roll No. 62179/04-26-2013
IBP NO. 536461/01-05-2026/Pasig City
PTR NO. MKT 10764120/01-05-2026/Makati City
MCLE Compliance No. VIII-0012898/04-14-2028

Doc. No.: 430;
Page No.: 89;
Book No.: 419;
Series of 2026.

ASIA PACIFIC MEDICAL CENTER
ILOILO

NOTICE OF REGULAR MEETING OF STOCKHOLDERS
June 18, 2026

The 2026 Regular Meeting of the Stockholders of Asia Pacific Medical Center-Iloilo, Inc. (formerly known as Allied Care Experts (ACE) Medical Center – Iloilo, Inc.) will be held on **18 June 2026 at 9:00 a.m.**

The meeting will be conducted via remote communication thru a **Zoom Conference**.

Though there is no physical venue, the Chairman will preside over the meeting at the principal office, **Asia Pacific Medical Center Hospital Building, Brgy. Ungka, Jaro, Iloilo City**.

Agenda of the Meeting is as follows:

1. Call to Order
2. Certification of Notice and Quorum
3. Approval of the Minutes of the Regular Stockholders' Meeting held on 18 June 2025
4. Presentation of the Annual Report and Approval of the Audited Financial Statements for the year ended 31 December 2025 and action thereon
5. Open Forum
6. Ratification and Approval of the previous acts and resolutions of the Board of Directors and Corporate Officers
7. Amendment of the Articles of Incorporation
   Art. III - Principal Office of the Corporation
   Art. VII - Authorized Capital Stock of the Corporation
8. Amendment of the By-laws
   Art. VI - Office
9. Appointment of External Auditor for the current year
10. Election of 2026 Board of Directors
11. Other Matters
12. Adjournment

Only stockholders of record as of **31 May 2026** are entitled to notice and to vote at this meeting.

The Company will not hold a physical meeting and will instead conduct the meeting via Zoom webinar. Stockholders can therefore only attend and participate in the meeting by remote communication. Stockholders also have the option to vote in absentia or appoint the Chairman as proxy.

Stockholders who intend to attend by remote communication shall inform the Company by email to **corpsec@apmciloilo.com** on or before **16 June 2026** subject to the procedure set in the Information Statement which will be posted in the Company's website **www.apmc-iloilo.com**.

In the same website, stockholders may access the following: (a) Management Report, (b) SEC Form 17A; (c) Minutes of the Meeting on 18 June 2025 and (d) Proxy Form for Attendance at Meeting and other meeting documents required under Section 49 of the Revised Corporation Code.

The link for the Zoom webinar will be sent to the email address of the stockholders who registered to attend via remote communication.

To those who would opt to participate by voting through the Chairman as proxy, the deadline for submission of proxies will be at **5:00 pm of 11 June 2026**. Those who are unable to join the meeting via remote communication but wish to vote on items in the agenda may appoint the Chairman as proxy with specific voting instructions which will be duly counted. Proxies can be submitted to the Office of the Corporate Secretary or via email to the aforementioned address. For individual stockholders, the submission must be accompanied by a copy of a government issued ID as proof of identification. For corporations, the submission must be accompanied by a certification from its Corporate Secretary stating the corporate officer's authority to represent and sign on behalf of the corporation. Kindly submit to the Office of the Corporate Secretary the original signed and notarized documents within a reasonable time after the resumption of regular business operations.

During the meeting, the Company shall entertain questions and comments after the presentation of the Annual Report. Questions which were not answered during the meeting shall be forwarded to the Office of the Corporate Secretary for the appropriate response via email.

For ASM-related queries, email to **corpsec@apmciloilo.com** or contact the Office of the Corporate Secretary at **(033) 3215748** and **09292703169**. For shareholding concerns, please contact the Investor Relations Office at **(033) 3215748** and **09292703169** or via email directly to **apmciloilo.investment@gmail.com.**

sgd. THERESE MARIE A. GERAFIL
Corporate Secretary

The Manila Times®

News source of choice. Trusted since 1898.

REPUBLIC OF THE PHILIPPINES)
CITY OF MANILA)S.S.

AFFIDAVIT OF PUBLICATION

I, **Eden F. Del Rosario**, of legal age, married, Filipino and a resident of #22 21st Aveñue, Cubao, Quezon City in the Philippines, after having been duly sworn according to law, do hereby depose and state:

That I am the Credit and Collection Head of **The Manila Times**, a newspaper which is published Online and Printed in English and Edited in Metro Manila, and circulated nationwide daily from Monday to Sunday with postal address at 2/F Sitio Grande, 409 A. Soriano Avenue, Intramuros, Manila

That the attached **NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 18, 2026 / THE 2026 REGULAR MEETING OF THE STOCKHOLDERS OF ASIA PACIFIC MEDICAL CENTER-ILOILO, INC. (FORMERLY KNOWN AS ALLIED CARE EXPERTS (ACE) MEDICAL CENTER - ILOILO, INC.) WILL BE HELD ON 18 JUNE 2026 AT 9:00 A.M. / ASIA PACIFIC MEDICAL CENTER ILOILO**

was posted online in **www.manilatimes.net** in its issue/s of **MAY 24 & 25, 2026**

In witness whereof, I signed this Affidavit in Manila, Philippines, this 25 MAY 2026 day of _____, 2026

EDEN F. DEL ROSARIO
Affiant

Subscribe and sworn to before me this 25 MAY 2026 day of _____, 2026 in Manila, Philippines, affiant exhibiting to me her **SSS ID No. 33-0045788-4**

Doc. No. 113
Page No 99
Book No. 11
Series of 2026

ATTY. WILLIAM M. AY-AY, CPA,CDPO
Attorney-at-Law/Notary Public
Roll No. 87630
IBP No. 568515/12-20-2025, Quezon City
PTR No. 8396900/01-05-2026/Quezon City
MCLE Compliance No. VIII-0027229 Until April 14, 2028
Admin Matters NP-197/2025-2025

2/F News Wing Sitio Grande Bldg., 409 A. Soriano Ave., Intramuros, Manila 1002 Philippines
E-mail: advertising@manilatimes.net • Website: www.manilatimes.net
Trunk Lines: 524-5664 to 67 • Advertising Department: 528-1729 Fax Number: 310-5582

ASIA PACIFIC MEDICAL CENTER ILOILO

PROXY

The undersigned stockholder of **ASIA PACIFIC MEDICAL CENTER-ILOILO, INC. (FORMERLY KNOWN AS ALLIED CARE EXPERTS (ACE) MEDICAL CENTER – ILOILO, INC.)** (the "Company") hereby appoints the Chairman of the meeting, as attorney-in-fact and proxy, to represent and vote all shares registered in his/her/its name at the annual meeting of stockholders of the Company on **18 June 2026** and at any of the adjournments thereof for the purpose of acting on the following matters:

1. Resolution approving the Minutes of the Previous Stockholders' Meeting held last 18 June 2025

   For ☐ Against ☐ Abstain ☐

2. Resolution noting the 2025 Annual Report and approving the 2025 Audited Financial Statements

   For ☐ Against ☐ Abstain ☐

3. Ratification and Approval of the previous acts and resolutions of the Board of Directors and Corporate Officers.

   For ☐ Against ☐ Abstain ☐

4. Resolution Approving the Amendment to **Article III** of the Corporation's Articles of Incorporation:

From	To
That the place where the principal office of the Corporation is located at Brgy. Ungka I, Jaro, Iloilo City, 5001.	That the place where the principal office of the Corporation is located at **Brgy. Ungka, Jaro, Iloilo City, 5000.**

For ☐ Against ☐ Abstain ☐

5. Resolution Approving the Increase of the Capital Stock of the Corporation by Amendment of **Article VII** of the Corporation's **Articles of Incorporation**:

From	To
That the authorized capital stock of the Corporation is TWO HUNDRED FORTY MILLION PESOS (P 240,000,000), Philippine Currency, and said capital stock is divided into two hundred forty thousand (240,000) shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) TWO HUNDRED THIRTY NINE THOUSAND FOUR HUNDRED (239,400) COMMON shares with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx	That the authorized capital stock of the Corporation is **FOUR HUNDRED EIGHTY MILLION PESOS (P 480,000,000)**, Philippine Currency, and said capital stock is divided into **four hundred eighty thousand (480,000)** shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) **FOUR HUNDRED SEVENTY NINE THOUSAND FOUR HUNDRED (479,400) COMMON shares** with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx

For ☐ Against ☐ Abstain ☐

6. Resolution Approving the Amendment to **Section I, Article VI** of the Corporation's By-Laws:

From	To
Section 1. The office of the corporation shall be located in Brgy. Ungka I, Jaro, Iloilo City, 5000. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.	**Section 1.** The office of the corporation shall be located in **Brgy. Ungka, Jaro, Iloilo City, 5000**. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.

For ☐ Against ☐ Abstain ☐

7. Election of Berces-Ocampo, Mendoza and Associates (BMA) as the Independent Auditor for the Current Year and Fixing of its Remuneration

   For ☐ Against ☐ Abstain ☐

8. Election of Directors

NOMINEES FOR REGULAR DIRECTOR	**NO. OF VOTES**
Biron, Brandt Luke Q.	_____
Biron, Ferjenel G.	_____
Dianco, Felibert O.	_____
Fernandez, Lemuel T.	_____
Gomez, Lusyl M.	_____
Lavilla, Meride D.	_____
Nolasco, Felix P.	_____
Ong, Mary Flor G.	_____
Regozo, Danilo C.	_____
Samoro, Fredilyn G.	_____
Suplico, Rolex T.	_____
Villaflor, Agnes Jean M.	_____

INDEPENDENT DIRECTOR

Bermudo- Belgira, Johanna Marie B.	_____
Debuque, Nathalie Ann F.	_____
Silverio, Lorna C.	_____

9. At his/her Discretion, the Proxy Named Above is Authorized to Vote Upon such Other Matters as may Properly Come Before the Meeting

   Yes ☐ No ☐

A scanned copy of this proxy must be submitted to the Corporate Secretary at corpsec@apmciloilo.com on or before **5:00 p.m. 11 June 2026**, the deadline for submission of proxies. For corporate stockholders, please attach to this proxy form the Secretary's Certificate on the authority of the signatory to appoint the proxy and sign this form.

The proxy shall be validated by the Committee on Inspection of Ballots and Proxy. It shall check and verify the eligibility of the person executing the proxy against the Official List of Stockholders as certified by the Corporate Secretary. The Committee shall also verify the signature on the proxy form with the signature on the stockholder's official records to ensure authenticity. The Committee shall ensure that proxy forms are submitted before the established deadline and maintain a log of all validated proxies, including details of the stockholder's name, proxy name, date of submission and validation status.

The proxy shall be notified of the status of their proxy submissions (validated or rejected) within five (5) days after submission.

This proxy, when properly executed, will be voted in the manner as directed herein by the stockholder(s). If no direction is made, this proxy will be voted for the election of all nominees and for the approval of the matters stated above and for such other matters as may properly come before the meeting in the manner described in the information statement and/or as recommended by the chairman.

A stockholder giving a proxy has the power to revoke it at any time before the right granted is exercised. A proxy is also considered revoked if the stockholder registers on the voting in absentia registration system.

_____

NAME OF AUTHORIZED SIGNATORY AND SIGNATURE

COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2026 December 31
(Fiscal Year Ending-Month and Day)

SEC FORM 20-ISA - Definitive Information Statement
(FORM TYPE)

(Period Ended Date)

(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any)

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 20-IS

INFORMATION STATEMENT PURSUANT TO SECTION 20 OF THE SECURITIES REGULATION CODE

1. Check the appropriate box:
[ ] Preliminary Information Statement
[/] Definitive Information Statement

2. Name of Registrant as specified in its charter
Asia Pacific Medical Center-Iloilo, Inc,

3. Metro Manila, Philippines
Province, country or other jurisdiction of incorporation or organization

4. SEC Identification Number CS201423954

5. BIR Tax Identification Code 008-922-703

6. Brgy. Ungka, Jaro, Iloilo City 5000
Address of principal office Postal Code

7. Registrant's telephone number, including area code (063) 9175234802
8. Date, time and place of the meeting of security holders
Date: 18 June 2026
Time: 9:00 AM
Place: No physical venue but the Chairman will preside at Asia Pacific Medical Center Hospital Building, Brgy. Ungka, Jaro, Iloilo City
Online web address for registration for remote communication and voting: https://apmc-iloilo.com/annualstockholdersmeeting2026/

9. Approximate date on which the Information Statement is first to be sent or given to security holders: 27 May 2026

10. Proxy is not solicited.

11. Securities registered pursuant to Sections 8 and 12 of the Code or Sections 4 and 8 of the RSA:

Title of Each Class	Number of Shares of Common Stock Outstanding or Amount of Debt Outstanding
Founder	600
Common	239,400
Amount of Debt	Php 1,823,309,661.40

12. Are any or all of registrant's securities listed in a Stock Exchange?

Yes _____No _✓_

None of the founder and common shares of APMCI are listed on the Philippine Stock Exchange

PART I.

INFORMATION REQUIRED IN INFORMATION STATEMENT

A. GENERAL INFORMATION

Item 1. Date, time and place of meeting of security holders

(a) Date: 18 June 2026
Time: 9:00 AM
Place: Asia Pacific Medical Center Hospital Building, Brgy. Ungka, Jaro, Iloilo City
Complete Mailing Address: Office of the Corporate Secretary
Asia Pacific Medical Center-Iloilo, Inc.
Brgy. Ungka, Jaro, Iloilo City
Online web address for registration for remote communication and voting:
https://apmc-iloilo.com/annualstockholdersmeeting2026

No physical venue but the Chairman will call and preside the stockholders' meeting at Asia Pacific Medical Center Hospital Building, Brgy. Ungka, Jaro, Iloilo City.

(b) Approximate date when the Information Statement is first sent out to stockholders of record: 27 May 2026

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

Item 2. Dissenters' Right of Appraisal

In accordance with Sec. 80 of the Revised Corporation Code of the Philippines, any stockholder shall have the right to dissent and demand payment of the fair value of his shares in the following instances:

1. In case of an amendment to the Articles of Incorporation which has the effect of changing or restricting the rights of any stockholder or class of shares, or of authorizing preferences in any respect superior to those of outstanding shares of any class, or of extending or shortening the term of corporate existence;
2. In case of sale, lease, exchange, transfer, mortgage, pledge or other disposition of all or substantially all of the corporate property and assets as provided in the Revised Corporation Code;
3. In case of merger and consolidation; and
4. In case of investment of funds for any purpose other than the primary purpose of the corporation.

The procedure for the exercise by a dissenting stockholder of his appraisal right are as follows:

(a) A stockholder must have voted against the proposed corporate action in order to avail himself of the appraisal right.

(b) The dissenting stockholder shall make a written demand on the Company within thirty (30) days after the date on which the vote was taken for payment for the fair value of his shares. The failure of the stockholder to make the demand within the thirty (30)-day period shall be deemed a waiver on his appraisal right.

(c) If the proposed corporate action is implemented or effected, the Company shall pay to such stockholder, upon surrender of corresponding certificate (s) of stock within ten (10) days after demanding payment for his shares, the fair value of the shareholder's shares in the Company as of the day prior to the date on which the vote was taken. Failure by the dissenting shareholder to surrender his shares within said ten (10)-day period shall, at the option of APMCI, terminate his appraisal rights.

(d) If within sixty (60) days from the date the corporate action was approved by the stockholders, the dissenting stockholder and APMCI cannot agree on the fair value of the shares, it shall be appraised and determined by three (3) disinterested persons, one of whom shall be named by the stockholder, another by APMCI and the third by the two (2) thus chosen.

a) The findings of a majority of the appraisers shall be final, and their award shall be paid by APMCI within thirty (30) days after such award is made. No payment shall be made to any dissenting stockholder unless APMCI has unrestricted retained earnings in its books to cover such payment.
b) Upon payment of the agreed or awarded price, the stockholder shall transfer his shares to the company.

No matter that will require the exercise of the stockholder's right of appraisal shall be taken up in the 2026 Annual Stockholders' Meeting.

Item 3. Interest of Certain Persons in or Opposition to Matters to be Acted Upon

None of the following persons have any substantial interest, direct or indirect in any matter to be acted upon other than election to office:

i. Directors or officers of the Company at any time since the beginning of the last fiscal year;
ii. Nominees for election as directors of the Company
iii. Associate of any of the foregoing persons

No director or nominee for election as director has informed the Company of his opposition to any matter to be acted upon at the Annual Stockholders' Meeting.

B. CONTROL AND COMPENSATION INFORMATION

Item 4. Voting Securities and Principal Holders Thereof

a. The Company has 240,000 outstanding shares as of 30 April 2026 composed of 600 Founder shares and 239,400 common shares. Every stockholder shall be entitled to one vote for each share of stock held as of the established record date.

b. All stockholders of record as of 31 May 2026 are entitled to notice and to vote at the Company's concerned annual stockholders' meeting.

c. Manner of Voting and Election of Directors (Cumulative Voting)

The requirements and procedure for electronic voting in absentia and participation by remote communication is attached in this Information Statement as **Annex A.**

A stockholder may also vote in the meeting pursuant to Sec 7, Article II of the By-laws by proxy executed in writing by the stockholder through the Chairman who will preside the meeting in Iloilo City as mandated by Section 15 of SEC Memorandum Circular No. 6 Series of 2020.

If the stockholder chooses to vote through proxy, APMC Iloilo requires the submission of a proxy form to the Corporate Secretary not later than **11 June 2026, 5:00 pm** via corpsec@apmciloilo.com. Unless otherwise provided in the proxy, it shall be valid only for the meeting at which it has been presented to the Secretary. Proxies filed with the Secretary may be revoked by the stockholder concerned either an instrument in writing duly presented and recorded with the Secretary prior to a scheduled meeting or by participation via remote communication provided he had previously registered to participate via remote communication.

The Committee on Inspection of Proxies and Ballots shall convene thru a meeting via remote communication on **15 June 2026 at 9:00 pm.** The Committee shall validate the proxies received. Any questions and issues relating to the validity and sufficiency, both as to form and substance of proxies shall only be resolved by the Corporate Secretary at that forum. The decision of the Corporate Secretary on the validity of the proxies shall be final and binding until and unless set aside by a court of competent jurisdiction.

The Stockholders are entitled to cumulative voting in the election of the Board of Directors, as provided by the Corporation Code.

Each common share of APMC Iloilo owned by a shareholder as of **31 May 2026** is entitled to one (1) vote (each, a Voting Share/s) except in the election of directors where one share is entitled to as many votes as there are Directors to be elected. The election of Directors shall be by online ballot and each stockholder entitled to vote may cast the vote to which the number of shares he owns entitles him, for as many persons as there are to be elected as Directors, or he may cumulate said shares and give one candidate as many votes as the number of directors to be elected multiplied by the number of his shares shall equal, or he may distribute them on the same principle among as many candidates as he may see fit, provided that the total number of votes cast by him shall not exceed the number of shares owned by him multiplied by the whole number of directors to be elected. Thus, since there are fifteen (15) directors to be elected, each Voting Share is entitled to fifteen (15) votes. One (1) block of ten (10) common shares would be entitled to 150 votes.

The Shares shall be voted through the Company's online voting portal. Votes will be counted by the Voting count system integral to the application and canvassed by the Board of Canvassers. The Board of Canvassers shall convene on **16 June 2026 at 9:00 pm** for partial canvassing of votes made through the online voting portal.

d. Security Ownership of Certain Record and Beneficial Owners and Management

1) Security Ownership of Certain Record and Beneficial Owners

Ferjenel G. Biron, Brandt Luke Q. Biron, Braeden John Q. Biron, Bryant Paul Q. Biron, and Maria Regina Isabelle D. Oca-Biron are the only record and/or beneficial owners of more than 5% of any class of registrant's voting securities as of 30 April 2026.

Title of Class	Names / Address of Record Owner	Name of Beneficial Owner/Relationship with Record Owner	Citizenship	Number of Shares Held	Percent
Common **Founder**	Biron, Ferjenel G. 82 Firefly Cor Butterfly Streets, Valle Verde VI, Pasig City	Biron, Ferjenel G./ Record Owner is also a Beneficial Owner.	Filipino	48,166 240	**20.17%**
Common **Founder**	Biron, Brandt Luke Q. Unit 4403, Trump Tower, Century City Kalayaan Avenue, Makati 1210	Biron, Brandt Luke Q./ Record Owner is also a Beneficial Owner.	Filipino	21,890 10	**17.94%**
Common **Founder** **Common** **Founder**		Trustor: Biron, Bryant Paul Q. Unit 903, Pacific Place. Pearl Drive, Ortigas Center, Pasig City Brother of the Record Owner.	Filipino	21,140 10 **TOTAL** 43,030 20	
Common	Oca-Biron, Maria Regina Isabelle D. Ilaya 2nd Dumangas, Iloilo	Oca-Biron, Ma. Regina Isabelle D./ Record Owner is also a Beneficial Owner	Filipino	60	**8.84%**
Common **Founder** **Common** **Founder**		Trustor: Biron, Braeden John Q. Unit 42C Kirov Tower, Estrella St. Rockwell Makati, 1210 Spouse of the Record Owner.	Filipino	21,140 10 **TOTAL** 21,200 10	

2) Security Ownership of Management

The following are each class of equity securities of the registrant beneficially owned by individual directors, officers and nominees as of 30 April 2026.

DIRECTORS, OFFICERS AND NOMINEES

Title of Class	Names of Beneficial Owner	Amount and Nature of Beneficial Ownership		Citizenship	Percent of Class
		Direct	Indirect		
Common **Founder**	**Fernandez, Lemuel T.**	1,930 10	None	Filipino	**0.81%**
Common **Founder**	**Gomez, Lusyl M.**	2,771 10	None	Filipino	**1.16%**
Common **Founder**	**Lavilla, Meride D.**	3,628 10 Total 3,638	2,430[1] 300[2] 300[3] 300[4] 10 Total 3,340	Filipino	**2.90%**
Common **Founder**	**Nolasco, Felix P.**	2,340 10 Total 2,350	2,340 10 Total 2,350	Filipino	**1.96%**
Common **Founder**	**Ong, Mary Flor G.**	3,352 10	None	Filipino	**1.40%**
Common **Founder**	**Regozo, Danilo C.**	3,658 10	None	Filipino	**1.53%**
Common **Founder**	**Villaflor, Agnes Jean M.**	2,748 10	500[5] 500[6]	Filipino	**1.56%**

[1] Owned by Francis G. Lavilla
[2] Owned by Francine Marie D. Lavilla
[3] Owned by Lou Valerie D. Lavilla
[4] Owned by Meryl Faith D. Lavilla
[5] Owned by Tristan Timothy M. Villaflor
[6] Owned by Trina Therese M. Villaflor

DIRECTORS AND NOMINEES

Class	Names of Beneficial Owner	Amount and Nature of Beneficial Ownership		Citizenship	Percent of Class
		Direct	Indirect		
Common Founder	**Biron, Ferjenel G**	48,166 240	None	Filipino	**20.17%**
Common Founder	**Biron, Brandt Luke Q.**	21,890 10	21,140[7] 10	Filipino	**17.94%**
Common Founder	**Dianco, Felibert O.**	3,340 10	None	Filipino	**1.40%**
Common Founder	**Samoro, Fredilyn G.**	6,748 20 Total 6,768	3,452[8] 10 Total 3,462	Filipino	**4.26%**
Common Founder	**Suplico, Rolex T.**	1990 10	None	Filipino	**0.83%**
Common	**Bermudo-Belgira, Johanna Marie B.**	10	None	Filipino	**.004%**
Common	**Silverio, Lorna C.**	500	None	Filipino	**.21%**
Common	**Debuque, Nathalie Ann F.**	10	None	Filipino	**.004%**

[7] Pursuant to a Voting Trust Agreement with Bryant Paul Q. Biron
[8] Shares owned by Heirs of Ronnie Samoro

EXECUTIVE OFFICERS

Class	Names of Beneficial Owner	Amount and Nature of Beneficial Ownership		Citizenship	Percent of Class
		Direct	Indirect		
Common	**Delos Reyes, Giovanni A.**	10	NONE	Filipino	**.004%**
Common	**Villanueva, Maylene B.**	10	NONE	Filipino	**.004%**
Common	**Fernandez, Toni Dinah Cheer D.**	NONE	1,930[7]	Filipino	**0.81%**
N/A	**Cortes, Cris T.**	NONE	NONE	Filipino	N/A
N/A	**Gerafil, Therese Marie A.**	NONE	NONE	Filipino	N/A

Except for **Ferjenel G. Biron** who owns **20.17%**; **Brandt Luke Q. Biron** who owns **17.94%**; **Fredilyn G. Samoro** who owns **4.26%**; and **Meride D. Lavilla** who owns **2.90%** of the outstanding shares, none of the company's directors, management and persons nominated owns directly or indirectly 2.0% or more of the outstanding capital stock of the Company.

VOTING TRUST HOLDERS OF 5% OR MORE

On 15 June 2023, Bryant Paul Biron and Braeden John Biron entered into separate voting trust agreements.

Bryant Paul Biron has entered into a Voting Trust Agreement in favor of Brandt Luke Biron, with address at Unit 4403, Trump Tower, Century City Kalayaan Avenue, Makati 1210, for a period of five (5) years, increasing his voting shares from 9.13% to 17.94% of the total voting stock.

Braeden John Biron has entered into a Voting Trust Agreement in favor of Maria Regina Isabelle Oca-Biron, with address at Ilaya 2nd Dumangas, Iloilo, for a period of three (3) years, increasing her voting shares from 0.02% to 8.83% of the total voting stock. The Securities and Exchange Commission (SEC) issued a Certificate of Filing of Voting Trust Agreement last 17 March 2025.

Title of Securities	Amount of Securities Under Trust or Agreement	Duration of the Agreement	Name and Address of Voting Trustee	Outline of Voting Rights	Trustor
Common	Php 21,140,000.00	Five years	Biron, Brandt Luke Address: Unit 4403, Trump Tower, Century City, Kalayaan Avenue, Makati 1210	Right to vote and be voted upon and vote in all matters and questions which may be brought before them.	**Bryant Paul Biron**
Founder	Php 10,000.00				
Common	Php 21,140,000.00	Three years	Oca-Biron, Ma. Regina Isabelle Address: Ilaya 2nd Dumangas, Iloilo	Right to vote and be voted upon and vote in all matters and questions which may be brought before them.	**Braeden John Biron**
Founder	Php 10,000.00				

[7] Shares owned by Lemuel Fernandez

CHANGES IN CONTROL

Since the beginning of the last fiscal year, the Company is not aware of any arrangement which may result in a change of control in the next twelve (12) months.

Item 5. Directors and Executive Officers

(a) The following are the names, ages, citizenship and periods of service of the incumbent directors/ and independent directors of the Company.

Name	Position	Age	Citizenship	Period during which individual has served as such
Biron, Ferjenel G.	Director / Chairman	61	Filipino	2014 to present
Belgira, Johanna Marie B.	Independent Director	38	Filipino	2024 to present
Biron, Brandt Luke Q.	Director	28	Filipino	2025 to present
Debuque, Nathalie Ann F.	Independent Director	32	Filipino	2025 to present
Dianco, Felibert O.	Director/ Chairperson, Internal Medicine/ Head, Cardiology Unit	52	Filipino	2020 (ID); 2020 to present
Fernandez, Lemuel T.	Director/ Assistant Treasurer/ Marketing Director	59	Filipino	2018-2020 (I.D.); 2020 to Present
Gomez, Lusyl M.	Director/ Assistant Secretary	66	Filipino	2017 to 2018 (ID) ; 2020 to present
Lavilla, Meride D.	Director / Vice Chairman / Director for Finance	63	Filipino	2014 to present
Nolasco, Felix P.	Director/ Hospital Director	73	Filipino	2014 to 2017; 2020 to present
Ong, Mary Flor G.	Director/Treasurer/ Head, Nutrition & Dietetics	53	Filipino	2023 to present
Regozo, Danilo C.	Director/Executive Vice President/ Chairperson, Family Medicine Department/ Director for Ancillary Services	63	Filipino	2014 to present
Samoro, Fredilyn G.	Director	61	Filipino	2014 to present
Silverio, Lorna C.	Lead Independent Director	78	Filipino	2025 to present
Suplico, Rolex T.	Director	67	Filipino	2020 to present
Villaflor, Agnes Jean M.	Director/ President	61	Filipino	2014 to present

b) The following are the names, ages, citizenship and periods of service of the persons nominated to become directors/ independent directors of the Company. They constitute the Final List of Candidates for the ensuing year, all of whom have accepted their respective nominations. The said list was duly approved by the 2025 Board of Directors after evaluation and upon endorsement by the Corporate Governance Committee, which presently discharges the functions of the Nomination and Election Committee. The said Committee is composed of Nathalie Ann F. Debuque, as Chairman, and Lorna C. Silverio, and Meride D. Lavilla, as members.

Name	Age	Citizenship	Period during which individual has served as such
REGULAR DIRECTORS			
1. Biron, Ferjenel G.	61	Filipino	2014 to present
2. Dianco, Felibert O.	52	Filipino	2020 to present
3. Fernandez, Lemuel T.	59	Filipino	2018-2019 (I.D.); 2020 to present
4. Gafate-Ong, Mary Flor	53	Filipino	2023 to present
5. Gomez, Lusyl M.	66	Filipino	2017-2018 (I.D.) ;2020 to present
6. Lavilla, Meride D.	63	Filipino	2014 to present
7. Nolasco, Felix P.	73	Filipino	2014 to 2017; 2020 to present
8. Regozo, Danilo C.	63	Filipino	2014 to present
9. Samoro, Fredilyn G.	61	Filipino	2014 to present
10. Suplico, Rolex T.	67	Filipino	2020 to present
11. Villaflor, Agnes Jean M.	61	Filipino	2014 to present
12. Biron, Brandt Luke Q.	28	Filipino	2025 to present
INDEPENDENT DIRECTORS			
1.Bermudo-Belgira, Johanna Marie B.	38	Filipino	2024 to present
2. Debuque, Nathalie Ann F.	32	Filipino	2025 to present
3. Silverio, Lorna C.	78	Filipino	2025 to present

The nominees were formally nominated by the shareholders of the Company as shown in the attached Final List of Candidates attached as **Annex C**. Johanna Marie B. Bermudo-Belgira, Nathalie Ann F. Debuque and Lorna Silverio are nominated as independent directors.

Ferjenel G. Biron, Felibert O. Dianco, Lemuel T. Fernandez, Lusyl M. Gomez, Meride D. Lavilla, Felix P. Nolasco, Mary Flor Gafate-Ong, Danilo C. Regozo, Fredilyn G. Samoro, Rolex T. Suplico, Agnes Jean M. Villaflor, Brandt Luke Q. Biron, are incumbent directors of the Company. None of the nominators are related to any of the nominees for independent directors.

The Corporate Governance Committee evaluated the qualifications of the nominees and prepared the Final List of Candidates in accordance with SRC Rule 38 (Requirements on Nomination and Election of Independent Directors) and the By-Laws of the Company.

Only nominees whose names appear in the Final List of Candidates are eligible for election as directors. No nominations will be entertained or allowed on the floor during the Annual Stockholders' Meeting.

c) The following are the names, ages and citizenship of the Company's executive officers in addition to its executive and independent directors listed above as of 30 April 2026.

Name	Position	Age	Citizenship	Period during which individual has served as such
Delos Reyes, Giovanni A.	Director for Admin. and Support Services	72	Filipino	2024 to present
Villanueva, Maylene B.	Compliance Officer	45	Filipino	2019 to present
Fernandez, Toni Dinah Cheer D.	Investor Relations Officer	57	Filipino	2020 to present
Cortes, Cris T.	Chief Finance Officer	38	Filipino	September 2023 to present
Gerafil, Therese Marie A.	Corporate Secretary/Data Protection Officer/Legal Officer	30	Filipino	January 2025 to present

The Business Profile of the incumbent directors and officers is attached hereto as **Annex B** while the profile of the nominees for directors for election at the annual stockholders' meeting is set forth in **Annex C1**. The certifications on the qualifications of independent directors are attached hereto as **Annex D to D2**. The Certificate of Qualification and permission of directors in government service are hereto attached as **Annex D3 to D5.**

TERM OF OFFICE

Article III, Section 4 of the Company's By-Laws provides:

> Section 4 – The Board of Directors shall be elected during each regular meeting of stockholders and shall hold office for one (1) year and until their successors are elected and qualified.
>
> The Board has established committees to assist in exercising its authority in monitoring the performance of the business of the Company. The committees, as detailed below, provide specific and focused means for the Board to address relevant issues including those related to corporate governance

COMMITTEES

NAME	AUDIT COMMITTEE	CORPORATE GOVERNANCE COMMITTEE	BOARD OF CANVASERS	INSPECTION OF BALLOTS AND PROXY COMMITTEE	DATA PRIVACY COMMITTEE	BOARD RISK AND OVERSIGHT COMMITTEE
Rolex T. Suplico					Chairman	
Johanna Marie B. Belgira	Chairman					Member
Mary Flor G. Ong						Member
Nathalie Ann F. Debuque	Member	Chairman			Member	Chairman
Meride D. Lavilla		Member				
Lorna C. Silverio	Member	Member			Member	
Ike T. Minerva				Chairman		
Ma. Iris V. Salazar			Chairman			
Grace Gallega Perez			Member			
Maria Geraldine Gubatina			Member			
Pedro Tingson				Member		
Romulo Barrameda				Member		

DIRECTORSHIP IN REPORTING COMPANIES

The following are the Directorships in other reporting companies of the incumbent Directors:

DIRECTORS	REPORTING COMPANIES
1. Biron, Ferjenel G.	Asia-Pacific Medical Center (APMC) - Aklan, Inc. Asia Pacific Medical Center (APMC) - Bacolod, Inc. Allied Care Experts (ACE) Medical Center – GENSAN, Inc. Allied Care Experts (ACE) Medical Center - Butuan, Inc. Allied Care Experts (ACE) Medical Center - Cagayan de Oro, Inc.
2. Biron, Brandt Luke Q.	NONE
3. Fernandez, Lemuel T.	NONE
4. Gomez, Lusyl M.	NONE
5. Lavilla, Meride D.	Asia Pacific Medical Center (APMC) - Aklan, Inc. Asia Pacific Medical Center (APMC) - Bacolod, Inc. Allied Care Experts (ACE) Medical Center – Cagayan de Oro, Inc.
6. Dianco, Felibert O.	NONE
7. Nolasco, Felix P.	Allied Care Experts (ACE) Medical Center - Tacloban, Inc. Allied Care Experts (ACE) Medical Center - Cebu, Inc.

8. Mary Flor G. Ong	NONE
9. Regozo, Danilo C.	Asia Pacific Medical Center (APMC) - Aklan, Inc. Asia Pacific Medical Center (APMC) - Bacolod, Inc.
10. Samoro, Fredilyn G.	Allied Care Experts (ACE) Medical Center – GENSAN, Inc. Allied Care Experts (ACE) Medical Center- Butuan, Inc.
11. Suplico, Rolex T.	NONE
12. Villaflor, Agnes Jean M.	Allied Care Experts (ACE) Medical Center – Cagayan de Oro, Inc. Allied Care Experts (ACE) Medical Center – GENSAN, Inc. Allied Care Experts (ACE) Medical Center- Butuan, Inc.
INDEPENDENT DIRECTORS	
13. Belgira, Johanna Marie B	NONE
14. Debuque, Nathalie Ann F.	NONE
15. Silverio, Lorna C.	NONE

SIGNIFICANT EMPLOYEES

The company does not believe that its business is dependent on the services of any particular employee who is not an executive officer.

FAMILY RELATIONSHIPS

Director and Chairman Ferjenel G. Biron is the father of Director Brandt Luke Q. Biron. Director Lemuel T. Fernandez is the spouse of Investor Relations Officer Toni Dinah Cheer Fernandez. The spouse of Director and Assistant Corporate Secretary Lusyl Gomez is the first cousin of Director and President Agnes Jean Villaflor.

Other than the foregoing, there are no other family relationships either by consanguinity or affinity up to the fourth civil degree between and among Directors, Executive Officers, or persons nominated.

INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS

a. Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City (Complaint for Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-emption, and for Attorney's Fees) Dax Matthew M. Quijano et.al. v. ACE Medical Center Cebu Inc. , Felix P. Nolasco, et.al.

On 7 March 2018, several complainants (Dax Matthew M. Quijano, et.al) through counsel filed a civil complaint against the Hospital and its Directors, including Felix Nolasco praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff's Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise preemptive rights to the increase of capital approved by the Board on November 12, 2016. The Defendants (based in Cebu) have already filed their Answer to the Complaint but the Manila based Doctors which include Dr. Nolasco had not been served the summons. On 5 August 2020, a Motion to Dismiss the Complaint was filed for lack of interest of plaintiffs to prosecute the case. The case was scheduled for mediation on 14 July 2021. Since an agreement was not reached, mediation was scheduled on 29 July 2021. No agreement was reached so it was sent back to court for judicial dispute resolution which was held on 9 February 2022. The JDR failed. The pre-trial conference which was previously scheduled on 13 April 2023 was cancelled and moved to 02 June 2023 at 10:45 am.

During the 13 August 2024 hearing, the Court informed the Parties that it needed time to evaluate the Motion for Partial Summary Judgement filed by complainants and reset the pre-trial conference on 16 October 2024 at 8:30 in the morning without prejudice to the resolution of the motion.

During the 16 October 2024 hearing, the Court informed the parties that it needs more time to resolve plaintiff's Motion for Partial Summary Judgement. The pre-trial conference was set on 05 February 2025 at 9:15 in the morning. On 05 February 2025, the Court set the pre-trial conference on 21 March 2025 at 9:15 in the morning without prejudice to the resolution of the Motion for Partial Summary Judgement.

On 21 March 2025, the pre-trial conference was reset on 23 May 2025 at 10:45 in the morning considering that plaintiffs' motion for partial summary judgment is still to be resolved by the court. On 23 May 2025, an Order was issued by the Regional Trial Court Branch XI of Cebu City resetting the pre-trial conference to 25 July 2025 at 10:00 in the morning, considering that there is still a pending motion for partial summary judgment. However, the same was cancelled. The next hearing was scheduled on 24 November 2025, at 9:15 a.m., but this was subsequently reset to 21 June 2026, at 8:00 a.m.

b. Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City (Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-Emption, and/or Attorney's Fees) Ferdinand P. Kionisala vs. Allied Care Experts (ACE) Medical Center- Cebu, Inc., Felix P. Nolasco et.al.

On 5 February 2018, complainant Ferdinand P. Kionisala filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff"s Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on 12 November 2016. The Cebu-based defendants had already filed their Answer to the Complaint and Dr. Kionisala has filed a Motion for Partial Summary Judgement, but the same was opposed by defendants on 2 May 2018. No ruling was made on such motion hence the case had not moved.

The Defendants filed a Motion to Dismiss the case for failure of the plaintiff to prosecute for lack of interest. The case was scheduled for mediation on 16 June 2021. Since an agreement was not reached, the pre-trial on 13 August 2021 proceeded as scheduled. On 5 November 2021, a hearing was held but no resolution was made. Another hearing was scheduled on 4 March 2022 but plaintiffs were unavailable. On 22 April 2022, another hearing was scheduled but plaintiff requested that his previous manifestation be addressed first. The hearing scheduled on 24 June 2022 was postponed.

The Court rendered on 09 August 2022 a partial summary judgement on plaintiff's prayer for issuance of certificates of stock leaving the other issues sought for trial on the merits. However, instead of presenting his evidence, plaintiff filed a motion to submit the case for decision based on legal issues through the filing of memorandum which is still pending resolution.

The Plaintiff submitted a motion to submit the case for decision based on legal issues, which was filed with the Court on 24 October 2022. The Defendant filed a comment on 07 November 2022. An order dated 30 June 2023, was received, in which the Court granted the Plaintiff's motion to submit the case for decision based on legal issues dated 18 October 2022. The Presiding Judge allowed both parties to file their respective memoranda, limited to the issue of the extent of the Plaintiff's preemptive right to purchase or subscribe to shares of stock in view of the Defendant Corporation's increase in capital stock, within 30 days from receipt of the said order.

The Defendant's counsel subsequently filed a Motion for Reconsideration seeking to set aside and deny the Plaintiff's motion to submit the case for decision based solely on the issue of whether the Plaintiff is entitled to the preemptive right to subscribe to one block of shares equivalent to 10 shares or only 3 shares, citing utter lack of merit. The Plaintiff's counsel filed an opposition to the Motion for Reconsideration.

The Defendant's Motion for Reconsideration of the Order dated 30 June 2023, which granted the Plaintiff's motion to submit the case for decision based on legal issues, remains pending resolution by the Court. As a matter of procedure, should the Court grant the Motion for Reconsideration, the case will proceed to pre-trial and trial. Otherwise, both parties will be directed to submit their respective memoranda in support of their respective claims and defenses, after which the case shall be deemed submitted for decision.

As of 30 April 2026, to the knowledge and information of the Company, except for the abovementioned Directors, none of the Company's other Directors or Executive Officers have been involved in any legal proceedings during the last five (5) years that are material to an evaluation of their ability or integrity to act as such.

RESIGNATION OF DIRECTORS

No director has resigned or declined to stand for re-election to the Board since the last Annual Stockholders' Meeting due to any disagreement with the company related to its operation, policies and practices.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In the normal course of business, the Company transacts with companies/individuals, which are considered related parties.

i.) Receivables against related parties (see Note 15 of AFS 2025)

As at end of 31 March 2026, the company has the following advances and receivables against related parties:

Receivable from:	Amount	Related to:	Particulars
Various ACE Hospitals	P47,472	APMC Iloilo, Inc	These are shared expenses with the other ACE Hospitals that were initially paid for by APMC Iloilo, Inc. Statements of Account were already sent to each of the Hospitals to collect these monies.
TIPP Plus Digital Solutions, Inc.	P6,902,784	Maylene Villanueva, Compliance Officer	TIPP Plus is the provider for the Custom-made HIS of APMCI. Maylene Villanueva is the President of the said company. TIPP Plus was engaged by the Company prior to her appointment as Compliance Officer and Corporate Secretary. In 2021, TIPP required 30% DP for USD 400K to be paid by APMCI. APMCI paid 50% of 30% downpayment for USD 60000 @ P 58.60/dollar. In March 2023 full payment of 30% DP for USD 60,000 @ P56 /dollar with VAT additional was made. Discounted contract price is USD 380k + VAT.

ii.) Key Management Personnel Compensation

Key Management compensation amounted to Php5,895,813 and Php7,571,693 for the period ended December 31, 2025, and 2024, respectively. These amounts are incorporated in the salaries and allowance account in the financial statements.

The Company does not provide post-employment benefits plans and equity-based compensation benefits to any of its directors and executive officers other than what is reasonably required by the Labor Code of the Philippines.

Item 6. Compensation of Directors and Executive Officers

(a) Summary of Compensation of Executive Officers

Information provided by the Finance Department as to the aggregate compensation paid or accrued to Asia-Pacific Medical Center – Iloilo Inc.'s Chief Executive Officer and other highly compensated executive officers, as well as other officers and directors during the last two completed fiscal years and the ensuing fiscal year is as follows:

The following summarizes the executive compensation received by the President and the top four (4) most highly compensated officers of the Company for 2025, 2024, and 2023. It also summarizes the aggregate compensation received by all the officers and directors, unnamed.

Name and Position	Year	Salaries	Bonuses	Others	Total
President and the top five (5) officers	2025	5,280,000.00	-	1,770,000.00	7,050,000.00
	2024	1,580,000.00	-	1,957,777.76	3,537,777.76
	2023	2,670,000.00	170,000.00	1,340,000.00	4,180,000.00
Aggregate compensation paid to all officers and directors as a group unnamed	2025	1,200,00.00	3,150,000.00	-	4,350,000.00
	2024	842,000.00	-	1,479,555.51	2,321,555.51
	2023	2,590,000.00	120,000.00	2,950,000.00	5,660,000.00

(b) Compensation of Directors

1. Standard Arrangements

During its 23 February 2018 meeting, the Board of Directors approved the following monthly salaries of its By-Laws and Executive Officers which took effect on 01 January 2019:

Position	Salary
Chairman	Fifty Thousand Pesos (PhP 50,000.00)
President	Fifty Thousand Pesos (PhP 50,000.00)
Vice Chairman	Thirty Five Thousand Pesos (PhP 35,000.00)
Executive Vice President	Thirty Five Thousand Pesos (PhP 35,000.00)
Corporate Secretary	Thirty Five Thousand Pesos (PhP 35,000.00)
Assistant Corporate Secretary	Twenty Five Thousand Pesos (PhP 25,000.00)
Treasurer	Thirty Five Thousand Pesos (PhP 35,000.00)
Assistant Treasurer	Twenty Five Thousand Pesos (PhP 25,000.00)

In addition, the Board of Directors has been accorded a per diem of Ten Thousand Pesos (Php 10,000.00) per regular and special board meeting and construction meeting as attended and in case of travels outside the principal place of business, an additional travel allowance of Ten Thousand Pesos (Php 10,000.00).

The salaries of other Executive Officers were approved by the Board of Directors through a resolution upon recommendation by the President until the creation of a Remuneration and Compensation Committee in June 2020.

Upon the recommendation of the Remuneration and Compensation Committee, the Board of Directors of the Company through Board Resolution No. 2023-05-08 as amended, approved an increase in the compensation of Corporate Officers to take effect upon the commencement of operations and booked as payable to Executive Directors subject to availability of funds, as follows:

Position	Salary
Chairman	One Hundred Thousand Pesos (PhP 100,000.00)
President	One Hundred Thousand Pesos (PhP100,000.00)
Vice Chairman	Eighty Thousand Pesos (PhP 80,000.00)
Executive Vice President	Eighty Thousand Pesos (PhP 80,000.00)
Corporate Secretary	Eighty Thousand Pesos (PhP 80,000.00)
Assistant Corporate Secretary	Fifty Thousand Pesos (PhP 50,000.00)
Treasurer	Eighty Thousand Pesos (PhP 80,000.00)
Assistant Treasurer	Fifty Thousand Pesos (PhP 50,000.00)

The company approved a reasonable per diem for Directors in the amount of Thirty Thousand Pesos (PhP 30,000.00) per Board Meeting, Five Thousand Pesos (PhP 5,000.00) for Executive Committee Meetings, Three Thousand Pesos (PhP 3,000.00) for other committee meetings and additional Fifteen Thousand Pesos (PhP 15,000.00) for out of town meetings.

Pursuant to Board Resolution No. 2025-05-17, approved on 18 May 2025, the compensation of the Chairman and Vice Chairman was reclassified to per diems, with the amount of Php 100,000 and Php 80,000 respectively, for one (1) meeting per month. No other additional per diems shall be granted for any subsequent meetings held within the same month.

2. Other Arrangements

There are no other arrangements pursuant to which any director of the Company was compensated or is to be compensated in 2025 and 2024 for any service provided as a director.

Item 7. Independent Public Accountants

a. Following the Supreme Court's decision on G.R. No. 246027 dated 28 January 2025 upholding Rule 68, paragraph 3 of the Implementing Rules and Regulations of the Securities Regulation Code (Republic Act No. [RA] 8799) and SEC Memorandum Circular No. 13, series of 2009 (SEC MC No. 13-2009), which required CPAs serving as external auditors for corporations issuing registered securities to obtain SEC accreditation, the Company, being a registered issuer, is required under the applicable rules to be audited by a Category "A" Auditor.

As Dimaculangan and Dimaculangan and Company CPAs' (DD & Co. CPAs) application for SEC accreditation as a Category A Auditor is still pending approval, DD & Co. CPAs voluntarily withdrew from its engagement as the Company's Principal Auditor for the year 2025, but the firm shall remain engaged as compiler for the said reporting period.

In view of the non-qualification of DD & Co. CPAs as a Category "A" Auditor, the Board of Directors, via referendum on 06 April 2026, appointed Berces-Ocampo, Mendoza and Associates (BMA), with Maria Cristina Josefina B. Ocampo as the signing partner, as the Company's Principal Auditor for the year 2025.

b. BMA is being recommended for election as external auditor for the current year as approved by the Board for a fee of Two Hundred Eighty Thousand Pesos (Php 280,000.00), exclusive of 15% of other fees which represents out of pocket expenses (OPE), with Maria Cristina Josefina B. Ocampo as the signing partner. The profile of BMA is attached to this Information Statement as **Annex E2.**

c. Representatives of the said firm are expected to be present at the Annual Stockholders' Meeting and will have the opportunity to make a statement if they desire to do so, and are expected to be available to respond to appropriate questions. In 2025, the Company's auditors did not perform any substantial non-audit services for the Company.

d. Changes in and disagreements with accountants on accounting and financial disclosure

There were no disagreements with Berces-Ocampo, Mendoza and Associates for the year 2025, and with Dimaculangan and Dimaculangan and Company CPAs for the years 2024, and 2023 on any matter relating to accounting principles or practices, disclosure of financial statements, auditing scope and procedures.

Note 3, Transition to the PFRS, to the financial statements provide discussion on the change in the financial reporting framework, pursuant to the Securities Regulation Code Rule 68, as Amended (2011), including adjustments made on prior period correction of errors in classification of accounts.

e. Audit and Audit Related Fees

The 2025 Audited Financial Statements of the Company with the External Auditors' PTR, Name of Certifying Partner and Address and Statement of Management's Responsibility are attached hereto as **Annex E3.**

THE AGGREGATE FEES BILLED ARE SHOWN BELOW:

The External Auditor has rendered:

Audit of the registrant's annual financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings or engagements for those fiscal years.

Other assurance and related services that are reasonable related to the performance of the audit or review of the registrant's financial statements.

The Audit Committee has approved the above-mentioned services The aggregate fees billed are shown below:

	2025	2024	2023
Total Audit Fees	200,000	286,570	242,000
Non-audit service fees: Other assurance services Tax services All other services	-	-	-
Total Non-audit fees	-	-	-
Total Audit and Non-audit Fees	200,000	286,570	242,000

Berces-Ocampo, Mendoza and Associates did not render tax or other professional services during the year. Audit service fee is exclusive of 15% which represents out of pocket expenses (OPE), plus 12% VAT in the amount of PHP 200,000 during the year ended December 31, 2025.

Likewise, Dimaculangan and Dimaculangan and Company CPAs did not render tax or other professional services during the years 2024 and 2023. Audit service fees are inclusive of 15% of other fees which represents out of pocket expenses (OPE) and QAR Fees plus 12% VAT amounted to Php 34,410 and Php 26,400 during the years ended December 31, 2024 and 2023, respectively.

Item 8. Compensation Plans

No action is to be taken in this meeting with respect to any plan pursuant to which cash or non-cash compensation may be paid or distributed.

Item 9. Authorization or Issuance of Securities

No action is to be taken with respect to the authorization or issuance of any securities other than what is currently being offered over-the-counter.

Item 10. Modification or Exchange of Securities

No action is to be taken with respect to the modification of any class of securities of the registrant or the issuance of one class of securities of the registrant in exchange for outstanding securities of another class.

Item 11. Financial and Other Information

As previously stated, no action is to be taken with any matter specified in Items 9 & 10.

Item 12. Merger, Consolidation, Acquisition and Similar Matters

No action is to be taken with respect to any transaction involving the following:

1) the merger or consolidation of the company into or with any person or of any other person into or with the company;
2) the acquisition by the company or any of its security holders of securities of another person
3) the acquisition by the registrant of any other going business or of the assets thereof;
4) the sale or other transfer of all or any substantial part of the assets of the company;
5) the liquidation or dissolution of the company.

Item 13. Acquisition/Disposition of Property

No action is to be taken with respect to an acquisition or disposition of any property by the company.

Item 14. Restatement of Accounts

No action is to be taken with respect to the restatement of any asset, capital, or surplus account of the company.

D. OTHER MATTERS

Item 15. Action with Respect to Reports

The following are the acts to be submitted for approval during the stockholders' meeting:

A. Minutes of the Annual Meeting of Stockholders held on 18 June 2025 (**Annex F**)

The approval or disapproval of the above Minutes will refer only to the correctness of the Minutes and will not constitute an approval/disapproval of the matters stated in the Minutes.

B. Annual Report and 2025 Audited Financial Reports

While the Annual Report which includes the Management Report as of 30 April 2026 (**Annex G**) shall only be noted, the 2025 Audited Financial Report shall be approved by the stockholders attending the meeting.

Item 16. Matters Not Required to be Submitted

No action is to be taken with respect to any matter which is not required to be submitted to a vote of security holders.

Item 17. Amendment of Charter, By laws or Other Documents

The Board of Directors of Asia Pacific Medical Center (APMC) - Iloilo, Inc. in its regular Board Meeting held last 28 September 2025, and 28 October 2025, with majority of the Directors present, approved the amendment of the following provisions of the Corporation's Amended Articles of Incorporation and Amended By-Laws respectively, with the following changes:

I. Articles of Incorporation

A. Article III

From	To	Reason and General Effect of Amendment
That the place where the principal office of the Corporation is located at Brgy. Ungka I, Jaro, Iloilo City, 5001	That the place where the principal office of the Corporation is located at **Brgy. Ungka, Jaro, Iloilo City, 5000**	The amendment is being made to reflect the correct address of the principal office of the Corporation.

B. Article VII

From	To	Reason and General Effect of Amendment
That the authorized capital stock of the Corporation is TWO HUNDRED FORTY MILLION PESOS (P 240,000,000), Philippine Currency, and said capital stock is divided into two hundred forty thousand (240,000) shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) TWO HUNDRED THIRTY NINE THOUSAND FOUR HUNDRED (239,400) COMMON shares with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx	That the authorized capital stock of the Corporation is **FOUR HUNDRED EIGHTY MILLION PESOS (P 480,000,000)**, Philippine Currency, and said capital stock is divided into **four hundred eighty thousand (480,000)** shares with a par value of One Thousand Pesos (P 1,000) per share divided as follows: a) **FOUR HUNDRED SEVENTY NINE THOUSAND FOUR HUNDRED (479,400) COMMON** shares with a par value of ONE THOUSAND PESOS (Php 1,000) per share; b) SIX HUNDRED (600) FOUNDER shares with a par value of ONE THOUSAND PESOS (PhP 1,000) per share. xxx	The proposed amendment to the Articles of Incorporation increasing the authorized capital stock is intended in order to support the Corporation's expansion plans, strengthen its operational capacity, finance the acquisition of additional medical equipment, and ensure the continuous delivery of quality healthcare services, as well as to support its long-term growth and sustainability.

II. By-Laws

A. Article IV, Section 1

From	To	Reason and General Effect of Amendment
The office of the corporation shall be located in Brgy. Ungka I, Jaro, Iloilo City, 5000. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require	The office of the corporation shall be located in **Brgy. Ungka, Jaro, Iloilo City, 5000**. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.	The amendment is being made to reflect the correct address of the principal office of the Corporation.

Item 18. Other Proposed Actions

(a.) Acts and Resolutions of the Board of Directors and Management from the date following the last Annual Stockholders' Meeting to the present including, but not limited to the following:

1. Approval of the retention of the 2025 set of officers as officers of the corporation for 2025 until their successors are elected.

Chairman:	Ferjenel G. Biron
Vice Chairman:	Meride D. Lavilla
Executive Vice President:	Danilo C. Regozo
Corporate Secretary:	Therese Marie A. Gerafil
Asst. Corporate Secretary:	Lusyl M. Gomez
Treasurer:	Mary Flor Gafate-Ong
Asst. Treasurer:	Lemuel T. Fernandez

2. Election of Agnes Jean M. Villaflor as the President of the Corporation for 2025 -2026, until her successor is elected.
3. Approval of the election of Lorna C. Silverio as the Lead Independent Director of the Corporation for 2025-2026 until her successor is elected.
4. Approval of the appointment of the Chairman and Members of the Audit Committee for 2025-2026:

Chairman:	Johanna Marie B. Belgira
Members:	Lorna C. Silverio
	Felibert O. Dianco

5. Approval of the appointment of the Chairman and Members of Corporate Governance Committee for 2025 -2026:

Chairman:	Nathalie Ann F. Debuque
Members:	Lorna C. Silverio
	Meride Lavilla

6. Approval of the appointment of the Chairman and Members of the Data Privacy Committee for 2025-2026.

    Chairman: Rolex T. Suplico
    Members: Lorna C. Silverio
    Nathalie Ann F. Debuque

7. Approval of the appointment of the Chairperson and Members of the Board Risk and Oversight Committee for 2025-2026:

    Chairman: Nathalie Ann F. Debuque
    Members: Johanna Marie B. Belgira
    Mary Flor G. Ong

8. Approval of the retention of 2024-2025 Chairperson and Members of the Board of Canvassers and Inspection of Ballots and Proxy Committee.
9. Approval that the Remuneration and Compensation Committee and Nominations and Election Committee be abolished and that their respective functions be integrated into the Corporate Governance Committee.
10. Approval of the appointment of Lusyl M. Gomez, M.D. as Director for Medical Services.
11. Approval of the appointment of Jerusha A. Comuelo, M.D. as Chairman of the Department of Pediatrics.
12. Approval of the appointment of Meride D. Lavilla, M.D. as Director for Finance.
13. Approval of the appointment of Independent Director Nathalie Ann F. Debuque as member of the Audit Committee, by virtue of the disqualification of Director Felibert O. Dianco.
14. Approval of the appointment of Dr. Royce Reyes as consultant for PhilHealth matters, with a monthly consultancy fee of Twenty Thousand Pesos (Php 20,000,00), net of tax, effective 01 August 2025; That the 20% of the total amount of previously denied claims that are successfully paid during the consultancy period shall be paid upon actual receipt of the corresponding payment for each claim and a review fee of One Hundred Fifty Pesos (Php 150.00) shall be applied to each new PhilHealth claim and returned-to-hospital (RTH) claim reviewed, which shall be remitted every 15th day of the month.
15. Approval that Asia Pacific Medical Center - Iloilo, Inc. be authorized to open and maintain corporate credit card account with Land Bank of the Philippines (LBP); that the following officers are hereby designated as the authorized signatories for the corporate credit card applications, availment, usage, and other related transactions with LBP;

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Meride D. Lavilla, M.D.	Vice Chairman/Director for Finance
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

16. Approval for the designation of the following Officers as the authorized signatories for and in connection with the Current and Savings Account of Asia Pacific Medical Center - Iloilo, Inc. maintained with Metropolitan Bank & Trust Company;

    SIGNING RULE: Two (2) of Set A for more than One Million or any two (2) of Set B for an amount of One Million and below:

Set A

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

Set B

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Meride D. Lavilla, M.D.	Vice Chairman/Director for Finance
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

17. Approval of the designation of the following Officers as the authorized signatories for and in connection with the Credit Account of Asia Pacific Medical Center - Iloilo, Inc. maintained with Land Bank of the Philippines;

    SIGNING RULE: Two (2) of the authorized signatories

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

18. Approval of the designation of the following Officers as the authorized signatories for and in connection with the Current Account of Asia Pacific Medical Center - Iloilo, Inc., maintained with Land Bank of the Philippines;

    SIGNING RULE: Two (2) of the authorized signatories

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Meride D. Lavilla, M.D.	Vice Chairman/Director for Finance
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

19. Approval of the designation of the following Officers as the authorized signatories of Asia Pacific Medical Center - Iloilo, Inc., for the purpose of executing, signing, and submitting all documents and transacting any and all business, matters, and dealings with Social Security System (SSS) and Home Development Mutual Fund (HDMF);

NAME	POSITION/DESIGNATION
Meride D. Lavilla, M.D.	Vice Chairman/Director for Finance
Cris T. Cortes, CPA	Chief Finance Officer
Mary Flor G. Ong, M.D.	Corporate Treasurer

20. Approval of the designation of the following Officers as the authorized signatories for and in connection with the Savings and Current Account of Asia Pacific Medical Center - Iloilo, Inc. maintained with the Bank of the Philippine Islands (BPI);

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Meride D. Lavilla, M.D.	Vice Chairman/Director for Finance
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

21. Approval of the reprinting of five hundred (500) stubs of Official Receipt of the Company.
22. Approval of the authority of the Corporate Secretary, Therese Marie A. Gerafil, to sign and file the General Information Sheet (GIS) of Asia Pacific Medical Center Iloilo for the year 2025.
23. Approval of the authority of Dr. Agnes Jean M. Villaflor, President, to transact, execute and sign all documents on behalf of the Corporation pertaining to its registration with the Board of Investments (BOI) under Corporate Recovery and Tax Incentives for Enterprises Act.
24. Approval of the authority of the Corporation to enter into transactions and contracts with, and/or avail of products, facilities, services of or through the representation of PLDT Inc., and its wholly/partly owned subsidiaries and/or affiliates including but not limited to Smart Communications, Inc., Digitel Mobile Philippines, Inc., and ePLDT, Inc. and approval of the authority of the President, Dr. Agnes Jean M. Villaflor, to sign, execute and/or deliver any and all documents, contracts, instruments for and on behalf of the Corporation, as may be appropriate and required by the foregoing transactions authorized above.
25. Approval of the Memorandum of Agreement (MOA) between West Visayas State University (WVSU) and APMC Iloilo for the use of the Body Box; and approval of the authority of Dr. Agnes Jean M. Villaflor, the President of APMC Iloilo, to sign, execute, and deliver the said MOA on behalf of the Corporation, and to perform all acts necessary to implement its provisions.
26. Approval of the designation of the following officers and/or personnel of the Corporation designated as Makers and Authorizers for the Corporation's LBP WeAccess account; and approval of the authority of the aforesaid Makers and Authorizers to perform and carry out their respective duties and responsibilities relative to the Corporation's LBP WeAccess account, subject to the terms and conditions prescribed by LBP.

NAME	POSITION/DESIGNATION	Role
Agnes Jean M. Villaflor	President	Authorizer
Cris T. Cortes	Chief Finance Officer	Authorizer
Jeannie Joy Paches	Payroll Officer	Maker
Jen Trexie Gallardo	Accounting Staff	Maker

27. Approval of the acquisition of an accounting module from Prometheus, subject to the following terms and conditions:
    - In the event of non-compatibility, non-functionality, or failure to deliver within the agreed timeline, the Corporation shall have no obligation to pay;
    - No down payment shall be made prior to the delivery, testing, and acceptance of the module by the Corporation.

    Approval of the authority of Dr. Agnes Jean M. Villaflor,, President of the Corporation, to negotiate, sign, and execute, for and on behalf of the Corporation, the corresponding contract, agreement, and all other documents necessary and incidental to the said acquisition.
28. Approval of the Interim Financial Statements of Asia Pacific Medical Center - Iloilo, Inc. for the 2nd Quarter of 2025.
29. Approval of the Audit Manual of Asia Pacific Medical Center - Iloilo, Inc.
30. Approval of the SEC Form 17Q (2nd Quarter Report) of Asia Pacific Medical Center - Iloilo, Inc.,
31. Approval of the authority of Therese Marie A. Gerafil, Corporate Secretary, to execute the Affidavit of Undertaking in connection with the Corporation's pending application for the amendment of its By-laws with the Securities and Exchange Commission (SEC).
32. Approval of the authority of Dr. Agnes Jean M. Villaflor, President, to transact, execute and sign all documents in behalf of the Corporation pertaining to its application for availment of Income Tax Holiday (ITH) incentive with the Board of Investments.

33. Approval of the renewal of the Short-Term Loan Line (STLL) and Domestic Bills Purchase Line (DBPL) with Land Bank of the Philippines of Asia Pacific Medical Center - Iloilo, Inc., with the following officers of the Corporation are hereby authorized to negotiate, sign, execute, and deliver any and all agreements, documents, and instruments as may be necessary to implement the renewal of the said facilities, and to perform any and all acts in connection therewith:

NAME	POSITION/DESIGNATION
Ferjenel G. Biron, M.D.	Chairman
Agnes Jean M. Villaflor, M.D.	President
Mary Flor G. Ong, M.D.	Corporate Treasurer

The above-mentioned signatories be given full power and authority to do and perform every act and thing whatsoever requisite and necessary to be done in and about the premises, as fully, to all intents and purposes as the Company will do if present, hereby ratifying and confirming all that the said signatories shall lawfully do or cause to be done.

34. Approval of the adoption of the Philippine National Drug Formulary (8th Edition) as the official Hospital Formulary of Asia Pacific Medical Center – Iloilo, Inc; and approval of any additions, deletions, or exemptions to the PNDF for specific institutional needs shall be evaluated and recommended by the Pharmacy and Therapeutics Committee, subject to approval by hospital management.
35. Approval of the amendment of the Article IV of the Articles of Incorporation; and granting the Corporate Secretary the authority and directed to prepare, sign, and file the necessary documents with the Securities and Exchange Commission (SEC) and other appropriate government agencies in order to implement and give full effect to the foregoing amendments.:

From	To
That the place where the principal office of the Corporation is located at Brgy. Ungka I, Jaro, Iloilo City, 5001.	That the place where the principal office of the Corporation is located at Brgy. Ungka, Jaro, Iloilo City, 5000.

36. Approval of the corrections of the typographical errors in the names of stockholders as indicated in Articles VIII and IX of the Articles of Incorporation, as follows:

From	To
Barrameda, Romulo S. Gonzales, Noel G. Gubatina, Ma. Geraldine L Nolasco, Eulena P. Salazar, Maria Iris V. Saquaian, Jeremy M. Tongo, Cesar D.	Barrameda, Romulo Jr. S. Gonzales, Noel J. Gubatina, Maria Geraldine L Nolasco, Maria Eulenia R. Salazar, Ma. Iris V. Saquian, Jeremy M. Tongo, Caesar D

The Corporation authorizes its Corporate Secretary, Therese Marie A. Gerafil, to institute and sign a Petition for Correction of Errors in the Amended Articles of Incorporation registered with the Securities and Exchange Commission on 02 August 2021; and that the Corporate Secretary granted full power and authority to do and perform any and all acts which may be necessary, proper, or incidental to the implementation of the foregoing resolution, including, but not limited to, the preparation, signing, and filing of the Petition, the Verification and Certification of Non-Forum Shopping, as well as any and all other documents related thereto;

37. Ratification of the approval via referendum of the Performance Evaluation Policy of the Corporation.
38. Ratification of the approval via referendum of the Anti-Sexual Harassment Policy of the Corporation.

39. Approval of the appointment of Atty. Jose M. Jose law offices or any of its lawyers, with office address at 60 Rivera Street, San Juan City, Metro Manila, as counsel in the case of "Kionisala V. Office of the Insurance Commission et. al." pending in the Court of Appeals Cebu and to cause the preparation, execution and signing of pleadings, motions, memoranda and such other documents as may be needed in the case, as well as to submit and present evidence on behalf of the Corporation.
40. Approval of the engagement of Ms. Nida Sonza as Medical Records Consultant, with a monthly consultancy fee of Twenty Thousand Pesos (Php 20,000.00)
41. Approval of the Strategic Planning and Performance Review of Asia Pacific Medical Center – Iloilo, Inc. conducted on November 28 and 29, 2025, with a total budget of Php 130,000.00 for the said activity, of which Php 90,000.00 shall be allocated for the engagement of the facilitator.
42. Approval of the Christmas Party of Asia Pacific Medical Center – Iloilo, Inc. held on December 6, 2025, with a total budget of Php 690,000.00, to cover the following expenses: Php 350,000.00 for food; Php 300,000.00 for Christmas Tokens; Php 20,000.00 for Representation Allowance; and Php 20,000.00 for Christmas Decorations.
43. Approval of the authority of the registration of the security interest over various medical equipment and chattels, subject to the terms and conditions approved by the Board; that the Corporation shall register a juridical account under its name with the Personal Property Security Registry (PPSR) of the Land Registration Authority (LRA) for the purpose of registering the security interest of the Land Bank of the Philippines (LBP) over said medical equipment and chattels, to serve as loan collateral and to facilitate all related transactions; and approval of the designation and authority of Dr. Agnes Jean M. Villaflor, President of the Corporation, to create and manage the corporate account necessary for such registration; to prepare, sign, submit, and receive all documents, applications, and correspondence relative to the registration of the security interest; and to perform such other acts as may be necessary to complete the registration process.
44. Ratification of the appointment of the following individuals for the positions as indicated herein, effective 01 October 2025:

Name	Designation
Clinical Departments	
Dr. Lusyl Gomez	Director, Medical Services
Dr. Giovanni A. de los Reyes	Director, Administrative and Support Service
Dr. Danilo C. Regoso	Director, Ancillary Department
Dr. Omar Z. Montejo	Director, Nursing Service Department
Dr. Meride L. Lavilla	Director, Finance Department
Dr. Ike T. Minerva	Chief of Clinics
Dr. Jerald G. Gomez	Chairman, Department of Surgery
Dr. Felibert O. Dianco	Chairman, Department of Internal Medicine
Dr. Liza M. Limsiaco	Chairman, Department of Obstetrics and Gynecology
Dr. Jerusha Comuelo	Chairman, Department of Pediatrics
Dr. Ruben B. Ramirez	Chairman, Department of Imaging
Dr. Danilo C. Regozo	Chairman, Department of Family Medicine
Dr. Ma. Iris V. Salazar	Chairman, Department of Pathology and Clinical Laboratory
Dr. Felix Ruben M. Fandinola	Chairman, Department of Anesthesiology
Medical and Clinical Services	
Dr. Demetrio T. Patrimonio	Head, NICU Team
Dr. Eli John A. Berami	Head, ICU Team
Dr. Regil C. Palmares	Head, High-Risk Pregnancy Team

Dr. Maria Ana P. Ausan	Head, High-Risk Pregnancy Member
Dr. Sylva L. Daulo	Head, Dental Unit
Dr. Felibert O. Dianco	Head, Cardiology Laboratory Unit
Dr. Ike T. Minerva	Head, Endoscopy Unit
Dr. Mary Flor G. Ong	Head, Nutrition and Dietetics Department
Dr. Ma. Julie Christi S. De La Gente	Head, Pulmonary Unit
Dr. Jimah S.Pacion	Head, Physical Medicine and Rehabilitation
Dr. Melchor A. Altillero Jr.	Head, Hemodialysis Unit
Dr. Liza Marie R. Lomigo	Head, Sleep Laboratory and CPAP Clinic
Dr. Eleonor D. Palac-Ibojos	Head, Pulmonary Rehabilitation Unit
Dr. Ryan Ed Comuelo	Head, Emergency Department
Dr. Rey Olac Jr.	Head, Blood Bank with Additional Function
Hospital Committees	Chairman
Intensive Care Unit	Dr. Eli John A. Berami
Code Blue Team	Dr. Eli John A. Berami
Information and Communication Technology	Dr. Giovanni A. de los Reyes
Infection and Prevention Control	Dr. Analyn G. Jumeras
Hospital Blood Transfusion	Dr. Maria Lita Fe Paclibar
Health Waste Management	Dr. Francis Roy Lavilla
Ethics and Grievance	Hon. Ma. Teresa Debuque
Patient Safety	Dr. Giovanni A. de los Reyes
Continuous Quality Improvement	Dr. Giovanni A. de los Reyes
Antimicrobial Stewardship	Dr. Analyn G. Jumeras
Credentialing and Privileging	Dr. Maria Geraldine L. Gubatina
Emergency and Disaster Preparedness	Dr. Romulo Barrameda
Pharmacologic and Therapeutics	Dr. Mary Flor G. Ong
Health Information Management	Dr. Giovanni A. de los Reyes
Occupational Safety and Health	Dr. Agnes Jean Villaflor
Newborn Screening	Dr. Demetrio T. Patrimonio
Newborn Hearing Screening	Dr. Jerusha Comuelo
Mother-Baby Friendly Hospital Initiative	Dr. Meride Lavilla
Family Planning Service	Dr. Liza Limsiaco
Immunization	Dr. Lusyl Gomez
National Tuberculosis Program	Dr. Ma. Cecilia P. Momville
Anti-Smoking	Dr. Giovanni A. de los Reyes
Generic Prescribing	Dr. Danilo C. Regozo
Hospital EmergencyManagement Services	Dr. Agnes Jean Villaflor
Stroke Ready Hospital Team	Dr. Anatalia Nina Tayo
Social Media Service Team	Dr. Giovanni A. de los Reyes
Chart	Dr. Omar Montejo
Bids and Awards Committee	Dr. Francis Roy Lavilla
Corporate Service Responsibility	Atty. Maylene B. Villanueva
Social and Events	Dr. Giovanni A. de los Reyes

Hospital Disposal	Dr. Giovanni A. de los Reyes
Environmental Care	Dr. Giovanni A. de los Reyes

The aforementioned Clinical Department Chairmen, Medical and Clinical Services Heads and Committee Chairmen shall directly coordinate with the Medical Director or Chief of Clinics, as the case may be, for monitoring and reporting purposes. The terms of office shall be for a period of One (1) year, unless rescinded or upon request by the concerned party for personal reasons.

45. Approval of the amendment of Article VI, Section 1 of the Corporation's By-Laws:

From	To
The office of the corporation shall be located in Brgy. Ungka I, Jaro, Iloilo City, 5000. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.	The office of the corporation shall be located in Brgy. Ungka, Jaro, Iloilo City, 5000. The corporation may have such other branch offices, whether within or outside the Philippines, as the Board of Directors may designate or as the business of the corporation may, from time to time, require.

46. Approval of the proposed extension of operational hours for PhilHealth, HMO, and Billing Units during weekends and holidays, with a duty schedule of 8:00 A.M. to 5:00 P.M., inclusive of one (1) hour lunch break, subject to compliance with labor standards, internal policies, and operational guidelines to be issued by Management.

47. Approval of the adoption and implementation of the proposed payment scheme based on the income classification standards of the Philippine Institute for Development Studies;

CLASS	RANGE OF MONTHLY FAMILY INCOME	GL PERCENTAGE (%) OF AVAILMENT OF THE HOSPITAL BILL
Rich	Php 219,140 and up	None
High Income (but not rich)	Php 131,484 to Php 219,140	20%
Upper Middle Class	Php 76,669 to Php 131,484	50%
Middle Class	Php 43,828 to Php 76,669	75%
Lower Middle Class	Php 21,194 to Php 43,828	85%
Indigent/Employee	Below Php 21,194	100%

48. Approval of the proposed increase in the Domestic Bills Purchase Line (DBPL) from the amount of Five Million Pesos (Php 5,000,000.00) to Ten Million Pesos (Php 10,000,000.00), with the Land Bank of the Philippines.
49. Ratification of the approval via referendum of SEC Form 17-Q (3rd Quarter Report) and the Interim Financial Statements of Asia Pacific Medical Center - Iloilo, Inc. for the 3rd Quarter of 2025
50. Approval of the authority of Mildred B. Robledo, to represent and transact on behalf of Asia Pacific Medical Center – Iloilo, Inc. in connection with the property located in Lanit, Jaro, Iloilo City, purchased by the Corporation; to appear before, and transact with, the Register of Deeds, Bureau of Internal Revenue (BIR), City Treasurer's Office, City Assessor's Office, and such other government agencies or instrumentalities as may be necessary for the processing of the Deed of Sale, transfer and issuance of new certificate of title, tax declarations, payment of taxes and fees, and other related transactions necessary to implement the said property acquisition; and approval of a professional fee in the amount of Fifty Thousand Pesos (Php 50,000.00) as compensation for the services to be rendered in connection with the foregoing transactions.

51. Approval of the application for registration of the Corporation's Computerized Accounting System (CAS), including the Computerized Books Of Accounts (CBA) and/or its Components/ Middleware / Electronic Storage System (ESS), with the Bureau of Internal Revenue; and approval of the authority of the President, Dr. Agnes Jean M. Villaflor, to prepare, to sign, submit, and file the application for registration, together with all required documents, certifications, system descriptions, sworn statements, and supporting papers, and to do all acts necessary or incidental to the registration thereof; and any and all acts performed in connection with the foregoing prior to the adoption of this Resolution are hereby ratified and confirmed.
52. Approval of the proposed changes in the Finance Department structure.
53. Approval of the proposed increase in hospital room rates, which shall take effect on 01 January 2026:

Room	From	To
Large Private Room	Php 4,900.00	Php 5,500.00
Private Room	Php 3,500.00	Php 4,000.00

54. Approval of the Service Package Planned Preventive Maintenance (PPM) of UIH machines in the Imaging Department for a period of three (3) years, covering 01 November 2025 to 31 October 2028, in the total amount of Php 5,668,000.00; And the corrective maintenance of the Floor-Mounted Digital Medical X-Ray Imaging System in the amount of Php 511,000.00.
55. Approval of the adoption of the Corporation's Mission, Vision, and Core Values.
56. Approval of the engagement of Ms. Roselle Marie Azucena as Strategic Planning Facilitator, with a monthly scheduled visit, under the following terms and conditions:
    - Professional Fee: Php 45,000.00 per month;
    - Gas Allowance: Php 3,200.00 per month; and
    - Travel: Provision of a round-trip ticket from Manila to Iloilo

    The scope of work, deliverables, performance expectations, and all other terms and conditions of the engagement shall be governed by and detailed in the duly approved Engagement Proposal and/or Engagement Agreement.
57. Approval of the hiring of regular hospitalists for the following departments and number of positions: Internal Medicine (IM) – four (4); Pediatrics – two (2); Obstetrics (OB) – one (1); and Surgery – one (1). The approved hospitalists shall render forty (40) hours of duty per week and shall be entitled to government-mandated benefits, in accordance with applicable labor laws;
58. Approval that the Financial Statements of the Corporation shall be subjected to audit at least twice each fiscal year.
59. Approval of the appointment of Dr. Amado M. Lavalle, Jr. as Chairman of the Department of Surgery, replacing Dr. Gerard Gomez, who resigned from the position as Chairman of the Department of Surgery of Asia Pacific Medical Center - Iloilo, Inc., effective 31 January 2026.
60. Approval of the designation of Dr. Felix Nolasco, Hospital Director, to temporarily assume the duties and responsibilities of the Director for Medical Services, pending the appointment of a permanent successor, following the resignation of Dr. Lusyl Gomez as Director for Medical Services of Asia Pacific Medical Center - Iloilo, Inc., effective 31 January 2026.
61. Approval of the renewal of the consultancy contract of Ms. Neema Muyco McTomney for the Nutrition and Dietetics Department, under a three-day work schedule per week, with a monthly consultancy fee of Thirty-Five Thousand Pesos (Php 35,000.00), for the period January 1 to December 31, 2026.
62. Approval of the renewal of the Mitsubishi Elevator Maintenance and Service Contract with International Elevator & Equipment, Inc., for a monthly service fee of Thousand Pesos (Php 5,000.00), covering the period from January 1 to December 31, 2026.
63. Approval of the renewal of the consultancy contract of Dr. Royce Reyes for the PHIC Department, for a period of three (3) months, effective February 1, 2026.
64. Approval of the granting of offsetting credits for the attendance of Officers, Managers, and Supervisors in the Business Review conducted every second (2nd) Sunday of the month. Offsetting credits shall be granted to Managers, Supervisors, and Officers who are required to attend official hospital activities conducted on weekends or holidays, provided that the activity proposal has been duly approved by Management and attendance is expressly mandated through an official memorandum. Offsetting credits shall not be construed as a general entitlement for overtime work or for additional services rendered outside regular working hours. A continuous whole day or a minimum of eight (8) hours of attendance shall be considered equivalent to one (1) offsetting credit. The availment of offsetting credits shall be subject to prior

approval by Management or the concerned Director or Division Head, taking into consideration the operational requirements of the hospital and ensuring that such availment will not prejudice the efficient operation of the department. Offsetting credits shall not be availed of consecutively and must be utilized on separate occasions. All earned offsetting credits must be used within one (1) year from the date they were earned; otherwise, they shall be deemed forfeited.

65. Approval of the preponement of the 2026 Annual Stockholders' Meeting from the Fourth (4th) Thursday of July to 28 May 2026. The meeting shall be held at APMC Iloilo, Brgy. Ungka, Jaro, Iloilo City, and conducted via remote communication.
66. Approval of the authority of the Accounting Department to collect the outstanding PTP payments from members of the medical staff, subject to the following guidelines:
    (1) Consultants who have been practicing in the hospital for less than one (1) year may be allowed to settle their PTP obligations through staggered payments within a maximum period of twelve (12) months. Payment shall be made through the issuance of post-dated checks (PDCs), in accordance with a payment schedule to be indicated in the billing notice to be prepared by the Accounting Department.
    (2) Consultants who have been practicing in the hospital for more than one (1) year and who have not fully settled their PTP obligations shall be required to pay their outstanding balance in full upon receipt of the billing notice.
    (3) Offsetting or deduction from professional fees shall not be allowed, in order to ensure compliance with proper accounting procedures.
    (4) The Accounting Department shall issue formal billing notices to the concerned consultants, clearly indicating the amount due, the schedule of payments, and the specific dates for the post-dated checks.
    (5) Department Heads shall assist in reminding and coordinating with their respective consultants regarding the settlement of their outstanding PTP obligations.
67. Approval of the 2025 Audited Financial Statements
68. Approval of the 2026 Audit Engagement Proposal of Dimaculangan and Dimaculangan and Company CPAs, covering both for interim and annual audit engagements
69. Approval of the designation of Ms. Cherre May Allin, in her capacity as Chief Pharmacist, as the Corporation's authorized representative responsible for compliance with the requirements of the Philippine Drug Enforcement Agency (PDEA), effective 06 April 2026.
70. Approval of the withdrawal of Dimaculangan and Dimaculangan and Co., CPAs as the Principal Auditor for the audit of the Company's financial statements for the year ending 31 December 2025, but will remain engaged to act as compiler, pending approval of its SEC accreditation; and approval of the engagement of Berces-Ocampo, Mendoza and Associates as the Company's Principal Auditor for the said reporting period, with an audit fee of Two Hundred Thousand Pesos (Php 200,000.00).
71. Approval of the increase in the authorized capital stock of the Corporation from Two Hundred Forty Million Pesos (PHP 240,000,000.00) to Four Hundred Eighty Million Pesos (PHP 480,000,000.00), divided into four hundred eighty thousand (480,000) shares with a par value of One Thousand Pesos (PHP 1,000.00) per share; and approval of the corresponding amendment of Article VII of the Articles of Incorporation of the Corporation to reflect such increase in authorized capital stock, subject to the approval by Stockholders representing two-thirds (2/3) of the outstanding capital stock of the Corporation and compliance with the requirements for filing of the Securities and Exchange Commission.
72. Approval of the designation of the following Directors, Officers, and personnel as members of the Annual Stockholders' Meeting (ASM) Committee:

    Chairman: Dr. Lusyl Gomez

    Members:

    Dr. Felibert Dianco
    Dir. Lemuel Fernandez
    Therese Marie Gerafil, Corporate Secretary
    Toni Dinah Cheer Fernandez, Investor Relations Manager
    Rocelyn Patopatin, Paralegal/IRO Staff
    Jonathan Padilla, Marketing Manager
    James Casiple, IT Manager
73. Approval of the authority Engr. Christian Klaus Mercado, Managing Head, to represent the Corporation before the DENR-EMB Region VI in connection with the Notice of Violation issued against the Corporation and in any matter relative to the Corporation's environmental compliance and regulatory requirements before the said office, including the authority to sign, execute, verify, and submit the necessary Answer, reports, documents, and other submissions as may be required.

74. Approval of the final list of nominees for election to the Board of Directors for the year 2026, as recommended and endorsed by the Corporate Governance Committee.
75. Approval of the additional budget in the amount of PHP 278,590.48 for the Phase 1 Rectification Project (2nd Floor).
76. Approval of the postponement of the 2026 Annual Stockholders' Meeting, initially scheduled on 28 May 2026 to 18 June 2026, 9:00 A.M., to be held at Asia Pacific Medical Center Iloilo, Brgy. Ungka, Jaro, Iloilo City via remote communication.
77. Approval of the Pre-Approval Policy of the Audit Committee for 2026.

(b) Election of the members of the Board, including the Independent Directors for the ensuing year.

(c) Election of the External Auditor and fixing its Compensation for the Current Year

Item 19. Voting Procedures

1. Voting Requirement

The amendment of Articles III and VII of the Articles of Incorporation will require the vote of at least two-thirds (⅔) of the outstanding capital stock.

The amendment of Article VI, Section 1 of the Company's By- Laws will require the vote of the majority of the outstanding capital stock.

Nominees for directors receiving the highest number of votes shall be declared elected.

All other matters to be brought for approval of the shareholders of APMCI at this year's Annual Stockholders' Meeting shall be decided by the majority vote of stockholders voting in absentia or remote communication or by proxy, a quorum being present.

2. Method of Voting: Straight and Cumulative Voting

In all items for approval, each voting share of stock entitles its registered owner as of the Record Date to one vote. Stockholders may vote by remote communication, proxy or in absentia.

In the election of directors, each stockholder may vote such number of shares for as many persons as there are directors to be elected, or he may cumulate the aforesaid shares and give one nominee as many votes as the number of directors to be elected multiplied by the number of his shares, or he may distribute them on the same principle among as many nominees as he shall see fit; provided that, the total number of votes cast by him shall not exceed the number of shares owned by him multiplied by the total number of directors to be elected.

A stockholder may vote electronically in absentia using the online voting portal, a link of which has been provided in this Information Statement. A stockholder voting electronically in absentia shall be deemed present for purposes of quorum.

Upon successful registration at the Annual Stockholders' Meeting, each stockholder will be provided a ballot within the period stated in **Annex A** to enable him to vote. All votes will be counted by the vote count system integrated in the voting application and tabulated and canvassed by the Board of Canvassers.

Proxies shall be in writing, signed and filed, by the stockholders, in the form provided in the Information Statement, and shall be received by the Corporate Secretary via email at **corpsec@apmciloilo.com** on or before **5:00 pm, 11 June 2026**. Proxy votes will be counted and tabulated by the Inspection of Proxies and Ballots Committee.

Item 20. Participation of Shareholders by Remote Communication

To save on costs, the Company will dispense with the physical attendance of stockholders at the meeting and will allow attendance only by remote communication, as set forth below, and by voting in absentia, as provided in Item 4(c) and Item 19 above, or voting through the Chairman of the meeting as proxy.

To enable the Company to perform validation procedures, identify the shareholders participating by remote communication and record their presence for purposes of quorum, the shareholders shall inform the Company by email to **corpsec@apmciloilo.com** on or before **16 June 2026** of their participation in the meeting by remote communication. Stockholders may email questions or comments prior to or during the meeting at the following email address: **corpsec@apmciloilo.com**. The detailed instructions for participation through remote communication are attached as **Annex A.**

COMPLIANCE WITH SECTION 49 OF THE REVISED CORPORATION CODE

In compliance with the requirements of Section 49 of the Revised Corporation Code, please see the following Annexes:

- **A.** Minutes of the Annual Stockholders' Meeting held last 18 June 2025 including the answers raised via email and chatroom which were not answered during the meeting **(Annex F)**
- **B.** Material Information on the Current Stockholders **(Annex H)**
- **C.** Management Report **(Annex G)**
- **D.** 2025 Audited Financial Statements **(Annex E3)**
- **E.** Directors' Profile **(Annex B)**
- **F.** Board Attendance Report **(Annex I)**
- **G.** Board Appraisal/Performance Report **(Annex J)**
- **H.** Board Compensation Report **(Annex K)**
- **I.** Candidates' Profile **(Annex C1)**
- **J.** Disclosure on Director's Self-Dealing and Related Party Transactions **(Annex L)**

DIVIDEND POLICY

The Company's Board is authorized to declare cash or stock dividends or a combination thereof. A cash dividend declaration requires the approval of the Board and no shareholder approval is necessary. A stock dividend declaration requires the approval of the Board and shareholders representing at least two-thirds of the Company's outstanding capital stock. Holders of outstanding shares on a dividend record date for such shares will be entitled to the full dividend declared without regard to any subsequent transfer of shares.

The Board of Directors has the power to fix and determine the amount to be reserved or provided for declaration and payment of dividends from APMCI's unrestricted retained earnings. The amount of such dividends (either in cash, stocks or property) will depend on the corporation's profits, cash flow, capital expenditure, financial condition and other factors and will follow the SEC guidelines on determination of retained earnings available for dividend declaration. The existence of surplus profit is a condition precedent before a dividend can be declared. The surplus profits or income must be a bona fide income founded upon actual earnings. Actual earnings or profits shall be the net income for the year based on Audited Financial Statements, adjusted for unrealized items, which are

considered not available for dividend declaration. Taking into account the Hospital's cash flows, capital expenditure, investment objective and financial condition, at least 10% of the actual earnings or profits may be declared by the Board.

No dividends were issued this year because the hospital had just commenced operations, the revenue generated was insufficient to offset the total operating expenses incurred during the year.

ATTENDANCE OF DIRECTORS DURING THE 2025 ASM

The attendance of the Directors during the 2025 ASM is disclosed in the Minutes of the previous meeting.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this report is complete and correct. This report is signed in the City of Iloilo on _____ of MAY 26 2026 2026.

By:

Asia Pacific Medical Center-Iloilo, Inc.
(Formerly: Allied Care Experts Medical Center-Iloilo, Inc.)
Issuer

THERESE MARIE A. GERAFIL
Corporate Secretary

REQUIREMENTS AND PROCEDURE FOR ELECTRONIC VOTING IN ABSENTIA AND PARTICIPATION BY REMOTE COMMUNICATION

I. ELECTRONIC VOTING IN ABSENTIA

1. **Stockholders as of 31 May 2026 ("Stockholders"), have the option of electronic voting in absentia on the matters in the Agenda, after complete registration and successful validation. To access the company Online Voting Portal, stockholders are required to provide their active, primary electronic mail (e-mail) addresses to the Corporation by informing the Corporation through the Corporate Secretary through email at corpsec@apmciloilo.com.**

2. **The deadline for registration to vote in absentia is 10 June 2026. Beyond this date, Stockholders may no longer avail of the option to vote in absentia. Stockholders who were not able to register may vote through the appointment of the Chairman or another stockholder as proxy or vote.**

   In the event that, as of the registration deadline, the number of voters duly registered in the system is less than seventy-five percent (75%) of the total number of voters entitled to register and vote in the Stockholders's Meeting, the Corporate Secretary is hereby authorized to extend the registration deadline for a period of up to three (3) calendar days. The Corporate Secretary may end such extension earlier if the required registration threshold is reached or if the Corporate Secretary determines that an earlier deadline is appropriate. Notice of any extension or earlier deadline shall be given to the voters by Publication in the website or in any manner prescribed by the Corporation.

3. **Written notice for registration may be sent to all stockholders through electronic email. To register at the company Online Voting Portal, simply follow the instructions sent to the e-mail address provided. Stockholders should complete the online registration form and submit for validation.**

4. **The following information must be filled up for the registration:**
   - **i. Complete Name**
   - **ii. Email address**
   - **iii. Mobile contact number**
   - **iv. Birthdate**

   Important Note: Incomplete or inconsistent information may result in an unsuccessful registration. As a result, Stockholders will not be allowed access to vote electronically in absentia, but may still vote through the Chairman of the meeting as proxy, by submitting a duly accomplished proxy form, on or before 5:00 pm of 11 June 2026.

5. **The validation process will be completed by the Corporation. Once validated, the Stockholder will receive an e-mail confirmation on their successful registration. This will also include the agenda of the meeting, profile of the nominees and voter's code. This code will be specific to every stockholder and will be used to access the online voting portal. The Definitive Information Statement and other meeting documents will also be available in the website.**

6. **The election for the Board of Directors will start at 9:00 am of 11 June 2026. Registered Stockholders will be provided with the online portal voting link which will require the voter's code to proceed.**

7. **Registered Stockholders have until 5:00 pm of 15 June 2026, to cast votes in absentia.**

8. **All agenda items indicated in the Notice of the Meeting will be set out in the online ballot and the registered Stockholder may vote as follows:**

    - **8.1 For items other than the Election of Directors, the registered Stockholders has the option to vote: Yes, No, or Abstain. The vote is considered cast for all the registered Stockholder's shares.**

    - **8.2 For the Election of Directors, the registered Stockholders may vote for all the nominees, or one nominee or some of the nominees only, in such number of shares as preferred by the Stockholder, provided that the total number of votes cast shall not exceed the number of shares owned, multiplied by the number of directors to be elected.**

9. **Once voting on the agenda items is finished, the registered Stockholder can proceed to submit the accomplished ballot by clicking the "Submit" button. The Online Voting Portal will prompt the Stockholder to confirm the submission of the ballot. The votes cast in absentia will have equal effect as votes cast in person or by proxy. After the ballot has been submitted, Stockholders may no longer change their votes.**

10. **The Board of Canvassers of the Corporation will canvass the votes cast in absentia after the result is generated by the voting count application while the Inspection of Proxies and Ballots Committee will count and tabulate the ballots cast by proxy.**

II. PARTICIPATION BY REMOTE COMMUNICATION

1. **Stockholders as of 31 May 2026 ("Stockholders") who registered in the Online Voting can also participate in the Meeting on 18 June 2026 by remote communication by accessing the ZOOM Webinar link to be provided via the Stockholders' registered email.**

2. **Stockholders as of 31 May 2026 who have not registered in the Online Voting Portal may still attend the Meeting remotely via Zoom Webinar link. Unregistered Stockholders are requested to notify the Company by email to corpsec@apmciloilo.com by 16 June 2026 of their intention to participate in the Meeting by remote communication.**

For validation purposes, unregistered Stockholders shall also provide the Company the following information: (i) name; (ii) address; (iii) telephone number.

3. **Only those Stockholders who have notified the company on or before 16 June 2026 of their intention to participate in the Meeting by remote communication will be allowed to vote on the date of the meeting and included in determining quorum, together with the Stockholders who voted in absentia and by proxy.**

4. **Stockholders may send their question and/or comments prior to or during the meeting at corpsec@apmciloilo.com.**

5. **The Company will endeavor to have a link to the recorded webcast of the Meeting posted on the Company's website and social media within five (5) days from the date of the meeting. Stockholders shall have two (2) weeks from posting to raise the Company any issues, clarifications and concerns on the Meeting conducted.**

For clarifications, please contact the Company's Office of the Corporate Secretary at corpsec@apmciloilo.com.

2025 DIRECTORS AND EXECUTIVE OFFICERS PROFILE

THE 2025 BOARD OF DIRECTORS

The By-laws of Asia Pacific Medical Center- Iloilo, Inc. (formerly known as Allied Care Experts Medical Center- Iloilo Inc.) currently has fifteen (15) Directors, three (3) of whom are Independent Directors.

Below is the profile of the 2025 Board of Directors which includes their qualifications and relevant experience, length of service in the corporation, and their board representations in other corporations. The directors assumed their directorship during the Asia Pacific Medical Center-Iloilo, Inc. Annual Stockholders' Meeting on 18 June 2025 for a term of one year, and until their successors are duly elected and qualified.

FERJENEL G. BIRON, MD
Director/Chairman

Dr. Biron is the Chairman of the Asia-Pacific Medical Center (APMC) Group of Hospitals, which includes APMC Aklan, APMC Bacolod, and APMC Iloilo. He served as President of these institutions hospitals from their respective incorporation until June 2020 for APMC Aklan, August 2021 for APMC Iloilo, and August 2022 for APMC Bacolod.

These hospitals were incorporated separately as Asia Pacific Medical Center-Iloilo, Inc. in December 2014, Asia Pacific Medical Center - Bacolod, Inc. in September 2017, and Asia Pacific Medical Center-Aklan, Inc. in December 2017.

He is also a member of the Board of Directors of Allied Care Experts (ACE) Medical Center – Butuan Inc., ACE Medical Center – GENSAN, Inc., and ACE Medical Center – Cagayan de Oro, Inc.

From 2020 to 2021, Dr. Biron was Chief Executive Officer of Endure Medical Inc. He currently serves as the President of Aesthetica Manila, Inc., and Smartlab Diagnostics, Inc., and as Chairman of several companies, including Park3 Realty & Development Corporation, EMI Properties OPC, Newlife Regenerative and Wellness Center, Obbo

	Holdings, Inc., Botikang Pinoy, Inc., Super BP Mart Corporation, Endure Medical Laboratories Inc. and Ferj Pharmacy Inc. In government service, Dr. Biron served as Chairman of the Committee on Trade and Industry in the House of Representatives where he led the passage of the Revised Corporation Code in 2019. He currently serves as Deputy Speaker in the House of Representatives.

	AGNES JEAN M. VILLAFLOR, MD, FPCP, FPSN Director/ President **Dr. Villaflor** has served as President of the Company since June 2025 and as a Director since December 2023. Prior to her appointment as President, she served as the Company's Medical Director until April 2025, Corporate Treasurer from June 2016 to December 2023, and Assistant Corporate Secretary from December 2014 to May 2016. She is currently an Independent Director of Allied Care Experts Medical Center Butuan, Inc. Allied Care Experts Medical Center Cagayan De Oro, Inc., and Allied Care Experts Medical Center GenSan, Inc., and has been the Medical Director of M3 Dialysis Center since 2007. She has likewise served as Medical Director and Corporate Secretary of Renal Specialty, Inc. since 2016. Dr. Villaflor is engaged as a Medical Specialist III at West Visayas State University Medical Center and concurrently serves as a Training Officer of the Department of Internal Medicine. She is likewise a Professorial Lecturer at the College of Medicine of West Visayas State University. She serves as Head of the Renal Care Center and the Section Head of Nephrology at the same institution, and as Head Nephrologist of M3 Dialysis Center Iloilo, Inc. and the Iloilo Mission Hospital Dialysis Unit. She is a Fellow of the Philippine College of Physicians and the Philippine Society of Nephrology, a member of the International Society of Nephrology, and is

	currently pursuing a Master of Arts in Hospital Administration at Cebu Doctors' University.

	MERIDE D. LAVILLA, MD, FPPS Director/Vice Chairman **Dr. Lavilla** is the current Vice Chairman of the Board. She also served the company as Assistant Corporate Treasurer from December 2014 to May 2016 and was the Corporate Secretary from June 2016 until she stepped down to become Assistant Corporate Secretary in September 2019, a position she held until her election as Vice Chairman in August 2021. She also served as the Corporate Treasurer from 2017 to 2018; Assistant Corporate Treasurer from 2019 to 2021; and Assistant Corporate Secretary from 2021 to 2022 of Asia Pacific Medical Center Bacolod Inc. She served as the Vice President of Asia Pacific Medical Center (APMC) - Aklan Inc. from 2017 to 2021. She has been a Director of Allied Care Experts (ACE) Medical Center Cagayan de Oro Inc. since 2016 and is the current Assistant Corporate Treasurer of the same corporation. She is also a Founding Member of ACE Medical Center-Butuan, Inc., and ACE Medical Center – GenSan. Dr. Lavilla served as Chairman of Excel Global Inc. from 2017-2020 and has served as the Corporate Secretary of Healthlink Iloilo, Inc. from 2009 to 2011, and a member of its Board of Directors since 2014. She is a member of the Philippine College of Occupational Medicine and is a Medical Retainer for Vitarich Corporation since 1998 and Angelina Bakeshop from 2008 to 2020. Dr. Lavilla became a Diplomate of the Philippine Pediatric Society in 1998 and a Fellow Member in 2014. She has been a Clinical Preceptor in Pediatrics for 2nd and 3rd year Medical Students of West Visayas State University, College of Medicine from 1994 to present. She is completing her thesis for Master of Arts in Hospital Administration at Cebu Doctors University. Aside from being a Physician, Dr. Lavilla is also a Registered Nurse.

DANILO C. REGOZO, MD, DFM, FPAFP
Director/Executive Vice President

Dr. Regozo currently serves as the Executive Vice President of the Company and the concurrent Director of the Ancillary Services Division. He has also been the Executive Vice President of Asia Pacific Medical Center – Bacolod, Inc. since 2017 and a member of the Board of Directors of Asia Pacific Medical Center–Aklan, Inc. since 2017. Dr. Regozo is also a member of the Board of Directors of Allied Care Experts (ACE) Medical Center - Butuan, Inc. and ACE Medical Center - GenSan since 2019. He also serves as the Chairman of the Board of Excel Global Inc. Dr. Regozo is the owner of Farmacia Neo and Regozo Family Medicine Clinic. He is a practicing Family Physician and a registered nurse and was conferred Diplomate status in Family Medicine in 1999, Fellow-Life of the Philippine Academy of Family Physicians in February 2014. He has been an Associate Member of the Philippine College of Occupational Medicine since 1994.

Within the Philippine Academy of Family Physicians – Iloilo Chapter, Dr. Regozo served as Treasurer from 2001 to 2003 and Vice President from 2003 to 2004. He is currently the Head of the Department of Family Medicine. He has also been actively involved in the Iloilo Medical Society, where he served as Assistant Secretary from 2014 to 2016, Vice President from 2016 to 2018, and Member of the Board of Directors from 2018 to 2019.

At present, Dr. Regozo is pursuing a Master of Arts in Hospital Administration at Cebu Doctors' University and is currently in the thesis writing stage of the program.

LUSYL M. GOMEZ, MD, DPPS
Director/Assistant Corporate Secretary

Dr. Gomez currently serves as the Assistant Corporate Secretary of the Company, having been reappointed to the position in June 2024 after previously serving in the same capacity from August 2021 to June 2023. On August 1, 2023, she was appointed as Chair of the Department of Pediatrics of APMCI, a position she held until June 30, 2025, after which she served as Director for Medical Services until January 31, 2026. She also served as Assistant Corporate Treasurer of the Company from October 2020 to August 2021 and as Vice President for Finance from 2018 until June 30, 2025. Earlier, she served as an Independent Director of the Company from September 2017 to August 2018 and was first elected as a Regular Director in 2018. Dr. Gomez is a Fellow of the Philippine Pediatric Society, a member of the Philippine College of Occupational Medicine, and an Associate Member of the Philippine Academy of Family Physicians. She likewise serves as Treasurer and Member of the Board of Healthlink (Iloilo), Inc. since 2008.

Dr. Gomez has also served as a Member of the Board of Directors of Wellness Medical Pharma for six (6) years and as its Treasurer for four (4) years. She was the VP for Operations of Excel Global, Inc. from 2016 to 2019; and currently the Head of Operations of IPEDCARE Plus Pharmacy since 2021. She was a Professor at the School of Dentistry of Iloilo Doctors College for three (3) years and previously served as a school physician at St. Therese College and STI College for three (3) years. In addition, she served as Vice President for Operations of Excel Global Inc. from 2016 to 2019 and as Head of Operations of Ipedcare Plus Pharmacy beginning in 2021.

Dr. Gomez is currently pursuing a Master of Arts in Hospital Administration at Cebu Doctors' University and is presently in the thesis-writing stage.

Mary Flor Gafate-Ong, MD, FPCP, FPCEDM
Director/Treasurer

Dr. Gafate-Ong was elected as a Regular Director on June 30, 2023 and was subsequently appointed as Treasurer of the Company on December 17, 2023. She is an Active Staff at the Department of Internal Medicine-Iloilo Mission Hospital and Asia Pacific Medical Center-Iloilo. She is a Visiting Staff at the Department of Internal Medicine at West Visayas State University Medical Center, Iloilo Doctors' Hospital, The Medical City-Iloilo, and Healthway QualiMed Hospital Iloilo. She is also a Member of the Faculty of the College of Dentistry of West Visayas State University, professorial lecturer at the College of Medicine of West Visayas State University and part-time Faculty of the College of Medicine of Central Philippine University. Last August 01, 2023, she was appointed as the Head of Nutrition and Dietetics Services. She has served as the Corporate Secretary of Excel Global, Inc. for six (6) years and is a member of the Board of Directors of NEFRON Dialysis Center, Inc. for six (6) years.

Dr. Ong graduated from West Visayas State University with a degree in Bachelor of Science in Biological Science and completed her Medical Degree in the same university.

LEMUEL T. FERNANDEZ
Director/Assistant Treasurer

Director Fernandez served as an Independent Director from 2018 to 2020 and was elected as a Regular Director of the Company on February 15, 2020, following his resignation as Independent Director, a position he held from August 2018 to February 2019. Mr. Fernandez has served as the Editor-in-Chief of The Daily Guardian since 2002 and as Chief Political Officer of the House of Representatives since 2016. He served as President of the Rotary Club of Iloilo in 2016 and as President of the Iloilo Press Club during the periods 1999–2000 and 2002–2003.

Mr. Fernandez earned his Bachelor of Arts degree from the University of Iloilo in 1988.

BRANDT LUKE Q. BIRON
Director

Director Biron holds various key positions in the Endure (Biron) Group of Companies. He is the President of Endure Medical Inc., NORIB Air Services OPC, Oncolife Corporation, Skingen Biotech Inc., Botikang Pinoy Franchising Corp., Botikang Pinoy Generix Inc., Botikang Pinoy Inc., Bread Kingdom OPC, and Endure Medical Laboratories Inc. He also serves as a Director of Park3 Realty & Development Corporation and Super BP Mart Corporation. He is a Senior Vice President at International Apex Pharmaceuticals, Inc., Corporate Secretary of EMI Properties OPC. and acts as Treasurer of Newlife Regenerative & Wellness Center, Inc., OBBO Holdings, Inc., Singapore Genebio, Inc. and Ferj Pharmacy, Inc.

Mr. Biron is currently pursuing a dual degree in Doctor of Medicine - Master in Business Administration at the Ateneo De Manila University School of Medicine and Public Health and started his post graduate internship in June 2025.

FELIBERT O. DIANCO, MD, FPCP, FPCC, FPSE
Director

Dr. Dianco was elected as Regular Director on August 26, 2021, to the present. He also served as Independent Director of the Company from October 29, 2020 to August 26, 2021. He is the Chairperson of the Internal Medicine Department and Head of the Cardiac Laboratory Unit of the Company since August 1, 2023.

He is also a professorial lecturer at West Visayas State University, College of Medicine, and Central Philippine University, College of Medicine. He had been a President of the Philippine Heart Association Western Visayas-Panay Chapter for two (2) years and previously a member of the Board of Directors and Treasurer of PCP – Western Visayas.
Dr. Dianco completed his Medical Degree in West Visayas State University. He also studied Master's in Hospital Administration at Cebu Doctors' University.



FELIX P. NOLASCO, MD, MMHoA, FPSOHNS, FPSCS, FPCS
Director

Dr. Nolasco is a Maxillofacial-Plastic Otolaryngologic - Head and Neck Surgery Specialist who was re-elected as Director of the Company in October 2020 and continues to serve as such up to the present. He had previously served as the Assistant Medical Director of the Company until he was appointed as the Hospital Director in January 2025. He also served the Board from December 2014 to September 2017.

Dr. Nolasco is presently the Chairman of Sto. Tomas Doctor's Hospital Medical Center since 2017. He was the Vice President, Assistant Medical Director and a Member of the Board of Directors of Allied Care Experts (ACE) Medical Center Cebu for six (6) years. He is also serving as the Vice Chairman of ACE Quezon City and former in ACE Baliwag and has been its Director for nine (9) years and eleven (11) years, respectively. Presently, Dr. Nolasco is also a Director of ACEMC-

	Baypointe, ACEMC-Pateros, ACEMC Baliwag, Mindoro Medical Center and SOMOS Medical Center. He has previously served as the Assistant Treasurer and is currently a Director of ACE Tacloban since 2016. Dr. Nolasco has previously held the following positions: President of Unihealth Baypointe Hospital Medical Center, Vice President of ACEMC Bohol, Inc., Vice Chairman of ACEMC-Baliwag, Medical Director and Administrator of Unihealth Paranaque Hospital and Medical Center. Further, Dr. Nolasco has served as Director of ACE Valenzuela for 8 years, ACE Baypointe for 8 years, Unihealth Paranaque Hospital and Medical Center for 8 years, Mindoro Medical Center for 4 years and SOMOS Medical Center for 4 years. On the academic side, he was the President of the Philippine Board of Otolaryngology-Head and Neck Surgery in 2020, after serving as a Director for many years. He was the President of the Phil. Society of Otolaryngology-Head and Neck Surgery Inc., in 2005, Founding Chairman of the Phil Academy of Cranio Maxillo Facial Surgery, PSOHNS, and Founding Director of the Otolaryngologic Maxillofacial Aesthetics Center at East Avenue Medical Center. He was a Chairman of the ENT-HNS, East Ave Med Center for seventeen (17) years and retired in 2017 as Chairman Emeritus. He was also a Former Executive Officer of the ENT-HNS Jose R. Reyes Memorial Medical Center and Consultant of the Department of Otolaryngology, UP-PGH Medical Center and served as OPD Otolaryngologist-Hearing Conservation Officer of the Subic Naval Base in 1984-1986.

FREDILYN G. SAMORO, MD, FPOGS
Director

Dr. Samoro has been one of the Directors of the Company since 2014. She served as Vice Chairman of the Board of Directors from August 2019 to October 2021 and was also previously the Vice President for Marketing. She is also the President of Allied Care Experts (ACE) Medical Center Inc., Butuan and ACE Medical Center – GENSAN, and also a Founding member of ACE CDO and Tagum Global Medical Center. She is the School Head/Chief Operations Officer of Iloilo Integrated School from 2005 to present and a member of the Board of Directors of MD Check Iloilo Inc. from 2009 to present. She is one of the Founding Members / Board of Directors of Healthlink Iloilo since 2005, and was elected as the Vice President last 2025.

Dr. Samoro also served as Vice President of the Philippine Obstetrical & Gynecological Society, Panay Chapter in 2013, and President of the Philippine Obstetrical and Gynecological Society in 2014. She served as Treasurer in the Council of Presidents of ACE Medical Center. Presently, she is writing her thesis for Master of Arts in Hospital Administration at Cebu Doctor's College.

ATTY. ROLEX T. SUPLICO
Director

Atty. Suplico was first elected as Director of the Company in October 2020. He is one of the country's foremost experts in telecommunications, radio and television broadcast, and franchise laws. He is the President of Great Odysseus Security Agency, Inc., Great Jupiter Mercantile, Inc., and R25 Manpower Services Corp. He is a founding member of the law firm of Suplico, Austria, and Marbella which is engaged in the general practice of law with offices at 18B Pet Plans Tower, 444 EDSA, Makati City, Metro Manila.

He is currently an Iloilo Provincial Board Member for the term 2025-2028. He served as Iloilo's Vice Governor from 2007-2010. He was a Deputy Minority Leader of the House of Representatives and a member of the Commission of Appointments from 2004-2007. From 1998-2007, he represented the Province of Iloilo's Fifth District as Congressman. He was also elected as Iloilo Provincial Board Member in 1995.

THE INDEPENDENT DIRECTORS

ATTY. JOHANNA MARIE BERMUDO-BELGIRA
Independent Director

Atty. Bermuda-Belgira was first elected as Independent Director on June 11, 2024. She is the Municipal Legal Officer of the Local Government Unit (LGU) of Barotac Nuevo, Iloilo since 2019. She concurrently serves as the Data Protection Officer Designate of the said LGU since 2023. She also acted as the Municipal Administrator of the said LGU from 2019 until 2022. Prior to her employment in the said LGU, she was a Local Legislative Staff Officer of the Iloilo Provincial Government from 2016 until 2019. She is a partner of Lutero, Andutan, Hongco, Bermudo and Gumboc Law Office since 2016 which is engaged in general practice of law in Iloilo City.

She is the Vice President, Internal Affairs of Junior Chamber International (JCI) Philippines Barotac Nuevo Tamasak Chapter and the General Legal Counsel of said organization from 2023 until 2025. She has been a consultant and retained counsel representing different corporations and businesses in Iloilo and Manila.

Atty. Bermudo finished her Master of Management in Business Management at University of the Philippines Visayas in 2023.



NATHALIE ANN F. DEBUQUE
Independent Director

Director Debuque currently holds the position of Vice Governor of the Province of Iloilo. She first gained national recognition in 2016 when she was elected as Mayor of the Municipality of Anilao at the age of 22, becoming the youngest mayor in the Philippines at the time. She served as Municipal Mayor of Anilao from 2016 to June 2025.

During her tenure as mayor, she implemented governance reforms anchored on transparency, accountability, youth empowerment, and participatory leadership. These efforts resulted in the Municipality of Anilao being awarded the Seal of Good Local Governance (SGLG) for six consecutive years. She also serves as the Treasurer of the League of Municipalities of the Philippines-Iloilo Chapter since 2016.

She obtained her Bachelor's Degree in Industrial Pharmacy from the University of the Philippines Manila in 2016.

LORNA C. SILVERIO
Independent Director

Director Silverio was elected as Independent Director last June 2025. She is a Filipino business executive and public servant with extensive experience in both government and corporate leadership. She currently serves as the Lead Independent Director of the company. In public service, she represented the 3rd Congressional District of Bulacan as a member of the House of Representatives of the Philippines from 2001 to 2010 and again from 2016 to 2025.

Aside from her legislative career, Director Silverio has been active in several business and professional organizations. She has served as Chairman of Smartlab Diagnostic & Dialysis Center, Inc. since 2018 and as Senior Financial Advisor of Air Philippines since 2014. She is also the Chairman of Philippine Development Corporation, a position she has held since 2016. In addition, she has been the President of

	SILCOR USA, Inc. since 2018 and Northern Star Development Corporation since 2020. Earlier in her career, she established Prime Sites Advertising Corporation, where she has served as Chairman and President since 1986. Her professional career reflects decades of leadership in both public governance and private enterprise.

OTHER EXECUTIVE OFFICERS

The following are the other Executive Officers of the Company who are not members of the Board of Directors:

	MAYLENE B. VILLANUEVA, CCO, AICD **Compliance Officer** **Atty. Villanueva** has served as the Compliance Officer of the Company since February 2019. She was also the previous Corporate Secretary of the Company from August 2019 to 2023. She is also the President of TIPP Digital Solutions, Inc., an IT solutions company, and the Managing Partner of Villanueva, Balio, and Ariston Law Offices. Her legal expertise encompasses government procurement, intellectual property, data privacy, labor, and various corporate laws. Atty. Villanueva also serves as the Compliance Officer of Asia Pacific Medical Center (APMC) - Aklan, Inc. since July 2021, Asia Pacific Medical Center - Bacolod since April 2022, and Allied Care Experts (ACE) Medical Center - Zamboanga since August 2024. She is the General Counsel of the Endure Medical Group (Biron Group of Companies). She also served as the Acting President of Phil Pharmawealth, Inc. from September 2021 to April 2022. Atty. Villanueva concurrently serves as the Corporate Secretary for Quiklab Diagnostics, Inc., Aesthetica Manila Inc., and Smartlab Diagnostics Inc. From 2019 to 2023, she was a Private Sector Representative on the Board of Trustees/Regents of Iloilo State University of Fisheries, Science and Technology (ISUFT and formerly ISCOF).

	Atty. Villanueva has held various positions in Junior Chamber International Philippines, including Area Vice President for Area 4 – Visayas in 2020, General Legal Counsel in 2019, and Regional Vice President for Western Visayas in 2016. She also served as the Revival President of the local organization, JCI Barotac Nuevo Tamasak from 2013 to 2014. She was conferred JCI Senatorship on May 6, 2022, by Junior Chamber International. Atty. Villanueva is a Certified Compliance Officer and Certified Tax Specialist through the Center for Global Best Practices, as well as an Associate Member of the Institute of Corporate Directors. Additionally, she is a Certified Data Protection Officer from the UP Open University and a Certified Level 2 Public Procurement Specialist through the GPPB-UP National Engineering Center program partnership.

	CRIS T. CORTES, CPA **Chief Finance Officer** **Mr. Cortes** is the Chief Finance Officer of the company. He passed the Philippine National Licensure Examination for Certified Public Accountant (CPA) (Given by the Board of Accountancy under Philippine Regulations Commission in October 2010) with professional and progressive experience to relevant exposures to various business sectors such as power, pharmaceutical, banking and finance, cooperative, and service in the field of accounting and external audit. He used to be the Senior Auditor of Ernst & Young (EY) – Trinidad from May 1, 2015 to April 30, 2016. He was also a Supervisor II of R. G. Manabat & Co. (formerly KPMG Manabat Sanagustin & Co., CPAs). Moreover, he used to be the Finance Head of Phil Pharmawealth, Inc. from January 26, 2017 to August 31, 2019.

THERESE MARIE A. GERAFIL, RPm
Corporate Secretary/Data Protection Officer/Legal Officer

Atty. Gerafil was appointed as Corporate Secretary of Asia Pacific Medical Center–Iloilo, Inc. (APMCI) in December 2024. She likewise serves as the Company's Legal Officer and Data Protection Officer.

Prior to joining APMCI, Atty. Gerafil served at the Department of Agrarian Reform Regional Office VI from October 2019 to December 2024. During her tenure, she held various positions; Agrarian Reform Program Officer II - Legal Officer (March - December 2024), Agrarian Reform Program Officer I (March 2022 - March 2024) and Agrarian Reform Program Technologist (March 2020 - March 2022). She was also designated as a member of the Bids and Awards Committee Secretariat, Executive and Management Committee Secretariat, and a member of the Contract Management Team of the Procurement Support Unit at DARRO VI. Before entering government service, she worked as a Hospital Psychometrician at the Neuroscience Center of St. Paul's Hospital of Iloilo from 2018-2019.

GIOVANNI A. DE LOS REYES, MD, FPCS, FPSGS
Director for Administration and Support Services

Dr. Delos Reyes is the Hospital Administrator of the Company. He was the former Chairman and training officer of the Department of Surgery at WVSU College of Medicine and University Medical Center. He was also the former OIC Medical Director at WVSU Medical Center from 2008-2010. He was the former Vice-President of Medical and Allied Sciences at WVSU from November 8, 2011 until March 18, 2018. He was the former Chief of Hospital of Holy Mary Women and Children Hospital from 2018 to 2022. He was an active member and Elder (Area Governance Team) of Couples for Christ Iloilo Area. His research paper " Comparative Study on the Use of Open Dressing versus Povidone Iodine Dressing in the Prevention of Superficial Site Surgical Site Infection on Clean and Clean-Contaminated Wounds" published in the proceedings of the 1st WVSU International Research Conference in February 2008.

TONI DINAH CHEER FERNANDEZ, MLMED
Investor Relations Officer

Mrs. Fernandez is a retired public secondary school Mathematics teacher. She had been a Department Head of the Iloilo National High School-School for the Future, a post she held for 5 years until her promotion as Academic Program Head of Accountancy, Business & Marketing strand of the same institution when the government rolled out its Senior High School program in 2016.

Mrs. Fernandez is the recipient of various international scholarships: the Japanese Monbukagsho (Department of Education, Science & Technology) for Teacher-trainee at Hiroshima University, Japan in 2001-2003 and the Australian Agency for International Development (AusAid) for Masters of Leadership and Management in Education, Major in School Leadership at the University of Newcastle, NSW, Australia in 2012-2013. She was also a Visiting International Faculty under the Cultural Exchange

	Program of the United States of America at Nash–Rocky Mount Schools in North Carolina in 2007-2008. Having finished a degree in Accountancy in 2019, Mrs. Fernandez is presently the Office Manager of the Investors Relation Office of the Asia Pacific Medical Center Iloilo Inc. She also doubles as Finance Manager of the Daily Guardian Multi-Media Services Incorporated, a family corporation which is into publishing, public relations and commercial printing for the past 20 years.

Annex "C"

FINAL LIST OF NOMINEES FOR ELECTION TO THE 2026 BOARD OF DIRECTORS

No	NOMINEE	NOMINATOR
	REGULAR DIRECTOR	
1	Brandt Luke Q. Biron	Joan B. Domingo
2	Ferjenel G. Biron	Rommel T. Nonato
3	Felibert O. Dianco	Christine G. Chatto
4	Lemuel T. Fernandez	Lory A. Wong
5	Lusyl M. Gomez	Michael Q. Limsiaco
6	Meride D. Lavilla	Mary Flor G. Ong
7	Felix P. Nolasco	Meride D. Lavilla
8	Mary Flor G. Ong	Francine Marie D. Lavilla
9	Danilo C. Regozo	Jonah M. Feca
10	Fredilyn G. Samoro	Eli John A. Berame
11	Rolex T. Suplico	Allan Steve B. Losaria
12	Agnes Jean M. Villaflor	Jill Victoria M. Hanopol
	INDEPENDENT DIRECTOR	
1	Johanna Marie B. Bermudo-Belgira	Roselle D. Lao
2	Nathalie Ann F. Debuque	Lyka Joy D. Gelle
3	Lorna C. Silverio	Randy S. Espinosa

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

ASIA PACIFIC MEDICAL CENTER ILOILO

ANNEX " C1"

ELECTION OF 2026 BOARD OF DIRECTORS CANDIDATES PROFILE

Nominees for Regular Directors

BRANDT LUKE Q. BIRON

Mr. Biron holds various key positions in the Endure (Biron) Group of Companies. He is the President of Endure Medical Inc., NORIB Air Services OPC, Oncolife Corporation, Skingen Biotech Inc., Botikang Pinoy Franchising Corp., Botikang Pinoy Generix Inc., Botikang Pinoy Inc., Bread Kingdom OPC, and Endure Medical Laboratories Inc. He also serves as a Director of Park3 Realty & Development Corporation and Super BP Mart Corporation. He is a Senior Vice President at International Apex Pharmaceuticals, Inc., Corporate Secretary of EMI Properties OPC and acts as Treasurer of Newlife Regenerative & Wellness Center, Inc., OBBO Holdings, Inc., Ferj Pharmacy, Inc. and Singapore Genebio, Inc.

Mr. Biron is currently pursuing a dual degree in Doctor of Medicine - Master in Business Administration at the Ateneo De Manila University School of Medicine and Public Health and started his post graduate internship in June 2025.

FERJENEL G. BIRON, MD

Dr. Biron is the Chairman of the Asia-Pacific Medical Center (APMC) Group of Hospitals, which includes APMC Aklan, APMC Bacolod, and APMC Iloilo. He served as President of these institutions hospitals from their respective incorporation until June 2020 for APMC Aklan, August 2021 for APMC Iloilo, and August 2022 for APMC Bacolod.

These hospitals were incorporated separately as Asia Pacific Medical Center-Iloilo, Inc. in December 2014, Asia Pacific Medical Center - Bacolod, Inc. in September 2017, Inc., and Asia Pacific Medical Center- Aklan, Inc. in December 2017.

He is also a member of the Board of Directors of Allied Care Experts (ACE) Medical Center – Butuan Inc., ACE Medical Center – GENSAN Inc., and ACE Medical Center – Cagayan de Oro, Inc.

From 2020 to 2021, Dr. Biron was Chief Executive Officer of Endure Medical Inc. He currently serves as the President of Aesthetica Manila, Inc., and Smartlab Diagnostics, Inc., and as Chairman of several companies, including Park3 Realty & Development Corporation, EMI Properties OPC, Newlife Regenerative and Wellness Center, Obbo Holdings, Inc., Botikang Pinoy, Inc., Super BP Mart Corporation, Ferj Pharmacy, Inc. and Endure Medical Laboratories Inc.

In government service, Dr. Biron served as Chairman of the Committee on Trade and Industry in the House of Representatives where he led the passage of the Revised Corporation Code in 2019. He currently serves as Deputy Speaker in the House of Representatives.

FELIBERT O. DIANCO, MD, FPCP, FPCC, FPSE

Dr. Dianco was elected as Regular Director on August 26, 2021, to the present. He also served as Independent Director of the Company from October 29, 2020 to August 26, 2021. He is the Chairperson of the Internal Medicine Department and Head of the Cardiac Laboratory Unit of the Company since August 1, 2023.

He is also a professorial lecturer at West Visayas State University, College of Medicine, and Central Philippine University, College of Medicine. He had been a President of the Philippine Heart Association Western Visayas-Panay Chapter for two (2) years and previously a member of the Board of Directors and Treasurer of PCP – Western Visayas.

He also studied Master's in Hospital Administration at Cebu Doctors' University.

LEMUEL T. FERNANDEZ

Mr. Fernandez served as an Independent Director from 2018 to 2020 and was elected as a Regular Director of the Company on February 15, 2020, following his resignation as Independent Director of Asia Pacific Medical Center–Iloilo, Inc., a position he held from August 2018 to February 2019. Mr. Fernandez has served as the Editor-in-Chief of The Daily Guardian since 2002 and as Chief Political Officer of the House of Representative since 2016. He served as President of the Rotary Club of Iloilo in 2016 and as President of the Iloilo Press Club during the periods 1999–2000 and 2002–2003.

Mr. Fernandez earned his Bachelor of Arts degree from the University of Iloilo in 1988.

LUSYL M. GOMEZ, MD, DPPS

Dr. Gomez currently serves as the Assistant Corporate Secretary of the Company, having been reappointed to the position in June 2024 after previously serving in the same capacity from August 2021 to June 2023. On August 1, 2023, she was appointed as Chair of the Department of Pediatrics of APMCI, a position she held until June 30, 2025, after which she served as Director for Medical Services until January 31, 2026. She also served as Assistant Corporate Treasurer from October 2020 to August 2021 and as Vice President for Finance of the Company from 2018 until June 30, 2025. Earlier, she served as an Independent Director of the Company from September 2017 to August 2018 and was first elected as a Regular Director in October 2020. Dr. Gomez is a Fellow of the Philippine Pediatric Society, a member of the Philippine College of Occupational Medicine, and an Associate Member of the Philippine Academy of Family Physicians. She likewise serves as Treasurer and Member of the Board of Healthlink (Iloilo), Inc. since 2008.

Dr. Gomez has also served as a Member of the Board of Directors of Wellness Medical Pharma for six (6) years and as its Treasurer for four (4) years. She was the VP for Operations of Excel Global, Inc. from 2016 to 2019; and currently the Head of Operations of IPEDCARE Plus Pharmacy since 2021. She was a Professor at the School of Dentistry of Iloilo Doctors College for three (3) years and previously served as a school physician at St. Therese College and STI College for three (3) years. In addition, she served as Vice President for Operations of Excel Global Inc. from 2016 to 2019 and as Head of Operations of Ipedcare Plus Pharmacy beginning in 2021.

MERIDE D. LAVILLA , MD, FPPS

Dr. Lavilla is the current Vice Chairman of the Board. She also served the company as Assistant Corporate Treasurer from December 2014 to May 2016 and was the Corporate Secretary from June 2016 until she stepped down to become Assistant Corporate Secretary in September 2019, a position she held until her election as Vice Chairman in August 2021. She also served as the Corporate Treasurer from 2017 to 2018; Assistant Corporate Treasurer from 2019 to 2021; and Assistant Corporate Secretary from 2021 to 2022 of Asia Pacific Medical Center Bacolod Inc. She served as the Vice President of Asia Pacific Medical Center (APMC) - Aklan Inc. from 2017 to 2021. She has been a Director of Allied Care Experts (ACE) Medical Center Cagayan de Oro Inc. since 2016 and is the current Assistant Corporate Treasurer of the same corporation. She is also a Founding Member of ACE Medical Center-Butuan, Inc., and ACE Medical Center – GenSan. Dr. Lavilla served as Chairman of Excel Global Inc. from 2017-2020 and has served as the Corporate Secretary of Healthlink Iloilo, Inc. from 2009 to 2011, and a member of its Board of Directors since 2014. She is a member of the Philippine College of Occupational Medicine and is a Medical Retainer for Vitarich Corporation since 1998 and Angelina Bakeshop from 2008 to 2020.

Dr. Lavilla became a Diplomate of the Philippine Pediatric Society in 1998 and a Fellow Member in 2014. She has been a Clinical Preceptor in Pediatrics for 2nd and 3rd year Medical Students of West Visayas State University, College of Medicine from 1994 to present. She is completing her thesis for Master of Arts in Hospital Administration at Cebu Doctors University. Aside from being a Physician, Dr. Lavilla is also a Registered Nurse.

FELIX P. NOLASCO, MD, MMHoA, FPSOHNS, FPSCS, FPCS

Dr. Nolasco is a Maxillofacial-Plastic Otolaryngologic - Head and Neck Surgery Specialist who was re-elected as Director of the Company in October 2020 and continues to serve as such up to the present. He had previously served as the Assistant Medical Director of the Company until he was appointed as the Hospital Director in January 2025. He also served the Board from December 2014 to September 2017.

Dr. Nolasco is presently the Chairman of Sto. Tomas Doctor's Hospital Medical Center since 2017. He was the Vice President, Assistant Medical Director and a Member of the Board of Directors of Allied Care Experts (ACE) Medical Center Cebu for six (6) years. He is also serving as the Vice Chairman of ACE Quezon City and former in ACE Baliwag and has been its Director for nine (9) years and eleven (11) years, respectively. Presently, Dr. Nolasco is also a Director of ACEMC-Baypointe, ACEMC-Pateros, ACEMC Baliwag, Mindoro Medical Center and SOMOS Medical Center. He has previously served as the Assistant Treasurer and is currently a Director of ACE Tacloban since 2016.

Dr. Nolasco has previously held the following positions: President of Unihealth Baypointe Hospital Medical Center, Vice President of ACEMC Bohol, Inc., Vice Chairman of ACEMC-Baliwag, Medical Director and Administrator of Unihealth Paranaque Hospital and Medical Center.

Further, Dr. Nolasco has served as Director of ACE Valenzuela for 8 years, ACE Baypointe for 8 years, Unihealth Paranaque Hospital and Medical Center for 8 years, Mindoro Medical Center for 4 years and SOMOS Medical Center for 4 years. On the academic side, he was the President of the Philippine Board of Otolaryngology-Head and Neck Surgery in 2020, after serving as a Director for many years. He was the President of the Phil. Society of Otolaryngology-Head and Neck Surgery Inc., in 2005, Founding Chairman of the Phil Academy of Cranio Maxillo Facial Surgery, PSOHNS, and Founding Director of the Otolaryngologic Maxillofacial Aesthetics Center at East Avenue Medical Center.

He was a Chairman of the ENT-HNS, East Ave Med Center for seventeen (17) years and retired in 2017 as Chairman Emeritus. He was also a Former Executive Officer of the ENT-HNS Jose R. Reyes Memorial Medical Center and Consultant of the Department of Otolaryngology, UP-PGH Medical Center and served as OPD Otolaryngologist-Hearing Conservation Officer of the Subic Naval Base in 1984-1986.

DANILO C. REGOZO, MD, DFM, FPAFP

Dr. Regozo currently serves as the Executive Vice President of the Company and the concurrent Director of the Ancillary Services Division. He has also been the Executive Vice President of Asia Pacific Medical Center – Bacolod, Inc. since 2017 and a member of the Board of Directors of Asia Pacific Medical Center–Aklan, Inc. since 2017. In addition, he serves as the Chairman of the Board of Excel Global Inc. Dr. Regozo is the owner of Farmacia Neo and Regozo Family Medicine Clinic. He is a practicing Family Physician and a registered nurse and was conferred Diplomate status in Family Medicine in 1999, Fellow-Life of the Philippine Academy of Family Physicians in February 2014. He has been an Associate Member of the Philippine College of Occupational Medicine since 1994.

Within the Philippine Academy of Family Physicians – Iloilo Chapter, Dr. Regozo served as Treasurer from 2001 to 2003 and Vice President from 2003 to 2004. He is currently the Head of the Department of Family Medicine. He has also been actively involved in the Iloilo Medical Society, where he served as Assistant Secretary from 2014 to 2016, Vice President from 2016 to 2018, and Member of the Board of Directors from 2018 to 2019.

At present, Dr. Regozo is pursuing a Master of Arts in Hospital Administration at Cebu Doctors' University and is currently in the thesis writing stage of the program.

MARY FLOR GAFATE-ONG MD, FPCP, FPCEDM

Dr. Gafate-Ong was elected as a Regular Director on June 30, 2023 and was subsequently appointed as Treasurer of the Company on December 17, 2023. She is an Active Staff at the Department of Internal Medicine-Iloilo Mission Hospital and Asia Pacific Medical Center-Iloilo. She is a Visiting Staff at the Department of Internal Medicine at West Visayas State University Medical Center, Iloilo Doctors' Hospital, The Medical City-Iloilo, and Healthway QualiMed Hospital Iloilo. She is also a Member of the Faculty of the College of Dentistry of West Visayas State University, professorial lecturer at the College of Medicine of West Visayas State University and part-time Faculty of the College of Medicine of Central Philippine University. Last August 01, 2023, she was appointed as the Head of Nutrition and Dietetics Services. She has served as the Corporate Secretary of Excel Global, Inc. for six (6) years and is a member of the Board of Directors of NEFRON Dialysis Center, Inc., for six (6) years.

Dr. Ong graduated from West Visayas State University with a degree in Bachelor of Science in Biological Science and completed her Medical Degree in the same university.

FREDILYN G. SAMORO, M.D., FPOGS

Dr. Samoro has been one of the Directors of the Company since 2014. She served as Vice Chairman of the Board of Directors from August 2019 to October 2021 and was also previously the Vice President for Marketing. She is also the President of Allied Care Experts (ACE) Medical Center Inc., Butuan and ACE Medical Center – GENSAN, and also a Founding member of ACE CDO and Tagum Global Medical Center. She is the School Head/Chief Operations Officer of Iloilo Integrated School from 2005 to present and a member of the Board of Directors of MD Check Iloilo Inc. from 2009 to present. She is one of the Founding Members / Board of Directors of Healthlink Iloilo since 2005, and was elected as the Vice President last 2025.

Dr. Samoro also served as Vice President of the Philippine Obstetrical & Gynecological Society, Panay Chapter in 2013, and President of the Philippine Obstetrical and Gynecological Society in 2014.SheisaPast Treasurer in the Council of Presidents of ACE Medical Center. Presently,she is writing her thesis for Master of Arts in Hospital Administration at Cebu Doctor's College.

ATTY. ROLEX T. SUPLICO

Atty. Suplico was first elected as Director of the Company in October 2020. He is one of the country's foremost experts in telecommunications, radio and television broadcast, and franchise laws. He is the President of Great Odysseus Security Agency, Inc., Great Jupiter Mercantile, Inc., and R25 Manpower Services Corp. He is a founding member of the law firm of Suplico, Austria, and Marbella which is engaged in the general practice of law with offices at 18B Pet Plans Tower, 444 EDSA, Makati City, Metro Manila.

He is currently an Iloilo Provincial Board Member for the term 2025-2028. He served as Iloilo's Vice Governor from 2007-2010. He was a Deputy Minority Leader of the House of Representatives and a member of the Commission of Appointments from 2004-2007. From 1998-2007, he represented the Province of Iloilo's Fifth District as Congressman. He was also elected as Iloilo Provincial Board Member in 1995.

AGNES JEAN M. VILLAFLOR, MD, FPCP, FPSN

Dr. Villaflor has served as President of the Company since June 2025 and as a Director since December 2023. Prior to her appointment as President, she served as the Company's Medical Director until April 2025, Corporate Treasurer from June 2016 to December 2023, and Assistant Corporate Secretary from December 2014 to May 2016. She is currently an Independent Director of Allied Care Experts Medical Center Butuan, Inc. Allied Care Experts Medical Center Cagayan De Oro, Inc., and Allied Care Experts Medical Center GenSan, Inc., and has been the Medical Director of M3 Dialysis Center since 2007. She has likewise served as Medical Director and Corporate Secretary of Renal Specialty, Inc. since 2016.

Dr. Villaflor is engaged as a Medical Specialist III at West Visayas State University Medical Center and concurrently serves as a Training Officer of the Department of Internal Medicine. She is likewise a Professorial Lecturer at the College of Medicine of West Visayas State University. She serves as Head of the Renal Care Center and the Section Head of Nephrology at the same institution, and as Head Nephrologist of M3 Dialysis Center Iloilo, Inc. and the Iloilo Mission Hospital Dialysis Unit. She is a Fellow of the Philippine College of Physicians and the Philippine Society of Nephrology, a member of the International Society of Nephrology, and is currently pursuing a Master of Arts in Hospital Administration at Cebu Doctors' University.

Nominees for Independent Directors

ATTY. JOHANNA MARIE B. BERMUDO-BELGIRA, MBM

Atty. Bermuda-Belgira was first elected as Independent Director on June 11, 2024. She is the Municipal Legal Officer of the Local Government Unit (LGU) of Barotac Nuevo, Iloilo since 2019. She concurrently serves as the Data Protection Officer Designate of the said LGU since 2023. She also acted as the Municipal Administrator of the said LGU from 2019 until 2022. Prior to her employment in the said LGU, she was a Local Legislative Staff Officer of the Iloilo Provincial Government from 2016 until 2019. She is a partner of Lutero, Andutan, Hongco, Bermudo and Gumboc Law Office since 2016 which is engaged in general practice of law in Iloilo City.

She is the Vice President, Internal Affairs of Junior Chamber International (JCI) Philippines Barotac Nuevo Tamasak Chapter and the General Legal Counsel of said organization from 2023 until 2025. She has been a consultant and retained counsel representing different corporations and businesses in Iloilo and Manila.

Atty. Bermudo finished her Master of Management in Business Management at University of the Philippines Visayas in 2023.

NATHALIE ANN F. DEBUQUE

Ms. Debuque currently holds the position of Vice Governor of the Province of Iloilo. She first gained national recognition in 2016 when she was elected as Mayor of the Municipality of Anilao at the age of 22, becoming the youngest mayor in the Philippines at the time. She served as Municipal Mayor of Anilao from 2016 to June 2025.

During her tenure as mayor, she implemented governance reforms anchored on transparency, accountability, youth empowerment, and participatory leadership. These efforts resulted in the Municipality of Anilao being awarded the Seal of Good Local Governance (SGLG) for six consecutive years. She also serves as the Treasurer of the League of Municipalities of the Philippines-Iloilo Chapter since 2016.

She obtained her Bachelor's Degree in Industrial Pharmacy from the University of the Philippines Manila in 2016.

LORNA C. SILVERIO

Ms. Silverio was elected as an Independent Director last June 2025. She is a Filipino business executive and public servant with extensive experience in both government and corporate leadership. She currently serves as the Lead Independent Director of the company. In public service, she represented the 3rd Congressional District of Bulacan as a member of the House of Representatives of the Philippines from 2001 to 2010 and again from 2016 to 2025.

Aside from her legislative career, Director Silverio has been active in several business and professional organizations. She has served as Chairman of Smartlab Diagnostic & Dialysis Center, Inc. since 2018 and as Senior Financial Advisor of Air Philippines since 2014. She is also the Chairman of Philippine Development Corporation, a position she has held since 2016. In addition, she has been the President of SILCOR USA, Inc. since 2018 and Northern Star Development Corporation since 2020. Earlier in her career, she established Prime Sites Advertising Corporation, where she has served as Chairman and President since 1986.

Her professional career reflects decades of leadership in both public governance and private enterprise.

ANNEX "D"

CERTIFICATION OF INDEPENDENT DIRECTOR

I, **JOHANNA MARIE B. BERMUDO-BELGIRA**, Filipino, of legal age and a resident of Block 18, Lot 8, Phase 1, Lindzville Subd., Cruz, Barotac Nuevo, Iloilo, after having been duly sworn to in accordance with law do hereby declare that:

1. I am a nominee for independent director of Asia Pacific Medical Center Inc.-Iloilo and have been its independent director since 2024;

2. I am affiliated with the following companies or organizations:

COMPANY/ORGANIZATION	POSITION/RELATIONSHIP	PERIOD OF SERVICE
LGU Barotac Nuevo, Iloilo	Municipal Legal Officer	2019- Present
Lutero, Andutan, Hongco, Bermudo and Gumboc Law Office	Partner	2016-Present
JCI Barotac Nuevo, Iloilo	Vice President-Internal Affairs	January 2026-Present

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of Asia Pacific Medical Center Inc.-Iloilo, as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances;

4. To the best of my knowledge, I am not related to any director/officer/substantial shareholder of Asia Pacific Medical Center Inc.-Iloilo other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code;

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding;

6. I have the required permission from Mayor Bryant Paul Q. Biron to be an independent director in, pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules;

7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances; and

8. I shall inform the Corporate Secretary of Asia Pacific Medical Center Inc.-Iloilo of any changes in the abovementioned information within five days from its occurrence.

Done this April 14, 2026 at Barotac Nuevo, Iloilo.

JOHANNA MARIE B. BERMUDO-BELGIRA

SUBSCRIBED AND SWORN to before me this April 14, 2026 at Barotac Nuevo, Iloilo, affiant personally appeared before me and exhibited to her IBP ID with No. 65335.

Doc. No. 19;
Page No. 13;
Book No. VII;
Series of 2026.

REYNOLD A. PEREZ
Notarial Registry No. 107
Until December 31, 2027
PTR No. 9689258 / 1-05-26 / Barotac Nuevo, Iloilo
IBP OR No. INV 574238 / 12-27-2025
Roll No. 51518
MCLE Compliance No. VIII-0015222 / 4-14-2028

Republic of the Philippines
Province of Iloilo
Municipality of Barotac Nuevo
OFFICE OF THE MAYOR

(033) 3319787
lgubarotacnuevo@gmail.com
2nd floor, New Municipal Hall, Barangay Tabucan, Barotac Nuevo 5007, Iloilo

CERTIFICATION

DATE : **14 April 2026**

TO : **ATTY. JOHANNA MARIE B. BERMUDO-BELGIRA**
Municipal Legal Officer
Municipality of Barotac Nuevo, Iloilo

Pursuant to Civil Service Resolution No. 99-1907 and Section 12, Rule XVIII of the Revised Civil Service Rules, this certification is issued granting permission to **ATTY. JOHANNA MARIE B. BERMUDO - BELGIRA** to be an independent director of **ASIA PACIFIC MEDICAL CENTER ILOILO, INC.**

This is issued for whatever purpose it may serve her.

Issued this 14th day of April, 2026 at Barotac Nuevo, Iloilo.

Approved:

BRYANT PAUL Q. BIRON
Municipal Mayor

CERTIFICATION OF INDEPENDENT DIRECTOR

I, NATHALIE ANN F. DEBUQUE, Filipino, of legal age and a resident of Barangay Dangula-an, Anilao, Iloilo after having been duly sworn to in accordance with law do hereby declare that:

1. I am a nominee for independent director of ASIA PACIFIC MEDICAL CENTER- ILOILO, INC and have been its independent director since _____(where applicable).

2. I am affiliated with the following companies or organizations (including Government-Owned and Controlled Corporations):

COMPANY/ORGANIZATION	POSITION/RELATIONSHIP	PERIOD OF SERVICE
PROVINCIAL GOVERNMENT OF ILOILO	VICE GOVERNOR	July 01, 2025 UP TO PRESENT

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ASIA PACIFIC MEDICAL CENTER –ILOILO, INC, as provided for in Section 38 of the SecuritiesRegulation Code, its Implementing Rules and Regulations and other SEC issuances.

4. I am related to the following director/officer/substantial shareholder of ASIA PACIFIC MEDICAL CENTER-ILOILO, INC. other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code. (where applicable)

NAME OF DIRECTOR/OFFICER/ SUBSTANTIAL SHAREHOLDER	COMPANY	NATURE OF RELATIONSHIP
MA. TERESA F. DEBUQUE	ASIA PACIFIC MEDICAL CENTER-ILOILO, INC.	MOTHER

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding / I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be):

OFFENSE CHARGED/INVESTIGATED	TRIBUNAL OR AGENCY INVOLVED	STATUS
NOT APPLICABLE		

6. In lieu of securing the required permission pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules, the Legal Opinion of the Provincial Legal Office is hereby attached as Annex "A".

7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances.

8. I shall inform the Corporate Secretary of ASIA PACIFIC MEDICAL CENTER-ILOILO, INC. of any changes in theabovementioned information within five days from its occurrence.

Done, this 14th day April 2026, at Anilao Iloilo.

NATHALIE ANN E. DEBUQUE
Affiant

SUBSCRIBED AND SWORN to before me this 15 APR 2026 day of _____ at BAROTAC NUEVO, ILOILO, affiant personally appeared before me and exhibited to me his/her Passport ID issued at DFA ILOILO on JULY 8, 2022.

Doc. No. 67;
Page No. 15;
Book No. LII;
Series of 2026

REYNOLD A. PEREZ
Notarial Registry No. 107
Until December 31, 2027
PTR No. 9689258 / 1-05-26 / Barotac Nuevo, Iloilo
IBP OR No. INV 574238 / 12-27-2025
Roll No. 51518
MCLE Compliance No. VIII-0015222 / 4-14-2028

Annex "A"

PROVINCIAL LEGAL OFFICE
PROVINCIAL CAPITOL, ILOILO CITY
TEL. NOS.: (033) 328 7968 LOC: 168 / (033) 328 7918 LOC: 118
Email: legal @ iloilo.gov.ph

MoRProGRe ILOILO
Movement for a Robust, Progressive, Globally Competitive and Resilient Province of Iloilo

REPUBLIC OF THE PHILIPPINES
OFFICE OF THE VICE GOVERNOR

RECEIVED
DATE: 7-17-2025 TIME: 4:25 pm
BY: L. LIM

1st Indorsement
July 17, 2025

Respectfully returned to the Office of the Governor, the herein request of Hon. Nathalie Ann F. Debuque ,Vice Governor, Province of Iloilo for an authority from the Governor as nominee for independent director of ASIA PACIFIC MEDICAL CENTER-ILOILO, INC.

The Vice Governor, acting within the scope of her powers and functions as provided by law, does not require prior authority from the Governor to enter into a transaction, particularly if such transaction is within the purview of the Vice Governor's legal and administrative functions.

Section 466 of RA 7160 otherwise known as the Local Government Code of 1991 of the Philippines provides the Powers, Duties and Functions of the Vice Governor, primarily including:

"(a) The vice-governor shall:

(1) Be the presiding officer of the Sangguniang Panlalawigan and sign all warrants drawn on the provincial treasury for all expenditures appropriated for the operation of the Sangguniang Panlalawigan."

This provision empowers the Vice Governor to act independently on matters involving the legislative branch of the provincial government.

The doctrine of separation of powers within local government units (LGUs) implies that the executive (Governor) and legislative (Sangguniang Panlalawigan, presided by the Vice Governor) are distinct and co-equal branches.

The permission as required citing Office of the President Memorandum Circular No. 17[1] and Section 12, Rule XVIII of the Revised Civil Service Rules does not apply.

Hence, any transaction entered into by the Vice Governor in her official or private capacity need no approval from the Governor. However, it is recommended that the Vice Governor shall disclose the subject transaction in her Statement of Assets and Liabilities(SALN).

Respectfully submitted.

ATTY. DENNIS T. VENTILACION
Provincial Legal Officer

Cc: Hon. Nathalie Ann F. Debuque
Vice Governor, Province of Iloilo

CERTIFIED MACHINE COPY FROM
THE ORIGINAL COPY ON FILE:

BELEN A. LOPEZ
SO III/RECORDS OFFICER

[1] Prohibiting Any Government Official And Employee From Accepting Private Employment In Any

CERTIFICATION OF INDEPENDENT DIRECTOR

I, LORNA C. SILVERIO Filipino, of legal age and a resident of 124 SAN AGUSTIN, SAN RAFAEL, BULACAN, afterhaving been duly sworn to in accordance with law do hereby declare that:

1. I am a nominee for independent director of ASIA PACIFIC MEDICAL CENTER-ILOILO, INC., and have been its independent director since 2025.

2. I am affiliated with the following companies or organizations (including Government-Owned and Controlled Corporations):

COMPANY/ORGANIZATION	POSITION/RELATIONSHIP	PERIOD OF SERVICE
NONE		

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ASIA PACIFIC MEDICAL CENTER ILOILO-,INC., as provided for in Section 38 of the SecuritiesRegulation Code, its Implementing Rules and Regulations and other SEC issuances.

4. I am not related to any Director, Officer, or substantial shareholder of ASIA PACIFIC MEDICAL CENTER -ILOILO, INC.,

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding.

6. I have the required permission from the Not applicable to be an independent director in ASIA PACIFIC MEDICAL CENTER ILOILO-,INC, pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules as shown in Annex A of this Certification.

7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance, and other SEC issuances.

8. I shall inform the Corporate Secretary of ASIA PACIFIC MEDICAL CENTER ILOILO-, INC of any changes in theabovementioned information within five days of its occurrence.

Done, this____day of APR 1 0 2026 at Bulacan.

LORNA C. SILVERIO
Affiant

SUBSCRIBED AND SWORN to before me this_____day of APR 1 0 2026 at PROVINCE OF BULACAN affiant personally appeared before me and exhibited to me her Passport # P2828966B issued by the DFA-MANILA , valid until August 21, 2029.

Atty. RANDOLF DE CASTRO
Notary Public for and in the Province of Bulacan
PNC-35-MB-2025/Until December 31, 2026
Roll of Attorneys No. 95485
PTR No. 5151[illegible]-05-2026/Bulacan
IBP No. 5132[illegible]-27-2025/Bulacan
Admitted to the BAR on January 24, 2025
MCLE Exempt-Governing Board Order No. [illegible]-2009

Doc. No. 219
Page No. 045
Book No. 005
Series of 2026

ASIA PACIFIC
MEDICAL CENTER
ILOILO

13 May 2026

ANNEX "D3"

CERTIFICATION

This is to certify that **DR. FERJENEL G. BIRON,** Member of the House of Representatives, Twentieth (20th) Congress, based on my personal knowledge possesses all the qualifications and none of the disqualifications to become a Member of the Board of Directors of the Company.

This Certification is issued in compliance with the disclosure requirements of the Securities and Exchange Commission.

MAYLENE B. VILLANUEVA
Compliance Officer

REPUBLIC OF THE PHILIPPINES
PROVINCE OF ILOILO
OFFICE OF THE
VICE GOVERNOR

CERTIFICATION

This is to certify that **ATTY. ROLEX T. SUPLICO,** Member of the Sangguniang Panlalawigan ng Iloilo, is hereby granted authority/permission to serve as a Director of ASIA PACIFIC MEDICAL CENTER ILOILO, INC., pursuant to Civil Service Resolution No. 99-1907 and Section 12, Rule XVIII of the Revised Civil Service Rules.

Issued this 20th day of May 2026 at Iloilo City, Iloilo, for whatever legal and lawful purpose this may serve.

NATHALIE ANN F. DEBUQUE
Vice Governor

5th Floor, New Iloilo Provincial Capitol Building, Muelle Loney St, Iloilo City Proper, Iloilo City, 5000
TELEPHONE NO. 328-7933 / 328-7987 EMAIL: officeofthevicegovernoriloilo@gmail.com

MoRProGRes ILOILO

ANNEX "D5"

Republic of the Philippines
House of Representatives
Quezon City, Metro Manila

REP. FERJENEL G. BIRON, M.D.
Deputy Speaker
Representative, 4th District of Iloilo
20th Congress

C E R T I F I C A T I O N

This is to certify that **MR. LEMUEL T. FERNANDEZ**, who currently serves as my Chief of Staff, is hereby granted authority/permission to run for and serve as Director of **Asia Pacific Medical Center Iloilo, Inc. (APMC Iloilo)**, subject to existing laws, rules, and regulations.

This Certification is issued this 26th day of May 2026 for whatever legal and lawful purpose it may serve.

REP FERJENEL G. BIRON, M.D.

Room 423, South Wing Annex Bldg., House of Representatives, Batasan Hills Quezon City, Philippines
Tel. No. 8-442-4183 / 8-931-5001 local 7992
Email: repferjenelbiron@gmail.com / ferjenelbiron@gmail.com

BERCES-OCAMPO, MENDOZA AND ASSOCIATES

May 13, 2026

The Board of Directors
ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
Barangay Ungka, Jaro, Iloilo City

Attention: **Ms. Agnes Jean M. Villaflor, MD, FPCP, FPSN**
President

Dear Ms. Villaflor,

We are pleased to submit our engagement proposal that sets forth the scope of professional services and outlines our basic audit procedures for the examination of the financial statements of **Asia Pacific Medical Center - Iloilo, Inc.** as of and for the year ended December 31, 2026.

This proposal presents the following:

I. Engagement Objectives and Professional Services to be Provided;

II. Audit Methodology;

III. Scope of Audit Services;

IV. Timetable; and

V. Professional Fees.

We are most grateful for the opportunity to offer our services to you. We look forward to your review and evaluation of this proposal and the opportunity to discuss our approach and fees to our mutual satisfaction.

I. ENGAGEMENT OBJECTIVES AND PROFESSIONAL SERVICES TO BE PROVIDED

Our overall objective is to conduct an efficient and effective audit to enable us to express our opinion on the financial statements of **Asia Pacific Medical Center - Iloilo, Inc.** as of and for the year ended December 31, 2026.

Our regular services will include the following:

- Annual examination and report upon the financial statements;

- Meeting with the designated committee to discuss audit plans and objectives, to review results of the audit, and to comment upon our findings;

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257, (+63) 922 869 1799, T (02) 87215294, E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

- Written commentary in the form of a management letter on the financial operations and internal accounting controls if necessary; and

- Attesting to statutory reports.

In addition to the above services, we expect to provide normal consultations concerning financial statements reporting, disclosures, accounting, and tax issues that may arise during the course of the engagement.

II. OUR AUDIT METHODOLOGY

For our client service, we have developed a uniform audit approach. This is designed to enable us to form an audit opinion in the most efficient, effective way at the same time adding value to your business. We achieve these objectives primarily by focusing our work on the major risks and the main audit issues in the business.

This approach has developed from our ability, in conjunction with management, to identify the key risk areas that could give rise to a material error in the accounts. In making judgments, we look not only at significant account balances and key operations but also at systems that are critical to the control of the business.

III. SCOPE OF OUR AUDIT SERVICES

The audit service will comprise all the work required to come up at an audit opinion for reporting purposes and statutory requirements.

Our examination of your financial statements will be made in accordance with the Philippine Standards on Auditing. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statements presentation.

The audit examination includes procedures designed to detect errors and irregularities that would have a material effect on the financial statements. However, as you are aware of, such examination is based on the concept of selective testing and is therefore subject to the inherent limitation that such matters, if they exist, may not be detected. In performing the audit procedures, however, we shall keep in mind that fraud may exist and will inform appropriate levels of management of weaknesses that we believe should be corrected and our recommendation in this respect.

The responsibility for the preparation of financial statements including adequate disclosure is that of the Management of the Company. This includes the maintenance of adequate accounting records and internal control, the selection and application of accounting policies, and the safeguarding of the assets of the company. As part of our audit process, we will require from management written confirmation concerning representations made to us in connection with the audit.

In any action for claim, for loss or damage arising out of the audit services rendered by the auditors procured by the company, the client agrees that the latter shall be liable only for

the proportionate share of the liability based on the degree of fault. The auditor's liability shall be restricted to damages of a direct or compensatory nature. In no case shall the auditor be held liable for any indirect or consequential loss or compensation for lost profits or a failure to make expected savings.

IV. TIMETABLE

In order to meet your desired deadline, we shall send you a letter for the submission of our audit requirements before we start our fieldwork together with our timetable.

V. PROFESSIONAL FEES

In consideration for the foregoing services, we propose to bill you a fee based on the actual time to be spent by the members of our staff computed at our prevailing standard rates, which we conservatively estimate will be a minimum of:

TWO HUNDRED EIGHTY THOUSAND PESOS (PhP280,000.00) – Year-end audit fee.

Out-of-pocket expenses shall be billed to you at **fifteen percent (15%)** of the resultant total audit fee separately without the need for supporting receipts other than our billing statements.

Terms: 50% downpayment and 50% full payment upon submission of reports.

The above fee quotation is premised on our getting assurance that maximum assistance and cooperation would be extended by your staff by keeping books of accounts/records, preparing schedules and locating important documents and that we would not encounter any extraordinary difficulty. If ever difficulties are encountered, we will let you know in advance before going further with our work. If this situation arises, there might be a need to request an upward adjustment of our professional fee should we find it inadequate to cover our cost, subject of course to your prior approval.

WHY BMA?

We believe that BMA is in a position to deliver the foregoing services in light of:

- Extensive experience of the principal and consultants in various industry sectors and functional areas;
- Access to "best practices" knowledge database; and
- Consistent reputation for delivery of the highest quality of services to its clients.

OUR ACCREDITATION:

Please refer to our government accreditation as follows:

- PRC/BOA Accreditation No. 9534 for the Firm up to August 8, 2028;

- PRC/BOA Registered Practitioner No. 9534/P-001 for the Signing Partner up to August 8, 2028;
- BIR Accreditation No. 07-000007-006-2026 for the Firm up to January 19, 2029;
- BIR Accreditation No. 07-000008-005-2026 for the Signing Partner up to January 19, 2029;
- SEC Accreditation No. 9534-SEC, Group A, for the Firm to engage in up to 2026 audit of SEC-covered institutions;
- SEC Accreditation No. 71098-SEC, Group A, for the Signing Partner to engage in up to 2026 audit of SEC-covered institutions;
- CDA Accreditation No. CEA 158-AF for the Firm up to March 7, 2026; and
- CDA Accreditation No. CEA 2016 for the Signing Partner up to February 8, 2031.

Should you be agreeable to this proposal, kindly indicate your conformity by signing on the space provided below and returning to us one copy of the signed proposal.

Respectfully yours,

BERCES-OCAMPO, MENDOZA AND ASSOCIATES

By:

Maria Cristina Josefina B. Ocampo
Managing Partner

CONFORME:

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC

By:

_____
Name and Signature

_____
Position

_____
Date

Audit Committee Pre-Approval Process

I. Statement of Principles

Under the Manual on Corporate Governance, the Audit Committee of the Board of Directors is responsible for the appointment, compensation and oversight of the work of the independent auditor. As part of this responsibility, the Audit Committee is required to pre-approve the audit and non-audit services performed by the independent auditor to assure the auditor's independence is not impaired. To observe the highest standards of governance and ensure independence, there is a need to specify the types of services that an independent auditor may not provide to the company, as well as the audit committee's administration of the engagement of the independent auditor. The following Audit and Non-Audit Services Pre-Approval Policy (the "Policy"), sets forth the procedures and the conditions pursuant to which services proposed to be performed by the independent auditor may be pre-approved.

The appendices to this policy describe the Audit, Audit-related, Tax and All Other services that have the general pre-approval of the Audit Committee. The term of any general pre-approval is 12 months (could be co-terminus) from the date of pre-approval, unless the Audit Committee considers a different period and states otherwise. The Audit Committee will annually review and pre-approve the services that may be provided by the independent auditor without obtaining specific pre-approval from the Audit Committee. The Audit Committee will add to or subtract from the list of general pre-approved services from time to time, based on subsequent determinations.

The purpose of this Policy is to set forth the procedures by which the Audit Committee intends to fulfill its responsibilities. It does not delegate the Audit Committee's responsibilities to pre-approve services performed by the independent auditor to management.

The independent auditor has reviewed this Policy and believes that adherence to the policy will not adversely affect the auditor's independence.

II. Delegation

The Audit Committee may delegate authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.

Under this provision, the Audit Committee has delegated its authority of pre-approval to the Chairman of the Audit Committee. The Chairman may pre-approve audit and no audit services on behalf of the Audit Committee and will be responsible for reporting any pre-approvals at the next scheduled Audit Committee meeting following the pre-approval of any such services.

III. Audit Services

The annual audit services engagement terms and fees will be subject to the specific pre-approval of the Audit Committee. Audit services include the annual financial statement audit and other procedures required to be performed by the independent auditor to be able to form an opinion on the Company's financial statements. The Audit Committee will monitor the Audit services engagement as necessary, but no less than on an annual basis, and will also approve, if necessary, any changes in terms, conditions and fees resulting from changes in audit scope, Company structure or other items.

In addition to the annual Audit services engagement approved by the Audit Committee, the Audit Committee may grant general pre-approval to other Audit services, which are those services that only the independent auditor reasonably can provide. Other Audit services may include statutory audits and services associated with SEC registration statements, periodic reports and other documents filed with the SEC.

The Audit Committee has pre-approved the Audit services in Appendix A. All other Audit services not listed in Appendix A must be specifically pre-approved by the Audit Committee.

IV. Audit-related Services

Audit-related services are assurance and related services that are reasonably related to the performance of the Audit or review of the Company's financial statements or that are traditionally performed by the independent auditor. Because the Audit Committee believes that the provision of Audit-related services does not impair the independence of the auditor, the Audit Committee may grant general pre-approval to Audit-related services.

The Audit Committee has pre-approved the Audit-related services in Appendix B. All other Audit-related services not listed in Appendix B must be specifically pre-approved by the Audit Committee.

V. Tax Services

The Audit Committee believes that the independent auditor can provide routine Tax services to the Company such as tax compliance, tax planning and tax advice without impairing the auditor's independence. Hence, the Audit Committee believes it may grant general pre-approval to those Tax services that have historically been provided by the auditor, that the Audit Committee has reviewed and believes would not impair the independence of the auditor.

Pursuant to the preceding paragraph, the Audit Committee has pre-approved the Tax Services in Appendix C. All other Tax services not listed in Appendix C must be specifically pre-approved by the Audit Committee.

VI. All Other Services

The prohibited non-audit services are:

- Bookkeeping or other services related to the accounting records or financial statements of the audit client
- Financial information systems design and implementation
- Appraisal or valuation services, fairness opinions or contribution-in-kind reports
- Actuarial services
- Internal audit outsourcing services
- Management functions
- Human resources
- Broker-dealer, investment adviser or investment banking services
- Legal services
- Expert services unrelated to the audit

All Other services must be specifically pre-approved by the Audit Committee.

VII. Pre-Approval Fee Levels or Budgeted Amounts

Pre-approval fee levels for all services to be provided by the independent auditor will be established annually by the Audit Committee. Any proposed services exceeding these levels or amounts will require specific pre-approval by the Audit Committee.

VIII. Procedures

All requests or applications for services to be provided by the independent auditor that do not require specific approval by the Audit Committee will be submitted to the Treasurer ("Treasurer") of the APMC Iloilo and must include a detailed description of the services to be rendered. The Treasurer will determine whether such services are included within the list of services that have received the general pre-approval of the Audit Committee. The Audit Committee will be informed on a timely basis of any such services rendered by the independent auditor.

Requests or applications to provide services that require specific approval by the Audit Committee will be submitted to the Audit Committee by both the independent auditor and the Treasurer, and must include a joint statement as to whether, in their view, the request or application is consistent with the SEC's rules on auditor independence.

Appendix A

Pre-Approved AUDIT SERVICES for 2026

Services

- assistance with and review of documents filed with the SEC including registration statements, 17Q and 17 A Reports, and other documents
- services associated with other documents issued in connection with securities offerings (*e.g.*, consents) assistance in responding to SEC comment letters
- statutory audits of the Company
- certificates, letters and opinions issued to regulators, agencies and other third-parties (*e.g.*, insurance, banking, environmental) regarding the Company's assets and/or operations that only the Company's independent auditors reasonably can provide

Pre-approval fee limit for Audit Services (other than registration statements)

PhP 300,000.00

Pre-approval fee limit for Audit Services pertaining to registration statements in connection with securities offerings

PhP 300,000 per registration statement

Appendix B

Pre-Approved AUDIT-RELATED SERVICES for 2026

Services

- due diligence services pertaining to potential business acquisitions or dispositions financial statement audits of employee benefit plans
- accounting consultations and audits in connection with acquisitions
- assistance with the Company's compliance initiative concerning the internal controls report of management such services to include (i) reviewing and evaluating the Company's documentation of internal controls, and (ii) meetings with the CFO and Company's Finance Team (but this pre-approval expressly does not authorize the Company to delegate to the Independent Auditor the management's responsibility to assess the Company's internal controls over financial reporting) consultations concerning principles of accounting and/or financial reporting treatment (under standards or interpretations by the SEC or other regulatory or standard-setting bodies)
- access to and use of APMCIs on-line accounting and auditing information tool (a resource for accounting and auditing standards and APMCI interpretive guidance)
- agreed-upon or expanded audit procedures related to accounting and/or billing records required to respond to or comply with financial, accounting or regulatory reporting matters

Pre-approval fee limit for Audit-Related Services

PhP **50,000.00**

Appendix C

Pre-Approved TAX SERVICES for 2026

Services

Note: The following are subject to the terms of subsection C of Section V of this policy.

- National and local tax compliance, including the preparation of original and amended tax returns and claims for refunds
- National and local tax planning and advice, including assistance with tax audits and appeals (but expressly excluding advocacy or litigation services), tax advice related to mergers and acquisitions, tax advice relating to employee benefit plans, and requests for rulings or technical advice from taxing authorities
- review of tax returns

Pre-approval fee limit for Tax Services

PhP 100,000.00

Appendix D

Pre-Approved ALL OTHER SERVICES for 2026

Service

None

Pre-approval fee limit for All Other Services

PhP 0

Berces-Ocampo, Mendoza and Associates

(Formerly Ocampo, Mendoza, Lim & Co.)

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257, (+63) 922 869 1799, T (02) 87215294, E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

Vision and Mission Statements

Our Vision

BMA at par with the world accountancy practice, with a heart.

Our Mission

To practice accountancy with integrity, honesty, sincerity, and concern for clients in order to contribute in the development of the nation and the Filipino people through the responsible practice of our profession.

Our Goal

To enhance the practice of our profession by adhering to professional ethics and at the same time contribute to the economic growth of clients by providing competent and relevant services.

About Us

Our Firm

Berces-Ocampo, Mendoza and Associates is a general professional partnership of certified public accountants (CPAs) offering full range of services from audit and accounting to tax consultancy. Our team serves both foreign firms with local operations in the country and domestic corporations.

We started our operation in 1992. Our principal office is located at Quezon City.

Our Accreditations

- Board of Accountancy

  Accreditation No. 9534 for the Firm

- Bureau of Internal Revenue

  Accreditation No. 07-000007-006-2026 – For the Firm

  Accreditation No. 07-000008-005-2026 – For Maria Cristina Josefina B. Ocampo

  Accreditation No. 07-000006-004-2026 – For Josefina F. Mendoza

- Cooperative Development Authority

  CEA 158-AF – For the Firm

  Accreditation No. CEA 2016 – For Maria Cristina Josefina B. Ocampo

  Accreditation No. CEA 2015 – For Josefina F. Mendoza

- Securities and Exchange Commission

  Accreditation No. 9534-SEC, Group A – For the Firm

  Accreditation No. 71098-SEC, Group A – For Maria Cristina Josefina B. Ocampo

Our Team

Our team is composed of two partners and twenty full-time staff. Our full partners are Maria Cristina Josefina B. Ocampo and Josefina F. Mendoza.

Audit & Assurance

We constantly deliver value-added assurance and other services to our clients by providing consultancy in financial, taxation and operational issues.

We always try to go beyond just issuing audit reports. Our teams are ready to help you in the different audit phases, from the planning phase of the audit to the issuance of the audit report. Our teams have relevant experiences in diverse industries, ranging from manufacturing to services providers.

Audit and Assurance Services

BMA provides audit and assurance services that go beyond numbers. We use up-to-date auditing techniques and procedures that, together with a thorough understanding of your business, result in an audit approach fully customized to your needs.

BMA audit team will regularly dialogue with you, so that we may address your most relevant needs and concerns.

Beyond our attest function, we provide timely and cost-effective recommendations that enhance internal control systems and procedures therefore adding value to your business.

Every engagement we handle involves the use of latest technology, techniques and procedures; a thorough understanding of the client's business; strict adherence to the highest standards of professional conduct, and a quality engagement team consisting of highly-skilled professionals.

Tax Advisory & Compliance

We at BMA conduct evaluation and assessment of a client's potential tax exposures and discuss its implications in the business operation. We try to help in devising ways for the client to transition for full tax compliance by minimizing the impact of new tax regulations on the company and submit recommendation to maximize financial savings in order to expand the client's business.

With years of experience in working with clients in various industries in different territories, our finance and accounting professionals have ample knowledge in the different taxation procedures that your business needs to seamless statutory financial reporting.

We help you identify the opportunities and pitfalls that can significantly affect your bottom line. Whatever you need, we are well-equipped to provide you with innovative yet practical solutions to minimize your tax exposure by means of legitimate tax planning and regular updates on the changing taxation system. We aim to minimize the impact of taxation, enabling you to maximize your potential savings and to expand your business.

Our Tax Advisory and Compliance provides:

- Tax advisory;
- Tax compliance;
- Tax issues and examination;
- Tax education and advocacy;

Business Process Solutions

BMA also provides support services for key accounting and administrative functions such as outsourced accounting, payroll, and accounting-and-compliance-related taxes.

We offer accounting services for owners of small-and medium-sized businesses to augment client's financial reporting requirements. We also conduct compliance review and help companies in steering towards full compliance.

Our Services:

- Internal Audit
- Tax cases and other concerns
- BIR and SEC filing
  - Business registration and licenses including PEZA and BOI;
  - Accounting and bookkeeping;
  - Reconstruction of books;
  - Feasibility studies and financial reports;
  - Assistance in installation and running of accounting software;
  - Business dissolution;
  - Due diligence; and
  - Documentation and operation manual preparation.

We at BMA commit ourselves in ensuring that we deliver services at the best of our abilities to help the clients in achieving its objectives and full potential.

Clientele and Industry

Our firm has been blessed through the years. At present and in the past we have served clients in the following areas of business:

Agriculture
Architecture, legal, medical and other professional Aviation schools
Business processing
Condo corporation
Construction and development Cooperatives
Economic zones (PEZA)
Educational institutions
Electronics and electronic components
Financing companies
Foreign representative offices
Hotel and restaurant including franchises
Import and export
Management companies
Manufacturing (oil mill, paper, IT, food, furniture, etc.)
Merchandising and retail companies
Not for profit organizations
Online marketing platform
Real estate
Rural banks
Service organizations including consultancy and professional
Sports clubs
Stockbrokers
Theater
Trading (car distribution or trade, multilevel marketing)
Wholesale and retail trade

The Partners

MARIA CRISTINA JOSEFINA B. OCAMPO
Managing Partner

Maria Cristina Josefina B. Ocampo is the Managing Partner and is the moving force behind the growth and expansion of the Firm. She graduated at the Polytechnic University of the Philippines with the degree of Bachelor of Science in Accountancy under the Honor Section. She is a Certified Public Accountant.

After graduation, she joined Rubberworld Philippines (Adidas) as internal auditor for more than two years before moving to San Buenaventura & Co. CPAs as associate auditor. She finally joined Carlos J. Valdes & Co., CPAs until the time she had established her own Audit Firm.

She is past President of the Philippine Institute of Certified Public Accountants (PICPA) Southern Metro Manila Chapter, of Philippine Association of Management Accountants, of Rotary Club of Batasan Hills. She is also an active member of Association of Certified Public Accountants in Public Practice (ACPAPP), Association of Certified Public Accountants in Commerce and Industry (ACPACI).

She is also an awarded Volunteer Peer Evaluator (VPE) by the Philippine Council for NGO Certifications (PCNC) (75 evaluations and counting). She is also an active member of the Technical Working Group of the Cooperative Development Authority (CDA) National Office, working on the guidelines for reporting and compliance of cooperatives in the Philippines.

Her background and client industry include manufacturing, hotel and restaurant, sports club, construction and development, real estate and condominium, not-for-profit organizations and associations, aviation schools and other educational institutions, economic zones, rural banks and financing companies, cooperatives, architecture, management companies and consultancy, legal and medical, stock brokerage, merchandising and service companies.

She is also well versed in various taxation issues including economic zone regulations and is capable of handling myriad tax cases.

JOSEFINA F. MENDOZA
Audit Partner

Josefina F. Mendoza has a degree of Bachelor of Science in Business Administration major in Accounting. She graduated at the Pamantasan ng Lungsod ng Maynila. She is a Certified Public Accountant and an active member of PICPA and ACPAPP.

Currently, she is a member of the Board of Directors of Ascent Knowledge Resources, Inc., a food and allied industries laboratory company in Balete Drive Ext., Quezon City. She also worked as a Treasury Head at Emilio Aguinaldo College Medical Center located at Dasmarinas, Cavite. She was previously connected as a Senior Auditor at All Asian Countertrade, Inc, a sugar trading firm with various subsidiaries related to food products. She also worked as an Internal Auditor at Medical Center Manila in Ermita, Manila.

Her background and client industry include manufacturing, stock brokerage, merchandising, sports clubs, trading, cooperatives and service companies.



Your BIR AFS eSubmission uploads were received

Inbox

Bureau of Internal Revenue Philippines
To: me, Cc: me · Thu, May 28 at 8:58 PM

Hi ALLIED CARE EXPERTS (ACE) MEDICAL CENTER - ILOILO INC.,

Valid files

- EAFS008922703OTHTY122025.pdf
- EAFS008922703ITRTY122025.pdf
- EAFS008922703AFSTY122025.pdf

Invalid file

- <None>

Transaction Code: **AFS-0-AG8HLHB50AB6E97EAN4XNXVQT0PRVYVP2**
Submission Date/Time: **May 28, 2026 08:58 PM**
Company TIN: **008-922-703**

Please be reminded that you accepted the terms and conditions for the use of this portal and expressly agree, warrant and certify that:

- The submitted forms, documents and attachments are complete, truthful and correct based on the personal knowledge and the same are from authentic records;
- The submission is without prejudice to the right of the BIR to require additional document, if any, for completion and verification purposes;
- The hard copies of the documents submitted through this facility shall be submitted when required by the BIR in the event of audit/investigation and/or for any other legal purpose.

This is a system-generated e-mail. Please do not reply.

ASIA PACIFIC
MEDICAL CENTER
ILOILO

STATEMENT OF MANAGEMENT'S RESPONSIBILITY FOR ANNUAL INCOME TAX RETURN

The management of **Asia Pacific Medical Center – Iloilo, Inc.** is responsible for all information and representations contained in the Annual Income Tax Return for the year ended December 31, 2025. Management is likewise responsible for all information and representations contained in the financial statements accompanying the Annual Income Tax Return covering the same reporting period. Furthermore, Management is responsible for all information and representations contained in all the other tax returns filed for the reporting period, including, but not limited to, the value added tax and/or percentage returns, withholding tax returns, documentary stamp tax returns, and any and all other tax returns.

In this regard, Management affirms that the attached audited financial statements for the year ended December 31, 2025 and the accompanying Annual Income Tax Return are in accordance with the books and records of **Asia Pacific Medical Center – Iloilo, Inc.**, complete and correct in all material respects. Management likewise affirms that:

(a) the Annual Income Tax Return has been prepared in accordance with the provisions of the National Internal Revenue Code, as amended, and pertinent tax regulations and other issuances of the Department of Finance and the Bureau of Internal Revenue;

(b) any disparity of figures in the submitted reports arising from the preparation of financial statements pursuant to financial accounting standards and the preparation of the income tax return pursuant to tax accounting rules has been reported as reconciling items and maintained in the Company's books and records in accordance with the requirements of Revenue Regulations No. 8-2007 and other relevant issuances;

(c) **Asia Pacific Medical Center – Iloilo, Inc.** has filed all the applicable tax returns, reports and statements required to be filed under the Philippine tax laws for the reporting period, and all taxes and other impositions shown thereon to be due and payable have been paid for the reporting period, except those contested in good faith.

FERJENEL G. BIRON
Chairman of the Board

AGNES JEAN M. VILLAFLOR
President

MARY FLOR ONG
Treasurer

Signed this 12th day of May 2026

Republic of the Philippines)
City of Pasig) S.S.

Subscribed and sworn to before me this MAY 12 2026, affiants exhibiting to me their Competent Evidences of Identity as follows:

Name	Taxpayer Identification Number
Ferjenel G. Biron	127-685-650

Notary Public

Doc. No. 279;
Page No. 57;
Book No. W;
Series of 2026.

BUWIS DST 2025 15774579

MAYLENE B. VILLANUEVA
NOTARY PUBLIC
City of Pasig and Municipality of Pateros
Appointment No. 332 (2025-2026) valid until December 31, 2026
Roll No. 60137; 03-22-12
MCLE Compliance VIII-0029185; 04/14/2025
IBP Lifetime Member 10763; 03-13-12, Iloilo,
PTR No. AA3978159, 01/05//2026, Pasig City
Suite 1601, 16th Floor, Tektite East Tower,
Exchange Road cor. Pearl Drive, Pasig City
Email Address: mbvnotarypublic@gmail.com

ASIA PACIFIC
MEDICAL CENTER
ILOILO

STATEMENT OF MANAGEMENT'S RESPONSIBILITY FOR ANNUAL INCOME TAX RETURN

The management of **Asia Pacific Medical Center – Iloilo, Inc.** *(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)* is responsible for all information and representations contained in the Annual Income Tax Return for the year ended December 31, 2025. Management is likewise responsible for all information and representations contained in the financial statements accompanying the Annual Income Tax Return covering the same reporting period. Furthermore, Management is responsible for all information and representations contained in all the other tax returns filed for the reporting period, including, but not limited to, the value added tax and/or percentage returns, withholding tax returns, documentary stamp tax returns, and any and all other tax returns.

In this regard, Management affirms that the attached audited financial statements for the year ended December 31, 2025 and the accompanying Annual Income Tax Return are in accordance with the books and records of **Asia Pacific Medical Center – Iloilo, Inc.**, complete and correct in all material respects. Management likewise affirms that:

(a) the Annual Income Tax Return has been prepared in accordance with the provisions of the National Internal Revenue Code, as amended, and pertinent tax regulations and other issuances of the Department of Finance and the Bureau of Internal Revenue;

(b) any disparity of figures in the submitted reports arising from the preparation of financial statements pursuant to financial accounting standards and the preparation of the income tax return pursuant to tax accounting rules has been reported as reconciling items and maintained in the Company's books and records in accordance with the requirements of Revenue Regulations No. 8-2007 and other relevant issuances;

(c) **Asia Pacific Medical Center – Iloilo, Inc.** has filed all the applicable tax returns, reports and statements required to be filed under the Philippine tax laws for the reporting period, and all taxes and other impositions shown thereon to be due and payable have been paid for the reporting period, except those contested in good faith.

FERJENEL G. BIRON
Chairman of the Board

AGNES JEAN M. VILLAFLOR
President

MARY FLOR G. ONG
Treasurer

Subscribed and sworn to before me this MAY 12 2026, affiants exhibiting to me their Competent Evidences of Identity as follows:

Name	Taxpayer Identification Number
Agnes Jean M. Villaflor	136-792-228
Mary Flor G.Ong	921-030-310

Notary Public

ATTY. APRIL GRACE T. GRANDE
For the City and Province of Iloilo
Notarial Commission Reg. No. 240
Until December 31, 2026
2nd Flr., D' Jabez Bldg., #21 Gen. Luna St.,
Iloilo City, Philippines
PTR No. 9155051 / Iloilo City / 01/05/2026
IBP No. 585819 / Pasig City 01/04/2026
Roll of Attorney's No. 76954
MCLE Compliance No. VIII-0014696 until 4/14/28

Doc. No. 377;
Page No. 77;
Book No. I;
Series of 2026.

ASIA PACIFIC
MEDICAL CENTER
ILOILO

STATEMENT OF MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL STATEMENTS

The management of **Asia Pacific Medical Center – Iloilo, Inc.** is responsible for the preparation and fair presentation of the financial statements including the schedules attached therein, for the years ended December 31, 2025, 2024 and 2023, in accordance with the Philippine Financial Reporting Standards (PFRS) Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

The Board of Directors reviews and approves the financial statements including the schedules attached therein, and submits the same to the shareholders.

FERJENEL G. BIRON
Chairman of the Board

AGNES JEAN M. VILLAFLOR
President

MARY FLOR ONG
Treasurer

Signed this 12th day of May 2026

Republic of the Philippines)
City of Pasig) S.S.

Subscribed and sworn to before me this MAY 12 2026, affiants exhibiting to me their Competent Evidences of Identity as follows:

Name	Taxpayer Identification Number
Ferjenel G. Biron	127-685-650

Notary Public

Doc. No. 277;
Page No. 57;
Book No. IV;
Series of 2026.

BUWIS RENTAS INTERNAS DSK2025 15774580 MAY 12 2026

MAYLENE B. VILLANUEVA * NOTARY PUBLIC ROLL NO. 60137 * PASIG CITY, PATEROS, PHIL.

MAYLENE B. VILLANUEVA
NOTARY PUBLIC
City of Pasig and Municipality of Pateros
Appointment No. 332 (2025-2026) valid until December 31, 2026
Roll No. 60137; 03-22-12
MCLE Compliance VIII-0029185; 04/14/2025
IBP Lifetime Member 10763; 03-13-12, Iloilo,
PTR No. AA3978159, 01/05//2026, Pasig City
Suite 1601, 16th Floor, Tektite East Tower,
Exchange Road cor. Pearl Drive, Pasig City
Email Address: mbvnotarypublic@gmail.com

ASIA PACIFIC
MEDICAL CENTER
ILOILO

STATEMENT OF MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL STATEMENTS

The management of **Asia Pacific Medical Center – Iloilo, Inc.** *(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)* is responsible for the preparation and fair presentation of the financial statements including the schedules attached therein, for the years ended December 31, 2025, 2024 and 2023, in accordance with the Philippine Financial Reporting Standards (PFRS) Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

The Board of Directors reviews and approves the financial statements including the schedules attached therein, and submits the same to the shareholders.

FERJENEL G. BIRON
Chairman of the Board

AGNES JEAN M. VILLAFLOR
President

MARY FLOR G. ONG
Treasurer

Signed this 12 day of May 2026

MAY 12 2026

Subscribed and sworn to before me this _____, affiants exhibiting to me their Competent Evidences of Identity as follows:

Name	Taxpayer Identification Number
Agnes Jean M. Villaflor	136-792-228
Mary Flor G. Ong	921-030-310

ATTY. APRIL GRACE T. GRANDE
Notary Public
For the City of Iloilo
Notarial Commission Reg. No. 240
Until December 31, 2026
2nd Flr., D' Jabez Bldg., #21 Gen. Luna St.,
Iloilo City, Philippines
PTR No. 9155051 / Iloilo City / 01/05/2026
IBP No. 585819 / Pasig City 01/04/2026
Roll of Attorney's No. 76954
MCLE Compliance No. VIII-0014696 until 4/14/28

Doc. No. 376 ;
Page No. 77 ;
Book No. II ;
Series of 2026.

PRC/BOA Accreditation No. 9534 for the Firm up to August 8, 2028
PRC/BOA Registered Practitioner No. 9534/P-001 for the Signing Partner up to August 8, 2028
BIR Accreditation No. 07-000007-006-2026 for the Firm up to January 19, 2029
BIR Accreditation No. 07-000008-005-2026 for the Signing Partner up to January 19, 2029
SEC Accreditation No. 9534-SEC, Group A, for the Firm to engage in up to 2026 audit of SEC-covered institutions
SEC Accreditation No. 71098-SEC, Group A, for the Signing Partner to engage in up to 2026 audit of SEC-covered institutions
CDA Accreditation No. CEA 158-AF for the Firm up to March 7, 2026
CDA Accreditation No. CEA 2016 for the Signing Partner up to February 8, 2031

REPORT OF INDEPENDENT AUDITORS

The Board of Directors and the Shareholders
Asia Pacific Medical Center – Iloilo, Inc.
Barangay Ungka, Jaro
Iloilo City

We have audited the financial statements of **Asia Pacific Medical Center – Iloilo, Inc.** for the year ended December 31, 2025 on which we have rendered the attached report dated May 14, 2026.

In compliance with SRC Rule 68 and based on certification from the Company's Corporate Secretary, **Asia Pacific Medical Center – Iloilo, Inc.** has sixty (60) shareholders each owning one hundred (100) or more shares.

BERCES-OCAMPO, MENDOZA AND ASSOCIATES

By:

María Cristina Josefina B. Ocampo
Partner
CPA Registration No. 71098
TIN 123-047-213
PTR No. 8353744 D
Issued January 5, 2026 at Quezon City

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257, (+63) 922 869 1799, T (02) 87215294, E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

PRC/BOA Accreditation No. 9534 for the Firm up to August 8, 2028
PRC/BOA Registered Practitioner No. 9534/P-001 for the Signing Partner up to August 8, 2028
BIR Accreditation No. 07-000007-006-2026 for the Firm up to January 19, 2029
BIR Accreditation No. 07-000008-005-2026 for the Signing Partner up to January 19, 2029
SEC Accreditation No. 9534-SEC, Group A, for the Firm to engage in up to 2026 audit of SEC-covered institutions
No. 71098-SEC, Group A, for the Signing Partner to engage in up to 2026 audit of SEC-covered institutions
CDA Accreditation No. CEA 158-AF for the Firm up to March 7, 2026
CDA Accreditation No. CEA 2016 for the Signing Partner up to February 8, 2031

REPORT OF INDEPENDENT AUDITORS ON SUPPLEMENTARY SCHEDULES

The Board of Directors and the Shareholders
Asia Pacific Medical Center – Iloilo, Inc.
Barangay Ungka, Jaro
Iloilo City

We have audited the financial statements of **Asia Pacific Medical Center – Iloilo, Inc.** for the year ended December 31, 2025, and, in accordance with Philippine Standards on Auditing, have issued our report thereon dated May 14, 2026.

Our audit was made for the purpose of forming an opinion on the basic financial statements taken as a whole. The accompanying Supplementary Schedules required Annex 68-J, Reconciliation of Retained Earnings Available for Dividend Declaration, and Schedule of Financial Indicators are the responsibility of the Company's management.

This supplementary schedule is presented for the purpose of complying with the Revised Securities Regulation Code (SRC) Rule No. 68 and is not part of the basic financial statements. This supplementary schedule has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, fairly states in all material respects the financial data required to be set forth therein in relation to the basic financial statements taken as a whole.

BERCES-OCAMPO, MENDOZA AND ASSOCIATES

By:

Maria Cristina Josefina B. Ocampo
Partner
CPA Registration No. 71098
TIN 123-047-213
PTR No. 8353744 D
Issued January 5, 2026 at Quezon City

Metro Manila, Philippines
May 14, 2026

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257; (+63) 922 869 1799; T (02) 8721 5294; E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

PRC/BOA Accreditation No. 9534 for the Firm up to August 8, 2028
PRC/BOA Registered Practitioner No. 9534/P-001 for the Signing Partner up to August 8, 2028
BIR Accreditation No. 07-000007-006-2026 for the Firm up to January 19, 2029
BIR Accreditation No. 07-000008-005-2026 for the Signing Partner up to January 19, 2029
SEC Accreditation No. 9534-SEC, Group A, for the Firm to engage in up to 2026 audit of SEC-covered institutions
SEC Accreditation No. 71098-SEC, Group A, for the Signing Partner to engage in up to 2026 audit of SEC-covered institutions
CDA Accreditation No. CEA 158-AF for the Firm up to March 7, 2026
CDA Accreditation No. CEA 2016 for the Signing Partner up to February 8, 2031

STATEMENT OF REPRESENTATION

The Securities and Exchange Commission
7907 Makati Avenue, Salcedo Village
Brgy. Bel-Air, Makati City

In connection with my examination of the financial statements of **Asia Pacific Medical Center – Iloilo, Inc.** which are to be submitted to the Commission, I hereby represent the following:

1. That I am in the active practice of the accounting profession and duly registered with the Board of Accountancy (BOA);

2. That said financial statements are presented in conformity with Philippine Financial Reporting Standards (PFRS) Accounting Standards in all cases where I shall express an unqualified opinion; except that in case of any departure from such principles, I shall indicate the nature of the departure, the effects thereof, and the reasons why compliance with the principles would result in a misleading statement, if such is a fact;

3. That I shall fully meet the requirements of independence as provided under the Code of Professional Ethics for CPAs;

4. That in the conduct of the audit, I shall comply with the Philippine Standards on Auditing; that in case of any departure or limitation in the scope of my audit, I shall indicate the extent of the limitation, the reasons therefore and the effects thereof on the expression of my opinion or that which may necessitate the negation of the expression of an opinion, if such is the case;

5. That I shall comply with the applicable rules and regulations of the Securities and Exchange Commission in the preparation and submission of financial statements; and

6. That relative to the expression of my opinion on the said financial statements, I shall not commit any acts discreditable to the profession as provided under the Code of Professional Ethics for CPAs.

As a CPA engaged in public practice, I make these representations in my individual capacity and as partner in the audit firm of Berces-Ocampo, Mendoza and Associates.

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257, (+63) 922 869 1799, T (02) 87215294, E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

BERCES-OCAMPO, MENDOZA, AND ASSOCIATES

By:

Maria Cristina Josefina B. Ocampo
Partner
CPA Registration No. 71098
TIN 123-047-213
PTR No. 8353744 D
Issued January 5, 2026 at Quezon City

Metro Manila, Philippines
May 14, 2026

PRC/BOA Accreditation No. 9534 for the Firm up to August 8, 2028
PRC/BOA Registered Practitioner No. 9534/P-001 for the Signing Partner up to August 8, 2028
BIR Accreditation No. 07-000007-006-2026 for the Firm up to January 19, 2029
BIR Accreditation No. 07-000008-005-2026 for the Signing Partner up to January 19, 2029
SEC Accreditation No. 9534-SEC, Group A, for the Firm to engage in up to 2026 audit of SEC-covered institutions
SEC Accreditation No. 71098-SEC, Group A, for the Signing Partner to engage in up to 2026 audit of SEC-covered institutions
CDA Accreditation No. CEA 158-AF for the Firm up to March 7, 2026
CDA Accreditation No. CEA 2016 for the Signing Partner up to February 8, 2031

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

The Board of Directors and the Shareholders
Asia Pacific Medical Center – Iloilo, Inc.
Barangay Ungka, Jaro
Iloilo City

Opinion

We have audited the financial statements of **Asia Pacific Medical Center – Iloilo, Inc.** which comprise the statement of financial position as of December 31, 2025, and the statements of comprehensive operation, changes in shareholders' equity and cash flows for the year then ended and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Asia Pacific Medical Center – Iloilo, Inc. as of December 31, 2025 and its financial performance and its cash flows for the year then ended in accordance with Philippine Financial Reporting Standards (PFRS) Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for Audit of Financial Statements* section of our report. We are independent of **Asia Pacific Medical Center – Iloilo, Inc.** in accordance with the International Ethics Standards Board for Accountants' *Code of Ethics for Professional Accountants* (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in the Philippines, the *Code of Ethics for Professional Accountants in the Philippines* (*Philippine Code of Ethics*), and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Other Matter

The financial statements of the Company for the year ended December 31, 2024 were audited by Dimaculangan, Dimaculangan and Company, CPA's whose report dated April 27, 2025 expressed an unqualified opinion.

754 Winland Tower Residences, 45 Tomas Morato Avenue, Quezon City 1112
C (+63) 918 807 8257, (+63) 922 869 1799, T (02) 87215294, E bercesocampomendoza.hr@gmail.com
Website: https://bmacpas.ph/

Responsibilities of Management and Those Charged with Governance for Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Philippine Financial Reporting Standards (PFRS) Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud of error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the

financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Our audit was conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information on taxes in the Notes to the Financial Statements in compliance with RR 15-2010 and RR 34-2020 of the Bureau of Internal Revenue and supplementary schedule of external audit fee-related information in accordance with Securities and Exchange Commission Memorandum Circular 18-2024 are not a required part of the basic financial statements. Such information are the responsibility of the management and have been subjected to the auditing procedures applied in our audit of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole.

BERCES-OCAMPO, MENDOZA AND ASSOCIATES

By:

Maria Cristina Josefina B. Ocampo
Partner
CPA Registration No. 71098
TIN 123-047-213
PTR No. 68353744 D
Issued January 5, 2026 at Quezon City

Metro Manila, Philippines
May 14, 2026

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
STATEMENT OF FINANCIAL POSITION
(With Comparative Figures in 2024)
(Amounts in Philippine Peso)

ASSETS	*Notes*	**December 31, 2025**	December 31, 2024
CURRENT ASSETS			
Cash	***4,6,26***	**23,296,041**	13,830,999
Receivables	***4,7,26***	**165,796,569**	82,430,163
Advances to contractors and suppliers	***4,8***	**72,449,059**	47,576,729
Medical and hospital supplies inventories	***4,9***	**59,994,528**	75,662,389
Prepayments and other current assets	***4,10***	**28,714,938**	16,812,711
		350,251,135	236,312,991
NON-CURRENT ASSETS			
Property and equipment (net)	***4,11***	**2,357,222,256**	2,238,660,948
Advances to related parties	***12,26***	**6,950,256**	39,030,125
		2,364,172,512	2,277,691,073
TOTAL ASSETS		**2,714,423,647**	2,514,004,064
LIABILITIES AND EQUITY			
CURRENT LIABILITIES			
Accounts payable and other liabilities	***4,13,26***	**689,539,570**	529,464,018
Loans payable to individuals	***14,26***	**15,703,226**	15,703,226
Notes payable - current portion	***15,26***	**191,558,072**	15,000,000
		896,800,868	560,167,244
NON-CURRENT LIABILITIES			
Notes payable - net of current portion	***15,26***	**807,792,965**	955,594,306
Loans payable to a related party	***12***	**544,871,969**	543,871,969
Deferred tax liability	***16,18***	**61,177,093**	-
		1,413,842,027	1,499,466,275
TOTAL LIABILITIES		**2,310,642,895**	2,059,633,519
EQUITY			
Share capital (net)	***4,17***	**240,000,000**	239,960,000
Share premium	***4,17***	**958,532,662**	957,372,662
Revaluation surplus	***16,18***	**183,531,277**	-
Deficit	***4,26***	**(978,283,187)**	(742,962,117)
		403,780,752	454,370,545
TOTAL LIABILITIES AND EQUITY		**2,714,423,647**	2,514,004,064

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
STATEMENT OF CHANGES IN EQUITY
(With Comparative Figures in 2024 and 2023)
(Amounts in Philippine Peso)

	Share Capital (Note 16)	Share Premium (Note 16)	Revaluation Surplus (Note 17)	Deficit (Note 1)	Total
EQUITY					
As at January 1, 2023	235,670,000	783,283,829	-	(197,870,210)	821,083,619
Additional share capital	4,290,000	-	-	-	4,290,000
Share premium	-	170,612,333	-	-	170,612,333
Net loss for the year	-	-	-	(147,332,832)	(147,332,832)
As at December 31, 2023	239,960,000	953,896,162	-	(345,203,042)	848,653,120
Proceeds from subscription receivable	-	3,476,500	-	-	3,476,500
Net loss for the year	-	-	-	(397,759,075)	(397,759,075)
As at December 31, 2024	**239,960,000**	**957,372,662**	-	**(742,962,117)**	**454,370,545**
Additional share capital	**40,000**	-	-	-	**40,000**
Share premium	-	**1,560,000**	-	-	**1,560,000**
Subscription receivable	-	**(400,000)**	-	-	**(400,000)**
Apparaisal increase (Land)	-	-	**183,531,277**	-	**183,531,277**
Net loss for the year	-	-	-	**(235,321,070)**	**(235,321,070)**
As at December 31, 2025	**240,000,000**	**958,532,662**	**183,531,277**	**(978,283,187)**	**403,780,752**

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
STATEMENT OF COMPREHENSIVE LOSS
(With Comparative Figures in 2024 and 2023)
(Amounts in Philippine Peso)

				For the years ended
	Notes	**December 31, 2025**	December 31, 2024	December 31, 2023
REVENUES	***4,19***	**452,165,666**	307,910,026	5,995,365
DIRECT COST	***4,20***	**259,501,745**	268,767,300	6,127,455
GROSS INCOME (LOSS)		**192,663,921**	39,142,726	(132,090)
OTHER INCOME	***4,6,21***	**10,314,981**	1,182,734	71,075
GROSS INCOME (LOSS)		**202,978,902**	40,325,460	(61,015)
OPERATING EXPENSES				
General and administrative expenses	***4,22***	**302,289,389**	282,385,327	110,301,610
LOSS FROM OPERATIONS		**(99,310,487)**	(242,059,867)	(110,362,625)
FINANCE COSTS	***4,15***	**(136,010,583)**	(155,699,208)	(36,970,036)
LOSS BEFORE INCOME TAX		**(235,321,070)**	(397,759,075)	(147,332,661)
INCOME TAX EXPENSE	***4,23***	**-**	-	(171)
NET LOSS		**(235,321,070)**	(397,759,075)	(147,332,832)
OTHER COMPREHENSIVE INCOME FOR THE YEAR	***16,18***	**183,531,277**	-	-
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		**(51,789,793)**	(397,759,075)	(147,332,832)
BASIC LOSS PER SHARE	***25***	**(980.50)**	(1,657.61)	(613.99)

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
STATEMENT OF CASH FLOWS
(With Comparative Figures in 2024 and 2023)
(Amounts in Philippine Peso)

			For the years ended	
	Notes	**December 31, 2025**	December 31, 2024	December 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES				
Net loss		**(235,321,070)**	(397,759,075)	(147,332,661)
Adjustments to reconcile loss to net cash used in operating activities:				
Depreciation	***4,11***	**150,719,634**	148,272,068	5,394,843
Interest income	***4,6,21***	**(1,002)**	(2,106)	(19,158)
Unrealized foreign exchange gain/(loss)	***4,6,21***	**3,505**	(310,228)	18,964
Interest expense	***4,15***	**136,010,583**	(155,699,208)	(36,970,036)
Operating cash outflows before changes in working capital		**51,411,649**	(405,498,549)	(178,908,048)
Changes in working capital components:				
Decrease (increase) in current assets:				
Receivables	***4,7,26***	**(83,366,406)**	(69,436,588)	(5,520,519)
Advances to contractors and suppliers	***4,8***	**(24,872,330)**	10,587,407	1,430,535
Medical and hospital inventories	***4,9***	**15,667,861**	(72,952,625)	(2,709,764)
Prepayments and other current assets	***4,10***	**(10,641,610)**	(14,036,648)	(1,262,234)
Increase (decrease) in current liabilities:				
Accounts payable and other liabilities	***4,13,26***	**160,075,552**	229,246,192	46,267,666
Net cash provided by/(used in) operations		**108,274,716**	(322,090,811)	(140,702,364)
Income tax paid	***4,23***	**(1,260,617)**	(953,920)	(171)
Interest received	***4,6,21***	**1,002**	2,106	19,158
Net cash provided by/(used in) operating activities		**107,015,101**	(323,042,625)	(140,683,377)
CASH FLOWS FROM INVESTING ACTIVITIES				
Reclassification (Additions) to construction-in-progress	***11***	-	1,900,987,351	(242,753,148)
Additions to property and equipment	***4,11***	**(24,572,572)**	(1,859,376,138)	(85,772,718)
Other non-current assets	***13,27***	**-**	(20,000)	171
Net cash provided by/(used in) investing activities		**(24,572,572)**	41,591,213	(328,525,695)
CASH FLOWS FROM FINANCING ACTIVITIES				
Advances to related parties	***12,26***	**32,079,869**	-	(3,434,352)
Payments of loans payable to individuals	***14,26***	**-**	(4,639,474)	(424,000)
Proceeds from principal on bank loans	***15***	**30,000,000**	-	**-**
Payments of principal on bank loans	***15,26***	**(1,243,269)**	(15,000,000)	(13,747,867)

Proceeds on loans payable	***15***	**-**	-	112,846,275
Interest paid	***4,15***	**(136,010,583)**	155,699,208	36,970,036
Proceeds from loans payable to a related party	***15***	**1,000,000**	150,437,000	155,600,000
Additional share capital	***4,17***	**40,000**	-	4,290,000
Additional share premium	***4,17***	**-**	-	170,612,333
Proceeds from subscription receivable	***4,17***	**1,160,000**	3,476,500	**-**
Net cash provided by/(used in) financing activities		**(72,973,983)**	289,973,234	462,712,425
NET EFFECT OF EXCHANGE RATE ADJUSTMENTS	***4,6,21***	**(3,505)**	310,228	(18,964)
NET INCREASE (DECREASE) IN CASH		**9,465,042**	8,832,050	(6,515,611)
CASH, beginning of the year	***4,6,26***	**13,830,999**	4,998,949	11,514,560
CASH, END OF THE YEAR	***4,6,26***	**23,296,041**	13,830,999	4,998,949
NONCASH INVESTING ACTIVITIES				
Accrued interest payable	***4,13,26***	**-**	-	25,635,193
Additions to construction-in-progress	***12***	**-**	-	(25,635,193)
		-	-	-

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.

NOTES TO FINANCIAL STATEMENTS
As of and for the years ended December 31, 2025, 2024 and 2023
(Amounts in Philippine Peso)

NOTE 1 - CORPORATE INFORMATION AND STATUS OF OPERATIONS

Corporate Information

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC. (the "Company") was incorporated as a domestic corporation under Philippine laws and was duly registered with the Securities and Exchange Commission (SEC) under registration no. CS201423954 on December 10, 2014.

The Company's primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and businesses such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinics, condo-hospitals, scientific research institutions and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional, medical or surgical services shall be performed by duly qualified and licensed physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The Company is a duly registered Board of Investment (BOI) - Accredited "New Operator of General Hospital" at Level 2 Category on a Non-Pioneering Status with Certificate of Registration No. 2023-065 in accordance with the provisions of the Omnibus Investment Code of 1987 (Executive Order No. 226) and pursuant to Title XIII of the Tax Code of 1997, as amended by Republic Act 11534, or the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.

The Certification entitles the Company to certain major incentives, to wit: (1) Income Tax Holiday (ITH) for six (6) years, Enhanced Deductions for five (5) years and (3) Duty exemptions for eleven (11) years. The Company should have started commercial operations in January 2023 (or within three (3) years from date of registration with the BOI) but availment shall in no case commence earlier than the date of registration with BOI.

The Company was granted by the Philippine Health Insurance Corporation of certificate of accreditation as a Level 2 Hospital (Accredited Beds: 100) which was granted on 6th day of January 2025 the certificate of which shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Philippine Hospital Association of certificate of membership as a Level 2 Hospital (Accredited Beds: 100) on 20th day of December 2024 and this certificate shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Department of Health, as a Level 2 Hospital (Accredited Beds: 100), with license number 06-0023-25-H2-2 and this license to operate shall be valid from January 1, 2025 to December 31, 2025.

On August 2, 2021, and in accordance with the approval of the appropriate regulatory authorities, including the Securities and Exchange Commission, the Company amended its corporate name from Allied Care Experts (ACE) Medical Center – Iloilo, Inc. to Asia Pacific Medical Center – Iloilo, Inc. The change in corporate name did not result in any change in the Company's legal personality, ownership structure, operations, or principal activities. Accordingly, all rights, obligations, contracts, and commitments previously entered into under the former corporate name

remain valid and enforceable and are deemed to continue under the Company's new registered corporate name.

The registered office is located at Barangay Ungka, Jaro, Iloilo City, where the hospital construction site is located.

Status of Operations

The Company commenced full commercial operations of its multi-disciplinary medical facility in 2024. The hospital provides a comprehensive range of services, including in-patient and out-patient care, as well as emergency medical services. Since the start of operations, the respective revenue centers have been activated and progressively scaled to achieve full operational capacity and status.

The activation of these revenue centers reflects the hospital's transition from development to full service delivery, enabling the facility to generate revenues across its core medical disciplines. The commencement of operations in 2024 marked a significant milestone in the Company's strategy to expand its healthcare services and establish a sustainable platform for long-term growth.

The hospital healthcare system is a highly specialized and capital-intensive undertaking. Establishing a multi-disciplinary medical facility requires substantial and sustainable infrastructure investments, which typically take an average of five (5) to seven (7) years after incorporation to complete construction and inaugurate its business line services.

Given the peculiarities of the industry, it generally requires an additional four (4) to five (5) years after inauguration to recover initial capital expenditures and achieve full commercial operations. This extended timeline reflects the scale of investment, the complexity of healthcare infrastructure, and the gradual ramp-up of patient volumes and service utilization.

Against this backdrop, Management is encouraged by the Company's performance. The 47% increase in gross revenues during the current year is well aligned with its projections and demonstrates strong progress toward achieving full competitive status among hospitals in the area. This growth affirms the Company's trajectory toward recovering its initial investments, strengthening its market position, and establishing a sustainable platform for long-term expansion in the healthcare sector.

Management expects continued growth driven by:

- Increasing patient volumes as the hospital builds its reputation and expands its catchment area.
- Diversification of medical services, including specialized care units and advanced diagnostic facilities.
- Operational efficiencies from scaling up revenue centers and optimizing healthcare delivery.
- Competitive positioning within the region, supported by the hospital's modern infrastructure and comprehensive service offerings.

These factors are expected to support the Company's long-term objective of achieving sustainable profitability and securing a strong competitive presence in the healthcare industry.

Management remains confident that the hospital is well-positioned to deliver sustainable healthcare services and long-term value to stakeholders.

Authorization for Issuance of the Financial Statements

The financial statements of the Company as at and for the year ended December 31, 2025, including its comparative figures as at 2024 and 2023, were approved and authorized for issuance by the Board of Directors on May 11, 2026.

NOTE 2 - FINANCIAL REPORTING FRAMEWORK AND BASIS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS

Statement of Compliance

Basis of Preparation

The financial statements of the Company have been prepared in compliance with the Philippine Financial Reporting Standards (PFRS) Accounting Standards which are based on International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB). PFRS consist of PFRS, Philippine Accounting Standards (PAS), and Philippine Interpretations issued by the Financial and Sustainability Reporting Standards Council (FSRSC) and the Board of Accountancy (BOA) and adopted by the Securities and Exchange Commission (SEC).

Basis of Measurement

The financial statements have been prepared under the historical cost basis, unless otherwise stated.

Functional and Presentation Currency

These financial statements are presented in Philippine Peso (PhP), the currency of the primary economic environment in which the Company operates. All amounts are rounded to the nearest peso, except when otherwise indicated.

NOTE 3 - ADOPTION OF NEW AND REVISED ACCOUNTING STANDARDS AND INTERPRETATIONS

Adoption of New and Revised Accounting Standards Effective in 2025

The Company adopted all applicable accounting standards and interpretations as at December 31, 2025. The new and revised accounting standards and interpretations that have been published by the International Accounting Standards Board (IASB) and approved by the Financial and Sustainability Reporting Standards Council (FSRSC) in the Philippines, that were assessed by the Management to be applicable to the Company's financial statements are as follows:

Adoption of Amended Standards Effective Beginning on or after January 1, 2025:

The accounting policies adopted are consistent with those of the previous financial year, except for the adoption of the following new and amended Standard which the Company adopted effective for annual period beginning January 1, 2025.

Unless otherwise indicated, the adoption of the new and amended standard did not have any material effect on the financial statements. Additional disclosures have been included in the notes to financial statements, as applicable.

- Amendments to PAS 21, *The Effects of Changes in Foreign Exchange Rates, Lack of Exchangeability* - The amendments specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking.

New and Amended PFRS and PIC Issuances in Issue but Not Yet Effective or Adopted

Unless otherwise indicated, the Company does not expect that the future adoption of the said pronouncements to have a significant impact on the financial statements.

The Company intends to adopt the following pronouncements when they become effective;

Effective beginning on or after January 1, 2026:

- Amendments to Illustrative Examples on PFRS 7, PFRS 18, PAS 1, PAS 8, PAS 26 and PAS 37, *Disclosures about Uncertainties in the Financial Statements*
- Amendments to PFRS 9 and PFRS 7, *Classification and Measurement of Financial Instruments*
- Amendments to PFRS 9 and PFRS 7, *Contracts Referencing Nature-dependent Electricity*
- Annual Improvements to PFRS Accounting Standards – Volume 11
  - Amendments to PFRS, 1, *Hedge Accounting by a First-time Adopter*
  - Amendments to PFRS 7, *Gain or Loss on Derecognition*
  - Amendments to PFRS 9, *Lease Derecognition of Lease Liabilities and Transaction Price*
  - Amendments to PFRS 10, *Determination of a 'De Facto Agent'*
  - Amendments to PAS 7, *Cost Method*

Effective beginning on or after January 1, 2027:

- PFRS 17, *Insurance Contracts* – The standard will replace PFRS 4, Insurance Contracts. It requires insurance liabilities to be measured at current fulfillment value and provides a more uniform measurement and presentation approach to achieve consistent, principle-based accounting for all insurance contracts. It also requires similar principles to be applied to reinsurance contracts held and investment contracts with discretionary participation features issued.

  On February 14, 2025, the Financial and Sustainability Reporting Standards Council (FSRSC) has approved the amendment to PFRS 17, Date of Initial application. The amendment further defer the date of initial application of PFRS 17 by an additional two years, to annual periods beginning on or after January 1, 2027.

  Under prevailing circumstances, the adoption of the forgoing new and amended PFRS is not expected to have any material effect on the financial statements of the Company. Additional disclosures were included in the financial statements, as applicable.

- PFRS 18, *Presentation and Disclosure in Financial Statements*
- PFRS 19, *Subsidiaries without Public Accountability*

- Amendments to PAS 21, *Translation to a Hyperinflationary Presentation Currency*

Deferred effectivity

- Amendments to PFRS 10, *Consolidated Financial Statements,* and PAS 28, *Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*.

NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING AND FINANCIAL REPORTING POLICIES

The significant accounting policies that have been used in the preparation of these financial statements are summarized below. These policies have been consistently applied to all years presented, unless otherwise stated.

Current versus Noncurrent Classification

The Company presents its assets and liabilities in the statements of financial position based on current/noncurrent classification.

An asset is current when it is:

- expected to be realized or intended to be sold or consumed in the normal operating cycle;
- held primarily for the purpose of trading;
- expected to be realized within twelve months after the reporting period; or
- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as noncurrent.

A liability is current when:

- it is expected to be settled in the normal operating cycle;
- it is held primarily for the purpose of trading;
- it is due to be settled within twelve months after the reporting period; or
- there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company also modifies classification of prior year amounts to conform to current year's presentation.

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability, takes place either:

- in the principal market for the asset or liability; or
- in the absence of a principal market, in the most advantageous market for the asset or liability, the principal or the most advantageous market must be accessible to the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use, or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Financial Instruments

A financial instrument is any contract that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial Recognition and Measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss (FVPL).

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. The Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

In order for a financial asset to be classified and measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)'

on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss.

The Company's business model for managing financial assets refer to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Financial assets at amortized cost (debt instruments);
- Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instrument);
- Financial assets designated at fair value through OCI with no recycling of cumulative gains or losses upon derecognition (equity instruments); and
- Financial assets at fair value through profit or loss.

Financial assets at amortized cost (debt instruments)

Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.

The Company's financial assets at amortized cost includes cash (excluding cash on hand), receivables and advances to related parties as at reporting date (see Notes 6, 7 and 12).

Financial assets at fair value through OCI (debt instruments)

For debt instruments at fair value through OCI, interest income, foreign exchange revaluation, if any, and impairment losses or reversals are recognized in the statements of profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit and loss.

The Company does not have debt instruments designated at fair value through OCI as at reporting dates.

Financial assets designated at fair value through OCI (equity instruments)

Upon initial recognition, the Company can elect to classify irrevocably its equity instruments as equity instruments designated at fair value through OCI when they meet the definition of equity under IAS 32 – *Financial Instruments: Presentation* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statements of profit or loss when the right of payment has been established, except when the Company benefits from such proceeds as recovery of part of the cost of the financial assets, in which case, such gains are recovered in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Company does not have equity instruments designated at fair value through OCI as at reporting dates.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statements of financial position at fair value with net changes in fair value recognized in the statements of profit or loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognized as other income in the statements of profit or loss when the right of payment has been established.

The Company does not have financial assets at fair value through profit or loss as at reporting dates.

Derecognition

The financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's statements of financial position) when:

- the rights to receive cash flows from the asset have expired, or
- the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risk and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risk and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a 'pass-through' agreement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership. When it has neither transferred nor retained substantially all of the risk and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on the basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Reclassification

The Company reclassifies its financial assets when, and only when, it changes its business model for managing those financial assets. The reclassification is applied prospectively from the first day of the first reporting period following the change in the business model (reclassification date).

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVPL, any gain or loss arising from the difference between the previous amortized cost of the financial asset and fair value is recognized in profit or loss.

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVOCI, any gain or loss arising from a difference between the previous amortized cost of the financial asset and fair value is recognized in OCI.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at amortized cost, its fair value at the reclassification date becomes its new gross carrying amount.

For a financial asset reclassified out of the financial assets at FVOCI category to financial assets at amortized cost, any gain or loss previously recognized in OCI, and any difference between the new amortized cost and maturity amount, are amortized to profit or loss over the remaining life of the investment using the effective interest method. If the financial asset is subsequently impaired, any gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

In the case of a financial asset that does not have a fixed maturity, the gain or loss shall be recognized in profit or loss when the financial asset is sold or disposed. If the financial asset is subsequently impaired, any previous gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at FVOCI, its fair value at the reclassification date becomes its new gross carrying amount. Meanwhile, for a financial asset reclassified out of the financial assets at FVOCI category to financial assets at FVPL, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss as a reclassification adjustment at the reclassification date.

Impairment

The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been significant increase in credit risk since initial recognition, a loss is required for credit expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full or in part before taking into account any credit enhancements held by the Company. A financial asset is written off in full or in part when there is no reasonable expectation of recovering the contractual cash flows.

Write-off

Financial assets are written-off when the Company has no reasonable expectations of recovering the financial asset either in its entirety or a portion of it. This is the case when the Company determines that the borrower does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. A write-off constitutes a derecognition event.

Financial Liabilities

Initial Recognition and Measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognized initially at fair value and in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Subsequent Measurement

The measurement of financial liabilities depends on their classified into two categories:

- Financial liabilities at fair value through profit or loss; and
- Financial liabilities at amortized cost (loans and borrowings).

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss are designated upon initial recognition at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by PFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognized in profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in PFRS 9 are satisfied.

The Company has not designated any financial liability at fair value through profit or loss at the end of each reporting period.

Financial liabilities at amortized cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings and other payables are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as "Finance cost" in the statements of comprehensive loss.

The Company's financial liabilities include accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, notes payable and loans payable to a related party (see Notes 12,14, and 15).
Derecognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statements of comprehensive loss.

Fair Value Option

The Company may, at initial recognition, irrevocably designate a financial asset or liability that would otherwise have to be measured at amortized cost or fair value through other comprehensive loss to be measured at fair value through profit or loss if doing so would eliminate or significantly reduce an accounting mismatch or otherwise results in more relevant information.

Classification of Financial Instrument between Liability and Equity

A financial instrument is classified as liability if it provides for a contractual obligation to:

- Deliver cash or another financial asset to another entity;
- Exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavorable to the Company; or
- Satisfy the obligation other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of own equity shares.

If the Company does not have an unconditional right to avoid delivering cash or another financial asset to settle its contractual obligation, the obligation meets the definition of a financial liability.

Offsetting of Financial Instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

The Company assesses that it has currently enforceable right to offset if the right is not contingent on a future event and is legally enforceable in the event of insolvency or bankruptcy of the Company and all of the counterparties.

Cash

Cash in the statements of financial position comprise of cash in banks and on hand that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value.

Advances to Contractors and Suppliers

Advances represent deposits or down payments (ranging from 25% to 50%) paid to contractors, merchants or broker-agents for specific completion or delivery of contractual obligations or service undertakings, including acquisition of medical machineries or clinical apparatus or equipment and medicinal inventories or supplies. These advances which are already paid but not yet incurred will be recognized either as an asset or an expense upon completion or delivery of such obligations, undertakings or acquisitions.

Medical and Hospital Supplies Inventories

Medical and hospital supplies inventories are initially measured at cost. Cost includes all costs of purchases, cost of conversion and other costs incurred in bringing the medical inventories and hospital supplies to their present location and condition. Medical inventories and hospital supplies are subsequently measured at the lower of cost (net realizable value). Cost is determined using the first-in, first-out (FIFO) method. At each reporting date, medical inventories and hospital supplies are assessed for impairment. If medical inventories and hospital supplies is impaired, the impairment loss is recognized immediately in the statements of comprehensive loss.

Prepayments and Other Current Assets

Prepayments represent expenses not yet incurred but already paid in cash. Prepayments are initially recorded as assets and measured at the amount of cash paid. Subsequently, these are charged to profit or loss as they are consumed in operations or expire with the passage of time.

Other current assets represent assets of the Company which are expected to be realized or consumed within one year or within the Company's normal operating cycle whichever is longer. Other current assets are both measured initially and subsequently presented in the financial statements at cost.

Property and Equipment

Property and equipment are initially measured at cost. The cost of an item of property and equipment consists of:

- its purchases price, including import duties and non-refundable purchases taxes, after deducting trade discounts and rebates; and
- any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent expenditures relating to an item of property and medical and hospital equipment that have already been recognized are added to the carrying amount of the asset when it is probable that future economic benefits, in excess of the originally assessed standard of performance of the

existing asset, will flow to the Company. All other subsequent expenditures are recognized as expenses in the period in which those are incurred.

At the end of each reporting period, items of property and equipment except land measured using the cost model are carried at cost less any subsequent accumulated depreciation and impairment losses. Land is carried at cost less any impairment in value. Land is not depreciated.

Land is carried at revalued amounts, being its fair value at the date of revaluation less any subsequent impairment losses. Revaluations are performed with sufficient regularity to ensure that the carrying amount does not differ materially from that which would be determined using fair value at the reporting date. Increases in the carrying amount of land arising from revaluation are recognized in equity under "Revaluation Surplus." Decreases that offset previous increases are charged against the surplus; other decreases are recognized in profit or loss. Land is not depreciated.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, if there is an indication of a significant change since the last reporting date. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

An item of property and equipment shall be derecognized upon disposal or when no future economic benefits are expected from its use or disposal. When assets are derecognized, their costs, accumulated depreciation and amortization and accumulated impairment losses are eliminated from the accounts. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in the statements of comprehensive loss.

Fully depreciated and fully amortized assets are retained by the Company as part of property and equipment until these are derecognized or until they are no longer in use.

Construction-in-progress

Construction-in-progress is stated at cost. This includes the costs related to the construction of the hospital building and installation of medical equipment, property development costs and other direct costs. Cost of borrowings and any additional costs incurred in relation to the project are recognized in this account. Construction-in-progress is not depreciated until such time that the relevant assets are completed and ready for its intended use.

The Company recognizes the effect of revisions in the total project cost estimates in the year in which these changes become known. Any impairment loss from the construction project is charged to operations during the period in which the loss is determined.

During the year, the Construction-in-progress was closed to Building account.

Impairment of Non-Financial Assets

At each reporting dates, the Company reviews the carrying amounts of its non-financial assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. When the asset does not generate cash flows that are independent from the other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of net realizable value and value-in-use. In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated1 than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately.

When an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior years. A reversal of an impairment loss is recognized as income.

Equity

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue cost.

Share capital

Share capital is recognized as issued when the stock is paid for or subscribed under a binding subscription agreement and is measured at par value.

Share premium

Share premium is the difference between the issue price and the par value of the stock and is known as securities premium. The shares are said to be issued at a premium when the issue price of the share is greater than its face value or par value.

Deficit

Deficit represents accumulated losses incurred by the Company. Deficit may also include effects of changes in accounting policy as may be required by the standard's transitional provision.

Other comprehensive income (loss)

Other comprehensive income (loss) is defined as comprising items of income and expense that is not recognized in profit or loss as required or permitted by other standards.

Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Revenue is measured by reference to the fair value of consideration received or receivable excluding discounts, returns and sales taxes. Revenue is recognized at a point in time or over a period of time.

Hospital services – Revenue from in-patient, out-patient, and emergency services is recognized when the services are rendered.

Sale of medicines and medical goods – Revenue is recognized at the point in time when control of the goods passes to the customer, generally upon delivery or sale at the hospital pharmacy.

Revenue recognition outside the Scope of PFRS 15

Interest Income

Interest income is recognized as it accrues, using the effective interest method under PFRS 9 – Financial Instruments. This approach reflects the effective yield on the related financial asset and allocates interest income over the relevant period in a manner that produces a constant periodic rate of return on the carrying amount of the asset.

Other Income

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

Costs and Expense Recognition

The Company presents expenses in the statement of income using the function of expense method. Direct costs represent expenses incurred that are specifically associated with the services rendered, while operating expenses include costs attributable to general, administrative, and other business activities. Expenses are recognized in profit or loss on accrual basis, meaning they are recorded when incurred and not when paid. Costs are matched with related income when association can be directly established, or allocated systematically when benefits are expected to arise over several periods. Expenditures that do not generate future economic benefits are recognized immediately in profit or loss.

Related Party Relationships and Transactions

Related party relationship exists when one party has the ability to control, directly, or indirectly through one or more intermediaries, the other party or exercises significant influence over the other party in making financial and operating decisions. Such relationships also exist between and/or among entities which are under common control with the reporting enterprise, or between, and/or among the reporting enterprise and its key management personnel, directors, or its shareholders. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

A related party transaction is a transfer of resources, services or obligations between related parties, regardless of whether a price is charged.

Foreign Currency Transactions

Transactions in currencies other than functional currency of the Company are recorded at the rates of exchange prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing at the end of the reporting period.

Employee Benefits

Employee benefits are all forms of consideration given by an entity in exchange for services rendered by its employees.

Short-term Benefits

Short-term employee benefits are those benefits expected to be settled wholly before twelve months after the end of the annual reporting period during which employee services are rendered, but do not include termination benefits. Short-term benefits given by the Company to its employees include salaries and wages, social security, health insurance and housing contributions, short-term compensated absences, bonuses and other non-monetary benefits. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

Retirement or Post-employment Benefits

The Company is subject to the provisions of Republic Act No. 7641 (known as the Retirement Law). This requires that in the absence of a retirement plan, an agreement providing benefits for retiring employees in the private sector, an employee upon reaching the age of 60 years or more, but not beyond 65 years, who has served at least 5 years in service, may retire and shall be entitled to a retirement pay equivalent to at least ½ month's salary for every year of service, fraction of at least 6 months being considered as 1 whole year. The current service cost is the present value of benefits, which accrue during the last year.

As at reporting date, the Company has not yet established a Retirement Benefits Plan for its employees since to date no employee is entitled to retirement benefits. The Company started commercial operation in December 2023.

Borrowing costs

Borrowing costs are generally recognized as expense in the year in which these costs are incurred. However, borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized. Capitalization of borrowing costs commences when the activities necessary to prepare the asset for intended use are in progress and expenditures and borrowing costs are being incurred. Borrowing costs are capitalized until the asset is available for their intended use. It includes interest expense, finance charges in respect of finance leases and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

Income Tax

Income tax expense represents the sum of the current tax expense and deferred tax expense.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the statements of comprehensive loss because it excludes items of income or

expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

Deferred tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax base used in the computations of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognized if the temporary difference arises from the initial recognition of goodwill.

The carrying amount of deferred tax assets is reviewed at each reporting dates and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Earnings (Loss) per Share

Basic earnings (loss) per share is calculated by dividing income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the year, after giving retroactive effect to any bonus issued/declared during the year, if any.

For the purpose of calculating diluted earnings per share, profit or loss for the year attributable to ordinary equity holders of the Company and the weighted average number of shares outstanding are adjusted for the effects of all dilutive potential ordinary shares.

Reclassification of Comparative amounts

In 2025, certain amounts in the comparative financial statements and notes disclosures have been reclassified to conform with current year's presentation.

Management believes that the foregoing reclassifications would reflect the true nature of the transactions and correct the classification, as well as conform to the prevailing standards, - which did not have any impact on prior year's statement of receipts and expenses and current standing (please refer to Note 13).

Summary of changes on liabilities arising from the reclassification are shown below:

Account	December 31, 2024 (Previously Stated)	Effect	December 31, 2024 (As reclassified)
ACCOUNTS PAYABLE AND OTHER LIABILITIES			
Accounts payable – contractors and suppliers[1)]	P 339,278,543	(68,409,287)	P 270,869,256
Accrued interest payable[2)]	95,515,462		95,515,462

Accounts payable – nontrade [4)]	33,513,950	35,497,050	69,011,000
Retention payable[3)]	42,061,657		42,061,657
Accrued expenses[5)]	13,359,749	3,904,654	17,264,403
Statutory liabilities[6)]	1,737,537		1,737,537
Other payables	3,997,120	29,007,583	33,004,703
TOTAL ACCOUNTS PAYABLE AND OTHER LIABILITIES	529,464,018	–	529,464,018

The reclassifications had no impact on current income tax and deferred tax, as the adjustments were limited to liability accounts only.

NOTE 5 - CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on the historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Judgments, estimates and assumptions are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The effects of any change in estimates are reflected in the financial statements as they become reasonably determinable.

Judgments in Applying the Company's Accounting Policies

In the process of applying the Company's accounting policies, management has made the following judgments, apart from those involving estimations, which have the most significant effect on the amounts recognized in the financial statements:

Business Model Assessment

Classification and measurement of financial assets depends on the results of the Solely Payments of Principal and Interest (SPPI) and the business model test. The Company determines the business model at a level that reflects how groups of financial assets are managed together to achieve a particular business objective. This assessment includes judgment reflecting all relevant evidence including how the performance of the assets is evaluated and their performance measured, the risks that affect the performance of the assets and how these are managed and how the managers of the assets are compensated. Monitoring is part of the Company's continuous assessment of whether the business model for which the remaining financial assets are held continues to be appropriate and if it is not appropriate, whether there has been a change in business model and so a prospective change to the classification of those assets.

Significant Increase of Credit Risk

Where the fair values of financial assets and financial liabilities recorded on the statement of financial position cannot be derived from active markets, they are determined using internal valuation techniques using generally accepted market valuation models. The input to these models is taken from observable markets where possible, but where this is not feasible, estimates are used in establishing fair values. These estimates may include considerations of liquidity, volatility and correlation.

Functional Currency

Based on the economic substance of the underlying circumstances relevant to the Company, the functional currency of the Company has been determined to be the Philippine Peso (₱). It is the currency that mainly influences the Company's operations.

Classification of Financial Instrument

The Company classifies a financial instrument, or its component parts, on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual agreement and the definitions of a financial asset, a financial liability or an equity instrument. The substance of a financial instrument, rather than its legal form, governs its classification in the statement of financial position.

Determination of Whether a Lease is a Finance or Operating Lease

The evaluation of whether an arrangement contains a lease is based on its substance. An arrangement is, or contains, a lease when the fulfillment of the arrangement depends on a specific asset or assets and the arrangement conveys the right to use the asset.

Recognition of Deferred Income Taxes

Significant judgment is required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain in the ordinary course of business. Recognition of deferred income taxes depends on management's assessment of the probability of available future taxable income against which the temporary difference can be applied.

Impairment of Non-Financial Assets

Property and equipment, inventories and intangible assets are periodically reviewed to determine any indications of impairment. Though the management believes that the assumptions used in the estimation of fair values are reasonable and appropriate, significant changes in these assumptions may materially affect the assessment of the recoverable amounts and any resulting impairment loss could have a material adverse effect in the results of operations.

Provisions and Contingencies

Judgment is exercised by management to distinguish between provisions and contingencies. Policies on recognition and disclosure of provision and disclosure of contingencies are discussed in Note 4, subheading "*Provisions and Contingencies*."

Estimates and Assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the financial reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year are discussed below:

Assessment for ECL on Other Financial Assets at Amortized Cost

The Company determines the allowance for ECL using general approach based on the probability-weighted estimate of the present value of all cash shortfalls over the expected life of financial assets at amortized cost. ECL is provided for credit losses that result from possible default events within the next 12-months unless there has been a significant increase in credit risk since initial recognition in which case ECL is provided based on lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not represent a significant risk in credit risk such as when non-payment was an administrative oversight rather than resulting from financial difficulty of the borrower.

The Company has assessed that the ECL on other financial assets at amortized cost is not material because the transactions with respect to these financial assets were entered into by the Company only with reputable banks and companies with good credit standing and relatively low risk of defaults. Accordingly, no provision for ECL on other financial assets at amortized cost was recognized as at December 31, 2025 and 2024.

The carrying amounts of other financial assets at amortized cost are as follows:

	2025	2024
Cash in banks*	**22,446,473**	10,956,804
Receivables	**165,796,569**	82,430,163
	188,243,042	93,386,967

**excluding petty cash fund amounting to ₱849,568 as at December 31, 2025 and ₱2,874,195 in 2024.*

Assessment for Impairment of Non-financial Assets

The Company assesses impairment on non-financial assets whenever events or changes in circumstances indicate that the carrying amount of the assets or group of assets may not be recoverable. The relevant factors that the Company considers in deciding whether to perform an asset impairment review include, among others, the following:

- Significant underperformance of a business in relation to expectations;
- Significant negative industry or economic trends; and
- Significant changes or planned changes in the use of the assets.

Whenever the carrying amount of an asset exceeds its recoverable amount, an impairment loss is recognized. Recoverable amounts are estimated for individual assets or, if it is not possible, for the cash-generating unit to which the asset belongs.

The recoverable amount of the asset is the greater of the fair value less cost of disposal or value in use. The fair value less cost of disposal is the amount obtainable from the sale of an asset in an arm's-length transaction. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

No impairment loss on non-financial assets was recognized as at December 31, 2025 and 2024.

The carrying amounts of non-financial assets are as follows:

	2025	2024
Advances to contractors	**26,481,056**	26,488,134
Advances to suppliers	**45,968,003**	21,088,595
Medical and hospital supplies inventories	**59,994,528**	75,662,389
Prepayments and other current assets	**28,714,938**	16,812,711
Property and equipment (net)	**2,357,222,256**	2,238,660,948
Advances to related parties	**6,950,256**	39,030,125
	2,525,331,038	2,417,742,902

Estimating Useful Lives of Assets

The Company estimates the useful lives of property and equipment and intangible assets based on the period over which the assets are expected to be available for use. The estimated useful lives of property and equipment and intangible assets are reviewed periodically and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence and legal or other limits on the use of the assets. In addition, estimation of the useful lives of property and equipment and intangible assets is based on collective assessment of industry practice, internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in estimates brought about by changes in factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of property and equipment and intangible assets would increase recorded operating expenses and decrease non-current assets.

Depreciation is calculated on a straight-line basis over the following estimated useful lives of the assets:

Categories	**Estimated Useful Life**
Building	50 years
Building improvement	50 years
Office equipment	3 - 5 years
Medical equipment	5 years
Hospital equipment	5-10 years
IT equipment and software	5 years
Kitchen tools	3-5 years
Hospital vehicle	5 years

As at December 31, 2025 and 2024, the Company's property and equipment had carrying amounts of ₱2,357,222,256 and ₱2,238,660,948, respectively, as disclosed in Note 11, and includes land and revaluation of the land.

Revaluation of Land

Management exercises judgement in determining whether the revaluation model provides a more reliable measure of the land's value compared to the cost model. This includes assessing the frequency of revaluations, the appropriateness of valuation techniques, and the independence and qualifications of external valuers. Judgement is also applied in deciding whether market transactions used as comparables are sufficiently similar to the Company's land holdings.

The fair value of land is determined based on market evidence of recent transactions for comparable properties. Significant assumptions include:

- Comparable property selection and adjustments for location, size, and use;
- Market conditions prevailing at the valuation date; and
- The absence of restrictions or encumbrances affecting the land's marketability.

Because these assumptions involve estimation, actual outcomes may differ, and future revaluations could result in material changes to the carrying amount of land and the related revaluation surplus.

Asset impairment other than goodwill

The Company performs an impairment review when certain impairment indicators are present.

Determining the recoverable amount of property and equipment, which require the determination of future cash flows expected to be generated from the continued use and ultimate disposition of such assets, requires the Company to make estimates and assumptions that can materially affect the financial statements. Future events could cause the Company to conclude that property and equipment are impaired. Any resulting impairment loss could have a material adverse impact on the financial condition and results of operations.

The preparation of the estimated future cash flows involves significant judgment and estimations. While the Company believes that its assumptions are appropriate and reasonable, significant changes in the assumptions may materially affect the assessment of recoverable values and may lead to future additional impairment charges.

As at December 31, 2025 and 2024, Management believes that the recoverable amounts of the Company's property and equipment approximate its carrying amounts. Accordingly, no impairment loss was recognized in both years.

Deferred tax assets

The Company reviews the carrying amounts of deferred tax assets at each financial reporting date and reduces deferred tax assets to the extent that it is no longer probable that sufficient future taxable income will be available to allow all or part of the deferred tax assets to be utilized. The Company did not recognize net deferred tax assets as at December 31, 2025 and 2024.

Deferred tax assets with full valuation allowance as at December 31, 2025, 2024 and 2023 amounted to ₱203,757,869, ₱168,867,765, and ₱69,505,158, respectively (see Note 23).

NOTE 6 - CASH

This account consists of:

	2025	2024
Cash in banks	**22,446,473**	10,956,804
Petty cash fund and cash on hand	**849,568**	2,874,195
	23,296,041	13,830,999

Cash includes petty cash fund and cash on hand and in banks that are unrestricted and available for current operations. This is stated in the statements of financial position at face amount.

Cash in banks generally earn interest at the prevailing bank's deposit rates. Interest earned from bank accounts amounted to ₱1,002, ₱2,106, and ₱19,158 in 2025, 2024 and 2023, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

Unrealized foreign exchange gain (loss) resulting from translation of foreign currency-denominated cash in bank into Philippine peso amounted to ₱3,505, (₱310,228) and ₱18,964 in 2025, 2024 and 2023, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

NOTE 7 - RECEIVABLES

This account consists of:

	2025	2024
Accounts receivable-government agencies[1)]	**90,686,847**	43,765,140
Due from HMO's[2)]	**50,848,955**	23,223,034
Other receivables[3)]	**14,197,241**	6,904,128
Deposits[4)]	**5,035,000**	5,035,000
Advances to employees and officers[5)]	**5,028,526**	3,502,861
	165,796,569	82,430,163

[1)]Accounts receivable pertains to financial assistance availed of by patients from the Department of Social Welfare and Development (DSWD), Philippine Health Insurance Corporation (PhilHealth) and Philippine Charity Sweepstakes Office (PCSO) and reimbursable to the company.

[2)]Due from HMO's pertains to reimbursements for hospital expenses and doctors' fees availed of by patients who are members of Health Maintenance Organization (HMOs).

[3)]Other receivables – represent promissory notes from local area patients which are collected in installments or staggered payments due within the year.

[4)] Deposits represent payments made by the Company to More Power Corporation, to Iloilo Medical Society, and to the Department of Health in connection with regulatory application requirements for the Company's drug testing services operations. These deposits are expected to be applied or recovered in accordance with the terms and conditions of the related agreements and regulatory requirements.

[5)]Advances to employees and officers represent advances that are deducted directly from payroll.

In determining the recoverability of receivables, the Company considers any change in the credit quality of the receivable from the date credit was initially granted up to the end of the reporting period. Considering that majority of the accounts are relatively guaranteed by accredited providers, the Company believes that no estimated credit loss is required for both years.

NOTE 8 - ADVANCES TO CONTRACTORS AND SUPPLIERS

This account consists of:

	2025	2024
Advances to contractors[1)]	**26,481,056**	26,488,134
Advances to suppliers[2)]	**45,968,003**	21,088,595
	72,449,059	47,576,729

[1)] Advances to contractors represent advances for each awarded project activity and are liquidated via deduction, on a pro-rata basis, from the contractor's periodic progress billings.

[2)] Advances to suppliers are downpayments made to suppliers of medical equipment and/or construction materials ordered. The amounts represent 15% - 50% of the total contract price of the items purchased.

NOTE 9 - MEDICAL AND HOSPITAL SUPPLIES INVENTORIES

This account consists of:

	2025	2024
Medical and laboratory supplies[1)]	**25,458,660**	35,412,213
General hospital maintenance supplies[2)]	**20,137,406**	22,887,457
Drugs and medicines for sale[3)]	**14,398,462**	17,362,719
	59,994,528	75,662,389

[1)]Medical and laboratory supplies refer to a wide array of materials, in the form of test or culture tubes and vessels, consumables, reagents, medical media and sera, etc., which are used in medical chemistry and various laboratory tests.

[2)]General hospital maintenance supplies pertain to purchases of cleaning and sanitation supplies for the hospital upkeep and general housekeeping.

[3)]Drugs and medicines for sale are medicinal and therapeutic substances (in capsule, tablet or liquid forms) available at the Hospital's pharmacy which are intended for patient care and treatment.

NOTE 10 - PREPAYMENTS AND OTHER CURRENT OTHERS

This account consists of:

	2025	2024
Input tax	**24,371,398**	12,424,124
Prepaid income tax (Note 24)	**3,522,368**	953,920
Prepaid insurance	**821,172**	1,535,864
Prepaid taxes and licenses	–	1,898,803
	28,714,938	16,812,711

NOTE 11 - PROPERTY AND EQUIPMENT (net)

Reconciliation of property and equipment (net) as at December 31, 2025 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	**28,291,630**	**1,836,316,739**	**33,721**	**3,427,143**	**355,432,128**	**114,697,074**	**13,835,359**	**32,215,795**	**10,478,200**	**2,394,727,789**
Additions	**–**	**–**	**74,187**	**119,988**	**23,459,584**	**516,153**	**402,660**	**–**	**–**	**24,572,572**
At end of year	**28,291,630**	**1,836,316,739**	**107,908**	**3,547,131**	**378,891,712**	**115,213,227**	**14,238,019**	**32,215,795**	**10,478,200**	**2,419,300,361**
Accumulated depreciation:										
At beginning of year	**–**	**36,726,335**	**3,934**	**1,576,267**	**70,413,534**	**29,905,788**	**6,256,872**	**9,088,471**	**2,095,640**	**156,066,841**
Depreciation	**–**	**36,726,335**	**15,249**	**590,365**	**74,338,896**	**27,989,028**	**2,520,962**	**6,443,159**	**2,095,640**	**150,719,634**
At end of year	**–**	**73,452,670**	**19,183**	**2,166,632**	**144,752,430**	**57,894,816**	**8,777,834**	**15,531,630**	**4,191,280**	**306,786,475**
Appraisal increase (Note 17):										
At beginning of year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
Increase for the year	**244,708,370**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**244,708,370**
At end of year	**244,708,370**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**244,708,370**
Net carrying value, December 31, 2025	**273,000,000**	**1,762,864,069**	**88,725**	**1,380,499**	**234,139,282**	**57,318,411**	**5,460,185**	**16,684,165**	**6,286,920**	**2,357,222,256**

Reconciliation of property and equipment (net) as at December 31, 2024 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	28,291,630	–	–	17,362,737	345,534,261	112,390,315	30,658	32,007,967	–	535,617,568
Additions	–	1,836,316,739	33,721	135,024	9,897,867	2,306,759	–	207,828	10,478,200	1,859,376,138
Reclassification	–	–	–	(14,070,618)	–	–	14,070,618	–	–	–
Retirement	–	–	–	–	–	–	(265,917)	–	–	(265,917)
At end of year	28,291,630	1,836,316,739	33,721	3,427,143	355,432,128	114,697,074	13,835,359	32,215,795	10,478,200	2,394,727,789
Accumulated depreciation:										
At beginning of year	–	–	–	5,136,096	–	–	–	2,658,677	–	7,794,773
Depreciation		36,726,335	3,934	655,926	70,413,534	29,476,120	2,470,785	6,429,794	2,095,640	148,272,068
Reclassification	–	–	–	(4,215,755)	–	429,668	3,786,087	–	–	–
At end of year	–	36,726,335	3,934	1,576,267	70,413,534	29,905,788	6,256,872	9,088,471	2,095,640	156,066,841
Net carrying value, December 31, 2024	28,291,630	1,799,590,404	29,787	1,850,876	285,018,594	84,791,286	7,578,487	23,127,324	8,382,560	2,238,660,948

No assets were used as collateral for any liability as of December 31, 2025 and 2024.

Depreciation on medical and hospital equipment shall commence when it is available for use – when it is in the location and condition necessary to be capable of operating in the manner intended by the Management. The depreciation expense of medical and hospital equipment amounting to ₱102,327,924 and 99,889,654 in 2025 and 2024 was charged to cost of services (see Note 20).

The Company has a total contract commitment to purchase medical equipment totaling ₱454,370,959 as at December 31, 2023. Advances to ACE hospitals, Endure Medical, Inc. and TIPP Digital Solutions Inc. amounting to ₱39,030,125 (Note 12) was recognized in the books as it represents advance payment for such medical equipment.

The land covered by TCT No. 095-2015000546 and TCT No. 095-2015000547 represent the area located at Barangay Sambag, Jaro District, Iloilo City, Panay Island, where the Company constructed a multidisciplinary special medical facility (hospital) (Note 12) and is the subject of a real estate mortgage as disclosed in Note 15.

During the year, the Company has had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026 by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. The valuation was determined as of December 31, 2025.

As a result of the appraisal conducted by an independent appraiser, the carrying amount of land increased by ₱244,708,370, which was recognized in equity under Revaluation Surplus in accordance with the applicable financial reporting framework. Accordingly, the land is carried at its revalued amount or fair market value of ₱273,000,000 as of December 31, 2025 (see Notes 11, 16 and 18).

Management has reviewed the carrying values of property and equipment as at December 31, 2025 and 2024, for any impairment. Based on the results of its evaluation, there are no indications that these assets are impaired.

NOTE 12 - RELATED PARTY TRANSACTIONS

In the normal course of business, the Company transacts with companies/individuals, which are considered related parties. The following transactions were carried out with related parties as at December 31, 2025 and 2024:

Advances to related parties:

Category	Outstanding Balance 2023	Amount of Transactions 2024	Outstanding Balance 2024	**Amount of Transactions 2025**	**Outstanding Balance 2025**	Terms	Conditions
Receivable – others (various ACE hospitals – note 7)	47,472	–	47,472	–	**47,472**	Non-interest bearing, to be collected in cash	Unsecured, unguaranteed, not impaired
Endure Medical, Inc. (note 7)	32,079,869	–	32,079,869	**(32,079,869)**	**–**	Non-interest bearing, to be collected in cash (a)	Unsecured, unguaranteed, not impaired

TIPP Digital Solutions Inc.	6,902,784	–	6,902,784	–	**6,902,784**	Non-interest bearing, to be collected in cash (b)	Unsecured, unguaranteed, not impaired
	39,030,125	–	39,030,125	**(32,079,869)**	**6,950,256**		

Advances from related parties:

Category	Outstanding Balance 2023	Amount of Transactions 2024	Outstanding Balance 2024	**Amount of Transactions 2025**	**Outstanding Balance 2025**	Terms	Conditions
Accounts Payable - Endure Medical, Inc.	45,233,526	18,534,833	63,768,359	**(3,091,827)**	**60,676,532**	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans payable to a related party	393,434,969	150,437,000	543,871,969	**1,000,000**	**544,871,969**	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	438,668,495	168,971,833	607,640,328	**(2,091,827)**	**605,548,501**		

Accounts payable – Endure Medical, Inc. is included under accounts payable – contractors and suppliers amounting to P60,676,532, P63,768,359, and P45,233,526 as of December 31, 2025, 2024, and 2023, respectively (see Note 13).

(a) Advances to a related party - Endure Medical, Inc.

The Company engaged the services of an indentor (Endure Medical, Inc.) which has relatively significant influence over the key management personnel of the Company. The Indentor facilitates the importation and acquisition of medical and hospital equipment, furniture and fixtures for the hospital building under construction (see Note 11).

The foregoing is classified as a related party transaction(s) (pursuant to the condition set forth in PAS 24), wherein the key management personnel of Endure Medical, Inc. has significant influence over the Company and its key officer.

(b) Advances to a related party - TIPP Digital Solutions Inc.

The account represents a 15% downpayment made for the acquisition of Healthcare Management Information System.

(c) Loans payable to a related party

The account represents an unsecured interest-bearing loan from Phil Pharmawealth, Inc., which has relatively significant influence over a key management personnel of the Company. The loan was incurred for payment of interest with Land Bank of the Philippines (LBP). The loan bears an interest rate ranging from 6.50%-8.50% per annum. Interest incurred for the years ended December 31, 2025, 2024 and 2023 and is reflected in the statements of comprehensive loss amounted to ₱72,419,241, ₱56,927,769, and ₱20,959,616, respectively. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Key Management Personnel Compensation

Key management compensation amounted to ₱5,895,813, ₱7,571,693, and ₱3,330,000 for the years ended December 31, 2025, 2024, and 2023, respectively. These amounts are incorporated in the salaries and allowances account in the financial statements.

NOTE 13 - ACCOUNTS PAYABLE AND OTHER LIABILITIES

This account consists of:

	2025	2024
Accounts payable – contractors and suppliers[1)]	**308,165,389**	270,869,256
Accrued interest payable[2)]	**160,840,676**	95,515,462
Accounts payable – nontrade [3)]	**110,346,682**	69,011,000
Retention payable[4)]	**40,795,308**	42,061,657
Accrued expenses[5)]	**6,725,263**	17,264,403
Statutory liabilities[6)]	**2,999,859**	1,737,537
Other payables[7)]	**59,666,393**	33,004,703
	689,539,570	529,464,018

[1)] Accounts payable – contractors and suppliers represent unpaid billings of the contractors and balances of equipment already installed in the construction building as of reporting date. This payable also included the related party of Endure Medical, Inc. (see note 12). This account is non-interest bearing, unsecured and non-collateral.

[2)] Accrued interest payable refers to interest expense incurred on loans from bank.

[3)] Accounts payable – nontrade pertains to unsettled fees to medical practitioners, legal, and other consultancy fees. It also includes obligations to housekeeping supplies and construction, which is a significant portion of the account.

[4)] Retention payable refers to the amount withheld by the Company from the contractor's periodic progress billings as provided for in their respective contract. This shall be released to the contractor, net of deductions, if any, upon full completion and turnover of the project and final acceptance by the Company.

[5)] Accrued expenses are normally settled within one year from financial reporting date.

[6)] Statutory liabilities pertain to tax withheld from payment to suppliers, employees' compensation and statutory contributions to SSS, PHIC and HDMF.

[7)] Other payables represent liabilities to suppliers and other parties for which no specific account classification has been designated. This account also includes payables pertaining to reimbursements, patient refunds, advances from officers and employees, and replenishment of the petty cash fund, which are non-interest bearing, non-collateralized, and payable on demand.

NOTE 14 - LOANS PAYABLE TO INDIVIDUALS

This account constitutes non-interest bearing, non-collateral and demandable obligations to shareholders which was primarily used by the Company to support the preliminary financing aspect

of the construction of the hospital structure amounting to P15,703,226 as of December 31, 2025 and 2024.

NOTE 15 - NOTES PAYABLE

Movement of notes payable as at December 31 is as follows:

	2025	2024
Beginning	**970,594,306**	985,594,306
Availment	**48,756,731**	-
Payment	**(20,000,000)**	(15,000,000)
	999,351,037	970,594,306

Notes payable are presented in the financial statements as follows:

	2025	2024
Current	**191,558,072**	15,000,000
Non-current	**807,792,965**	955,594,306
	999,351,037	970,594,306

The Landbank of the Philippines – Iloilo Branch (LBP – Iloilo) extended to the Company several term loans equivalent to a credit line facility totaling **₱1.060 BILLION** to finance the construction of hospital structure and the acquisition of various medical equipment and fixtures.

The foregoing credit line facility consists of a term loan 1 the availment of which was granted on 2015 amounting to **₱465 MILLION** allotted to finance the construction of hospital building. However, term loan 2 availment amounting to **₱35 MILLION** was eventually cancelled or withdrawn. Subsequently, the bank approved on July 31, 2019, term loan 3 in the amount of **₱195 MILLION** for hospital structure and term loan 4 amounting to **₱400 MILLION** allotted for the acquisition of medical equipment and fixtures.

The loan is available in several drawdowns, payable ranging from 8 years to 10 years in ladderized quarterly amortizations, including grace periods ranging from 1 year to 4 years on principal amortization, with an interest rate of 5% to 6.63% per annum payable quarterly in arrears from date of loan release.

As discussed in Note 11, the loan is collaterized and secured by a Real Estate Mortgage (REM) on both parcels of land owned by the Company, including present and future improvements thereon and Chattel Mortgage on various medical equipment, furniture, and fixtures.

On November 29, 2023, Land Bank of the Philippines approved the restructuring of the total outstanding balance of Term Loans 1, 3, and 4 amounting to ₱985,594,306. The restructuring extended the repayment period up to seven (7) years from the date of effectivity, with a one (1) quarter grace period on both principal and interest.

In 2024, the Bank further approved Term Loan 6 and a Working Capital Line amounting to ₱70 million and ₱30 million, respectively.

As of December 31, 2025 and 2024, the Company's total outstanding loans and borrowings amounted to ₱999,351,037 and ₱970,594,306, respectively. Correspondingly, interest expense recognized in profit or loss for the years then ended amounted to ₱72,419,241 in 2025 and

₱98,771,439 in 2024. Due to the restructuring arrangement, the finance costs related to these loans cannot be specifically allocated to the hospital building and medical equipment and fixtures.

Since the hospital structure is already in the state of its intended use (operational), the related borrowing costs (finance costs) are no longer allocated, yet rather - charged to and absorbed by operations. Hence, the total finance cost for the years 2025, 2024 and 2023 were presented as follows:

	2025	2024	2023
A. Construction in Progress			
a.) Construction of hospital building	–	–	38,111,109
b.) Medical equipment and fixtures	–	–	16,010,421
Sub-total	–	–	54,121,530
B. Operations	**136,010,583**	155,699,208	36,970,036
Total	**136,010,583**	155,699,208	91,091,566

NOTE 16 - DEFERRED TAX LIABILITY

Deferred tax liability is measured at the tax rate applied in which the liability is recognized based on the tax regulation rate enacted by the end of the reporting period. It is computed and determined by the product or equivalent of the 25% tax regulation rate as applied to the total revaluation surplus amounting to P244,708,370 and nil as of December 31, 2025 and 2024 (see Note 11).

Deferred tax liability resulting from the revaluation of land is as follows:

	2025	2024
Deferred tax liability	**61,177,093**	–

NOTE 17 - SHARE CAPITAL

Details of the Company's share capital as at December 31, 2025 are as follows:

	No. of Shares	**Amount**
Authorized share capital – ₱1,000 par value		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total authorized share capital	**240,000**	**240,000,000**
Subscribed share capital:		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total subscribed share capital	**240,000**	**240,000,000**
Paid-up share capital:		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total paid-up share capital	**240,000**	**240,000,000**

Details of the Company's share capital as at December 31, 2024 are as follows:

	No. of Shares	Amount
Authorized share capital – ₱1,000 par value		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total authorized share capital	240,000	240,000,000

Subscribed share capital:		
Founder shares	600	600,000
Common shares	239,360	239,360,000
Total subscribed share capital	239,960	239,960,000

Paid-up share capital:		
Founder shares	600	600,000
Common shares	239,360	239,360,000
Total paid-up share capital	239,960	239,960,000

In 2018, the Company filed a Registration Statement covering the proposed Initial Public Offering (IPO) of its 36,000 common shares. Said registration statement was approved on December 27, 2019, in accordance with the provisions of the SEC's Securities Regulation Code (see Note 1).

As of date, pursuant to SEC's approval, the Company issued a total of **THIRTY-SIX THOUSAND (36,000)** common shares. The related share premium after deducting transaction costs associated with the issuance of shares amounted to ₱957,372,662. The common share offer price amounted to ₱250,000 up to ₱400,000 per block [one (1) block = ten (10) common shares].

Founder shares have the exclusive right to vote and be voted upon as directors for five (5) years from the date of SEC registration. Thereafter, the holders of Founder's shares shall have the same rights and privileges as holders of common shares.

NOTE 18 - REVALUATION SURPLUS

The Company's revaluation surplus amounting to ₱244,708,370 is the difference between the market value of ₱273,000,000 and the land's initial cost as at December 31, 2025. The valuation of its parcels of land was performed by independent appraisers and reflected in its report of March 2026 covering December 31, 2025. The fair value was determined by reference to market transactions on an arm's length term at the date of valuation (see Notes 11 and 16).

The value of the parcels of land was arrived at using a combination of cost and market (or direct sales comparison) approach. Cost approach is based on the principle of substitution, which holds that an informed buyer would not pay more for a given property than the cost of an equally desirable alternative. Market data approach is an appraisal technique in which the market value estimate is predicted based upon prices paid in actual market transactions and current listings, the former fixing the lower limit of value in a static or advancing market (pricewise) and fixing the higher limit of value in a declining market; and the latter fixing the higher limit in any market.

NOTE 19 - REVENUES

Revenues for the year ended are as follows:

	2025	2024	2023
Sale of services	**514,069,665**	349,859,649	7,024,531
Sale of goods	**5,847,025**	2,952,362	55,823
	519,916,690	352,812,011	7,080,354
Less: Sales discount on services	**(67,672,300)**	(43,380,347)	(954,589)
Sales discount on goods	**(46,026)**	(1,221,433)	(21,006)
Sales return and allowances	**(32,698)**	(300,205)	(109,394)
	(67,751,024)	(44,901,985)	(1,084,989)
Net Revenues	**452,165,666**	307,910,026	5,995,365

Sale of services pertains to billings for patient care services, including doctors' appointments and consultancies, surgical procedures, medical chemistry and laboratory analyses and ancillary services.

Sale of goods refers to the sale of medications and medical supplies provided to patients during their stay or confinement or as part of their treatment plan.

Discounts and allowances – are cost of provision for free services at certain times, discounts or returns to underprivileged patients, senior citizens and employees.

An analysis in the timing of revenue recognition is as follows:

	2025	2024	2023
Revenue recognized over the period of time	**452,165,666**	307,910,026	5,995,365

NOTE 20 - DIRECT COSTS

This account consists of the following:

	2025	2024	2023
Cost of hospital services:			
Hospital supplies	**136,033,287**	102,251,913	1,379,238
Depreciation	**102,327,924**	99,889,654	–
Salaries and wages	**21,140,534**	37,167,173	1,055,245
Professional fees	**-**	27,184,394	3,644,291
Utilities	**-**	2,274,166	48,681
	259,501,745	268,767,300	6,127,455

Direct costs are explicit expenditures with specific identification to the corresponding cost centers of hospital services.

NOTE 21 - OTHER INCOME

Details of account consist of:

	2025	2024	2023
Unrealized foreign exchange gain (Note 6)	**3,505**	(310,228)	18,964
Interest income (Note 6)	**1,002**	2,106	19,158
Other income	**10,310,474**	1,490,856	32,953
	10,314,981	1,182,734	71,075

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

NOTE 22 - GENERAL AND ADMINISTRATIVE EXPENSES

Details of accounts consist of:

	Notes	**2025**	2024	2023
Salaries and allowances		**111,313,162**	87,491,420	65,369,297
Utilities		**54,800,309**	51,738,090	8,323,809
Depreciation	*11*	**48,391,711**	48,382,414	5,394,843
Professional and legal fees		**25,287,779**	33,272,069	1,193,873
SSS, PHIC and HDMF contributions		**13,743,882**	14,586,982	7,865,598
Security services		**12,334,776**	8,684,813	3,074,911
Housekeeping		**9,322,573**	8,415,291	460,633
Office supplies		**7,827,951**	8,509,166	3,501,593
Taxes and licenses		**5,802,631**	6,926,145	7,417,040
Repairs and maintenance		**4,239,547**	901,410	786,245
Insurance		**2,465,225**	2,305,495	445,426
Communication		**1,110,669**	811,393	511,602
Transportation and travel		**1,002,276**	1,190,229	305,828
Board meetings and conferences		**341,050**	4,862,485	2,257,500
Entertainment and representation		**313,229**	292,075	9,612
Trainings and seminars		**255,299**	954,891	1,418,787
Advertising		**104,984**	749,906	605,967
Rental		**18,947**	44,211	3,500
Miscellaneous		**3,613,389**	2,266,842	1,355,546
		302,289,389	282,385,327	110,301,610

NOTE 23 - INCOME TAX

Computation of income tax due (RCIT or MCIT, whichever is higher) is as follows:

I. Regular Corporate Income tax (RCIT)	**2025**	2024	2023
Loss before income tax	**(235,321,070)**	(397,759,075)	(147,332,832)
Add (deduct) reconciling items:			
Interest expense arbitrage	**251**	526	4,789
Unrealized forex gain (Notes 6 and 20)	**(3,505)**	310,228	(18,964)
Interest income subjected to final tax (Notes 6,21)	**(1,002)**	(2,106)	(19,158)
Taxable loss	**(235,325,326)**	(397,450,427)	(147,365,993)
Tax rate	**25%**	25%	25%
Tax Assets	**(58,831,332)**	(99,362,607)	(36,841,498)

In accordance with its registration with the Board of Investment (BOI), the Company is granted an Income Tax Holiday (ITH) for a period of six (6) years, effective from December 8, 2023 to December 8, 2029.

During this incentive period, the Company's registered activities are exempt from the Regular Corporate Income Tax (RCIT) and the Minimum Corporate Income Tax (MCIT) of 2% on gross income. This tax incentive is subject to the Company's continued compliance with the terms and conditions as set forth in its registration agreement and the requirements of the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act (see Note 1).

II. Tax Due (RCIT or MCIT whichever is higher)	**2025**	2024	2023
RCIT or MCIT	**–**	–	–
Less: Tax credits or payments			
Prior years excess tax credits	**(953,920)**	–	–
Quarterly income tax payments (1st-3rd quarter)	**–**	–	–
Creditable withholding tax (1st - 3rd quarter)	**(2,126,309)**	–	–
Creditable withholding tax (4th quarter)	**(442,139)**	(953,920)	–
Prepaid Income Tax (Note 10)	**(3,522,368)**	(953,920)	–

III. Net Operating Loss Carry-Over (NOLCO)

Revenue Regulation 25-2020, implementing Section 4 of the Bayanihan to Recover as One or Bayanihan 2 Act, particularly on the NOLCO of companies wherein The Bureau of Internal Revenue (BIR) has extended to five years the carry-over period for net operating losses incurred by businesses in 2020 and 2021 (due to the impact of the coronavirus pandemic).

Year Incurred	**Expiration date**	**Beginning balance**	**Additions**	**Expired**	**Claimed**	**Ending Balance**
NOLCO						
2020	2025	43,425,573	–	(43,425,573)	–	–-
2021	2026	34,889,728	–	–	–	34,889,728
		78,315,301	–	(43,425,573)	–	34,889,728

On June 30, 2022 the NOLCO carry over period was reverted back to three years. Thus, as at December 31, 2025, NOLCO that can be claimed as deduction from future taxable income are as follows:

Year Incurred	**Expiration date**	**Beginning balance**	**Additions**	**Expired**	**Claimed**	**Ending Balance**
NOLCO						
2022	2025	34,889,728	52,339,339	(52,339,339)	–	34,889,728
2023	2026	–	147,365,993	–	–	182,255,721
2024	2027	–	397,450,427	–	–	579,706,148
2025	**2028**	–	**235,325,326**	–	–	**815,031,474**
		34,889,728	**832,481,085**	**(52,339,339)**	**–**	**815,031,474**

IV. Deferred Tax Assets

The significant component of the Company's deferred tax assets are as follows:

	2025	2024	2023
NOLCO	**815,031,474**	675,471,060	278,020,633
Tax rate	**25%**	25%	25%
	203,757,869	168,867,765	69,505,158

MCIT	–	–	–
	203,757,869	168,867,765	69,505,158
Valuation allowance (Note 5)	**(203,757,869)**	(168,867,765)	(69,505,158)
Deferred tax asset (other noncurrent assets)	–	–	–

The Company provides full valuation allowance on its deferred tax assets from NOLCO since management believes that the Company will not be able to generate future taxable income in which such can be applied. The deferred tax asset of the Company arising from net operating loss carry over (NOLCO) prior to 2021 can be charged against future taxable income of the next three (3) years. On the other hand, deferred tax assets arising from NOLCO for the years 2020 and 2021 can be charged against future taxable income of the next five (5) taxable years.

NOTE 24 - LEASES

The Company has adopted PFRS 16. However, the Company does not have lease arrangements for its building, as the property is owned by the Company and recognized as part of property and equipment.

As of the reporting date, the Company has no significant lease contracts that would require recognition of right-of-use assets and lease liabilities. Accordingly, the impact of PFRS 16 on the financial statements is not material.

NOTE 25 - BASIC LOSS PER SHARE

Basic loss per share is computed as follows:

	2025	2024	2023
Loss attributable to ordinary shares	**(235,321,070)**	(397,759,075)	(147,332,832)
Divide by: Weighted average number of ordinary shares outstanding	**240,000**	239,960	239,960
Basic loss per share	**(980.50)**	(1,657.61)	(613.99)

There are no potential dilutive ordinary shares outstanding as at December 31, 2025, 2024 and 2023.

NOTE 26 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Financial Risk

The Company's financial risk management policies seek to minimize potential adverse effects of financial risk such as credit risk, liquidity risk, and interest rate risk to its financial assets and financial liabilities.

The Company's principal financial assets and financial liabilities consist of cash (excluding petty cash fund), receivable - others, other non-current assets payable (excluding deferred tax assets), accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, loans payable to a related party and notes payable which arise from operations.

The Company's Board of Directors reviews and approves the policies for managing each of these risks and these are summarized below:

Credit risk

Credit risk is the risk that the third party will default on its obligation to the Company and cause the Company to incur financial loss. The Company's business policy aims to limit the amount of credit exposure to any individual client and financial institution. The Company has credit management policies in place to ensure that contracts are entered into with clients who have sufficient financial capacity and good credit history.

The Company's financial assets at amortized cost are composed of cash (excluding petty cash fund), receivable – others, advances to related parties and other assets under the noncurrent assets (excluding deferred tax assets). The Company limits its exposure to credit risk by investing its cash only with banks that have good credit standing and reputation in the local and international banking industry. These instruments are graded in the top category by an acceptable credit rating agency and, therefore, are considered to be low credit risk investments.

Receivable - others and other assets under the non-current assets are being monitored on a regular basis to ensure timely execution of necessary intervention efforts to minimize credit losses.

It is the Company's policy to measure ECL on the above instruments on a 12-month basis. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not represent significant credit risk such as when non-payment arising from administrative oversight rather than resulting from financial difficulty of the borrower.

The table below presents the summary of the Company's exposure to credit risk and shows the credit quality of the assets by indicating whether the assets are subjected to 12-month ECL or lifetime ECL. Assets that are credit-impaired are separately presented.

	As at December 31, 2025			
	Financial assets at amortized cost			
	12-month ECL	Lifetime ECL – not credit impaired	Lifetime ECL – credit impaired	Total
Cash in banks*	**22,446,473**	–	–	**22,446,473**
Receivables	**165,796,569**	–	–	**165,796,569**
	188,243,042	–	–	**188,243,042**

**Excluding petty cash fund amounting to ₱849,568 as at December 31, 2025.*

As at December 31, 2024

	Financial assets at amortized cost			
	12-month ECL	Lifetime ECL – not credit impaired	Lifetime ECL – credit impaired	Total
Cash in banks*	10,956,804	–	–	10,956,804
Receivables	82,430,163	–	–	82,430,163
	93,386,967	–	–	93,386,967

**Excluding petty cash fund amounting to ₱2,874,195 as at December 31, 2024.*

Interest Rate Risk

Interest rate risk refers to the possibility that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate.

The primary source of the Company's interest rate risk relates to its cash in banks, notes payable and loans payable to a related party (Notes 6, 14 and 15).

Cash in banks are subject to prevailing market interest rates. Considering that such financial assets have short-term maturities, the Company does not foresee any cash flow and fair value interest rate risks to have a significant impact on the Company's operations.

Likewise, notes payable and loans payable to a related party are subject to prevailing market interest rates. As such, these are subject to fluctuations in market interest rates for a given period.

The Company has no established policy in managing interest rate risk. Any favorable or unfavorable effect of the fluctuations on the interest rates are absorbed by the Company. The effect of such is presented in the Company's financial performance.

Liquidity Risk

In the management of liquidity, the Company monitors and maintains a level of cash deemed adequate by the management to finance the Company's operations and mitigate the effects of fluctuations in cash flows.

The table below summarizes the maturity profile of the Company's financial assets and liabilities based on contractual and undiscounted payments:

As at December 31, 2025

	On Demand	**Within 1 year**	**More than 1 year but less than 5 years**	**More than 5 years**	**Total**
Financial Assets:					
Cash*	**22,446,473**	–	–	–	**22,446,473**
Receivable - others	**165,796,569**	–	–	–	**165,796,569**
Advances to related parties	**6,950,256**	–	–	–	**6,950,256**
	195,193,298	–	–	–	**195,193,298**

**Excluding petty cash fund and cash on hand amounting to ₱849,568 December 31, 2025.*

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Liabilities:					
Accounts payable and other liabilities***	**308,520,389**	**378,019,323**	–	–	**686,539,712**
Loans payable to individuals	–	**15,703,226**	–	–	**15,703,226**
Loans payable to a related party	–	–	**544,871,969**	–	**544,871,969**
Notes payable	**191,558,072**	–	**807,792,965**	–	**999,351,037**
	500,078,461	**393,722,549**	**1,352,664,934**	–	**2,246,465,944**

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

As at December 31, 2024

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Assets:					
Cash*	10,956,804	–	–	–	10,956,804
Receivable - others	82,430,163	–	–	–	82,430,163
Advances to related parties	39,030,125	–	–	–	39,030,125
	132,417,092	–	–	–	132,417,092

**Excluding petty cash fund and cash on hand amounting to ₱2,874,195 as at December 31, 2024.*

Financial Liabilities:					
Accounts payable and other liabilities***	363,618,023	164,108,458	–	–	527,726,481
Loans payable to individuals	–	15,703,226	–	–	15,703,226
Loans payable to a related party	–	–	543,871,969	–	543,871,969
Notes payable	15,000,000	–	955,594,306	–	970,594,306
	378,618,023	179,811,684	1,499,466,275		2,057,895,982

****Excluding government liabilities amounting to ₱1,737,537 as at December 31, 2024.*

FAIR VALUES OF FINANCIAL INSTRUMENTS

The carrying amounts and estimated fair values of the Company's financial assets and financial liabilities are presented below:

	As at December 31, 2025		As at December 31, 2024	
	Carrying Amounts	**Fair Values**	Carrying Amounts	Fair Values
Financial Assets:				
Cash*	**22,446,473**	**22,446,473**	10,956,804	10,956,804
Receivable - others	**165,796,569**	**165,796,569**	82,430,163	82,430,163
Advances to related parties	**6,950,256**	**6,950,256**	39,030,125	39,030,125
	195,193,298	**195,193,298**	132,417,092	132,417,092

**Excluding petty cash fund and cash on hand amounting to ₱849,568 and ₱2,874,195 as at December 31, 2025 and 2024.*

Financial Liabilities:				
Accounts payable and other liabilities***	**686,539,712**	**686,539,712**	527,726,481	527,726,481
Loans payable to individuals	**15,703,226**	**15,703,226**	15,703,226	13,703,226
Loans payable to a related party	**544,871,969**	**544,871,969**	543,871,969	540,871,969
Notes payable	**999,351,037**	**999,351,037**	970,594,306	975,594,306
	2,246,465,944	**2,246,465,944**	2,057,895,982	2,057,895,982

****Excluding government liabilities amounting to ₱2,999,859 and ₱1,737,537 as at December 31, 2025 and 2024, respectively.*

Assumption Used to Estimate Fair Values

The carrying amounts of cash, receivable - others, accounts payable and other liabilities, loans payable to individuals, and loans payable to a related party approximate their fair values as at reporting dates due to the short-term nature of the transactions.

The carrying amount of notes payable approximates its fair value due to pre-determined contractual cash flow arrangements based on an applicable and regular re-priceable Philippine Dealing System Treasury (PDST) floating rate covering the term of the loan, as provided by the financial lending institution.

The fair value of refundable deposits cannot be measured reliably since there was no comparable market data and inputs for the sources of fair value such as discounted cash flows analysis. However, Management believes that their carrying amounts approximate their fair value.

Fair Value Hierarchy

The Company uses the following hierarchy for determining the fair value of financial assets and liabilities:

- Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- Level 3 - Inputs are unobservable for the asset or liability

The table below summarizes the classification of the Company's financial assets and liabilities based on the fair value measurement hierarchy:

	As at December 31, 2025		
	Quoted Prices in Active Markets (Level 1)	**Significant Observable Inputs (Level 2)**	**Significant Un-observable Inputs (Level 3)**
Financial Assets:			
Cash*	**-**	**22,446,473**	**-**
Receivable – others	**-**	**165,796,569**	**-**
	-	**188,243,042**	**-**

**Excluding petty cash fund and cash on hand amounting to ₱849,568 as at December 31, 2025.*

	As at December 31, 2025		
	Quoted Prices in Active Markets (Level 1)	**Significant Observable Inputs (Level 2)**	**Significant Un-observable Inputs (Level 3)**
Financial Liabilities:			
Accounts payable and other liabilities***	–	**686,539,712**	–
Loans payable to individuals	–	**15,703,226**	–
Loans payable to a related party	–	**544,871,969**	–
Notes payable	–	**999,351,037**	–
	–	**2,246,465,944**	–

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

	As at December 31, 2024		
	Quoted Prices in Active Markets (Level 1)	Significant Observable Inputs (Level 2)	Significant Un-observable Inputs (Level 3)
Financial Assets:			
Cash*	–	10,956,804	–
Receivable – others	–	82,430,163	–
	–	93,386,967	–

**Excluding petty cash fund and cash on hand amounting to ₱2,874,195 as at December 31, 2024.*

Financial Liabilities:			
Accounts payable and other liabilities***	–	527,726,481	–
Loans payable to individuals	–	15,703,226	–
Loans payable to a related party	–	543,871,969	–
Notes payable	–	970,594,306	–
	–	2,057,895,982	–

****Excluding government liabilities amounting to ₱1,737,537 as at December 31, 2024.*

There were no reclassifications made between the different fair value hierarchy level as at December 31, 2025 and 2024.

CAPITAL MANAGEMENT

The primary objective of the Company's capital management is to ensure that it maintains healthy capital ratios in order to support its business, pay existing obligations and maximize shareholders value.

The Company manages capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust capital, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes during the years ended December 31, 2025 and 2024.

The following table pertains to the account balances the Company considers as its core economic capital:

	2025	2024
Share capital	**240,000,000**	239,960,000
Share premium	**958,532,662**	957,372,662
Revaluation surplus	**183,531,277**	-

Deficit	**(978,283,187)**	(742,962,117)
	403,780,752	454,370,545

The loan agreement with Landbank (Note 16) provides certain restrictions and requirements with respect to, among others, maintenance of financial ratios (debt-to-equity ratio of 80:20), percentage of ownership of specific shareholders, creation of property encumbrances and additional guarantees for the incurrence of additional long-term indebtedness.

As of reporting dates, all covenants and requirements are complied with except for the required financial ratio wherein the financial institution was made aware of since the Company has not yet started commercial operations.

FINANCIAL RATIOS

The following were the financial ratios of the Company for the years ended December 31, 2025, and 2024:

Particulars	**2025**	2024
Current ratio	**0.39**	0.42
Solvency ratio	**1.17**	1.22
Debt to-equity	**5.72**	4.53
Asset to equity	**6.72**	5.53
Return on equity	**(0.55)**	(0.61)
Return on assets	**(0.090)**	(0.16)

Computation of the above financial ratios are as follows:

- Current ratio = Current assets divided by current liabilities
- Solvency ratio = Total assets divided by total liabilities
- Debt-to-equity = Total liabilities divided by total equity
- Asset-to-equity = Total assets divided by total equity
- Return on equity = Net income divided by average total equity for the periods indicated
- Return on assets = Net income divided by average total assets for the periods indicated

SUPPLEMENTARY INFORMATION REQUIRED BY REVENUE REGULATION (RR)

The following information is presented for purposes of filing with the BIR and is not a required part of the basic financial statements.

Revenue Regulations (RR) 15-2010

On November 25, 2010, the Bureau of Internal Revenue (BIR) issued Revenue Regulations (RR) 15-2010, which requires certain information on taxes, duties, and license fees paid or accrued during the taxable year to be disclosed as part of the notes to financial statements. This supplemental information, which is an addition to the disclos*u*res mandated under PFRS Accounting Standards is presented as follows:

Output Value-Added Tax

Details of the Company's output VAT declared consist of:

	2025
Exempt sales	**346,939,834**
Vatable sales	**2,709,043**
VAT rate	**12%**
	325,085

Input Value-Added Tax

Details of the Company's Input VAT claimed consist of:

	2025
At beginning of year	**12,424,126**
Current purchases and payments for:	
Domestic purchase of capital goods not exceeding 1M	–
Domestic purchase of capital goods exceeding 1M	–
Domestic purchase of goods other than capital goods	**6,956,177**
Domestic purchases of services	**5,316,180**
At end of year	**24,696,483**

Computation of Net VAT payable is as follows:

	2025
Output VAT payable	**325,085**
Less: Input VAT claimed	**(24,696,483)**
Excess Input VAT for the year	**(24,371,398)**
Less: Payments made during the year	–
Input VAT Carry-over (Note 10)	**(24,371,398)**

Documentary Stamp Tax

Documentary stamp tax paid by the Company during the year amounted to ₱3,417,800 for the additional availment of notes payable.

Taxes and licenses

Details of the Company's other local and national taxes for the year are as follows:

	2025
Documentary Stamp Tax	3,417,800
Real Property Tax	1,942,564
Land Registration Authority	316,326
Business Permit Fee	87,724
Community Tax Certificate	10,480
Others	27,737
	5,802,631

Withholding Taxes

Withholding taxes paid by the Company for the year are as follows:

	2025
Compensation withholding tax	**343,493**
Expanded withholding tax	**8,923,991**
	9,267,484

Deficiency Tax Assessment and Tax Cases

The Company has no deficiency tax assessments or any tax cases, litigation, and/or prosecution in court or bodies outside the Bureau of Internal Revenue as of December 31, 2025.

RR 19-2020 and RR 34-2020

In 2020, the Bureau of Internal Revenue (BIR) issued the foregoing Revenue Regulations for the effective implementation of Philippine Accounting Standard No. 24 (PAS 24) governing the guidelines and procedures for "transfer pricing documentations" involving related party transactions thru the submission of BIR Form No. 1709 and the supporting documents, as an attachment to the financial statements to be filed with the BIR.

The Company reported net operating losses for the current taxable year and the immediately preceding two (2) consecutive taxable years, hence, meets the criteria provided by these Revenue Regulations, and accordingly, required to submit BIR Form 1709.

* * *

SCHEDULES

ASIA PACIFIC MEDICAL CENTER – ILOILO, NC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
As at December 31, 2025

Schedule A. Financial Assets

Name of issuing entity and association of each issue	Number of shares or principal amount of bonds and notes	Amount shown in the statements of financial position	Value based on market quotation at end of reporting period	Income received and accrued
Cash	N/A	23,296,041	N/A	2,106
Receivable - others	N/A	165,796,569	N/A	N/A
Other non-current assets*	N/A	-	N/A	N/A

**excluding deferred tax assets*

Schedule B. Amounts Receivable from Directors, Officers, Employees, Related Parties and Principal Stockholders (Other than Related Parties)

Name and designation of debtor	Balance at beginning of period	Additions	Deductions		Current	Non-current	Balance at end of period
			Amounts collected	Amounts written-off			
Endure Medical, Inc.	32,079,869	-	(32,079,869)	N/A	-	N/A	-
TIPP Digital Solutions, Inc.	6,902,784	-	N/A	N/A	6,902,784	N/A	6,902,784

Schedule C. Amounts Receivable from Related Parties which are eliminated during Consolidation of Financial Statements

Name and designation of debtor	Balance at beginning of period	Additions	Deductions		Current	Non-current	Balance at end of period
			Amounts collected	Amounts written-off			
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Schedule D. Long –Term Debt

Title of issue and type of obligation	Amount authorized by indenture	Amount shown under caption "Current portion of long-term debt" in related statement of financial position	Amount shown under caption "Long-term debt" in related statement of financial position
Non-interest-bearing Notes Payable	999,351,037	191,558,072	807,792,965

Schedule E. Indebtedness to Related Parties (Long –Term Loans from Related Companies)

Name of related party	Balance at beginning of period	Balance at end of period
Loans payable to a related party	543,871,969	544,871,969
Accounts payable	63,768,359	60,676,532

Schedule F. Guarantees of Securities of Other Issuers

Name of issuing entity of securities guaranteed by the Company for which this statement is filed	Title of issue of each class of securities guaranteed	Total amount guaranteed and outstanding	Amount owned by person for which statement is filed	Nature of guarantee
N/A	N/A	N/A	N/A	N/A

Schedule G. Capital Stock

Title of issue	Number of shares authorized	Number of shares issued and outstanding as shown under related statement of financial position caption	Number of shares reserved for options, warrants, conversion and other rights	Number of shares held by related parties	Directors, officers and employees	Others
Founder's Shares	600	600	-	-	60	-
Common Shares	240,000	240,000	-	-	60	-

RECONCILIATION OF RETAINED EARNINGS
AVAILABLE FOR DIVIDEND DECLARATION
As at December 31, 2025

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
Brgy. Ungka, Jaro Iloilo City

Unappropriated Retained Earnings, as adjusted to available for dividend distribution, beginning of the year		**(742,962,117)**
Add: **Net Income (Loss) actually earned/realized during the period**		
Net loss during the period closed to Retained Earnings	(235,321,070)	
Less: **Non-actual/unrealized income net of tax**		
Equity in net income of associate/joint venture	-	
Unrealized foreign exchange gain - (after tax) except those attributable to Cash and Cash Equivalents	-	
Unrealized actuarial gain	-	
Fair value adjustment (mark-to-market gains)	-	
Fair value adjustment of Investment Property resulting to gain	-	
Adjustment due to deviation from PFRS - gain	-	
Other unrealized gains or adjustments to the reatined earnings as a result of certain transactions accounted for under the PFRS	-	
Sub-total	-	
Add: **Non-actual Losses**		
Depreciation on revalution increment (after tax)	-	
Adjustment due to deviation from PFRS - loss	-	
Loss on fair value adjustment of investment property (after tax)	-	
Sub-total	-	
Net Income (Loss) Actually Earned During the Period		**(235,321,070)**
Add (Less):		
Dividend declarations during the period	-	
Appropriations of Retained Earnings during the period	-	
Reversals of appropriations	-	
Effects of prior period adjustments	-	
Treasury Shares	-	
Sub-total		-
TOTAL RETAINED EARNINGS, END OF THE PERIOD AVAILABLE FOR DIVIDEND		**(978,283,187)**

SCHEDULE OF FINANCIAL SOUNDNESS INDICATORS

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
As of December 31, 2025

Ratio	Formula	December 31, 2025	December 31, 2024
Liquidity Ratios:			
Current Ratio	Current Assets	**350,251,135**	236,312,991
	Current Liabilities	**896,800,868**	560,167,244
		0.39:1	0.42:1
Quick Ratio	Quick Assets	**189,092,610**	96,261,162
	Current Liabilities	**896,800,868**	560,167,244
		0.21:1	0.17:1
Solvency Ratios:			
Debt-to-Asset Ratio	Total Liabilities	**2,310,642,895**	2,059,633,519
	Total Assets	**2,714,423,647**	2,514,004,064
		0.85	0.82
Debt-to-Equity Ratio	Total Liabilities	**2,310,642,895**	2,059,633,519
	Total Equity	**403,780,752**	454,370,545
		5.72:1	4.53:1
Asset-to-Equity Ratio	Total Assets	**2,714,423,647**	2,514,004,064
	Total Equity	**403,780,752**	454,370,545
		6.72:1	5.53:1
Profitability Ratios:			
Interest Rate Coverage Ratio	Net Income (Loss) Before Interests and Interest Expense	**(99,310,487)**	(242,059,867)
		136,010,583	155,699,208
		-73.02%	-155.47%
Return on Equity	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Average Total Equity	**429,075,648**	454,370,545
		-54.84%	-87.54%
Return on Assets	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Average Total Assets	**2,614,213,855**	2,514,004,064
		-9.00%	-15.82%
Net Profit Margin	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Revenues	**452,165,666**	307,910,026
		-52.04%	-1.291802934

SCHEDULES

ASIA PACIFIC MEDICAL CENTER – ILOILO, NC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
As at December 31, 2025

Schedule A. Financial Assets

Name of issuing entity and association of each issue	Number of shares or principal amount of bonds and notes	Amount shown in the statements of financial position	Value based on market quotation at end of reporting period	Income received and accrued
Cash	N/A	23,296,041	N/A	2,106
Receivable - others	N/A	165,796,569	N/A	N/A
Other non-current assets*	N/A	-	N/A	N/A

**excluding deferred tax assets*

Schedule B. Amounts Receivable from Directors, Officers, Employees, Related Parties and Principal Stockholders (Other than Related Parties)

Name and designation of debtor	Balance at beginning of period	Additions	Deductions		Current	Non-current	Balance at end of period
			Amounts collected	Amounts written-off			
Endure Medical, Inc.	32,079,869	-	(32,079,869)	N/A	-	N/A	-
TIPP Digital Solutions, Inc.	6,902,784	-	N/A	N/A	6,902,784	N/A	6,902,784

Schedule C. Amounts Receivable from Related Parties which are eliminated during Consolidation of Financial Statements

Name and designation of debtor	Balance at beginning of period	Additions	Deductions		Current	Non-current	Balance at end of period
			Amounts collected	Amounts written-off			
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Schedule D. Long –Term Debt

Title of issue and type of obligation	Amount authorized by indenture	Amount shown under caption "Current portion of long-term debt" in related statement of financial position	Amount shown under caption "Long-term debt" in related statement of financial position
Non-interest-bearing Notes Payable	999,351,037	191,558,072	807,792,965

Schedule E. Indebtedness to Related Parties (Long –Term Loans from Related Companies)

Name of related party	Balance at beginning of period	Balance at end of period
Loans payable to a related party	543,871,969	544,871,969
Accounts payable	63,768,359	60,676,532

Schedule F. Guarantees of Securities of Other Issuers

Name of issuing entity of securities guaranteed by the Company for which this statement is filed	Title of issue of each class of securities guaranteed	Total amount guaranteed and outstanding	Amount owned by person for which statement is filed	Nature of guarantee
N/A	N/A	N/A	N/A	N/A

Schedule G. Capital Stock

Title of issue	Number of shares authorized	Number of shares issued and outstanding as shown under related statement of financial position caption	Number of shares reserved for options, warrants, conversion and other rights	Number of shares held by related parties	Directors, officers and employees	Others
Founder's Shares	600	600	-	-	60	-
Common Shares	240,000	240,000	-	-	60	-

RECONCILIATION OF RETAINED EARNINGS
AVAILABLE FOR DIVIDEND DECLARATION
As at December 31, 2025

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
Brgy. Ungka, Jaro Iloilo City

Unappropriated Retained Earnings, as adjusted to available for dividend distribution, beginning of the year		**(742,962,117)**
Add: **Net Income (Loss) actually earned/realized during the period**		
Net loss during the period closed to Retained Earnings	(235,321,070)	
Less: **Non-actual/unrealized income net of tax**		
Equity in net income of associate/joint venture	-	
Unrealized foreign exchange gain - (after tax) except those attributable to Cash and Cash Equivalents	-	
Unrealized actuarial gain	-	
Fair value adjustment (mark-to-market gains)	-	
Fair value adjustment of Investment Property resulting to gain	-	
Adjustment due to deviation from PFRS - gain	-	
Other unrealized gains or adjustments to the reatined earnings as a result of certain transactions accounted for under the PFRS	-	
Sub-total	-	
Add: **Non-actual Losses**		
Depreciation on revalution increment (after tax)	-	
Adjustment due to deviation from PFRS - loss	-	
Loss on fair value adjustment of investment property (after tax)	-	
Sub-total	-	
Net Income (Loss) Actually Earned During the Period		**(235,321,070)**
Add (Less):		
Dividend declarations during the period	-	
Appropriations of Retained Earnings during the period	-	
Reversals of appropriations	-	
Effects of prior period adjustments	-	
Treasury Shares	-	
Sub-total		-
TOTAL RETAINED EARNINGS, END OF THE PERIOD AVAILABLE FOR DIVIDEND		**(978,283,187)**

SCHEDULE OF FINANCIAL SOUNDNESS INDICATORS

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
As of December 31, 2025

Ratio	Formula	December 31, 2025	December 31, 2024
Liquidity Ratios:			
Current Ratio	Current Assets	**350,251,135**	236,312,991
	Current Liabilities	**896,800,868**	560,167,244
		0.39:1	0.42:1
Quick Ratio	Quick Assets	**189,092,610**	96,261,162
	Current Liabilities	**896,800,868**	560,167,244
		0.21:1	0.17:1
Solvency Ratios:			
Debt-to-Asset Ratio	Total Liabilities	**2,310,642,895**	2,059,633,519
	Total Assets	**2,714,423,647**	2,514,004,064
		0.85	0.82
Debt-to-Equity Ratio	Total Liabilities	**2,310,642,895**	2,059,633,519
	Total Equity	**403,780,752**	454,370,545
		5.72:1	4.53:1
Asset-to-Equity Ratio	Total Assets	**2,714,423,647**	2,514,004,064
	Total Equity	**403,780,752**	454,370,545
		6.72:1	5.53:1
Profitability Ratios:			
Interest Rate Coverage Ratio	Net Income (Loss) Before Interests and	**(99,310,487)**	(242,059,867)
	Interest Expense	**136,010,583**	155,699,208
		-73.02%	-155.47%
Return on Equity	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Average Total Equity	**429,075,648**	454,370,545
		-54.84%	-87.54%
Return on Assets	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Average Total Assets	**2,614,213,855**	2,514,004,064
		-9.00%	-15.82%
Net Profit Margin	Net Profit (Loss)	**(235,321,070)**	(397,759,075)
	Revenues	**452,165,666**	307,910,026
		-52.04%	-1.291802934

For BIR Use Only | BCS/ Item:

Republic of the Philippines
Department of Finance
Bureau of Internal Revenue

BIR Form No.
1702-EX
January 2018 (ENCS) v2
Page 1

Annual Income Tax Return

Corporation, Partnership and Other Non-Individual Taxpayer EXEMPT under the Tax Code, as Amended, [Sec. 30 and those exempted in Sec. 27(C)] and Other Special Laws, with NO Other Taxable Income

Enter all required information in CAPITAL LETTERS. Mark applicable boxes with an "X". Two copies MUST be filled with the BIR and one held by the taxpayer.

1702-EX 01/18ENCS v2 P1

1 For (●) Calendar ( ) Fiscal
2 Year Ended *(MM/20YY)* 12/20 25

3 Amended Return? ( ) Yes (●) No
4 Short Period Return ( ) Yes (●) No

5 Alphanumeric Tax Code (ATC)
IC 011 Exempt Corporation on Exempt Activities (●)
IC 021 General Professional Partnership ( )

Background Information

6 Taxpayer Identification Number (TIN) 008 – 922 – 703 – 0000
7 RDO Code 074

8 Registered Name *(Enter only 1 letter per box using CAPITAL LETTERS)*
ASIA PACIFIC MEDICAL CENTER - ILOILO INC.

9 Registered Address *(Indicate complete address. If the registered address is different from the current address, go to the RDO to update registered address by using BIR Form No. 1905)*
BRGY. UNGKA, JARO ILOILO CITY

9A Zip code 5000

10 Date of Incorporation/Organization *(MM/DD/YYYY)* 12/10/2024
11 Contact Number 3202232

12 Email Address apmci.taxcompliance@gmail.com

13 Method of Deductions (●) Itemized Deductions [Section 34 (A-J), NIRC] ( ) Optional Standard Deduction (OSD) - 40% of Gross Income [applicable only to General Profession Partnership (GPP) per RA No. 10963]

14 Legal Basis of Tax Relief / Exemption (Specify)
RA NO.11534 OR CREATE ACT

15 Investment Promotion Agency (IPA) / Government Agency *(specify)*
BOARD OF INVESTMENTS

16 Registered Activity / Program *(Registration Number)*
PSIC 86121 OR 2023-065

17 Effectivity Date of Tax Relief / Exemption (MM/DD/YYYY)
From 12/08/2023 To 12/08/2029

PART II - TOTAL TAX PAYABLE (DO NOT ENTER CENTAVOS; 49 centavos or less drop down; 50 or more round up)

18 Tax Due *(From Part IV Item 41)*	0.00
19 Less: Total Tax Credits/Payments *(From Part IV Item 50)*	3,522,368.00
20 Total (Overpayment) *(Item 18 Less Item 19)* *(From Part IV Item 51)*	-3,522,368.00
21 Add: Penalty - Compromise	0.00
22 TOTAL AMOUNT PAYABLE / (Overpayment) *(Sum of Items 20 & 21)*	-3,522,368.00

If overpayment, mark one (1) box only. (Once the choice is made, the same is irrevocable)
( ) To be refunded ( ) To be issued a Tax Credit Certificate (TCC) (●) To be carried over as a tax credit for next year/quarter

We declare under the penalties of perjury that this return and all its attachments, have been made in good faith, verified by us, and to the best of our knowledge and belief, are true and correct, pursuant to the provisions of the National Internal Revenue Code, as amended, and the regulations issued under authority thereof. *(If signed by an Authorized Representative, indicate TIN and attach authorization letter)*

23 Number of Attachments 00

CKRT T. CORTES
Signature over Printed Name of President/Principal Officer/Authorized Representative | Signature over Printed Name of Treasurer/Assistant Treasurer

Title of Signatory | 0 TIN 0 | Title of Signatory | 0 TIN 0

Part III - Details of Payment

Particulars	Drawee Bank/ Agency	Number	Date *(MM/DD/YYYY)*	Amount
24 Cash/Bank Debit Memo				
25 Check				
26 Tax Debit Memo				
27 Others *(Specify Below)*				

Machine Validation / Revenue Official Receipt Details *[if not filed with an Authorized Agent Bank (AAB)]*

Stamp of Receiving Office/AAB and Date of Receipt (RO's Signature/Bank Teller's Initial)

BIR Form No. 1702-EX January 2018 (ENCS) v2 Page 2	**Annual Income Tax Return** Corporation, Partnership and Other Non-Individual Taxpayer EXEMPT under the Tax Code, as Amended, [Sec. 30 and those exempted in Sec. 27(C)] and Other Special Laws, with NO Other Taxable Income	1702-EX 01/18ENCS v2 P2

TIN	Registered Name
008 922 703 0000	ASIA PACIFIC MEDICAL CENTER - ILOILO INC.

Part IV - Computation of Tax	(Do NOT enter Centavos; 49 centavos or less drop down; 50 or more round up)
28 Sales/Receipts/Revenues/Fees	519,916,690.00
29 Less: Sales Returns, Allowances and Discounts	67,751,024.00
30 Net Sales/Receipts/Revenues/Fees *(Item 28 less Item 29)*	452,165,666.00
31 Less: Cost of Sales/Services	259,501,745.00
32 Gross Income from Operation *(Item 30 Less Item 31)*	192,663,921.00
33 Add: Other Income	10,310,474.00
34 Total Gross Income *(Sum of Items 32 and 33)*	202,974,395.00
Less: Deductions Allowable under Existing Law	
A. Itemized Deduction	
35 Ordinary Allowable Itemized Deductions *(From Part VI Schedule I Item 18)*	438,299,721.00
36 Special Allowable Itemized Deductions *(From Part VI Schedule II Item 5)*	0.00
37 Total Itemized Deductions *(Sum of Items 35 and 36)*	438,299,721.00
B. Optional Standard Deduction (OSD)	
38 OSD *(40% of Item 34)(applicable to GPP per RA No. 10963)*	0.00
39 Net Taxable Income / (Loss) *(If Itemized: Item 34 Less Item 37;) If OSD: Item 34 Less Item 38)*	-235,325,326.00
40 Tax Rate	0.00 %
41 Tax Due *(Item 39 x Item 40) (To Part II Item 18)*	0.00
Less: Tax Credits / Payments (attach proof)	
42 Prior Year's Excess Credits	953,920.00
43 Income Tax Payment from Previous Quarter/s	0.00
44 Creditable Tax Withheld from Previous Quarter/s per BIR Form No. 2307	2,126,309.00
45 Creditable Tax Withheld per BIR Form No. 2307 for the 4th Quarter	442,139.00
46 Foreign Tax Credits, if applicable	0.00
47 Tax Paid in Return Previously Filed, if this is an Amended Return	0.00
Other Tax Credits / Payments *(specify)*	
48	0.00
49	0.00
50 Total Tax Credits / Payments *(Sum of Items 42 to 49) (To Part II Item 19)*	3,522,368.00
51 Total (Overpayment) *(Item 41 Less Item 50) (To Part II Item 20)*	-3,522,368.00
Part V - Tax Relief Availment	
52 Regular Income Tax Otherwise Due *(Item 39 of Part IV x Applicable Income Tax Rate)*	0.00
53 Special Allowable Itemized Deductions *(Item 36 of Part IV x Applicable Income Tax Rate)*	0.00
54 Total Tax Relief Availment *(Sum of Items 52 and 53)*	0.00

BIR Form No. **1702-EX** January 2018 (ENCS) v2 Page 3

Annual Income Tax Return

Corporation, Partnership and Other Non-Individual Taxpayer EXEMPT under the Tax Code, as Amended, [Sec. 30 and those exempted in Sec. 27(C)] and Other Special Laws, with NO Other Taxable Income

1702-EX 01/18ENCS v2 P3

Tax Identification Number (TIN): 008 922 703 0000

Registered Name: ASIA PACIFIC MEDICAL CENTER - ILOILO INC.

Part VI - Schedules

(Do NOT enter Centavos; 49 centavos or less drop down; 50 or more round up)

Schedule 1 - Ordinary Allowable Itemized Deductions *(attach additional sheet/s, if necessary)*

1	Ammortizations	0.00
2	Bad Debts	0.00
3	Charitable and Contributions	0.00
4	Depletion	0.00
5	Depreciation	48,391,711.00
6	Entertainment, Amusement and Recreation	0.00
7	Fringe Benefits	0.00
8	Interest	136,010,583.00
9	Losses	0.00
10	Pension Trusts	0.00
11	Rental	18,947.00
12	Research and Development	0.00
13	Salaries, Wages, and Allowances	111,313,162.00
14	SSS, GSIS, Philhealth, HDMF, and Other Contributions	13,743,882.00
15	Taxes and Licenses	5,802,631.00
16	Transportation and Travel	1,002,276.00
17	Others (Deductions Subject to Withholding Tax and Other Expenses) [Specify below; Add additional sheet(s) if necessary]	
a	Janitorial and Messengerial Services	0.00
b	Professional Fees	25,287,779.00
c	Security Services	12,334,776.00
d	UTILITIES	54,800,309.00
e	OFFICE SUPPLIES	7,827,951.00
f	REPAIRS AND MAINTENANCE	4,239,547.00
g	INSURANCE	2,465,225.00
h	COMMUNICATION	1,110,669.00
i	OTHERS	13,950,273.00
18	**Total Ordinary Allowable Itemized Deductions** (Sum of Items 1 to 17i) *(To Part IV Item 35)*	438,299,721.00

Schedule 2 - Special Allowable Itemized Deductions *(attach additional sheet/s, if necessary)*

	Description	Legal Basis	Amount
1			0.00
2			0.00
3			0.00
4			0.00
5	**Total Special Allowable Itemized Deductions** *(Sum of Items 1 to 4)* *(To Part IV Item 36)*		0.00

Schedule 3 - Reconciliation of Net Income per Books Against Taxable Income *(attach additional sheet/s, if necessary)*

1	Net Income(loss) per Books	-235,321,070.00
	Add: Non-Deductible Expenses/Other Income	
2	INTEREST EXPENSE ARBITRAGE	251.00
3		0.00
4	Total *(Sum of Items 1 to 3)*	-235,320,819.00
	Less: A) Non-Taxable Income and Income Subjected to Final Tax	
5	INTEREST INCOME	1,002.00
6	UNREALIZED FOREX GAIN	3,505.00
	B) Special Deductions	
7		0.00
8		0.00
9	Total *(Sum of Items 5 to 8)*	4,507.00
10	**Net Taxable Income/(Loss)** *(Item 4 Less Item 9)*	-235,325,326.00

ASIA PACIFIC MEDICAL CENTER ILOILO

MINUTES OF THE 2025 ANNUAL STOCKHOLDERS' MEETING
OF ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.[1]
Wednesday, 18 June 2025 at 9:00 A.M.
via Remote Communication through Zoom Meeting
APMC Iloilo Board Room, Brgy. Ungka, Jaro, Iloilo City

Stockholders Present and Represented[2]	**No. Of Shares**	**Percentage**
Total Number of Outstanding Shares	**239,990**	**100%**
Total Number of Shares of Stockholders Present via Remote Communication	**120,658**	**50.28%**
Total Number of Shares of Stockholders Voting in Absentia	**82,682**	**34.45%**
Total Number of Shares of Stockholders Represented By Proxy	**3,830**	**1.59%**
Total Number of Shares Not Represented	**32,820**	**13.68%**

Directors and/or Officers Present:

Name	**Designation**
Dr. Ferjenel G. Biron	Chairman, Board Director
Dr. Meride D. Lavilla	Vice Chairman, Board Director
Dr. Amado M. Lavalle Jr.	President, Board Director
Dr. Danilo C. Regozo	Executive Vice President, Board Director
Dr. Lusyl M. Gomez	Assistant Corporate Secretary, Board Director
Dr. Mary Flor G. Ong	Corporate Treasurer, Board Director
Mr. Lemuel T. Fernandez	Asst. Corporate Treasurer, Board Director
Dr. Felibert O. Dianco	Board Director
Dr. Felix P. Nolasco	Board Director
Dr. Fredilyn G. Samoro	Board Director
Atty. Rolex T. Suplico	Board Director
Dr. Agnes Jean M. Villaflor	Board Director
Mrs. Ma. Teresa F. Debuque	Lead Independent Director
Atty. Johanna Marie B. Bermudo-Belgira	Independent Director
Dr. Jerusha A. Comuelo	Independent Director

Key Officers Present:

Name	**Designation**
Atty. Maylene B. Villanueva	Compliance Officer
Mr. Cris T. Cortes	Chief Finance Officer
Atty. Therese Marie A. Gerafil	Corporate Secretary/Data Privacy Officer
Dr. Giovanni A. Delos Reyes	Director for Administration and Support Services
Mrs. Toni Dinah Cheer D. Fernandez	Investor Relations Officer

DRAFT

[1] *This Minutes of the Meeting is subject to approval of the stockholders in the 2026 Annual Stockholders' Meeting*

[2] *The complete list of stockholders present and represented is attached hereto as* ***Annex "A"***

OPENING FORMALITIES

After the Invocation and National Anthem, the host/facilitator of the meeting welcomed the Board of Directors, Officers, Founders, and Stockholders of the Asia Pacific Medical Center-Iloilo, Inc.

Call to Order

Dr. Ferjenel G. Biron, the Chairman of Asia Pacific Medical Center Iloilo, called the Annual Stockholders' Meeting to order at 9:18 in the morning of June 18, 2025.

The Chairman mentioned that the meeting is held via remote communication through the Zoom webinar application and is being recorded in compliance with the requirements of the Securities and Exchange Commission. Before he began the meeting proper, he greeted the directors, officers and guests who are present in the meeting.

Certification of Notice and Quorum

The Corporate Secretary, Therese Marie Gerafil, stated that as required by the Securities Regulation Code (SRC) and in compliance with the Revised Corporation Code and the Notice of the Securities and Exchange Commission (SEC) dated 12 March 2025, the notice of the Annual Stockholders' Meeting was published in the business section of two (2) newspapers of general circulation namely, The Manila Times and Manila Standard. The notices were published in print and online format for two consecutive days. The last day of publication, 27 May 2025, was at least twenty-one (21) days prior to the date of the meeting. Affidavits of publication were executed by the respective authorized representatives of Manila Times and Manila Standard, the publishing companies engaged by Management for the purpose. The affidavits were presented onscreen by the Corporate Secretary and duly submitted for the record. She added that the notice of the meeting was also posted in the company's website at www.apmc-iloilo.com. She then certified that the stockholders have been notified of the meeting in accordance with the Company's by-laws and applicable rules including the internal guidelines in participation in the Annual Stockholders Meeting via remote communication and voting in absentia under the extraordinary circumstances which are embodied in the Definitive Information Statement which the SEC approved.

The Corporate Secretary certified that there was quorum based on the tally of those who successfully registered online and validated proxies on hand. The number of shareholders present and represented by proxies, are as follows:

Stockholders	No. of Shares	Percentage
Voting in Absentia	82,682	34.45%
Remote Communication	120,658	50.28%
By Proxy	3,830	1.59%
Total	**207,170**	**86.32%**

Rules of Conduct and Procedure

The Chairman requested the Corporate Secretary to briefly discuss the rules of conduct and the voting procedure of the annual stockholders' meeting.

The Corporate Secretary explained that the voting rights of each stockholder and the requirements and procedures for participation by remote communication and voting in absentia has been set forth in the Definitive Information Statement. She then proceeded to discuss the following highlighted points for the stockholders:

1. Stockholders who have successfully completed the registration and verification procedure on or before June 10, 2025 for voting in absentia and June 16, 2025 for remote communication, may participate in today's virtual meeting and shall be considered present for quorum purposes.

2. Stockholders who registered online or who notified the company via email to corpsec@apmciloilo.com of their intention to participate in this meeting via remote communication may send their questions and comments on Agenda matters to the same email address. For the orderly conduct of business, these questions will be addressed later in the meeting. Question received after 9 this morning will responded to via email due to the time element involved in this virtual meeting.

3. The matters submitted for voting are as follows:
    - Approval of the Minutes of the 2024 Annual Stockholders Meeting held on 11 June 2024

- Noting of APMC Iloilo's Annual Report which consists of the Chairman's Message, President's Report/Message and Audio Visual Presentation to the stockholders, and to approval of the Audited Financial Statement as of December 31, 2024

- Ratification of each and every act and resolution from the last Annual Stockholders' Meeting on 11 June 2024 up to the present date, of the Board of Directors and Executive Officers of Asia Pacific Medical Center-Iloilo, Inc.

- Amendment of Corporation's By-laws on:

  Art. II, Sec. 1 - Regular Meetings of Stockholders
  Art. II, Sec. 3 - Place of Meeting of Stockholders
  Art. II, Sec. 6 - Conduct of Meeting of Stockholders
  Art. II, Sec. 7 - Manner of Voting of Stockholders
  Art. III, Sec. 6 - Conduct of the Meeting of Board of Directors

- Appointment of External Auditor for 2025-2026
- Election of Directors for 2025-2026

4. In this Annual Stockholders' Meeting, voting in absentia is recognized. Stockholders who had cast their votes for the proposed resolutions and Election of Directors for 2025 from June 11 to June 15, 2025 in the Online Voting Portal can still join the meeting and the polls shall remain open until the end of the meeting for stockholders who has successfully registered to cast their votes electronically in the Online Voting Portal.

5. The Initial Votes have been tabulated at the end of the Proxy validation process by the Inspection of Ballots and Proxies Committee and the Results of the preliminary canvassing for the Voting in Absentia system was conducted by the Board of Canvassers, with the assistance of the third party provider. These votes are from stockholders owing 195,670 voting shares representing 100% shares present in the meeting and 81.53% of the total outstanding shares of 239,990. She also mentioned that the final results of the votes with full details of affirmative and negative votes as well as abstentions will be reflected in the minutes of the meeting.

6. Finally, she reminded the stockholders that the virtual meeting is being recorded in audio and video format in compliance with the requirements of the Securities and Exchange Commission.

Approval of the Minutes of the Regular Stockholders' Meeting held on 11 June 2024

The Chairman then proceeded to the next item on the Agenda which is the approval of the Minutes of the Annual Stockholder's Meeting held on 11 June 2024.

The Corporate Secretary stated that a copy of the 2024 Minutes of the Annual Stockholders Meeting was prepared in accordance with the requirements of the Revised Corporation Code. She further stated that the matters approved in the previous stockholder's meeting were provided under Annex F of the Definitive Information Statement which was uploaded in the company's website. She then proposed that the reading of the Minutes of the 2024 Annual Stockholder's Meeting be dispensed with and the Minutes be approved as appearing in the company's records.

In response, the Chairman duly noted the proposal. He inquired if there were any inquiries on the matter. The Corporate Secretary answered that there were no inquiries submitted via email.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares present and voted in favor on the said matter.

ASM Resolution No. 2025-01

RESOLVED, to approve the Minutes of the 2024 Annual Stockholders' Meeting held on 11 June 2024.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,360	99.17%
Against	0	0%
Abstain	1,670	0.83%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have approved the Minutes of the 2024 Annual Stockholders' Meeting held last 11 June 2024 and declared that ASM Resolution No. 2025-01 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Annual Report with AVP

The presentation of the Annual Report consists of the Chairman's Message, Management Report by the President, audio visual presentation of the hospital and presentation of the 2024 Audited Financial Statements by the Corporate Treasurer.

Chairman's Message

The Chairman welcomed the Board of Directors, management, stockholders and other stakeholders and expressed heartfelt appreciation to the members of the Board, management, stockholders, and stakeholders and expressed gratitude for their unwavering support to APMC Iloilo's mission of providing exceptional and patient-centered healthcare.

The Chairman reported on the successful construction and operations of the 100-bed facility—recognized for having the most advanced hospital architecture in Western Visayas—while candidly addressing the financial challenges of sustaining a capital-intensive institution. Despite increasing patient census, current revenues remain insufficient to cover financial obligations. A call for agility from the Board and management and continued steadfastness from stockholders was made to ensure long-term sustainability.

The Chairman announced the acquisition of a Cardiac CT Coronary Angiogram (CCTA), a non-invasive, cutting-edge diagnostic tool that improves early detection of coronary artery disease and solidifies APMC Iloilo's position at the forefront of medical innovation in the region. Stockholders were encouraged to help disseminate this significant advancement, reinforcing the hospital's role as a leader in healthcare innovation and medical excellence, ensuring that the community benefits from the latest advancements in cardiac care.

Acknowledging public concerns regarding perceived high costs associated with the hospital's modern and state-of-the-art facilities, the Chairman reiterated the Board's commitment to accessible, affordable, and high-quality patient care. Stockholders were asked to help communicate this message to the community. The Chairman affirmed that exceptional patient care can be delivered without imposing excessive financial burdens.

A major challenge was identified in the delayed payments from government partners. To address this, initiatives are being made to streamline billing and collection processes. Moreover, concerted efforts to expedite our PhilHealth reimbursements were made, ensuring that payments for the services provided are timely received. The implementation of an integrated hospital information system has significantly contributed in bolstering the hospital's financial position, which enables APMC Iloilo to continue offering high-quality care to its patients.

Moreover, the Chairman reported that the current patient census is on par with other hospitals in the region. The Chairman stressed the importance of patient feedback and reported ongoing improvements in wait times, service delivery, and the overall patient experience. A robust feedback resolution system is being implemented.

The Chairman outlined upcoming strategic initiatives to increase hospital visibility and accessibility, including marketing efforts, referral network expansion, and diversification of services, aimed at boosting patient census and revenues. To further enhance service delivery, the hospital intends to raise additional capital and explore partnerships with local organizations aligned with its mission.

The Chairman reaffirmed APMC Iloilo's commitment to transparency and accountability through timely disclosures of financial reports. He acknowledged the stockholders' trust and investment as essential to the hospital's progress.

In closing, the Chairman appealed to stockholders for continued patience and support during this critical phase. Stockholders' trust and and belief in APMC Iloilo's mission were acknowledged as the bedrock of success. The message concluded with a powerful reminder that "healthcare is a team sport" and emphasized the collective effort required to ensure APMC Iloilo's growth and long-term success.

Management Report

The President greeted the Chairman of the Board, Dr. Ferjenel Biron, members of the Board of Directors, founders, investors, and honored guests. He reflected on the hospital's successful first year of operations, citing remarkable growth, resilience in the face of challenges, and steadfast commitment to excellence, innovation, and compassionate care.

The President reported that Asia Pacific Medical Center Iloilo (APMCI) has exceeded expectations in operational performance and quality patient care. He emphasized that the hospital has evolved into a lasting legacy built on service, innovation, and excellence.

The President presented the following operational highlights:

- The Ambulatory Care Unit attended to 16,933 patients;
- The Emergency Room and Urgent Unit served 5,460 patients;
- A total of 838 surgical procedures were performed in the hospital's state-of-the-art operating theaters;
- The Stroke Unit, duly accredited by the Stroke Society of the Philippines, was added to the ICU complex.

The hospital has twenty four (24) accredited HMOs, which accounted for 26% of total patients served, and extended assistance to 1,289 patients; 267 under DSWD, 324 under PCSO, and 698 under the MAIFIP Program. To further boost revenue, the hospital offered executive packages to patients and investors.

The hospital is supported by 550 medical staff and 641 employees, maintaining a high retention rate of 98.6% and a turnover rate of 1.3%. Licensed as a Level 2 facility by the Department of Health and registered with the Department of Labor and Employment, APMCI continues to deliver comprehensive services and quality care. The hospital, through the Nursing Service Division, instituted a series of activities focused on competency, staff development, and implementation of approved policies and procedures. Furthermore, programs on mental health, immunization, cardiology seminar, and basic IV therapy training, including blood donation programs are being conducted by the hospital.

The implementation of the hospital information system has efficiently managed operation through integration of the system to all the departments. TIPPLUS system is fully integrated with Imaging Department and other specialized areas to enhance seamless operation.

The Outpatient Clinics that caters to both general & specialize medical & surgical conditions attended to a total of 12,658 patients with a monthly average of 1,054 patients. Peak admission were notable during the month of August. Overall, patient volume for outpatient and inpatient during the 1st quarter of 2025 followed a similar pattern as the previous year, although there is a trend toward increasing volume. The patient admission vs discharged during the 1st Quarter of 2025 showed similar pattern as the previous year.

The President reported that the hospital's gross revenue originated from a wide spectrum of inpatient & outpatient services. Among the revenue generating areas, Pharmacy constitutes the majority of the sales accounting for 28.5%. Additionally, the Room Accommodation & Pathology contributed 20% & 16.6%, respectively. The comparative sales for 1st Quarter of 2024 and 2025 presents parallel lines, indicating consistent sales growth trajectory in the initial two quarter periods.

For the calendar year ending December 31, 2023 and 2024, hospital revenue amounted to P307.90 million. This originated from patient collections, extensive marketing initiatives & product refinements. Direct costs are directly attributable to patient care and various factors, such as startup costs, heightened patient volume, and the necessity for specialized equipment.

While steady sales growth was observed, increased general and administrative expenses due to infrastructure development, marketing, and personnel expansion contributed to higher general and administrative costs. The hospital's improved Quick Asset Ratio and increased long-term debt reflect both stronger cash flow and the need to support operational sustainability. Thus, stockholders can expect to earn returns on their investment after the hospital generates net income.

The President acknowledged ongoing challenges in meeting the growing demand for specialized services and maintaining financial sustainability amidst fluctuating admission and operational costs.

In closing, the President expressed his deepest gratitude to the staff, partners, and supporters. Their dedication, trust and shared vision have been instrumental in the hospital's progress. He ended his message with APMC Iloilo's guiding principle: "Professional Medicine, Personal Care."

Presentation of the 2024 Audited Financial Statements

After the President's report, an Audio Visual Presentation of the hospital was shown on screen. Then after, the Corporate Treasurer, Dr. Mary Flor Gafate-Ong presented the 2024 Audited Financial Statement which was also attached to the Definitive Information Statement.

The Corporate Treasurer reported that the independent Auditor, Dimaculangan, Dimaculangan and Co. CPAs, appointed during the 2024 Annual Stockholders' Meeting, rendered an opinion that the financial statements of APMC Iloilo fairly presented in all material respect. The financial position of the hospital as of December 31, 2024 and 2023 is in accordance with the Philippines Financial Reporting Standard.

As of December 31, 2024, total assets stood at Php 2,514,004,064, marking a 2.5% increase from the previous year. Current Assets amounted to Php 231,277,991, while non-current assets amounted to Php 2,282,726,072, primarily due to the reclassification of the completed hospital building valued at Php 1,836,310,239.24, and additional purchases of property and equipment. The net carrying value of the non-current assets amounted to Php 2,282,726,071 and Php 2,377,073,892 as at December 31, 2024, and 2023, respectively.

The total liabilities increased by 28.4% to Php 2,059,633,519 in December 31, 2024, with current liabilities at Php 560,167,244 as compared to December 31,2023 which is valued at Php 240,045,064. The non-current liabilities are non-interest and interest bearing loans made by the company which summed up to Php 1,499,466,275 in December 2024 and Php 1,364,029,275 in December 2023.

Consequently, the total equity declined to Php 454,370,545 from Php 848,653,120 in 2023. The total liabilities and equity as of December 31, 2024 reconciled with the total assets of the corporation amounting to Php 2,514,004,064.

For the year ended December 31, 2024, the Company generated a revenue of Php 307,910,026 and a gross income of Php 39,142,726.

The substantial operating expenses, primarily driven by the recognition of completed hospital building construction and the finance costs incurred from banks, resulted in a comprehensive loss of Php 397,759,075 and Php 147,332,832, for the fiscal years ended December 31, 2024, and 2023, respectively.

The basic loss per share amounted to Php 1,657.61 and Php 613.99 for the years ended December 31, 2024 and 2023, respectively. There are no potential dilutive ordinary shares outstanding seen in the last three (3) years.

On December 27, 2019, the Securities and Exchange Commission approved the registration statement of the company covering its proposed initial public offering of its 36,000 common shares. As of December 31, 2024, the share capital remains 239,960,000. The share premium for the year ended December 31,2024 is Php 957,373,662, with a deficit of Php 742,962,117.

The statements of cash flows are from operating, investing and financing activities of the company. Considering the comprehensive losses as earlier reported, plus the adjustments from depreciation, amortization, interest income and primarily from interest expenses, the operating cash outflow is Php 405,188,321 in 2024, while Php 178,927,012 in 2023.

With some adjustment changes in the working capital components, the decrease in the current assets and the increase in current liabilities and the small adjustment from the received interest, the net cash used in operating activities for the year ended December 2024 is Php 322,752,397 while in the year ended December 2023, it was Php 144,136,522.

By December 31, 2024, total cash used in investing activities amounted to Php 41,611,213. A significant portion was allocated to construction in progress amounting to Php1,900,721,434 while Php1,859,110,221 was utilized for the acquisition of property and equipment.

Financing activities during the year generated cash flows primarily from additional share capital, share premium, subscription receivables, and loans payable, net of principal and interest payments on bank loans. The net cash provided by financing activities amounted to Php 289,973,234 in 2024, while Php 466,146,777 in 2023.

In terms of cash flow movement, as of 31 December 2024, a net increase was recorded amounting to Php 8,832,050, resulting in a year-end cash balance of Php 13,830,999. This is in contrast to the net decrease of Php 6,515,611 in 2023, which ended with cash balances of Php 4,998,949.

After the Treasurer's Report, the Chairman inquired from the Corporate Secretary if there are any other matters that the stockholders must be informed of. In response, the Corporate Secretary answered that in compliance with the Revised Corporation Code, the stockholders must be informed of the total compensation received by each director during the past year.

Considering the financial condition of the hospital, the Chief Finance Officer prepared a report on the per diems received by individual directors which was attached in the Information Statement together with a detailed Management Report that is compliant with the requirements of the Securities Regulation Code.

The Chairman then asked the Corporate Secretary if there were any inquiries on the matter. In response, the Corporate Secretary answered that there were no questions submitted online regarding the matter. Since there were no queries, the Chairman requested the Corporate Secretary to present the proposed resolution and the report for the tally of votes.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares present and voted in favor on the said matter.

ASM Resolution No. 2025-02

RESOLVED, to note the 2024 Annual Report and to approve the 2024 Audited Financial Statements as of December 31, 2024.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,430	99.20%
Against	0	0%
Abstain	1,600	0.80%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have noted the 2024 Annual Report and approved the 2024 Audited Financial Statements as of December 31, 2024 and declared that ASM Resolution No. 2025-02 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Open Forum

The stockholders were given the opportunity to ask questions regarding the company's performance, strategic direction, and other matters of interest. The questions raised by the stockholders were read by the representative from the Investors Relations Office, Ms. Ginalyn V. Tan.

First question was regarding the status of the stockholders' identification cards which was raised by Dr. Nathalie Marie R. Deslate-Zaldarriaga. In response, Dr. Agnes Jean M. Villaflor explained that the processing of the stockholders' ID is currently ongoing. However, due to the significant volume of IDs to be printed, there has been an unavoidable delay in the production timeline. The Management wishes to assure the stockholders that all necessary efforts are being made to expedite the printing and distribution of the ID cards. The target is to complete the issuance of the IDs within the year. In the meantime, the identification and verification of stockholders remain manageable, as the official stockholders' list is readily available and accessible to authorized personnel.

Second question is from Ms. Melinda Chavez, inquiring if the hospital currently offers any medical packages or health service benefits which may be availed of by stockholders. This question was directed to the President. The President informed the stockholders that Asia Pacific Medical Center Iloilo offers Executive Packages available until December 31, 2025, as part of the hospital's continuing commitment to promote health and wellness among its stakeholders.

These packages are offered exclusively to investors at a 50% Managerial Discount, and each package includes a comprehensive set of diagnostic and preventive laboratory tests, chest X-ray (PA view), as well as special procedures such as Electrocardiogram (ECG), 2D Echocardiography, Whole Abdomen Ultrasound, and Dental Oral Prophylaxis.

The President then presented the available packages and their corresponding discounted rates as follows:

- Basic Executive Package – ₱6,747.45
- Male Executive Package – ₱10,553.45
- Female Executive Package – ₱11,822.35

Investors were encouraged to avail of these packages and to contact the hospital for further details or assistance in scheduling their appointments.

The third question is from Ms. Bernadetter Castilla Yanson who inquired if the Corporation has already declared dividends, and if so, the basis and schedule of its distribution.

The moderator respectfully requested the Chairman to address the question. In response, the Chairman explained that the Corporation has not yet declared any dividends, as it has only commenced operations approximately eighteen (18) months ago. The declaration of dividends, if and when made, shall be sourced from the Corporation's unrestricted retained earnings and may be distributed in the form of cash, property, or stock, proportionate to the outstanding shares held by each stockholder. The decision to declare and distribute dividends rests with the Board of Directors, taking into account several financial factors, including but not limited to, the Corporation's net income, liquidity position, cash flow, projected capital expenditures, and overall financial condition.

The Investor Relation Office Staff thanked the Chairman and reminded the stockholders that for any inquiries regarding their investments, they can reach the IRO through Facebook, email or contact number at (033) 3215748.

Other questions raised during the Annual Stockholders' Meeting are hereto attached as **Annex "B"**.

Ratification and Approval of All the Acts and Proceedings of the Board of Directors and Corporate Officers

The Chairman proceeded to the next item on the Agenda which is the ratification and approval of all the acts, proceedings and resolutions of the Board of Directors and Corporate Officers since the Annual Stockholders Meeting on 11 June 2024 up to the present, as reflected on the Minutes of the Meetings of the Board of Directors. The summary of these acts, proceedings and resolutions were included in the Information Statement. Furthermore, these were approved in the meetings of the Board and are covered by the Minutes which are on file with the Office of the Corporate Secretary.

The Chairman then asked the Corporate Secretary if there were inquiries received on this matter. The Corporate Secretary confirmed that there were no questions received online regarding the matter.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares present and voted in favor on the said matter.

ASM Resolution No. 2025-03

RESOLVED, to ratify and approve the previous acts and resolutions of the Board of Directors and Corporate Officers, from the last Annual Stockholders' Meeting on 11 June 2024 up to the present date.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,300	99.13%
Against	10	0.01%
Abstain	1,720	0.86%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have ratified and approved the previous acts and resolutions of the Board of Directors and Corporate Officers, from the last Annual Stockholders' Meeting on 11 June 2024 up to the present date and declared that ASM Resolution No. 2025-03 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Amendment of By-Laws on the Regular Meeting of Stockholders

The Chairman proceeded with the next item on the Agenda which is the amendment of Article II Section 1 of the Corporation's By-Laws on the Regular Meeting of the Stockholders. He explained the reason for the amendment is to ensure compliance with SEC guidelines in case of postponements or changes in the schedule of Annual Stockholders' Meeting. He then asked the Corporate Secretary if there were any inquiries regarding the matter, to which the Corporate Secretary responded that there were no inquiries for the same.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares voted in favor on the said matter.

DRAFT

ASM Resolution No. 2025-04

RESOLVED, to amend **Article II, Section 1** of the Company's By-Laws on the Regular Meeting of Stockholders, from:

Section 1. Regular Meetings - The Regular meetings of Stockholders for the purpose of electing directors and for the transaction of such business as may properly come before meeting, shall be held at the principal office of the corporation on the THIRD SUNDAY OF APRIL, of each year. The Board of Directors may provide, however, that the regular meeting shall be held at such other date and time as shall be specified in the notice of the meeting.

To:

Section 1. Regular Meetings - The Regular meetings of Stockholders for the purpose of electing directors and for the transaction of such business as may properly come before meeting, shall be held at the principal office of the corporation on the FOURTH THURSDAY OF JULY, of each year. The Board of Directors, may provide, however, that the regular meeting shall be held at such other date and time as shall be specified in the notice of the meeting, **in accordance with the guidelines of the Securities and Exchange Commission.**

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,530	99.25%
Against	10	0.01%
Abstain	1,490	0.74%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have approved the amendment of Article II, Section 1 of the Corporation's By-laws and declared that ASM Resolution No. 2025-04 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Amendment of By-Laws on the Place of Meeting of the Stockholders

The Chairman proceeded with the next item on the Agenda which is the amendment of Article II Section 3 of the Corporation's By-Laws on the Place of Meeting of the Stockholders. The amendment is being made to harmonize the by-laws with the relevant provisions of the Revised Corporation Code and SEC Memorandum Circular No. 6, Series of 2020 to provide clarity on the procedure. He then asked the Corporate Secretary if there were any inquiries regarding the matter, to which the Corporate Secretary responded that there were no questions received for the same.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares voted in favor on the said matter.

ASM Resolution No. 2025-05

RESOLVED, to amend **Article II, Section 3** of the Corporation's By-Laws on the Place of Meeting of Stockholders, from:

Section 3. Place of Meeting - Stockholders' meeting, whether regular or special, shall be held in the principal office of the corporation or at any place designated by the Board of Directors in the city or municipality where the principal office of the corporation is located.

To:

Section 3. Place of Meeting - Stockholders' meeting, whether regular or special, shall be held in the principal office of the corporation or at any place designated by the Board of Directors in the city or municipality where the principal office of the corporation is located.

When the meeting is conducted through tele/video conferencing, the presiding officer shall call and preside the stockholders' meeting, whether regular or special, at the principal of the corporation or if not practicable, in the city or municipality where the principal office of the Corporation is located.

DRAFT

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,540	99.26%
Against	0	0%
Abstain	1,490	0.74%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have approved the amendment of Article II, Section 3 of the Corporation's By-laws and declared that ASM Resolution No. 2025-05 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Amendment of By-Laws on the Conduct of Meeting of the Stockholders

The Chairman proceeded with the next item on the Agenda which is the amendment of Article II Section 6 of the Corporation's By-Laws on the Conduct of Meeting of the Stockholders. The amendment is being made to harmonize the by-laws with the relevant provisions of the Revised Corporation Code and SEC Memorandum Circular No. 6, Series of 2020 to provide clarity on the procedure.

He then asked the Corporate Secretary if there were any questions received regarding the matter, to which the Corporate Secretary responded that there were no inquiries received for the same.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares voted in favor on the said matter.

ASM Resolution No. 2025-06

RESOLVED, to amend **Article II, Section 6** of the Corporation's By-Laws on the Conduct of Meeting of Stockholders, from:

Section 6. Conduct of Meeting – Meeting of the stockholders shall be presided over by the Chairman or, in his absence, by the President. The Secretary shall act as Secretary of every meeting, but if not present, the Chairman of the meeting shall appoint a secretary of the meeting. The Chairman of the meeting may adjourn the meeting without notice other than that announced at the meeting.

Stockholders who cannot physically attend at stockholders' meetings may participate in such meetings through remote communication.

To:

Section 6. Conduct of Meeting – Meeting of the stockholders shall be presided over by the Chairman or, in his absence, by the President. The Secretary shall act as Secretary of every meeting, but if not present, the Chairman of the meeting shall appoint a secretary of the meeting. The Chairman of the meeting may adjourn the meeting without notice other than that announced at the meeting.

The meeting may be conducted through tele/video conferencing.

Stockholders who cannot physically attend or vote at stockholders' meetings can participate and vote through remote communication such as video conferencing, teleconferencing, or other alternative modes of communication that allow them reasonable opportunities to participate.

If a stockholder intends to participate in a meeting through remote communication, he/she shall notify in advance the Presiding Officer and the Corporate Secretary of his/her intention. The Corporate Secretary shall note such fact in the Minutes of the meeting.

The Board shall adopt internal procedures for the conduct of stockholders' meetings through remote communication or other alternative modes of communication to address administrative, technical and logistical issues.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,540	99.25%
Against	10	0.01%
Abstain	1,480	0.74%
Total	**200,030**	**100%**

The Chairman reported that the stockholders have approved the amendment of Article II, Section 6 of the Corporation's By-laws and declared that ASM Resolution No. 2025-06 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Amendment of By-Laws on the Manner of Voting by the Stockholders

The Chairman proceeded with the next item on the Agenda which is the amendment of Article II Section 7 of the Corporation's By-Laws on the Manner of Voting by the Stockholders. The amendment is being made to harmonize the by-laws with the relevant provisions of the Revised Corporation Code and SEC Memorandum Circular No. 6, Series of 2020 to provide clarity on the procedure. He then asked the Corporate Secretary if there were any inquiries regarding the matter, to which the Corporate Secretary responded that there were no inquiries received for the same.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares voted in favor on the said matter.

ASM Resolution No. 2025-07

RESOLVED, to amend **Article II, Section 7** of the Corporation's By-Laws on the Manner of Voting, from:

Section 7. Manner of Voting - At all meetings of stockholders, a stockholder may vote in person or by proxy executed in writing by the stockholder or his duly authorized attorney-in-fact. Unless otherwise provided in the proxy, it shall be valid only for the meeting at which it has been represented to the Secretary.

All proxies must be in the hands of the Secretary not later than seven (7) calendar days before the scheduled meeting. Based on the scheduled stockholders' meeting, the deadline of submission is on the SECOND SUNDAY OF APRIL on or before 5:00 p.m. Such proxies filed with the Secretary may be revoked by the stockholder concerned either in an instrument in writing duly presented and recorded with the Secretary prior to a scheduled meeting or by his personal presence at the meeting. The decision of the Secretary on the validity of the proxies shall be final and binding until set aside by a court of competent jurisdiction.

To:

Section 7. Manner of Voting - At all meetings of stockholders, a stockholder may vote in person **or in absentia** or by proxy executed in writing by the stockholder or his duly authorized attorney-in-fact. Unless otherwise provided in the proxy, it shall be valid only for the meeting at which it has been represented to the Secretary.

All proxies must be in the hands of the Secretary not later than seven (7) calendar days before the scheduled meeting. Based on the scheduled stockholders' meeting, the deadline of submission is on the **THIRD THURSDAY OF JULY** on or before 5:00 p.m.

Such proxies filed with the Secretary may be revoked by the stockholder concerned either in an instrument in writing duly presented and recorded with the Secretary prior to a scheduled meeting or by his personal presence at the meeting. The decision of the Secretary on the validity of the proxies shall be final and binding until set aside by a court of competent jurisdiction.

Online voting shall be allowed when meetings are held via remote communication.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,410	99.19%
Against	0	0%
Abstain	1,620	0.81%
Total	**200,030**	**100%**

The Chairman reported that based on the voting results, the stockholders have approved the amendment of Article II, Section 7 of the Corporation's By-laws and declared that ASM Resolution No. 2025-07 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Amendment of By-Laws on the Conduct of Meeting of the Board of Directors

The Chairman proceeded with the next item on the Agenda which is the amendment of Article III Section 6 of the Corporation's By-Laws on the Conduct of Meeting of the Board of Directors. The amendment is being made to harmonize the by-laws with the relevant provisions of the Revised Corporation Code and SEC Memorandum Circular No. 6, Series of 2020 to provide clarity on the procedure. He then asked the Corporate Secretary if there were any inquiries regarding the matter, to which the Corporate Secretary responded that there were no inquiries received for the same.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares voted in favor on the said matter.

DRAFT

ASM Resolution No. 2025-08

RESOLVED, to amend **Article III, Section 6** of the Corporation's By-Laws on the Conduct of the Meeting of the Board of Directors, from:

Section 6. Conduct of the Meeting - Meetings of the Board of Directors shall be presided over by the Chairman of the Board, or in his absence, the President, or if none of the foregoing is in office and present and acting, by any other director chosen by the Board. The Secretary of every meeting shall be the Secretary, but if neither the secretary nor an Assistant Secretary is present, the Chairman of the meeting shall appoint a secretary of the meeting.

Directors who cannot physically attend or vote at Board Meetings can participate in voting through remote communications such as, video conferencing, teleconferencing or other alternative modes of communication that will allow them reasonable opportunities to participate. However if a Director intends to participate in a meeting through remote communications, he shall notify in advance the presiding officer and the corporate secretary of his/her intention so the corporate secretary shall note such fact in the minutes of the meeting.

The Board shall also adopt internal procedures for the conduct of Board Meetings through remote communications or other alternative modes of communications to address administrative, technical and logistical issues.

The notice of meetings may be sent to all Directors through electronic mail, messaging services stating the date, time and place of the meeting and must be sent to every Director at least five (5) days prior to the scheduled meeting. A Director or Trustees may waive this requirement either expressly or impliedly.

The notice of meeting shall include the following information:

a.Date, Time and Place of the meeting;

b. Agenda of the meeting;

c. All pertinent materials for discussion which shall be numbered and marked in such manners that all directors or trustee can easily follow and participate in the meeting;

d. That a director may participate via remote communication;

e. Contact information of the corporate secretary or office staff whom the director may communicate

f. When the meeting is for election or directors or officers, the requirements and procedure for nomination and election;

g. The fact that there will be a visual and/or audio recording of the meeting; and

h.Other instructions to facilitate participation in the meeting through remote communications.

To:

Section 6. Conduct of the Meeting - Meetings of the Board of Directors shall be presided over the Chairman of the Board, or in his absence, the President, or if none of the foregoing is in office and present and acting, by any other director chosen by the Board. The Secretary of every meeting shall be the Secretary, but if neither the secretary nor an Assistant Secretary is present, the Chairman of the meeting shall appoint a secretary of the meeting.

The meeting may also be conducted through remote communication such as video conferencing, teleconferencing or other alternative modes of communication that allow directors reasonable opportunities to participate. However, directors cannot attend or vote by proxy.

A Director who intends to participate in a meeting through remote communication shall notify in advance the Presiding Officer and the Corporate Secretary of his/her intention. The Corporate Secretary shall note such fact in the Minutes of the meeting.

The Board shall also adopt internal procedures for the conduct of Board Meetings through remote communications or other alternative modes of communications to address administrative, technical and logistical issues.

Notice of board meetings may be sent to all directors or trustees through electronic mail, messaging service or such other manner as may be provided in the by-laws or by board resolution.

Notice of regular or special board meetings stating the date, time and place of the meeting must be sent to every director or trustee at least five (5) days prior to the scheduled meeting, unless a longer time is provided in the Manual of Corporate Governance to be approved by the Board. A director or trustee may waive this requirement, either expressly or impliedly.

The notice of meeting shall include the following information:

a.Date, Time and Place of the meeting;

b. Agenda of the meeting;

c. All pertinent materials for discussion which shall be numbered and marked in such manners that all directors or trustee can easily follow and participate in the meeting;

d. That a director may participate via remote communication;

e. Contact information of the corporate secretary or office staff whom the director may communicate

f. When the meeting is for election for directors or officers, the requirements and procedure for nomination and election;

g. The fact that there will be a visual and/or audio recording of the meeting; and

h.Other instructions to facilitate participation in the meeting through remote communications.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,500	99.24%
Against	0	0%
Abstain	1,530	0.76%
Total	**200,030**	**100%**

The Chairman reported that based on the voting results, the stockholders approved the amendment of Article III, Section 6 of the Corporation's By-laws and declared that ASM Resolution No. 2025-08 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Appointment of External Auditors

Moving to the next Agenda, the Chairman requested the Chairman of the Audit Committee, Dr. Jerusha A. Comuelo to report on the nominated External Auditor.

Dr. Comuelo reported that, following a thorough evaluation and deliberation on the performance of the audit firm Dimaculangan & Dimaculangan for the past fiscal year, the Audit Committee has endorsed to the Board of Directors the reappointment of the said firm as the Company's External Auditor, with an audit fee of Php 325,024.00. She further stated that Diamculangan & Diamculangan has once again been nominated to serve as the External Auditor of the Company for the current fiscal year.

The Chairman inquired if there were questions regarding the reappointment of the External Auditor. In response, the Corporate Secretary stated that there were no online questions submitted regarding the item.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes of the majority of the stockholders owning outstanding shares present and voted in favor on the said matter.

ASM Resolution No. 2025-09

RESOLVED, as endorsed by the Audit Committee and the Board of Directors, to approve the election of Dimaculangan, Dimaculangan and Co. CPAs as independent auditor of the Company for the Year 2025-2026 and fixing of its Remuneration.

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,560	99.27%
Against	0	0%
Abstain	1,470	0.73%
Total	**200,030**	**100%**

The Chairman reported that based on the voting results, the stockholders approved the re-appointment of Diamculangan & Dimaculangan as external Auditor of the Company for the year 2025-2026 and declared that ASM Resolution No. 2025-09 has been approved. He then requested the Corporate Secretary to let the minutes reflect the votes on the matter.

Election of the Board of Directors

The Chairman requested Director Atty. Rolex T. Suplico, Chairman of the Nominations and Election Committee (NOMELEC), to explain the next item on the Agenda. Director Suplico mentioned that in accordance with the APMC Iloilo's By-laws, Manual on Corporate Governance and other pertinent rules and regulations of the Securities and Exchange Commission, he presented the following stockholders nominated to the Board of Directors for the ensuing term:

Nominees for Regular Board of Directors

1. Dr. Ferjenel G. Biron
2. Mr. Brandt Luke Q. Biron
3. Dr. Felibert O. Dianco
4. Mr. Lemuel Fernandez
5. Dr. Lusyl M.Gomez
6. Dr. Meride D.Lavilla
7. Dr. Felix P. Nolasco
8. Dr. Mary Flor Gafate-Ong
9. Dr. Danilo C. Regozo
10. Dr. Fredilyn G. Samoro
11. Atty. Rolex T. Suplico
12. Dr. Agnes Jean M. Villaflor

Nominees for Independent Board Directors

1. Atty.Johanna Marie B. Bermudo-Belgira
2. Ms. Nathalie Ann F. Debuque
3. Mrs. Lorna C. Silverio

Atty. Belgira, Ms. Debuque and Mrs. Silverio have been nominated as Independent Directors. The Nominations and Election Committee of the Board has ascertained that the fifteen (15) nominees, including the three (3) nominees for Independent Directors possess the necessary qualifications. All nominees have given their consent to their respective nominations. The profiles and business experiences of all the nominees are set out in Annex " C1" of the Information Statement.

The Chairman asked the Corporate Secretary whether there were inquiries received regarding the matter. In response, the Corporate Secretary confirmed that there were no questions submitted online regarding the matter.

The Chairman then requested the Corporate Secretary to report regarding the votes on the foregoing item on the Agenda.

DRAFT

The votes for all the nominees for Regular Directors and Independent Directors are as follows:

Director	No. of Votes	
Regular Directors		
Ferjenel G. Biron	541,061	Re-elected
Fredilyn G. Samoro	335,644	Re-elected
Brandt Luke Q. Biron	312,424	Newly elected
Rolex T. Suplico	192,858	Re-elected
Lemuel T. Fernandez	189,941	Re-elected
Agnes Jean M. Villaflor	182,180	Re-elected
Danilo C. Regozo	169,417	Re-elected
Meride D. Lavilla	160,354	Re-elected
Felix P. Nolasco	96,330	Re-elected
Mary Flor Gafate-Ong	78,344	Re-elected
Lusyl M. Gomez	74,392	Re-elected
Felibert O. Dianco	66,728	Re-elected
Independent Directors		
Nathalie Ann F. Debuque	227,541	Newly elected
Johanna Marie B. Bermudo-Belgira	165,950	Re-elected
Lorna C. Silverio	159,880	Newly elected

The Corporate Secretary mentioned that the Board of Canvassers has tallied the ballots and the proxies received for the twelve (12) nominees for the twelve (12) seats for Regular Directors and three (3) nominees for the (3) seats for Independent Directors or a total of fifteen (15) nominees for the fifteen (15) seats in the Board.

Upon the request of the Chairman, the Corporate Secretary presented the proposed resolution and the tally of votes on the said matter.

ASM Resolution No. 2025-10

RESOLVED, as it is hereby **RESOLVED** to elect the following as Directors of the Corporation to serve as such, beginning 18 June 2025 until their successors are elected and qualified:

Dr. Ferjenel G. Biron
Mr. Brandt Luke Q. Biron
Dr. Felibert O. Dianco
Mr. Lemuel T. Fernandez
Dr. Lusyl M. Gomez
Dr. Meride D. Lavilla
Dr. Felix P. Nolasco
Dr. Mary Flor Gafate-Ong
Dr. Danilo C. Regozo
Dr. Fredilyn G. Samoro
Atty. Rolex T. Suplico
Dr. Agnes Jean M. Villaflor
Atty. Johanna Marie B. Bermudo-Belgira
Ms. Nathalie Ann F. Debuque
Mrs. Lorna C. Silverio

The final and official voting results for the above resolution are as follows:

Vote	No. of Shares Voting	Percentage
For	198,320	99.15%
Against	0	0%
Abstain	1,710	0.85%
Total	**200,030**	**100%**

The Chairman declared that the fifteen (15) nominees, which consists of twelve nominees for regular directors and three (3) nominees for independent directors are duly elected as directors of the company for 2025-2026. He then requested the Corporate Secretary to let the minutes reflect the tally of the votes on the said matter.

The Chairman extended his gratitude to the outgoing members of the Board of Directors.

Recognition was given to Dr. Amado M. Lavalle, Jr., who has been with the Company since 2014. Dr. Lavalle has been part of the Company's journey—witnessing and shaping its early foundations and contributing to many of its significant milestones. As President, Dr. Lavalle has exemplified unwavering dedication and steadfast leadership.

Likewise, the Chairman thanked Dr. Jerusha Comuelo and Mrs. Ma. Teresa Debuque, who have served as Independent Directors of the Company. Their wisdom, guidance and thoughtful insights have been instrumental in the Company's sustained growth and success.

Although Dr. Lavalle and Dr. Comuelo will be stepping down from their roles as Directors of the Company, they will continue their professional practice in the hospital. Their continued presence and expertise will remain a valued part APMC Iloilo.

The Chairman also formally welcomed the newly elected Director, Mr. Brandt Luke Biron and Independent Directors, Ms. Nathalie Ann Debuque and Mrs. Lorna Silverio. The Board expressed its confidence that the newly elected Directors will bring valuable perspectives and thoughtful contributions to the Company, continuing to uphold the standards of excellence and service that define APMC Iloilo.

Adjournment

Considering all the items in the Agenda were discussed, the 2025 Annual Stockholders' Meeting of Asia Pacific Medical Center - Iloilo, Inc. was adjourned. The Chairman expressed his gratitude to everyone for their continued support.

Prepared by:

ORIGINAL SIGNED
THERESE MARIE A. GERAFIL
Corporate Secretary

DRAFT

ASIA PACIFIC MEDICAL CENTER ILOILO

Annex "A"

2025 ANNUAL STOCKHOLDERS' MEETING
OF ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
Wednesday, 18 June 2025 at 9:00 A.M.
via Remote Communication through Zoom Meeting
Brgy. Ungka, Jaro, Iloilo City

ATTENDANCE OF STOCKHOLDERS

Present via Remote Communication			
Stockholder	**Type of Shares**	**No. of Shares**	**Beneficial Owner**
Barrameda, Romulo	Founder Shares	10	Barrameda, Romulo
	Common Shares	1,890	
Biron, Ferjenel G.	Founder shares	240	Biron, Ferjenel G.
	Common Shares	48,266	
Comuelo, Jerusha A.	Founder Shares	10	Comuelo, Jerusha A.
	Common Shares	3,452	
Cruz, Maita	Founder Shares	10	Cruz, Maita
	Common Shares	1,100	
Daulo, Sylva	Founder Shares	10	Daulo, Sylva
	Common Shares	3,050	
De. Castro, Ma. Gloria T.	Founder Shares	10	De. Castro, Ma. Gloria T.
	Common Shares	1,390	
Dianco, Felibert	Founder Shares	10	Dianco, Felibert
	Common Shares	3,360	
Domingo Jr., Carmelo	Founder Shares	10	Domingo Jr., Carmelo
	Common Shares	3,390	
Fernandez, Lemuel T.	Founder Shares	10	Fernandez, Lemuel T.
	Common Shares	1,930	
Gafate-Ong, Mary Flor	Founder Shares	10	Gafate-Ong, Mary Flor
	Common Shares	3,452	
Gomez, Lusyl M.	Founder Shares	10	Gomez, Lusyl M.
	Common Shares	2,771	
Gonzales, Noel J.	Founder Shares	10	Gonzales, Noel J.
	Common Shares	3,390	
Hayano, Windie V.	Founder Shares	10	Hayano, Windie V.
	Common Shares	1,990	
Lavalle Jr. Amado M.	Founder Shares	10	Lavalle Jr. Amado M.
	Common Shares	3,708	
Lavilla, Francis	Founder Shares	10	Lavilla, Francis
	Common Shares	2,430	
Lavilla, Meride	Founder Shares	10	Lavilla, Meride
	Common Shares	3668	

DRAFT

Nolasco, Eulenia	Founder Shares	10	Nolasco, Eulenia
	Common Shares	2340	
Nolasco, Felix	Founder Shares	10	Nolasco, Felix
	Common Shares	2340	
Patrimonio, Demetrio Jr. T.	Founder Shares	10	Patrimonio, Demetrio Jr. T.
	Common Shares	1,890	
Regozo, Danilo C.	Founder Shares	10	Regozo, Danilo C.
	Common Shares	3,678	
Samoro, Fredilyn	Founder Shares	20	Samoro, Fredilyn
	Common Shares	6,778	
Samoro, Ronnie Z. (Heirs) Samoro, Karmela Marie, Katrina Belle Marie, Fredilyn and Kim Karolyn	Founder Shares	10	Samoro, Ronnie Z. (Heirs) Samoro, Karmela Marie, Katrina Belle Marie, Fredilyn and Kim Karolyn
	Common Shares	3,452	
Saquian, Jeremy	Founder Shares	10	Saquian, Jeremy
	Common Shares	1,890	
Suplico, Rolex	Founder Shares	10	Suplico, Rolex
	Common Shares	1,990	
Villaflor, Agnes Jean M.	Founder Shares	10	Villaflor, Agnes Jean M.
	Common Shares	3,758	
Abdul Baki, Rogeline	Common Shares	10	Abdul Baki, Rogeline
Aguirre, Richie Roy	Common Shares	10	Aguirre, Richie Roy
Alfeche, Lawrence	Common Shares	10	Alfeche, Lawrence
Alfeche, Mary Giselle	Common Shares	10	Alfeche, Mary Giselle
Alipen, Ma. Zara	Common Shares	10	Alipen, Ma. Zara
Amsua, Lina	Common Shares	10	Amsua, Lina
Ancheta, Ana	Common Shares	10	Ancheta, Ana
Araneta, Yves Ann	Common Shares	10	Araneta, Yves Ann
Arellano Elvira	Common Shares	10	Arellano Elvira
Armentia, Clemente	Common Shares	10	Armentia, Clemente
Arsenal, Lorna	Common Shares	10	Arsenal, Lorna
Articulo, Wendel	Common Shares	10	Articulo, Wendel
Avelino, Rosine	Common Shares	10	Avelino, Rosine
Bacero, Bernadette J.	Common Shares	10	Bacero, Bernadette J.
Bachoco, Michelle	Common Shares	10	Bachoco, Michelle
Balajadia, Ysrael	Common Shares	10	Balajadia, Ysrael
Balderas, Roger P.	Common Shares	10	Balderas, Roger P.
Baligala, Amy	Common Shares	10	Baligala, Amy
Benliro, Arlyn	Common Shares	10	Benliro, Arlyn
Bermudo- Belgira, Johanna Marie	Common Shares	10	Bermudo- Belgira, Johanna Marie
Brazas, Jodelyn	Common Shares	10	Brazas, Jodelyn
Brillantes, John	Common Shares	10	Brillantes, John
Bucane, Maria Victoria	Common Shares	10	Bucane, Maria Victoria
Buensuceso, Jay	Common Shares	10	Buensuceso, Jay
Cabanda Emilyn	Common Shares	10	Cabanda Emilyn

DRAFT

Cabanilla-Belotindos, Jennifer	Common Shares	10	Cabanilla-Belotindos, Jennifer
Cabatbat, Honorato	Common Shares	10	Cabatbat, Honorato
Calubia, Fritz Alvin	Common Shares	10	Calubia, Fritz Alvin
Caluyo- Sarita Christille Lindy Joyce	Common Shares	10	Caluyo- Sarita Christille Lindy Joyce
Cambas-Trabado, Jennifer Rose	Common Shares	10	Cambas-Trabado, Jennifer Rose
Capundo- Juanico, Lorna Joyce	Common Shares	10	Capundo- Juanico, Lorna Joyce
Carancio, Ivy D.	Common Shares	10	Carancio, Ivy D.
Cardona, Genevieve	Common Shares	10	Cardona, Genevieve
Casiano, Patricia	Common Shares	10	Casiano, Patricia
Castañeda, Ma. Theresa	Common Shares	10	Castañeda, Ma. Theresa
Castellano, Socorro	Common Shares	10	Castellano, Socorro
Chavez, Melinda	Common Shares	10	Chavez, Melinda
Coronilia, Paul Christian	Common Shares	10	Coronilia, Paul Christian
Depalac, Jonas	Common Shares	10	Depalac, Jonas
Deslate, Carmelo	Common Shares	10	Deslate, Carmelo
Deslate, Natalie Marie	Common Shares	10	Deslate, Natalie Marie
Dichoson, Dovy	Common Shares	10	Dichoson, Dovy
Erfe, Grace Marie	Common Shares	10	Erfe, Grace Marie
Ervite, Flocerfina	Common Shares	10	Ervite, Flocerfina
Escutin, Joselito	Common Shares	10	Escutin, Joselito
Facultad, Sussie	Common Shares	10	Facultad, Sussie
Francisco, Kris Raymund	Common Shares	10	Francisco, Kris Raymund
Galele, Marilyn	Common Shares	10	Galele, Marilyn
Galo, Rey Ian	Common Shares	10	Galo, Rey Ian
Garcia, Ma. Sancha Pauline A.	Common Shares	10	Garcia, Ma. Sancha Pauline A.
Garibay, Angelita	Common Shares	10	Garibay, Angelita
Gaw Te, John Sy	Common Shares	10	Gaw Te, John Sy
Gaw, Ma. Luisa Tan	Common Shares	10	Gaw, Ma. Luisa Tan
Gealon, Ma. Christine D.	Common Shares	10	Gealon, Ma. Christine D.
Gepolongca, Gil	Common Shares	10	Gepolongca, Gil
Germinal, Ramel Joseph	Common Shares	10	Germinal, Ramel Joseph
Guillermo, Ramon	Common Shares	10	Guillermo, Ramon
Haddad, Delia	Common Shares	10	Haddad, Delia
International Builders Corporation	Common Shares	1,200	International Builders Corporation
Jalbuena, Lou Camille	Common Shares	10	Jalbuena, Lou Camille
Japitana, Imee J.	Common Shares	10	Japitana, Imee J.
Jaranilla, Joan	Common Shares	10	Jaranilla, Joan
Jon-Gulmatico, Ma. Carmella	Common Shares	10	Jon-Gulmatico, Ma. Carmella

Jordan Roma Joy	Common Shares	10	Jordan Roma Joy
Konig, Fely S.	Common Shares	10	Konig, Fely S.
Kourakos, Marilou	Common Shares	10	Kourakos, Marilou
Lapating, Hope	Common Shares	20	Lapating, Hope
Laurea, Glenda B.	Common Shares	10	Laurea, Glenda B.
Lavente, Perla S.	Common Shares	10	Lavente, Perla S.
Ledesma, Harold C.	Common Shares	10	Ledesma, Harold C.
Leonor, John Raymond A.	Common Shares	10	Leonor, John Raymond A.
Limsiaco, Liza	Common Shares	10	Limsiaco, Liza
Limsiaco, Michael Q.	Common Shares	10	Limsiaco, Michael Q.
Lumicday Ii , Jonathan	Common Shares	10	Lumicday Ii , Jonathan
Maala, Mary Pinky	Common Shares	10	Maala, Mary Pinky
Mabanes, Josephine V.	Common Shares	10	Mabanes, Josephine V.
Majarucon, Roy D.	Common Shares	10	Majarucon, Roy D.
Mallorca, Marissa P.	Common Shares	10	Mallorca, Marissa P.
Malones, Rodelin D.	Common Shares	10	Malones, Rodelin D.
Marquez, Lucille	Common Shares	10	Marquez, Lucille
Masangya, Cynthia M.	Common Shares	10	Masangya, Cynthia M.
Mendiola, Elnora F.	Common Shares	10	Mendiola, Elnora F.
Militar Jr., Casiano	Common Shares	10	Militar Jr., Casiano
Mirasol, Al Joevid B.	Common Shares	10	Mirasol, Al Joevid B.
Molina, Felice G.	Common Shares	10	Molina, Felice G.
Molina, Mary Grace	Common Shares	10	Molina, Mary Grace
Monsale, April Joy P.	Common Shares	10	Monsale, April Joy P.
Navarro, Josefa	Common Shares	10	Navarro, Josefa
Navigar, Beverly Joy	Common Shares	10	Navigar, Beverly Joy
Nazario, Anthony P.	Common Shares	10	Nazario, Anthony P.
Nieves, Cirilo Jr.	Common Shares	10	Nieves, Cirilo Jr.
Padilla, Leo Sinforoso	Common Shares	10	Padilla, Leo Sinforoso
Panerio, Douglas	Common Shares	10	Panerio, Douglas
Panila Jumar	Common Shares	10	Panila Jumar
Pedregoza, Marie Chris	Common Shares	10	Pedregoza, Marie Chris
Pet, Eugene Stan Engelbert	Common Shares	10	Pet, Eugene Stan Engelbert
Pet, Ma. Rona	Common Shares	10	Pet, Ma. Rona
Potato, Camilie R.	Common Shares	10	Potato, Camilie R.
Prieto , Mayflor	Common Shares	10	Prieto , Mayflor
Rabe, Hairen	Common Shares	10	Rabe, Hairen
Rivas, Jennifer	Common Shares	10	Rivas, Jennifer
Salada, Jerwin	Common Shares	10	Salada, Jerwin
Salazar, Ma. Iris	Common Shares	415	Salazar, Ma. Iris
Salgado, Arlene Joy	Common Shares	10	Salgado, Arlene Joy

Samoro, Elmer	Common Shares	10	Samoro, Elmer
Serrato, Ruth	Common Shares	10	Serrato, Ruth
Siva, Atanasia	Common Shares	10	Siva, Atanasia
Sobredo, Errol	Common Shares	10	Sobredo, Errol
Sola, Bryan Paul	Common Shares	10	Sola, Bryan Paul
Sorolla , Doreen Joy	Common Shares	10	Sorolla , Doreen Joy
Sucaldito, Bertie	Common Shares	10	Sucaldito, Bertie
Suñer, Pelita	Common Shares	10	Suñer, Pelita
Tajanlangit, Ruperto	Common Shares	10	Tajanlangit, Ruperto
Tibudan, Ariel E.	Common Shares	10	Tibudan, Ariel E.
Tuzan , Alberto	Common Shares	10	Tuzan , Alberto
Velasco, Paz E.	Common Shares	10	Velasco, Paz E.
Villanueva, Maylene	Common Shares	10	Villanueva, Maylene
Villarina, Axel H.	Common Shares	10	Villarina, Axel H.
Yanson, Bernadette	Common Shares	10	Yanson, Bernadette
Yelo, Anatalie	Common Shares	10	Yelo, Anatalie
Zamora, Amparo	Common Shares	10	Zamora, Amparo
Sub-total		**120,658**	

DRAFT

Voting in Absentia			
Stockholder	**Type of Shares**	**No. of Shares**	**Beneficial Owner**
Biron, Brandt Luke Q.	Founder Shares	10	Biron, Brandt Luke Q.
	Common Shares	21,890	
	Founder Shares	10	Biron, Bryant Paul Q.
	Common Shares	21,140	
Debuque, Ma. Teresa F.	Founder Shares	10	Debuque, Ma. Teresa F.
	Common Shares	2,030	
Gallega-Perez, Ma. Grace	Founder Shares	10	Gallega-Perez, Ma. Grace
	Common Shares	3,442	
Minerva, Ike T.	Founder Shares	10	Minerva, Ike T.
	Common Shares	3,390	
Oca-Biron, Ma. Regina Isabelle	Common Shares	60	Oca-Biron, Ma. Regina Isabelle
	Founder Shares	10	Biron, Braedan John Q.
	Common Shares	21,140	
Ramirez, Ruben B.	Founder Shares	20	Ramirez, Ruben B.
	Common Shares	5,930	
Tingson, Pedro Jr. F.	Founder Shares	10	Tingson, Pedro Jr. F.
	Common Shares	1,890	
Alipao, Jason	Common Shares	10	Alipao, Jason
Andersson, Remedios	Common Shares	10	Andersson, Remedios
Angelo, Francis Allan	Common Shares	10	Angelo, Francis Allan
Aragona, Rolando Jr	Common Shares	10	Aragona, Rolando Jr
Armonio, Emelyn	Common Shares	10	Armonio, Emelyn
Arroyo, Caroline	Common Shares	10	Arroyo, Caroline
Arroyo, Charmie	Common Shares	10	Arroyo, Charmie
Balmores, Jobeth	Common Shares	10	Balmores, Jobeth
Barabona, Adnel	Common Shares	10	Barabona, Adnel
Bayo-Ang, Maricar	Common Shares	10	Bayo-Ang, Maricar
Bedia, Alex	Common Shares	10	Bedia, Alex
Benecio,Airis Belle	Common Shares	10	Benecio,Airis Belle
Beray, Edilyn	Common Shares	10	Beray, Edilyn
Bermejo, Fernando B	Common Shares	10	Bermejo, Fernando B
Bermejo, Stella Jun	Common Shares	10	Bermejo, Stella Jun
Brazas, Haide	Common Shares	10	Brazas, Haide
Brazas, Joel	Common Shares	10	Brazas, Joel
Caipang, Christina Joy Rossetti	Common Shares	10	Caipang, Christina Joy Rossetti

DRAFT

Caluyo, Lynneth	Common Shares	10	Caluyo, Lynneth
Camique, Katherine	Common Shares	10	Camique, Katherine
Caro, Miguel Angelo	Common Shares	10	Caro, Miguel Angelo
Castromayor, John C	Common Shares	10	Castromayor, John C
Cencia, Eriberto Jr.	Common Shares	10	Cencia, Eriberto Jr.
Chatto, Christine	Common Shares	10	Chatto, Christine
Clar, Cynthia May	Common Shares	10	Clar, Cynthia May
Constantino, Lilibeth	Common Shares	10	Constantino, Lilibeth
Cuadra, Emilia	Common Shares	10	Cuadra, Emilia
Custodio, Grace Laarni	Common Shares	10	Custodio, Grace Laarni
De La Serna, Melvin	Common Shares	10	De La Serna, Melvin
De Los Reyes, Giovanni	Common Shares	10	De Los Reyes, Giovanni
Degoma, Nerisa	Common Shares	10	Degoma, Nerisa
Del Rosario, Louise Cecille	Common Shares	10	Del Rosario, Louise Cecille
Dignadice, Gerlie	Common Shares	10	Dignadice, Gerlie
Erfe, Domingo	Common Shares	10	Erfe, Domingo
Escutin, Mary Josephine	Common Shares	10	Escutin, Mary Josephine
Fabia, Daisy Corazon F	Common Shares	10	Fabia, Daisy Corazon F
Faculin, Carleen Mae	Common Shares	10	Faculin, Carleen Mae
Favila, Joel	Common Shares	10	Favila, Joel
Feca, Jonah	Common Shares	10	Feca, Jonah
Feranco, Gina	Common Shares	10	Feranco, Gina
Fuentes, Richelle	Common Shares	10	Fuentes, Richelle
Gardose, Therese Joy	Common Shares	10	Gardose, Therese Joy
Gatdula, Solomon Ryan	Common Shares	10	Gatdula, Solomon Ryan
Gavieta, May Joy	Common Shares	10	Gavieta, May Joy
Gerochi-Gepullano Aiza Psyra	Common Shares	10	Gerochi-Gepullano Aiza Psyra
Gervero, Joel	Common Shares	10	Gervero, Joel
Gonzaludo, Nerfe	Common Shares	10	Gonzaludo, Nerfe
Griengo, John Kenneth	Common Shares	10	Griengo, John Kenneth
Guzman, Johann Paul	Common Shares	10	Guzman, Johann Paul
Hanopol, Jill Victoria	Common Shares	10	Hanopol, Jill Victoria
Inocencio, Christopher	Common Shares	10	Inocencio, Christopher
Jamotoya, Roy	Common Shares	10	Jamotoya, Roy
Jarantilla, Maria Cecilia	Common Shares	10	Jarantilla, Maria Cecilia
Kanaan, Charles Fredericke Halim Lopez	Common Shares	10	Kanaan, Charles Fredericke Halim Lopez
Labating, Ma. Sheila	Common Shares	10	Labating, Ma. Sheila
Lacuesta, Victor	Common Shares	10	Lacuesta, Victor
Lañosa, Mary Grace	Common Shares	10	Lañosa, Mary Grace
Lavilla, Francine Marie	Common Shares	300	Lavilla, Francine Marie

DRAFT

Lavilla, Lou Valerie	Common Shares	300	Lavilla, Lou Valerie
Leccio, Aladino	Common Shares	10	Leccio, Aladino
Lim, Emmanuel Leo	Common Shares	10	Lim, Emmanuel Leo
Llenos, Mary Geonette	Common Shares	10	Llenos, Mary Geonette
Londres-Lerona, Louie Marie	Common Shares	10	Londres-Lerona, Louie Marie
Martinez, Fritz David	Common Shares	10	Martinez, Fritz David
Millamena, Heidi Ii	Common Shares	10	Millamena, Heidi Ii
Mondia, Ma. Fay	Common Shares	10	Mondia, Ma. Fay
Natividad, Perlin	Common Shares	10	Natividad, Perlin
Navarra, Ma. Espiritu	Common Shares	10	Navarra, Ma. Espiritu
Navigar, Jr. Rey	Common Shares	10	Navigar, Jr. Rey
Hipe Nelson	Common Shares	10	Hipe Nelson
Ng, John Michael	Common Shares	10	Ng, John Michael
Padilla, Tatiana Lisa Marie	Common Shares	10	Padilla, Tatiana Lisa Marie
Palabrica, Michael Jhon	Common Shares	10	Palabrica, Michael Jhon
Panes, Elena	Common Shares	10	Panes, Elena
Pasuelo, Janet	Common Shares	10	Pasuelo, Janet
Pedroso, Donna Ma	Common Shares	10	Pedroso, Donna Ma
Penetrante, Aileen	Common Shares	10	Penetrante, Aileen
Pineda, Imee Claire	Common Shares	10	Pineda, Imee Claire
Pineda, Mary Cris	Common Shares	10	Pineda, Mary Cris
Rafio, Luningning	Common Shares	10	Rafio, Luningning
Rafio, Mario	Common Shares	10	Rafio, Mario
Refugio, Carlos Jr.	Common Shares	10	Refugio, Carlos Jr.
Roquios, Jose Redmond Eric	Common Shares	10	Roquios, Jose Redmond Eric
Salazar, Jose Maria Jr.	Common Shares	10	Salazar, Jose Maria Jr.
Saromines, Sheryll	Common Shares	10	Saromines, Sheryll
Silao, Sigrid Anne	Common Shares	10	Silao, Sigrid Anne
Sobrevega, Jose June	Common Shares	10	Sobrevega, Jose June
Sorongon, Pearl Joy Cuadras	Common Shares	10	Sorongon, Pearl Joy Cuadras
Suñer, Clement Cezar	Common Shares	10	Suñer, Clement Cezar
Tabang, Mary Joy	Common Shares	10	Tabang, Mary Joy
Tabuga, Raymund	Common Shares	10	Tabuga, Raymund
Tampos, Althea T	Common Shares	10	Tampos, Althea T
Tan, Romulo	Common Shares	10	Tan, Romulo
Tanquerido, Jose Lex	Common Shares	10	Tanquerido, Jose Lex
Tigulo, Rowena	Common Shares	10	Tigulo, Rowena
Trabado, Karla Franchesca	Common Shares	10	Trabado, Karla Franchesca
Tung, Bryan Kevin	Common Shares	10	Tung, Bryan Kevin
Uygongco, Terence	Common Shares	10	Uygongco, Terence

DRAFT

Villanueva, Shella Marcela	Common Shares	10	Villanueva, Shella Marcela
Villareal, Clyde	Common Shares	10	Villareal, Clyde
Yap, Gemma	Common Shares	10	Yap, Gemma
Yap, Lazarina	Common Shares	100	Yap, Lazarina
Sub-total		**82,682**	

Represented by Proxy			
Stockholder	**Type of Shares**	**No. of Shares**	**Appointed Proxy**
GUBATINA, MARIA GERALDINE L.	Founder Share	10	Chairman
	Common Shares	1,890	
UNIVERSITY OF SAN AGUSTIN REPRESENTED BY FR. JESSIE TABOBO, OSA	Common Shares	1,400	Chairman
BALSAMO, SUSAN	Common Shares	10	Chairman
DEBUQUE, NATHALIE ANN	Common Shares	10	Chairman
SILVERIO, LORNA, C.	Common Shares	500	Chairman
DEPALAC, JONAS, A.	Common Shares	10	Chairman
Sub-total		**3,830**	
TOTAL		**207,170**	

DRAFT

Annex "B"

Questions raised during the Annual Stockholders' Meeting

Question from Alberto Tuzan:

May we inquire regarding the 2024 monthly occupancy room rate based on 100-bed capacity and the expected monthly revenue if the hospital operates on a 100% occupancy rate?

For the calendar year ending 31 December 2024, the hospital recorded a gross revenue of Php 352,812,010.89, with an average monthly occupancy rate of 47.52%. This translates to an average monthly gross revenue of Php 29,401,000.91. Based on these figures, it is projected that if the hospital operates at a 100% occupancy rate, the expected monthly gross revenue would amount to approximately Php 61,865,683.60.

DRAFT

ASIA PACIFIC MEDICAL CENTER ILOILO

ANNEX "G"

MANAGEMENT REPORT AS OF 30 APRIL 2026

A. DESCRIPTION OF BUSINESS

Asia Pacific Medical Center – Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.) (hereinafter "APMCI" or The Company) is a domestic corporation duly organized under the existing laws of the Republic of the Philippines. The Securities and Exchange Commission granted the Company corporate existence on 10 December 2014.

APMCI has an authorized capital stock of Two Hundred Forty Million Pesos (240,000,000.00) divided into Six Hundred (600) Founders' Shares and Two Hundred Thirty-Nine Thousand Four Hundred (239,400) Common Shares both with a par value of One Thousand Pesos (Php1,000.00) per share. These shares are fully subscribed and paid.

APMCI was organized to maintain, operate, own, and manage hospitals, medical and related healthcare facilities, and businesses such as, but without restriction to clinical laboratories, diagnostic centers, ambulatory clinics, condo hospitals, scientific research, and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic, or similar care. Purely professional, medical, or surgical services shall be performed by duly qualified physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

To support the construction of its initial hospital project, the Company applied for and was issued a Permit to Offer Securities on 27 December 2018 thru SEC MSRD Order No. 37 Series of 2018. The company also obtained a loan facility from the Development Bank of the Philippines. The construction of Asia Pacific Medical Center-Iloilo commenced sometime in October 2015.

On 14 April 2023, the Board of Investments approved the registration of the Company as a New Operator of General Hospital Level 2 under Tier I of the 2022 Strategic Investment Priority Plan (SIPP) of R.A. 11534 (CREATE Act). The registration entitles the Company an Income Tax Holiday for six (6) years, enhanced deduction for five (5) years and duty exemption for eleven (11) years.

As of 31 December 2025, the construction of the multi-disciplinary hospital being developed by the Company was **100.00% complete.**

APMCI has not filed for bankruptcy, receivership nor has been a subject of similar proceedings.

Neither has there been a material reclassification, merger, consolidation, or purchase or sale of a significant amount of its assets not in the ordinary course of business.

Asia Pacific Medical Center – Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center -Iloilo Inc.) is a 9 – storey 100 – bed capacity hospital with helipad and perimeter and basement parking that can accommodate 6 Mini buses, 5 ambulances, 80 cars and 11 motorcycles with total floor area of 28,550.50 sq. meters constructed in a 6,000 sq.m. property located at Brgy. Ungka, Jaro, Iloilo City. It intends to apply for additional authorized bed capacity as soon as hospital admissions exceed the current authorized bed capacity. It provides services to residents of Jaro, Iloilo City, nearby Barangays and Municipalities, the whole of Iloilo and the neighboring provinces which are considered its catchment areas.

The Company is engaged principally in the operation of a hospital business. Its revenues are derived primarily from hospital operations, including patient admissions, outpatient consultations, diagnostic and imaging services, laboratory services, and other ancillary and specialty medical services.

The Company operates under the regulatory supervision of the Department of Health ("DOH"), PhilHealth, local government units, and other government agencies having jurisdiction over hospitals and healthcare facilities.

APMCI is a multidisciplinary specialty medical facility that houses medical specialists who are subscribers to the capital stock of the Corporation. The markets for its shares are mostly medical specialists and individuals who are related to medical specialists and corporate investors who invested their money in the hospital.

The act of purchasing the securities being offered does not automatically entitle such purchaser to practice his profession and use the facilities of APMCI, although it is a prerequisite. Physicians and medical specialists who are subscribers to at least one (1) block or ten (10) shares of the capital stock, whether founder or common shares, and have paid in full may be allowed to practice. Such purchasers have to undergo the required screening process and must possess the minimum requirements as indicated in the Articles of Incorporation, By–Laws, and Internal Rules of the Hospital. After successfully passing this process, the applicant shall then be entitled to the privileges offered by the Hospital. The privilege to practice in the Hospital is subject to restrictions, limitations, and obligations as may be imposed by APMCI pursuant to its rules and duly approved resolutions. Medical Specialists who have been granted the privilege to practice shall continuously possess the required qualifications and may be subjected to post-qualification assessment to ensure the quality of service provided by the hospital.

APMCI collects from each duly admitted medical specialist a one-time "privilege to practice" fee amounting to One Hundred Fifty Thousand Pesos (Php150,000.00) plus monthly fees for maintenance and utilities used for the Clinic.

On 3 November 2023, the Company was issued its License to Operate by the DOH as a Level 2 Hospital. The Company commenced hospital operations on 8 December 2023 upon the start of patient admissions. Prior thereto,on 13 November 2023, the Company opened its Outpatient Departments as part of its initial activities following the issuance of its LTO.

A Tertiary Hospital is a hospital that provides tertiary care, which is health care from specialists in a large hospital after referral from primary care and secondary care. Tertiary Hospitals offer training programs for doctors who want to go into specialization.

Under the Rules and Regulations Governing the New Classification of Hospitals and Other Health Facilities in the Philippines (Effective: August 18, 2012), a tertiary hospital provides health care from specialists in a large hospital after referral from primary care and secondary care. A Level 2 Hospital is required to possess, among others, all Level 1 capabilities and certain additional service capacities. These include:

1. An organized staff of qualified and competent personnel with a Chief of Hospital/Medical Director and appropriate board-certified Clinical Department Heads;
2. Departmentalized and equipped with the service capabilities needed to support board-certified/eligible medical specialists and other licensed physicians rendering services in the specialties of Medicine, Pediatrics, Obstetrics and Gynecology, Surgery; including their subspecialties and ancillary services;
3. A general intensive care unit for critically ill patients;
4. A neonatal intensive care unit;
5. Provision for HRPU (High Risk Pregnancy Unit);
6. Provision for respiratory therapy services;
7. A DOH licensed tertiary clinical laboratory; and
8. A DOH licensed level 3 imaging facility with mobile x-ray inside the institution and with capability for contrast examinations.

Asia Pacific Medical Center - Iloilo aspires to become a tertiary hospital in the future in order to further enhance and expand the delivery of quality healthcare services to the people of Iloilo Province and Iloilo City. This vision is anchored not only on serving the Ilonggo community, but also on addressing the healthcare needs of neighboring provinces throughout the Panay Region. Through this endeavor, the institution remains committed to championing excellence in healthcare and contributing to the advancement of accessible, comprehensive, and patient-centered medical services in the region.

SERVICES

The Company provides a range of hospital and medical services through its inpatient, outpatient, diagnostic, therapeutic, and ancillary service units.

Its current diagnostic and imaging services include:

- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) Scan
- Mammography
- Echocardiography

The Company also provides or operates the following specialized services and units:

- Regenerative Medicine Center
- Hemodialysis Center
- Blood Bank with expanded functions
- High-Risk Pregnancy Unit
- Endoscopy Center
- Newborn Hearing Screening Test
- Antimicrobial Resistance Surveillance Program

Under the Yakap Program of the Philippine Health Insurance Corporation ("PhilHealth"), the Company provides outpatient cancer screening services, including:

- Mammography
- Breast ultrasound
- Liver ultrasound
- Alpha-fetoprotein (AFP) testing
- Low-dose chest CT scan

Planned Services and Expansion

The Company may expand its service offerings in the future, including the potential addition of bone densitometry and liver elastometry services subject to applicable regulatory approvals, capital expenditure requirements and market conditions.

As part of its business development plans, the Company is evaluating the establishment or expansion of additional specialty and ancillary services, including the following:

- Cardiac Catheterization Laboratory
- Oncology Center and Transfusion Unit
- Infertility Unit
- Research Center
- Ophthalmology Operating Room
- HIV Hub
- Ambulatory Surgical Clinic
- Wellness Center

These proposed initiatives and plans are prospective in nature and remain subject to feasibility review, regulatory compliance, funding availability, demand conditions, and approval by management and, where required, the Board of Directors.

The issuer belongs to an industry which caters to the need of the public and medical specialists for hospital facilities. There are no recognized trends within such industry. The geographic area of competition is in Iloilo City wherein the following Hospitals are operating:

NAME OF HOSPITAL	ADDRESS	BED CAPACITY	CATEGORY	LEVEL CLASSIFICATION
AMOSUP (Associated Marine Officers' and Seamen's Hospital Iloilo)	Onate St., Mandurriao, Iloilo City	42	Private	2
Iloilo Doctors Hospital	Infante St., Molo, Iloilo City	300	Private	3
Iloilo Mission Hospital	Mission Road, Jaro, Iloilo City	261	Private	3
Medicus Medical Center Iloilo	Dr. Rizalina Bernardo Avenue, San Rafael Mandurriao, Iloilo City	150	Private	2
Metro Iloilo Hospital and Medical Center, Inc.	Metropolis Avenue, Brgy. Tagbak, Jaro, Iloilo City	110	Private	2
Qualimed Hospital	Donato Pison Avenue, San Rafael Mandurriao, Iloilo City	104	Private	2
St. Paul's Hospital	General Luna St., Brgy., Danao, Iloilo City	265	Private	3
The Medical City Iloilo	Locsin St., Molo, Iloilo City	108	Private	2
West Visayas State University Medical Center (DOH Facility)	E. Lopez St., Jaro, Iloilo City	300	Public	3

Western Visayas Medical Center (DOH Facility)	Q. Abeto St., Mandurriao, Iloilo City	700	Public	3
Western Visayas Sanitarium & General Hospital (DOH Facility)	RG7G+ CQ9, Oton-San Jose Santa Barbara Rd, Santa Barbara, Iloilo	300	Public	2

The strategic location of APMCI primarily influences the decision of the medical specialists to subscribe to the shares of stock in APMCI. Once the Doctor decides where to practice, price and quality of facility management come as the next factors. The good location, proximity to patients, reasonableness of the offer price, and quality of the facilities enable APMCI to effectively compete with its competitors within the area.

APMCI is primarily owned and managed by doctor specialists who have established a medical practice in the locality. This unique setup is a strong strategic factor of the hospital since each doctor-owner has established patient following in their respective fields. APMCI places itself as a center for Clinical Competence and Patient Safety. Among its flagship plans, will be the creation of a High-Risk Pregnancy and Women's Health Center, Male and Female Fertility Center, Health and Aesthetic Centre, Regenerative Medicine, and among other services, the hospital is preparing to build a Cardiac Cath laboratory and Rehabilitation Center, an Eye Center, and Oncology Center.

The hospital is currently working on an international accreditation with an ISO-International Organization for Standardization which is a worldwide federation of national standard bodies and Joint Commission International, standards of which properly define the performance, expectations, structures, and functions of a hospital which seeks accreditation. Its major thrust is in the delivery of quality healthcare and patient safety.

The hospital offers both preventive and medical treatment packages at a very competitive cost, if not lesser than the nearby hospital facilities, without compromising the quality of healthcare service it delivers to its patients. The hospital makes sure that by following the policies of the Credentials and Privileging Committee, the medical staff of APMC Iloilo are clinically competent and certified specialists.

Aside from these, patients find a better ambiance with APMCI due to its carefully planned, designed, and constructed hospital building. Its advantage is not simply its newly built structure, but it also boasts of new facilities and equipment, plus the competency of its Medical Specialists.

SUPPLIERS, SERVICE PROVIDERS AND MAJOR CONTRACTORS

The Company procures medicines, medical supplies, medical equipment, utilities, and support services from various third-party suppliers and service providers. Management believes that alternative sources are generally available for most of its regular supply and service requirements, subject to pricing, quality, availability, and regulatory standards.

Certain specialized medical equipment, supplies, and maintenance support may be sourced from a limited number of qualified suppliers or distributors as follows:

1. Biospectra Marketing
2. BTL Medical Technologies Inc.
3. Endure Medical Inc.
4. Excel Global Inc.
5. Jamesluise Medical Device Enterprises
6. Labsolution Technologies Inc.
7. Oxford Distributions Inc.
8. Scientific Biotech Specialties Inc.
9. UNILAB Inc.
10. Zuellig Pharma Corporation

TRANSACTIONS WITH AND/OR DEPENDENCE ON RELATED PARTIES

The Company has entered into a Memorandum of Agreement for the granting of discounts to its stockholders with the following hospitals and vice versa:

1. Asia Pacific Medical Center - Bacolod, Inc.
2. Allied Care Experts Medical Center - Baliwag, Inc.
3. Allied Care Experts Medical Center - Bayawan, Inc.
4. Allied Care Experts Medical Center - Baypointe, Inc.
5. Allied Care Experts Medical Center - Bohol, Inc.
6. Allied Care Experts Medical Center - Butuan, Inc.
7. Allied Care Experts Medical Center – Cagayan De Oro, Inc.
8. Allied Care Experts Medical Center - Cebu, Inc.
9. Allied Care Experts Medical Center - Dipolog, Inc.
10. Allied Care Experts Dumaguete Doctors, Inc.
11. Allied Care Experts Medical Center - General Santos, Inc.
12. Allied Care Experts Medical Center - Legazpi, Inc.
13. Allied Care Experts Medical Center - Mandaluyong, Inc.
14. Allied Care Experts Medical Center - Palawan, Inc.
15. Allied Care Experts (ACE) Medical Center - Pateros, Inc.
16. Allied Care Experts (ACE) Medical Center - Quezon, Inc.
17. Allied Care Experts (ACE) Medical Center - Tacloban, Inc.
18. Allied Care Experts Medical Center - Valenzuela, Inc.
19. Asia Pacific Medical Center - Aklan, Inc.

The availability of discounts and other privileges shall be subject to the internal policies of the aforementioned hospitals, without prejudice to the financial condition of the referral hospital.

RELATED PARTY TRANSACTIONS

In the normal course of business, the Company transacts with companies/individuals, which are considered related parties. The following transactions were carried out with related parties as of March 31, 2026, and December 31, 2025:

Advances to related party:

	For the Period Ended March 31, 2026 and December 31, 2025				
	March 31, 2026		**December 31, 2025**		
	Amount of Transactions	**Outstanding Balance**	**Amount of Transactions**	**Outstanding Balance**	Terms and Conditions
Endure Medical, Inc. [(a)]	**(P32,079,869)**	**P -**	**(P32,079,869)**	**P -**	Non-interest bearing, to be collected in cash, unsecured, unguaranteed, not impaired
TIPP Digital Solutions Inc. [(b)]	**-**	**6,902,784**	**-**	**6,902,784**	
Receivable – others (various ACE Hospitals)	**-**	**47,472**	**-**	**47,472**	
	(P32,079,869)	**P6,950,256**	**(P32,079,869)**	**P6,950,256**	

(a) Advances to related parties – Endure Medical, Inc.

The Company engaged the services of an Indentor (Endure Medical, Inc.) which had relatively significant influence over a key management personnel of the Company. The Indentor facilitates the importation and acquisition of medical equipment, furniture, and fixtures for the hospital allotment.

(b) Advances to related parties – TIPP Digital Solutions Inc.

The account represents payments made for the acquisition of Healthcare Management Information System.

Advances from related party:

	March 31, 2026		December 31, 2025			
	Amount of Transactions	Outstanding Balance	Amount of Transactions	Outstanding Balance	Terms	Conditions
Loans payable to a related party	**-**	**544,871,969**	**P1,000,000**	**P544,871,969**	Interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Accounts Payable - Endure Medical, Inc.	**P134,139,564**	**P194,816,096**	**(3,091,827)**	**60,676,532**	Non-interest bearing to be paid in cash	Unsecured, unguaranteed, not impaired
	P134,139,564	**P739,688,065**	**P2,091,827**	**P605,548,501**		

Accounts payable – Endure Medical, Inc. is included under accounts payable – contractors and suppliers amounting to ₱194,816,096, ₱60,676,532, and ₱63,768,359 as of March 31, 2026, December 31, 2025, and 2024, respectively.

(a) Loans payable to a related party

The account represents an unsecured interest-bearing loan from Phil Pharmawealth, Inc., which has relatively significant influence over a key management personnel of the Company. The loan was incurred for payment of interest with Land Bank of the Philippines (LBP). The loan bears an interest rate ranging from 6.50%-8.50% per annum. Interest incurred for the years ended March 31, 2026, 2025 and 2024 and is reflected in the statements of comprehensive loss amounted to ₱-, ₱72,419,241, and ₱56,927,769, respectively. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

INVOLVEMENT IN LEGAL PROCEEDINGS

Petition for Certiorari under Rule 65 against the Office of the Insurance Commissioner, Allied Care Experts Medical Center-Valenzuela, Allied Care Experts Medical Center- Pateros, Allied Care Experts Medical Center-Baypointe, Allied Care Experts Medical Center – Quezon City, Allied Care Experts (ACE) Medical Center- Baliwag and Asia Pacific Medical Center- Iloilo (Formerly Allied Care Experts Medical Center- Iloilo)

The petition dated 04 February 2022 was filed before the Court of Appeals against the Office of the Insurance Commissioner, Allied Care Experts Medical Center - Valenzuela, Allied Care Experts Medical Center - Pateros, Allied Care Experts Medical Center - Baypointe, Allied Care Experts Medical Center – Quezon City, Allied Care Experts Medical Center- Baliwag and Asia Pacific Medical Center - Iloilo (Formerly Allied Care Experts Medical Center- Iloilo).

Almost years after APMC Iloilo received the resolution of the Insurance Commission on the request for investigation of Ferdinand Kionisala declaring that the benefits and privileges enjoyed by him or offered by any of the named respondents he impleaded on his complaint is not a pre-need contract, agreement, deed, nor plan contemplated under the law and that ACEMC – Cebu or any other respondent named on this matter are not engaged in pre-need business hence not required to secure a separate license for such before the insurance Commission, he filed a Motion for Reconsideration dated 25 November 2020. After the denial of the Motion for Reconsideration in a letter dated 29 November 2021 where the IC declared that the Complainant's Motion for Reconsideration is bereft of any novel compelling arguments or new pieces of evidence to consider in order to depart from our previous ruling, Ferdinand Kionisala filed a special civil action for Certiorari under Rule 65 before the Court of Appeals alleging that the Insurance Commission acted with grave abuse of discretion amounting to lack or excess of jurisdiction when it found that the contracts sold or offered for sale to the public are not pre-need contracts or are not processing pre-need plans and when it ignored the evident fact that the benefit and privileges are the cause or consideration of the contracts between private respondents and the members of the general public.

Mr. Kionisala prayed that the Court of Appeals set aside the letter dated December 11, 2018 and letter dated November 29 2021 be nullified and set aside and that the Insurance Commission be ordered to take appropriate action(s) against the private respondents for violating the Pre- Need Code of the Philippines.

In a resolution dated 26 July 2022, the Eighteenth (18th) Division of the Court of Appeals directed the petitioners to rectify the infirmity observed in the petition, within an inextendible period of ten (10) days from notice which is the submission of a mere plain photostatic copy of the assailed letter dated 11 December 2018. Petitioner submitted its compliance on 22 September 2022, a copy of which was received by APMC Iloilo on 19 October 2022.

On 01 September 2025, APMC Iloilo received a Resolution dated 05 March 2025, directing the parties to file their respective Comments on the petitioner's Petition for Certiorari within an inextendible period of ten (10) days from notice. APMC Iloilo subsequently filed its Comment on 11 September 2025.

As of 30 April 2026, to the knowledge and information of the Company, there are no other pending material legal proceedings that involve APMCI or any of its properties aside from the aforementioned case.

B. SECURITIES OF THE REGISTRANT

Market Price

The Company markets and offers the securities through organic employees who are well versed with Hospital operations. Management believes that the strategic location of the Hospital, the facilities and the services it will provide, and the people behind the Hospital, are sufficient to entice medical specialists and prospective investors to consider the offer. The Company greatly relies on these organic employees and satisfied patients to spread the word about the facilities the Hospital can offer. There is no public trading market for the Company's shares.

Asia Pacific Medical Center-Iloilo, Inc. is offering Three Thousand Six Hundred (3,600) blocks of common shares in tranches, through a series of offerings at an offer price in progressive amounts.

The staggered Offer Price per series of shares for sale to the public was arrived at by considering several factors including but not limited to: the timing of purchase relative to the completion of the Hospital and its facilities, the number of applicants the Hospital could serve and accommodate, the total development costs based on cost assessments of the engineers, architects and other professionals hired for the project, comparable price of similarly situated structure with similar facilities, market demand, risk undertaken by the original stockholders, the exclusive and premium nature of the Hospital and its intended patients and the acceptability of the pricing strategy to the current market.

The breakdown of the Offer Price is presented as follows:

Number of Blocks of Common Shares	Maximum Proposed Selling	Price per block
Series 1st	**2,600 blocks**	**P250, 000 per block**
2nd	**500 blocks**	**P300, 000 per block**
3rd	**500 blocks**	**P400, 000 per block**

The first Two Thousand Six Hundred (2,600) blocks had been sold at a maximum price of Two Hundred Fifty Thousand Pesos (Php 250,000. 00) per block by the third quarter of October 2019 and another One Hundred Ten (110) blocks at a maximum price of Three Hundred Thousand Pesos (Php300,000.00) per block were subscribed by December 31, 2019. The remaining Three Hundred Ninety (390) blocks at a maximum price of Three Hundred Thousand Pesos (Php300,000.00) per block were sold in the year 2020. Three (3) blocks at a maximum price of Four Hundred Thousand Pesos (Php400,000.00) per block of the third series shares were also sold by December 2020. An additional three (3) blocks from the same series were sold in the year 2021. In 2022, another Sixty Five (65) blocks of shares were sold at a maximum price of Four Hundred Thousand Pesos (Php400,000.00) per block. For the year 2023, Four Hundred Twenty Five (425) blocks of shares were sold from the 3rd series. The last selling price was Four Hundred Pesos (PHP 400,000.00) per block. The 3rd series were never offered until the 2nd series had been sold out in the same manner that the 2nd series were never offered to the public until the shares from the first series had also been sold out. The offered shares are not listed on the Exchange and are issued over the counter only, through the Company's employees acting as sales persons as reflected in its Registration Statement. The percentage of public ownership of the Company as of 30 April 2026 is 15%.

The 3,600 blocks that were offered to the public are sold primarily to Medical Specialists who possess the minimum qualifications and are deemed fit to practice, upon recommendation by the Credentials Committee and approved by the Board and Management of Asia Pacific Medical Center- Iloilo, Inc. Other purchasers are non-medical specialists who are related to medical specialists and those who purchased the shares purely for investment purposes.

There is no amount that is subject to Outstanding Options.

Amount of Equity that has been proposed to the publicly offered by the Registrant is 1B.

HOLDERS

There are approximately Thirty Four (34) holders of Founder Shares and approximately Three Thousand Sixty Two (3,062) holders of common shares of the company as of 30 April 2026.

Ferjenel G. Biron, Brandt Luke Q. Biron, Braeden John Q. Biron, Bryant Paul Q. Biron, and Maria Regina Isabelle D. Oca-Biron are the only record and/or beneficial owners of more than 5% of any class of registrant's voting securities as of 30 April 2026.

Class	Names / Address of Record Owner	Name of Beneficial Owner/Relationship with Record Owner	Citizenship	Number of Shares Held	% to Total Outstanding Shares
Common Founder	**BIRON, FERJENEL G.**/ 82 Firefly Cor. Butterfly St., Valle Verde VI,Pasig City	BIRON, FERJENEL G./ Record Owner is also Beneficial Owner	Filipino	48,166 240	**20.17%**
Common Founder	**BIRON, BRANDT LUKE** **Q.**/ Unit 4403 Trump Tower, Century City,Kalayaan Avenue, Makati City, Metro Manila	BIRON, BRANDT LUKE Q./ Record Owner is also Beneficial Owner	Filipino	21,890 10	17.94%
Common Founder		Trustor: BIRON, BRYANT PAUL Q./ Unit 903, Pacific Place. Pearl Drive, Ortigas Center, Pasig City Brother of the Record Owner.	Filipino	21,140 10 **TOTAL** 43,030 20	
Common Founder					
Common	**OCA-BIRON, MA. REGINA ISABELLE D.** Ilaya 2nd Dumangas, Iloilo	OCA-BIRON, MA. REGINA ISABELLE D./ Record Owner is also Beneficial Owner	Filipino	60	8.84%
Common Founder		Trustor: BIRON, BRAEDEN JOHN Q./ Unit 42C Kirov Tower, Estrella St. Rockwell, Makati, 1210 Spouse of the Record Owner.	Filipino	21,140 10 **TOTAL** 21,200 10	
Common Founder					

The Top 20 Stockholders as of 30 April 2026 are as follows:

Class	Names / Address of Record Owner	Name of Beneficial Owner/Relationship with Record Owner	Citizenship	Number of Shares Held	% to Total Outstanding Shares
Common Founder	**BIRON, FERJENEL G.** 82 Firefly Cor. Butterfly St., Valle Verde VI,Pasig City	BIRON, FERJENEL G/ Record Owner is also Beneficial Owner	Filipino	48,166 240	20.17%
Common Founder	**BIRON, BRANDT LUKE Q.** Unit 4403 Trump Tower, Century City, Kalayaan Avenue, Makati City, Metro Manila	BIRON, BRANDT LUKE Q./ Record Owner is also Beneficial Owner	Filipino	21,890 10	17.94%
Common Founder Common Founder		Trustor: BIRON, BRYANT PAUL Q./ Unit 903, Pacific Place. Pearl Drive, Ortigas Center, Pasig City Brother of the Record Owner.	Filipino	21,140 10 **TOTAL** 43,030 20	
Common	**OCA-BIRON, MA. REGINA ISABELLE** Ilaya 2nd, Dumangas, Iloilo	Oca-Biron, Ma. Regina Isabelle D./ Record Owner is also Beneficial Owner	Filipino	60	8.84%
Common Founder Common Founder		Trustor: BIRON, BRAEDEN JOHN Q. / Ilaya 2nd, Dumangas, Iloilo Spouse of the Record Owner.	Filipino	21,140 10 **TOTAL** 21,200 10	
Common Founder Common Founder	**SAMORO, FREDILYN G./** Block 31 Lot 5, Ana Ros Village, Guzman St., Mandurriao, Iloilo City HEIRS OF SAMORO, RONNIE (Fredilyn Samoro, Kim Karolyn Samoro, Karmela Marie Samoro, Katrina Belle Marie Samoro)/ Block 31 Lot 5, Ana Ros Village, Guzman St., Mandurriao, Iloilo City	SAMORO, FREDILYN G./ Record Owner is also Beneficial Owner HEIRS OF SAMORO RONNIE (Fredilyn Samoro, Kim Karolyn Samoro, Karmela Marie Samoro, Katrina Belle Marie Samoro)	Filipino	6,748 20 3,452 10	4.26%
Common Founder Common Founder Common	**LAVILLA, MERIDE D./** Lot 11 Block 6, Pasacao St., Puerto Real, Subd., Lapaz, Iloilo City LAVILLA,FRANCIS G./ Lot 11 Block 6, Pasacao St., Puerto Real, Subd., Lapaz, Iloilo City LAVILLA, LOU VALERIE D./ Lot 11 Block 6, Pasacao St., Puerto Real, Subd., Lapaz, Iloilo City	LAVILLA, MERIDE D./ Record Owner is also Beneficial Owner LAVILLA,FRANCIS G./ Record Owner is also Beneficial Owner LAVILLA, LOU VALERIE D./ Record Owner is also Beneficial Owner	Filipino	3,628 10 2,430 10 300	2.90%

Common	LAVILLA, FRANCINE MARIE D./ Lot 11 Block 6, Pasacao St., Puerto Real, Subd., Lapaz, Iloilo City	LAVILLA,FRANCINE MARIE D./ Record Owner is also Beneficial Owner		300	
Common	LAVILLA, MERYLL FAITH D./ Lot 11 Block 6, Pasacao St., Puerto Real, Subd., Lapaz, Iloilo City	LAVILLA, MERYLL FAITH D./ Record Owner is also Beneficial Owner		300	

Common Founder	RAMIREZ, RUBEN B./ Unit 522 The Uptown Place, General Luna St., Iloilo City	RAMIREZ, RUBEN B./ Record Owner is also Beneficial Owner	Filipino	5,930 20	2.48%
Common Founder Common Founder	NOLASCO, FELIX P./ 553 Batulao St., Ayala Alabang Village, Muntinlupa City NOLASCO, EULENIA P./553 Batulao St., Ayala Alabang Village, Muntinlupa City	NOLASCO, FELIX P./ Record Owner is also Beneficial Owner NOLASCO, MARIA EULENIA R. / Record Owner is also Beneficial Owner	Filipino	2,340 10 2,340 10	1.96%
Common Founder	LAVALLE, AMADO JR. M./ Lot 8 Block 8, Bankers Village, Tabuc Suba, Iloilo City	LAVALLE,AMADO JR. M./ Record Owner is also Beneficial Owner	Filipino	3,658 10	1.53%
Common Founder	REGOZO, DANILO C./ 185 A. Barangay Bonifacio, Tanza, Iloilo City	REGOZO, DANILO C./ Record Owner is also Beneficial Owner	Filipino	3,658 10	1.53%
Common Founder	VILLAFLOR, AGNES JEAN M./ Lot 6 Block 2, Sacred Heart Subd., Hibaoan, Mandurriao, Iloilo City	VILLAFLOR, AGNES JEAN M./ Record Owner is also Beneficial Owner	Filipino	2,748 10	1.15%
Common Founder	COMUELO, JERUSHA A./ Metropolis Brgy. Bito-on, Jaro, Iloilo City	COMUELO, JERUSHA A./ Record Owner is also Beneficial Owner	Filipino	3,452 10	1.44%
Common Founder	ONG, MARY FLOR G./ Lot 15 & 16 Blk. 36 Westwood Subd., Dungon-C, Iloilo City	ONG, MARY FLOR G./ Record Owner is also Beneficial Owner	Filipino	3,352 10	1.40%
Common Founder	GALLEGA-PEREZ, MA. GRACE/ 264 Laguda Subd. Lapaz, Iloilo City	GALLEGA-PEREZ, MA. GRACE/ Record Owner is also Beneficial Owner	Filipino	3,432 10	1.43%
Common Founder	DOMINGO, CARMELO JR./ 7 Diamond St., Las Piñas Royole Estate, Pulang Lupa Dos, Las Piñas City 1742	DOMINGO, CARMELO JR. / Record Owner is also Beneficial Owner	Filipino	3,390 10	1.42%
Common Founder	GONZALES, NOEL J./ Muebles Italiano Building, Paseo de Magallanes, SSHW, Makati City	GONZALES, NOEL J./ Record Owner is also Beneficial Owner	Filipino	3,400 10	1.42%

Common Founder	MINERVA, IKE T./ Brgy. Barroc Tigbauan, Iloilo	MINERVA, IKE T. / Record Owner is also Beneficial Owner	Filipino	3,390 10	1.42%
Common Founder	DIANCO, FELIBERT O./ 05011C Commonwealth Drive Passi City, Iloilo	DIANCO, FELIBERT O. / Record Owner is also Beneficial Owner	Filipino	3,340 10	1.40%
Common Founder	DAULO, SYLVA L./ Mirasol Subd., Nabitasan, Lapaz, Iloilo City	DAULO, SYLVA L. / Record Owner is also Beneficial Owner	Filipino	3,040 10	1.27%
Common Founder	GOMEZ, LUSYL M./ Blk1 Lot 14 Savannah Crest A, Abilay Norte, Oton, Iloilo	GOMEZ, LUSYL M. / Record Owner is also Beneficial Owner	Filipino	2,771 10	1.16%

Dividends declared by the Company on its shares of stocks are payable in cash or in additional shares of stocks. The payment of dividends in the future will depend upon the earnings, cash flow, and financial condition of the Company and other factors.

Cash dividends require the approval by the Company's Board, but not that of the stockholders. Property dividends, which may come in the form of additional shares of stocks are subject to approval by both the Company's Board of Directors and the Company's stockholders. The SEC must also approve the payment of stock dividends.

There are no cash dividends or description of any restrictions that limit the payment of dividends. However, there were no dividends issued for the past two years because the company has no unrestricted retained earnings having commenced operations only last 2023.

Recent Sales of Unregistered or Exempt Securities including Recent Issuance of Securities Constituting an Exempt Transaction

There are no shares issued by the Company within the past three (3) years, which were not registered with the SEC pursuant to the Securities Regulation Code.

C. MANAGEMENT'S DISCUSSION AND ANALYSIS (MD&A) or PLAN OF OPERATION AS OF 30 APRIL 2026

PLAN OF OPERATION

Asia Pacific Medical Center–Iloilo, Inc. ("APMC Iloilo" or the "Hospital") incurred net losses during the last two fiscal years. Management attributes such losses primarily to the Hospital's early-stage operating profile following inauguration, the fixed costs inherent in hospital operations, the gradual build-up of patient volumes, and the continuing expenditures necessary to support personnel, equipment, utilities, and other operational requirements.

Management notes that, based on industry experience and as observed by the Hospital's independent auditor, healthcare institutions of similar scale typically require approximately four (4) to five (5) years from inauguration to recover initial capital expenditures and attain more stable operating levels. In this regard, management believes that the Hospital's financial performance to date remains generally consistent with the expected development period of a newly established hospital facility.

During the current year, the Hospital recorded a 47% increase in gross revenues compared to the previous year. Management believes that this growth is aligned with internal projections and reflects continued improvement in patient volumes, service utilization, physician referrals, and market awareness within the City and Province of Iloilo. Although the Hospital has not yet attained profitability, management considers the current revenue growth trend to be a positive indicator of its ongoing operational development.

For the next twelve (12) months, the Hospital's plan of operation shall focus on: (i) increasing patient volumes and revenues, (ii) improving operating efficiency and expense management, (iii) strengthening liquidity and collections, and (iv) supporting operations and future growth through additional capitalization.

Management's principal operating objectives are to:

1. Increase patient volumes in major service lines, including inpatient, outpatient, emergency, surgery, women's health, pediatrics, diagnostics, laboratory, imaging, and ancillary services;
2. Improve utilization of existing facilities, equipment, and manpower;
3. strengthen referral relationships with physicians, clinics, and healthcare providers in Iloilo and nearby areas;
4. Improve billing, claims processing, and collection efforts, particularly for government healthcare programs, HMOs, corporate accounts, and self-pay patients;
5. Implement cost management measures, including tighter control over operating expenses, inventory, manpower, and non-essential expenditures; and
6. Preserve liquidity through internally generated cash flows, working capital management, and, when necessary, capital-raising or financing initiatives.

As part of its capital strengthening measures, management intends to recommend an increase in the Hospital's authorized capital stock, subject to approval by the Board of Directors and stockholders. The Hospital also plans to pursue a second round of public offering of its shares, subject to compliance with the requirements of the Securities and Exchange Commission and other applicable regulatory approvals.

Management believes that, if successfully implemented, these capital measures will provide additional resources to support operations, strengthen the Hospital's balance sheet, and fund priority investments. However, there can be no assurance that such capital-raising initiatives will be completed within the expected timeframe.

The Hospital likewise intends to continue prioritizing the development of its core revenue-generating departments while exercising prudent control over operating costs and limiting capital expenditures to those necessary for patient care, operational continuity, compliance, and selected service improvements. Currently, the Company employs approximately seven hundred fifty six (756) individuals. The decision to hire additional employees will be contingent upon the outcome of the upcoming hospital census.

Management recognizes that the execution of its plan of operation remains subject to various risks and uncertainties, including competitive conditions, cost inflation, staffing constraints, reimbursement and collection delays, regulatory developments, and broader economic conditions. While there can be no assurance that the Hospital will achieve profitability within the next twelve (12) months, management believes that its current revenue growth trend and planned capital measures provide a reasonable basis for the continuation of operations and the gradual improvement of financial performance.

The Company intends to purchase the following equipment to attract more patients:

1. Pet scan
2. Cath lab Machine
3. Mechanical Ventilators (High-End With Advanced Modes) -Avea (3IN1 Ventilator)
4. Cyber Ho Magneto System 152W Holmium: YAG Surgical Laser System
5. Hospital Waste Management Plant
6. Sonomammography
7. M822 Leica Microscope
8. Portable Ultrasound(Ge)
9. Mammo(Ui)2D
10. KW ON-Grid Rooftop Solar
11. Alcon Centurion Phacoemulsification Machine
12. 2D Echo Vivid T9 (GE)
13. Ultrasound LOGIQ P8 (GE)
14. Cardiac Rehab System
15. Polysomnography Machine (Sleep Machine)
16. NCV/EMG

17. EEG
18. Infusion Pump
19. Super Inductive System BTL-6000
20. Syringe Pump
21. Sewage Treatment Plant
22. Bone Densitometry
23. Treadmill (GE)
24. Biosafety Cabinet Class III
25. Calibration Tools
26. ECG Machine (GE)
27. Detecto Weighing Scale
28. Ortho Table
29. Fracture Bed

These are expected to enhance service capacity and support the Hospital's operational and revenue growth objectives, subject to funding availability.

MANAGEMENT DISCUSSION and ANALYSIS

STATEMENTS OF RESULT OF OPERATIONS

Results of operation for the periods ended March 31, 2026, December 31, 2025 and 2024

	31-Mar-26	31-Dec-25	31-Dec-24
Revenue	P107,536,458	P452,165,666	P307,910,026
Cost of hospital services	(66,207,525)	(259,501,745)	(268,767,300)
Gross income (loss)	41,328,933	192,663,921	32,142,726
Other income	2,776,785	10,314,981	1,182,734
Gross income (loss)	44,105,718	202,978,902	40,325,460
General and admin expenses	(71,870,856)	(302,289,389)	(282,385,327)
Loss from operations	(27,765,138)	(99,310,487)	(242,059,867)
Finance cost	(35,890,364)	(136,010,583)	(155,699,208)
Net Loss Before Income Tax	(P63,655,502)	(235,321,070)	(397,759,075)
Income Tax Expense	-	-	-
Net Loss	(P63,655,502)	(235,321,070)	(397,759,075)
Other Comprehensive Income for the Year	-	183,531,277	-
Total Comprehensive Loss for the Year	**(P63,655,502)**	**(P51,789,793)**	**(P397,759,075)**

STATEMENTS OF FINANCIAL CONDITION

Statement of Financial Position
For Comparable Periods
March 31, 2026 and December 31, 2025

			Horizontal Analysis		Vertical Analysis		
ASSETS	**31-March-26**	**31-Dec-25**	**Inc./(Dec.)**	**%**	**31-March-26**	**31-Dec-24**	
CURRENT ASSETS							
Cash	P26,414,935	P23,296,041	3,118,894	13.39%	0.96%	0.86%	[I.II]
Receivables	192,816,543	165,796,569	27,019,974	16.30%	7.04%	6.11%	[I.II]
Advances to contractors and suppliers	89,868,430	72,449,059	17,419,371	24.04%	3.28%	2.67%	[I.II]
Medical and hospital supplies inventories	47,935,244	59,994,528	(12,059,284)	-20.10%	1.75%	2.21%	[I.II]
Prepayments and other current assets	33,109,906	28,714,938	4,394,968	15.31%	1.21%	1.06%	[I.II]
TOTAL CURRENT ASSETS	**390,145,058**	**350,251,135**	**39,893,923**	**11.39%**	**14.24%**	**12.90%**	[I.II]
NON-CURRENT ASSETS							
Property and equipment (net)	2,342,868,883	2,357,222,256	(14,353,373)	-0.61%	85.51%	86.84%	[I.I]
Advances to related parties	6,950,256	6,950,256	-	0.00%	0.25%	0.26%	
TOTAL NON-CURRENT ASSETS	**2,349,819,139**	**2,364,172,512**	**(14,353,373)**	**-0.61%**	**85.76%**	**87.10%**	[I.I]

TOTAL ASSETS	**2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	**[I]**
LIABILITIES AND EQUITY							
CURRENT LIABILITIES							
Accounts payable and other liabilities	717,399,179	689,539,570	27,859,609	4.04%	26.18%	25.40%	**[II]**
Loans payable to individuals	91,589,939	15,703,226	75,886,713	483.26%	3.34%	0.58%	**[II]**
Notes payable - current portion	227,010,404	191,558,072	35,452,332	18.51%	8.29%	1.66%	**[II]**
TOTAL CURRENT LIABILITIES	**1,035,999,522**	**896,800,868**	**139,198,654**	**15.52%**	**37.81%**	**27.64%**	
NON-CURRENT LIABILITIES							
Notes payable - net of current portion	757,790,363	954,351,037	(50,002,602)	-6.19%	27.66%	35.16%	**[II]**
Loans payable to related party	544,871,969	544,871,969	-	0.00%	19.89%	20.07%	**[II]**
Deferred tax liability	61,177,093	61,177,093	-	0.00%	2.23%	2.25%	**[II]**
TOTAL NON-CURRENT LIABILITIES	**1,363,839,425**	**1,560,400,099**	**(50,002,602)**	**-3.54%**	**49.78%**	**55.23%**	
TOTAL LIABILITIES	**2,399,838,947**	**2,310,642,895**	**89,196,052**	**3.86%**	**87.59%**	**82.87%**	**[II]**
EQUITY							
Share Capital (net)	240,000,000	240,000,000	-	0.00%	8.76%	8.84%	
Share Premium	958,532,662	958,532,662	-	0.00%	34.98%	35.31%	
Revaluation surplus	183,531,277	183,531,277	-	0.00%	6.70%	6.76%	
Retained Earnings/(Deficit)	(1,041,938,689)	(978,283,187)	(63,655,502)	6.51%	-38.03%	-36.04%	
TOTAL EQUITY	**340,125,250**	**403,780,752**	**(63,655,502)**	**-15.76%**	**12.41%**	**17.13%**	**[III]**
TOTAL LIABILITIES AND EQUITY	**P2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	

For Comparable Periods March 31, 2026 and 2025

(Revenue, Direct, Cost and Gross Loss)

			Horizontal Analysis		Vertical Analysis	
	31-March-26	**31-March-25**	**Inc./(Dec.)**	**%**	**31-March-26**	**31-March-25**
Net Revenue	P107,536,458	P82,148,885	25,387,573	30.90%	100.00%	100.00%
Direct Cost	(66,207,525)	(63,974,470)	2,233,055	-3.49%	61.57%	77.88%
Gross profit/(loss)	41,328,933	18,174,415	23,154,518	127.40%	38.43%	22.12%
Other income	2,776,785	816,308	1,960,477	240.16%	2.58%	0.99%
Gross income / (loss)	44,105,718	18,990,723	25,114,995	132.25%	41.01%	23.12%
General and admin expenses	(71,870,856)	(64,381,440)	7,489,416	-11.63%	66.83%	78.37%
Loss from operations	(27,765,138)	(45,390,717)	(17,625,579)	38.83%	25.82%	55.25%
Finance cost	(35,890,364)	(42,918,349)	(7,027,985)	16.38%	33.38%	52.24%
Net Income / (loss) for the period	**(P63,655,502)**	**(P88,309,066)**	**(P24,653,564)**	**27.92%**	**59.19%**	**107.50%**

REVENUE

During the first quarter ending March 31, 2026, Hospital generated Php107.54 million in revenue, net of discounts, representing a 30.90% increase from the previous year's Php82.15 million. This positive trend underscores the hospital's commitment to fostering patient relationships and continuously enhancing its products and services. Hospital's gross revenue of Php122.94 million includes the following services:

- Pharmacy: Php35.91 million (29.21%)
- Room accommodation: Php22.31 million (18.15%)
- Laboratory: Php19.04 million (15.49%)
- Imaging: Php10.96 million (8.91%)
- Central supply room: Php10.69 million (8.70%)
- Pulmonary: Php5.56 million (4.52%)
- Dialysis: Php4.91 million (4.00%)
- Other specialized healthcare services: Php13.56 million (11.03%)

DIRECT COST

Direct costs, directly attributable to patient care, experienced an increase due to factors such as the procurement of medications and supplies, the surge in patient volume, and the requirement for specialized equipment and personnel. For the third quarter concluded on March 31, 2026, Php66.21 million, comprising Php39.71 million in direct hospital supplies and Php26.50 million in direct overheads.

GENERAL AND ADMIN EXPENSES

This account consists of:

	For the 1st quarter periods March		Horizontal Analysis	
	2026	2025	Inc./(Dec.)	%
Salaries and Wages	P23,491,369	P25,710,653	(P2,219,284)	-8.63%
Utilities Expenses	12,563,082	7,829,492	4,733,590	60.46%
Depreciation	11,948,988	11,578,310	370,678	3.20%
Professional Fees	5,761,241	4,561,761	1,199,480	26.29%
SSS, PHIC and HDMF Contributions	3,852,257	4,121,398	(269,141)	-6.53%
Security Services	3,043,597	2,628,907	414,690	15.77%
Office Supplies	2,642,211	1,487,591	1,154,620	77.62%
Housekeeping Expense	1,898,531	2,870,819	(972,288)	-33.87%
Repairs and Maintenance Expenses	883,183	256,136	627,047	244.81%
Taxes and Licenses	643,111	1,620,623	(977,512)	-60.32%
Communication Expenses	393,281	174,399	218,882	125.51%
Training, Workshop, Seminar	277,750	112,694	165,056	146.46%
Transportation and Travel Expenses	112,756	350,658	(237,902)	-67.84%
Entertainment and Representation Expenses	111,836	45,849	65,987	143.92%
Board meetings and conferences	15,000	-	15,000	100.00%
Advertising Expenses	-	9,585	(9,585)	-100.00%
Miscellaneous Expenses	4,232,663	1,022,565	3,210,098	313.93%
TOTAL	**P71,870,856**	**P64,381,440**	**P7,489,416**	**11.63%**

General and administrative expenses for the 1st quarter ending March 31, 2026, amounted to Php71.87 million, a 11.63% increase from the previous year's Php64.38 million. This substantial increase reflects core business operations expenses, including salaries and wages (Php23.49 million), utilities (Php12.56 million), depreciation (Php11.94 million), professional consultancy fees (Php5.76 million), housekeeping and security services (Php4.94 million), taxes and license fees (Php0.64 million), and other expenses (Php 12.54 million). The significant increase in depreciation expenses is attributed to the building amounting to Php9.19 million as of March 31, 2026.

Other Income

Other income is mostly derived from interest income earned from bank; affiliation fee and other miscellaneous income amounted to Php2,174; and Php2.77 million, during the first quarter period ending March 31, 2026, respectively.

Finance Costs

This consists of interest expenses incurred on bank and related party loans. For the 1st quarter ended March 31, 2026, bank loans incurred Php18.98 million in interest, while related party loans incurred Php16.91 million.

Net Losses for the Period

Despite its financial deficit, the hospital encountered challenges during the first quarter of 2026. To sustain its operations, it requires an increase in patient admissions and collaborates with affiliated physicians for referrals and marketing initiatives. We remain optimistic about overcoming these obstacles and delivering exceptional hospital services.

For Comparable Periods December 31, 2025 and 2024
(Revenue, Direct, Cost and Gross Loss)

Account	For the years ended December 31		Horizontal Analysis		Vertical Analysis		
	2025	2024	Inc./(Dec.)	%	2025	2024	
Revenue	P452,165,666	P307,910,026	P144,255,640	46.85%	100.00%	100.00%	
Direct Cost	259,501,745	268,767,300	9,265,555	(3.45%)	57.39%	87.29%	[A]
Gross Loss	192,663,921	39,142,726	153,521,195	392.21%	42.61%	12.71%	
Other Income	10,314,981	1,182,734	9,132,247	772.13%	2.28%	0.38%	[B]
Gross Income/(Loss)	202,978,902	40,325,460	162,653,442	403.35%	44.89%	13.10%	
General and Admin Expenses	(302,289,389)	(282,385,327)	(19,904,062)	7.05%	66.85%	91.71%	[C]
Loss From Operations	(110,362,625)	(242,059,867)	142,749,380	(58.97%)	21.96%	78.61%	
Finance Cost	(36,970,036)	(155,699,208)	19,688,625	(12.65%)	30.08%	50.57%	[D]
Net Loss	(235,321,070)	(397,759,075)	(162,438,005)	40.84%	52.04%	129.18%	[E]
Other Comprehensive Income	183,531,277	-	183,531,277	100.00%	40.59%	-	
Total Comprehensive Loss	(P51,789,793)	(P397,759,075)	(P345,969,282)	(86.98%)	-11.45%	-129.18%	

[A] Revenue and Direct Cost

Revenue and direct costs have substantially increased since the company commenced its inaugural full year of hospital operations.

Revenue
As at December 31, 2025, Hospital generated a revenue, net of discounts and allowances, of Php452.17 million, representing a 46.85% increase from the preceding year's Php307.91 million. This positive trend underscores the hospital's unwavering commitment to fostering patient relationships and enhancing its product and service offerings. Hospital revenue encompasses both inpatient and outpatient services for the following:

- Pharmacy: Php152.29 million (29.29% of Gross Revenue)
- Room accommodation: Php 98.01 million (18.85% of Gross Revenue)
- Laboratory Services: Php 83.29 million (16.02% of Gross Revenue)
- Central supply room: Php 49.70 million (9.56% of Gross Revenue)
- Imaging: Php 46.51 million (8.95% of Gross Revenue)
- Pulmonary: Php 20.25 million (3.9% of Gross Revenue)
- Cardio/Neuro Services: Php16.15 million (3.11% of Gross Revenue)
- Other specialized healthcare services: Php 53.73 million (10.33% of Gross Revenue)

Direct Costs
Direct costs decreased by Php 9.27 million (3.45%) can be attributed to the hospital's efforts to renegotiate contracts with existing suppliers, identify cost-effective suppliers, utilize bulk purchasing discounts, and optimize procurement strategies. These actions resulted in a reduction in the cost of medicines and medical supplies during the year. For the year ending December 31, 2025, direct costs amounted to P259.50 million, which comprised of direct hospital supplies amounted to P136.03 million and direct overheads amounted to P123.47 million.

[B] Other Income

Other income is mostly derived from interest income earned from bank; unrealized foreign exchange gain and other miscellaneous income amounted to Php1,002; Php3,505 and Php10,310,474 as at December 31, 2025, respectively.

[C] General and Admin Expenses

This account consists of:

	For the Years Ended December 31		Horizontal Analysis		
	2025	2024	Inc./(Dec.)	%	
Salaries and Wages	P111,313,162	P87,491,420	23,821,742	27.23%	[C1]
Utilities Expenses	54,800,309	51,738,090	3,062,219	5.92%	[C2]
Depreciation	48,391,711	48,382,415	9,296	0.02%	
Professional Fees	25,287,779	33,272,069	(7,984,290)	(24.00%)	
SSS, PHIC and HDMF Contributions	13,743,882	14,586,982	(843,100)	(5.78%)	
Security Services	12,334,776	8,684,813	3,649,963	42.03%	
Housekeeping Expenses	9,322,573	8,415,291	(681,215)	10.78%	
Office Supplies	7,827,951	8,509,166	(681,215)	(8.01%)	
Taxes and Licenses	5,802,631	6,926,145	(1,123,514)	(16.22%)	
Repairs and Maintenance Expenses	4,239,547	901,410	3,338,137	370.32%	[C3]
Insurance Expenses	2,465,225	2,305,495	159,730	6.93%	
Communication Expenses	1,110,669	811,393	299,276	36.88%	
Transportation and Travel Expenses	1,002,276	1,190,229	(187,953)	(15.79%)	
Board Meetings and Conferences	341,050	4,862,485	(4,521,435)	(92.99%)	

		Entertainment and Representation Expenses	313,229	292,075	21,154	7.24%
		Training, Workshop, Seminar	255,299	954,891	(699,592)	(73.26%)
		Advertising Expenses	104,984	749,906	(644,264)	(57.14%)
		Rental Expenses	18,947	44,211	(25,264)	(57.14%)
		Miscellaneous Expenses	3,613,389	2,266,841	1,346,548	59.40%
		TOTAL	P302,289,389	P282,385,327	P19,904,062	6.58%

[C.1] Salaries and Wages. During the year, there was a slight increase in general and administrative expenses amounting to Php19.90 million, or 6.58%. This overall increase reflects significant company-related expenses associated with core business operations, including the salary standardization modifications implemented in the second quarter. However, employee turnover experienced a notable rise towards the end of the period, particularly around October 2025. This increase in turnover effectively mitigated the impact of the salary hike. As of December 31, 2025, salaries and wages amounted to Php 111.31 million. Furthermore, management successfully managed the effects of inflation by implementing cost-cutting measures throughout the period.

[C.2] Utilities Expense. Utilities expense, consisting of electricity, water, fuel, and related services, increased in 2025. Electricity represents the largest component, with higher usage observed in May, July, and August in line with increased hospital census. During the year, the electricity charges incurred amounted to Php52.47 million.

[C.3] Repairs and Maintenance Expenses. Repairs and maintenance expenses increased due to higher service requirements across hospital equipment and facilities. A significant repair transaction occurred in June 2025 relating to hospital equipment amounted to Php2.22 million, which is the preventive maintenance fee of the Mobile Digital X-ray equipment of the Imaging Department. The increase is operational, with certain transactions considered non-recurring.

[D]	**Finance Cost**	This account provides an overview of interest expenses incurred by the hospital from bank and related party loans. For the year ended December 31, 2025, interest incurred from bank loans and related party loans amounted to P72.42 million and P63.32 million, respectively. This decline in interest expenses is attributed to LBP's interest rate adjustment. The hospital remains committed to timely payment of its interest and principal obligations to LBP throughout the specified period.
[E]	**Other Comprehensive Income**	This account pertains to Revaluation Surplus, net of Deferred Tax Liability recognized as at December 31, 2025. The company's land was appraised in 2026 by Cubing Surveying, an SEC-accredited professional valuer. Independent appraisers performed the valuation of its parcels of land, resulting in a report of March 2026 covering December 31, 2025. The Company's revaluation surplus, net of deferred tax liability, was ₱183,531,277 as of December 31, 2025. Deferred tax liability is measured at the tax rate applied when the liability is recognized, based on the tax regulation rate enacted by the end of the reporting period. It is computed as the product of the 25% tax regulation rate and the total revaluation surplus of ₱244,708,370. As of December 31, 2025, the deferred tax liability from land revaluation amounted to ₱61,177,093.

Changes in Financial Position for Comparative periods March 31, 2026 and December 31, 2025

			Horizontal Analysis		Vertical Analysis		
ASSETS	**31-March-26**	**31-Dec-25**	**Inc./(Dec.)**	**%**	**31-March-26**	**31-Dec-24**	
CURRENT ASSETS							
Cash	P26,414,935	P23,296,041	3,118,894	13.39%	0.96%	0.86%	[I.II]
Receivables	192,816,543	165,796,569	27,019,974	16.30%	7.04%	6.11%	[I.II]
Advances to contractors and suppliers	89,868,430	72,449,059	17,419,371	24.04%	3.28%	2.67%	[I.II]
Medical and hospital supplies inventories	47,935,244	59,994,528	(12,059,284)	-20.10%	1.75%	2.21%	[I.II]
Prepayments and other current assets	33,109,906	28,714,938	4,394,968	15.31%	1.21%	1.06%	[I.II]
TOTAL CURRENT ASSETS	**390,145,058**	**350,251,135**	**39,893,923**	**11.39%**	**14.24%**	**12.90%**	[I.II]
NON-CURRENT ASSETS							
Property and equipment (net)	2,342,868,883	2,357,222,256	(14,353,373)	-0.61%	85.51%	86.84%	[I.I]
Advances to related parties	6,950,256	6,950,256	-	0.00%	0.25%	0.26%	
TOTAL NON-CURRENT ASSETS	**2,349,819,139**	**2,364,172,512**	**(14,353,373)**	**-0.61%**	**85.76%**	**87.10%**	[I.I]
TOTAL ASSETS	**2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	[I]
LIABILITIES AND EQUITY							
CURRENT LIABILITIES							
Accounts payable and other liabilities	717,399,179	689,539,570	27,859,609	4.04%	26.18%	25.40%	[II]
Loans payable to individuals	91,589,939	15,703,226	75,886,713	483.26%	3.34%	0.58%	[II]
Notes payable - current portion	227,010,404	191,558,072	35,452,332	18.51%	8.29%	1.66%	[II]
TOTAL CURRENT LIABILITIES	**1,035,999,522**	**896,800,868**	**139,198,654**	**15.52%**	**37.81%**	**27.64%**	
NON-CURRENT LIABILITIES							
Notes payable - net of current portion	757,790,363	954,351,037	(50,002,602)	-6.19%	27.66%	35.16%	[II]
Loans payable to related party	544,871,969	544,871,969	-	0.00%	19.89%	20.07%	[II]
Deferred tax liability	61,177,093	61,177,093	-	0.00%	2.23%	2.25%	[II]
TOTAL NON-CURRENT LIABILITIES	**1,363,839,425**	**1,560,400,099**	**(50,002,602)**	**-3.54%**	**49.78%**	**55.23%**	
TOTAL LIABILITIES	**2,399,838,947**	**2,310,642,895**	**89,196,052**	**3.86%**	**87.59%**	**82.87%**	[II]
EQUITY							
Share Capital (net)	240,000,000	240,000,000	-	0.00%	8.76%	8.84%	
Share Premium	958,532,662	958,532,662	-	0.00%	34.98%	35.31%	
Revaluation surplus	183,531,277	183,531,277	-	0.00%	6.70%	6.76%	
Retained Earnings/(Deficit)	(1,041,938,689)	(978,283,187)	(63,655,502)	6.51%	-38.03%	-36.04%	
TOTAL EQUITY	**340,125,250**	**403,780,752**	**(63,655,502)**	**-15.76%**	**12.41%**	**17.13%**	[III]
TOTAL LIABILITIES AND EQUITY	**P2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	

[I]	**Assets**	As of the first quarter period ending March 31, 2026, the Company's assets have exhibited a consistent growth trajectory. This growth is primarily attributed to the strong performance of essential financial assets, including cash, receivables, and hospital supplies. These assets are necessary for ensuring patient care and optimizing operational efficiency. As of March 31, 2026, the Company's total assets were Php2.74 billion, with Php0.39 billion (14.24%) in current assets and Php2.34 billion (85.76%) in non-current assets.
[I.I]	**Non-Current Assets**	The Company's non-current assets consisted of the following: **Property and Equipment, Net of Depreciation** As of March 31, 2026, this account consists of the land with revalued carrying amount of Php273.00 million, Building - Php1,753.77 billion, medical equipment - Php238.97 million, hospital equipment - Php50.05 million, kitchen tools - Php15.22 million, hospital vehicles - P5.76 million, and office equipment - Php6.10 million. During the year, the Company had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026, by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. **Advances to Related Party** Advances to related parties have no movement as of March 31, 2026
[I.II]	**Current Assets**	**The current assets consist of the following:** **Cash and Cash Equivalents** The surge in cash and cash equivalents is attributable to collections from its revenue streams. The hospital consistently encounters substantial increments in patient volume and revenue generation. Despite commencing operations, it encountered challenges, including escalating patient admissions to sustain daily operations and relying on its affiliate physicians for referrals. Furthermore, the hospital engaged in marketing and promotional endeavors to attract potential patients. It remains optimistic about overcoming these challenges as it continues to provide hospital services to the public. **Medical and Hospital Supplies Inventories** As of March 31, 2026, the inventory account comprises general hospital maintenance supplies; medical and laboratory supplies; and drugs and medicines, amounting to Php21.53 million, Php19.26 million, and Php7.15 million, respectively. **Trade and Other Receivables** The hospital's trade and other receivables indicate a positive financial position, although cash payments have not yet been received. Several factors contribute to this delay, including the billing methods employed for patients, the payment processes of insurance companies, and the payment arrangements made by patients for their medical care. As of March 31, 2026, the hospital's trade and other receivables encompass funds from PHIC (Php72.92 million), HMOs (Php55.10 million), Government Institutions (Php44.23 million), and other sources (Php20.57 million). Refundable deposits, including Php5.00 million to MORE POWER Corporation, Php15,000 to Iloilo Medical Society for office rent, and Php20,000 for drug testing services from the Department of Health, have been reclassified to the other receivable, current assets account. These deposits are expected to be applied for or recovered as per the agreements and regulatory requirements. **Advances to contractors and suppliers** Advances to contractors and suppliers. Advances to contractors are recognized as a benefit for each project awarded and are liquidated through deduction, on a pro-rata basis, from the contractor's periodic progress billings. As a result of the building's completion, there was no material movement to this account as at March 31, 2026. Advances to suppliers increased by Php17.42 million (24.04%), representing down payments made to various hospital suppliers as at March 31, 2026. **Prepayments and other Current Assets** The account represents the unutilized cost of insurance amounted to Php0.82 million, Php24.34 million for the excess of input over output VAT and the carryover of input VAT from previous periods, and prepaid income tax of Php7.94 million, as at March 31, 2026.

[II]	**Liabilities**	**Accounts Payables and Other Liabilities** This account consists of the following: Accounts payable - contractors and suppliers amounting to Php368.59 million; Retention Payable amounting to Php40.56 million; Accrued Interest Payable Php172.20 million; and other payables amounting to Php136.05 million. **Loans Payable to Related Parties** These are loans extended by Phil Pharmawealth, Inc. (PPI) to the Company. As of December 31, 2024, the balance stands at P544.87 million. These loans were granted to help pay off company obligations. **Loans from Individuals** These are loans provided to the Company to help in the construction of the hospital building and sustain its operations. These are gradually liquidated whenever funds are available. As of March 31, 2026, the balance amounted to Php91.59 million. **Notes Payable (LBP)** In 2023, Landbank of the Philippines, approved the restructuring of the total outstanding balance of term loan 1, 3 and 4 in the amount of Php985,594,306 up to seven (7) years from date of effectivity with one (1) quarter grace period on principal and interest. In 2024, it approved Term Loan 6 and a Working Capital Line for P70 million and P30 million, respectively. As at March 31, 2026, the outstanding balance amounted to Php984.80 million and interest expense incurred amounted to Php18.98 million. **Deferred Tax Liabilities** This account represents the recognized deferred tax liability on revaluation resulted from the conducted land appraisal.
[III]	**Equity**	The Company's land was appraised in 2026 by Cubing Surveying, an SEC-accredited professional valuer. The appraisal report, issued on March 9, 2026, used the Sales Comparison Approach based on recent comparable property transactions. As of December 31, 2025, the revaluation resulted in a surplus of Php244,708,370. As of March 31, 2026, the total equity stood at Php340.13 million, a decrease of Php63.66 million (15.76%) resulting from the loss incurred during the quarter.

TRENDS, EVENTS and UNCERTAINTIES THAT HAVE HAD OR THAT ARE REASONABLY EXPECTED TO AFFECT REVENUES OR INCOME

1. Challenges in liquidity and cash flow management

The Company's current ratio slightly decreased to 0.38:1 in the first quarter of 2026 from 0.39:1 in December 2025. Increased patient volume and revenue led to higher receivables, while cash collections were delayed due to billing cycles, insurance claims, patient payments, and government remittances. Current liabilities rose significantly due to the recognition of the current portion of long-term bank loans and stockholder advances. Management implemented measures to strengthen cash collection and improve working capital management. These initiatives aim to enhance liquidity, improve cash flow, and ensure timely obligation settlement.

2. No Off-Balance Sheet Transactions or Relationships

There are no off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the Company with unconsolidated entities or other people created during the period.

3. No Material Impact on Income from Continued Operation

During the first quarter ending March 31, 2026, Hospital generated Php107.54 million in revenue, a 30.90% increase from the previous year. This growth reflects the hospital's commitment to patient relationships and product/service enhancements. Despite the increase in revenue, operating expenses likewise increased in line with the operational requirements. Further, no material financial obligations are triggered by events, defaults, or accelerations.

4. Significant Capital Expenditures

There were no material commitments to capital expenditure during the period. The increase in Asset to Equity ratio can be attributed to the appraisal of the Company's Land in December 2025. The land is carried at its revalued amount or fair market value of ₱273,000,000 as of December 31, 2025.

5. Seasonal Impact on Financial Performance

Hospitals often experience higher patient admissions during illness outbreaks, while elective surgeries and non-urgent procedures may decline during holidays or adverse weather, temporarily reducing revenue. Natural events like typhoons or floods and global economic uncertainties may indirectly affect the Company through inflationary pressures, increased fuel and transportation costs, fluctuating medical supplies and pharmaceutical prices, and supply chain disruptions. Management monitors performance to mitigate fluctuations and remains optimistic that ongoing service enhancements and operational strategies will address these issues. Other than the above, there are no seasonal aspects that materially impacted the Company's financial condition or results of operations for the period.

As of March 31, 2026:

1. The company's improved quick asset and current ratios reflect enhanced liquidity, primarily due to increased collections from patient admissions and receivables from PhilHealth and other government agencies such as DSWD and PCSO. While the hospital remains operational, it continues to face initial challenges, including the need to boost patient admissions, reduce reliance on affiliate doctors for referrals, and strengthen marketing efforts to expand its patient base. Management remains optimistic that these issues will be addressed in the coming quarters through ongoing service enhancements and operational strategies. There are no seasonal aspects that had any material impact on the financial condition or results of operations of the Company.

2. There are no events or any default or acceleration of an obligation that will trigger direct or contingent financial obligation that is material to the Company.

3. There are no off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the Company with unconsolidated entities or other persons created during the period.

4. The company has no investment on foreign securities.

5. There were material commitments for capital expenditure during the period.

KEY PERFORMANCE INDICATORS (KPIS)

	Definition	31-March-26	31-Dec-25	Remarks
1. Liquidity				
Quick Asset Ratio	$\frac{\text{Cash + Receivables}}{\text{Current Liabilities}}$	0.21:1	0.21:1	During the first quarter of its operations in 2026, the hospital encountered an elevated level of trade and other receivables. This suggests that the hospital has generated revenue but has not yet received cash payments due to billing processes, insurance claims, or patient payment arrangements. Additionally, current liabilities have experienced significant increase. The rise in current liabilities can be attributed to the recognized current portion of the long-term bank loan and advances from the

				stockholders to be utilized for operational purposes. Consequently, strategies have been implemented to optimize cash collection, thereby enhancing the company's access to funds and facilitating its timely payment of debts.
Current Ratio	Current Assets / Current Liabilities	0.38:1	0.39:1	The Company's current ratio slightly decreased to 0.38:1 in the first quarter of 2026 from 0.39:1 in December 2025. Increased patient volume and revenue led to higher receivables, while cash collections were delayed due to billing cycles, insurance claims, patient payments, and government remittances. Current liabilities rose significantly due to the recognition of the current portion of long-term bank loans and stockholder advances. Management implemented measures to strengthen cash collection and improve working capital management. These initiatives aim to enhance liquidity, improve cash flow, and ensure timely obligation settlement.
2. Solvency				
Debt to Equity Ratio	Long Term Debt / Equity	4.01:1	3.50:1	The rise in long-term debt is attributed to additional loans granted to the hospital, while the revenue generated from sales has not yet been sufficient to cover the expenses incurred in the monthly operations.
3. Profitability				
Net Profit Margin	Net Income / Total Revenue	0.00	0.00	While sales growth has been favorable, operational expenses have experienced an increase. Undeterred by these challenges, the hospital maintains optimism about surmounting them in the forthcoming years and providing exceptional healthcare services to our community.
Return on Equity	Net Income / Stockholder's Equity	0.00	0.00	Stockholders can expect to earn returns on their investment after the hospital generates net income.
4. Leverage				
Debt to Total Asset Ratio	Total Liabilities / Total Asset	0.88:1	0.85:1	There has been a slight increase in total liabilities compared to total assets. The hospital is still in debt to Land Bank for loans used for constructing the building and acquiring state-of-the-art medical equipment. The increase in liabilities also includes current liabilities.
Asset To Equity Ratio	Total Asset / Equity	8.06:1	6.72:1	This increase in the ratio indicates that a substantial portion of the hospital's assets, including the most recent medical equipment, the hospital's buildings, and its infrastructure, is being financed through loans and borrowing.
5. Interest Rate Coverage Ratio	Earnings Before Interests & Taxes / Interest Expense	0.00	0.00	An increase in the Interest Coverage Ratio (ICR) can be attributed to the company's efforts in timely payments and effective debt management throughout the year.

EXTERNAL AUDIT FEES (SEC MC No. 14, Series of 2004)

The 2025 Audited Financial Statements of the Company with the External Auditors' PTR, Name of the Certifying partner and Address, and the Statement of Manager's Responsibilities are attached hereto as **Annex E3.**

THE AGGREGATE FEES BILLED ARE SHOWN BELOW:

The External Auditor has rendered:

Audit of the registrant's annual financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings or engagements for those fiscal years.

Other assurance and related services that are reasonable related to the performance of the audit or review of the registrant's financial statements.

The Audit Committee has approved the above-mentioned services. The aggregate fees billed are shown below:

	2025	2024	2023
Total Audit Fees	200,000	286,570	242,000
Non-audit service fees: Other assurance services Tax services All other services	-	-	-
Total Non-audit fees	-	-	-
Total Audit and Non-audit Fees	200,000	286,570	242,000

Berces-Ocampo, Mendoza and Associates did not render tax or other professional services during the year. Audit service fee is exclusive of 15% which represents out of pocket expenses (OPE), plus 12% VAT in the amount of PHP 200,000 during the year ended December 31, 2025.

Likewise, Dimaculangan and Dimaculangan and Company CPAs did not render tax or other professional services during the years 2024 and 2023. Audit service fees are inclusive of 15% of other fees which represents out of pocket expenses (OPE) and QAR Fees plus 12% VAT amounted to Php 34,410 and Php 26,400 during the years ended December 31, 2024 and 2023, respectively.

D. CERTAIN RELATIONS AND RELATED TRANSACTIONS

The Company has completed the construction of its hospital facility, which commenced commercial operations in December 2023. Among the visions of the directors and founders of the hospital is to provide Ilonggos the best hospital facility in the region which is at par with those that are in highly urbanized regions as Manila and Cebu. To realize this vision, the directors and founders decided that they should provide state of the art equipment and those that are considered top notch in the medical industry. Anent to this, the company engaged the services of Endure Medical, Inc. an esteemed and trusted importer, to help the company in the importation of its equipment. Endure Medical, Inc. is owned and managed by the family of Dr. Ferjenel Biron, Chairman of APMCI Board.

In 2017, the directors and shareholders of the company were mandated and empowered to contribute resources and make cash advances in favor of the company to augment the development/construction of its medical structures and appurtenances. These advances have been gradually liquidated over the years. As of October 2020, these have all been fully paid.

In June 2021, the company initially borrowed money from Phil Pharmawealth Inc., a pharmaceutical company owned by the family of Dr. Ferjenel Biron, Chairman of the Board of APMC Iloilo. The loan was intended to pay off necessary obligations of the company. Subsequently, additional loans were made after. These are interest bearing loans (4.50% to 6.50%) that are agreed to be paid subject to availability of funds.

Also, the company employed the services of TIPP Plus Digital Solutions for the custom-made Hospital Management Information System that the hospital will be using. TIPP Plus' President is Atty. Maylene Villanueva who is the Compliance Officer of APMC Iloilo, Inc. The engagement of TIPP Plus Digital Solutions was done prior to the latter's appointment.

E. MANAGEMENT AND CERTAIN SECURITY HOLDERS BOARD OF DIRECTORS AND EXECUTIVE OFFICERS

The overall management and supervision of the Company is undertaken by the Board. The Company's executive officers and management team cooperate with the Board by preparing appropriate information and documents concerning the Company's business operations, financial condition and results of its operations for its review. Currently, the Board consists of fifteen (15) members, of which three (3) are independent directors.

The table below set forth the members of the Company's Board as of 30 April 2026.

Name	Position	Age	Citizenship	Occupation	Business/Clinic
Biron, Ferjenel G.	Director/ Chairman	61	Filipino	Businessman/ Congressman / General Medicine	Aesthetica Manila, Inc., Smartlab Diagnostics and Dialysis Center, Inc., Park3 Realty & Development Corporation, EMI Properties, OPC, Newlife Regenerative & Wellness Center Inc., Obbo Holdings, Inc., Botikang Pinoy, Inc., Super BP Mart Corporation, Endure Medical Laboratories, Inc., Ferj Pharmacy, Inc. Asia-Pacific Medical Center - Aklan, Inc., Asia-Pacific Medical Center - Bacolod Inc., Representative of the Fourth (4th) District of Iloilo
Belgira, Johanna Marie B.	Independent Director	36	Filipino	Municipal Legal Officer/ Practicing Lawyer/ Businesswoman	Legal Department, 2nd floor, New Municipal Hall, Tabucan, Barotac Nuevo, Iloilo/Lutero, Andutan, Hongco, Bermudo and Gumboc Law Office, No. 38 Fortunata Street, Iloilo City/ Jinsilseong Samgyeopsal Restaurant, General Luna St. Iloilo City

Biron, Brandt Luke Q.	Director	28	Filipino	Businessman	Botikang Pinoy Franchising Corp, Botikang Pinoy Generix, Botikang Pinoy Inc., Bread Kingdom OPC, Endure Medical Laboratories Inc., Endure Medical, Inc., Int'l Apex Pharmaceuticals, Inc., Nori Air Services OPC, Oncolife Corporation, Phil Pharmawealth Inc., Skingen Biotech, Inc., Super BP Mart Corporation Ferj Pharmacy, Inc.
Debuque, Nathalie Ann F.	Independent Director	32	Filipino	Vice Governor	Province of Iloilo
Dianco, Felibert O.	Director	52	Filipino	Internal Medicine/ Cardiologist	Asia Pacific Medical Center-Iloilo, Inc., Iloilo City
Fernandez, Lemuel T.	Director/ Asst. Corporate Treasurer	59	Filipino	Businessman	Daily Guardian, Mandurriao, Iloilo City
Gomez, Lusyl M.	Director/ Asst. Corporate Secretary	67	Filipino	Pediatrics	IpedCare, Qualimed Hospital Iloilo, Asia Pacific Medical Center- Iloilo, Inc., Iloilo City
Lavilla, Meride D.	Director/Vice Chairman	63	Filipino	Pediatrician	St. Paul's Hospital Iloilo City, Iloilo Mission Hospital Iloilo City, West Visayas State University Medical Center Iloilo City, Medicus Medical Center Iloilo City, Qualimed Medical Center Iloilo City, Asia Pacific Medical Center- Iloilo, Inc. Iloilo City
Nolasco, Felix P.	Director	73	Filipino	ENT-HNS Specialist	Asian Hospital Medical Center

Ong, Mary Flor G.	Director/ Corporate Treasurer	53	Filipino	Internal Medicine-Endocrinology, Diabetes and Metabolism	Iloilo Mission Hospital, Iloilo City, Asia Pacific Medical Center-Iloilo, Inc., Iloilo City
Regozo, Danilo C.	Director/ Executive Vice President	63	Filipino	Family Medicine	Farmacia Neo, Tanza Iloilo City (Clinic); Iloilo Doctors' Hospital, Iloilo Mission Hospital, The Medical City Iloilo, Medicus Medical Center Iloilo, Asia Pacific Medical Center- Iloilo, Inc. Iloilo City
Samoro, Fredilyn G.	Director	61	Filipino	Obstetrics and Genecology	Clinic Room 103 Healthlink, Mabini Street, Iloilo City, Asia Pacific Medical Center - Iloilo, Inc. Iloilo City
Silverio Lorna C.	Lead Independent Director	78	Filipino	Businesswoman	Northeast Star Development - OPC, Makati City, Aesthetica Manila, Pasig City, Philippine Development Corporation, San Rafael Bulacan, Prime Site Advertizing- Makati City
Suplico, Rolex T.	Director	67	Filipino	Lawyer/ Businessman	Suplico and Austria Law Office, SP Member, 5th District of Iloilo
Villaflor, Agnes Jean M.	Director/ President	61	Filipino	Nephrologist	M3 Dialysis Center Iloilo, West Visayas State University Medical Center, Iloilo Mission Hospital, St Paul's Hospital Iloilo, Iloilo Doctors Hospital, The Medical City Iloilo, Medicus Medical Center, Asia Pacific Medical Center- Iloilo, Inc.

During the Annual Stockholders Meeting held on 18 June 2025, all the above were elected as Board of Directors and Officers of the Corporation for the year 2025 until their successors are elected.

During the Organizational Meeting on the same date, the newly elected Directors approved the retention of the 2024 set of officers. Other than the aforementioned Directors and Officers, the following persons occupy key management positions.

The Table below sets forth the company's executive officers in addition to its executive directors listed above as of 30 April 2026.

Name	Position	Age	Citizenship	Occupation	Business
Delos Reyes, Giovanni A.	Director for Admin and Support Services	72	Filipino	Practicing General Surgeon	Health Partners Condo Clinic, Brgy. San Rafael Mandurraio, Iloilo
Fernandez, Toni Dinah Cheer D.	Investor Relations Manager	57	Filipino	Businesswoman	Daily Guardian
Cortes, Cris T.	Chief Finance Officer	38	Filipino	Accountant	None
Villanueva, Maylene B.	Compliance Officer	45	Filipino	Corporate Lawyer	Villanueva Balio and Ariston Law Offices
Gerafil, Therese Marie A.	Corporate Secretary/ Legal Officer / Data Protection Officer	30	Filipino	Lawyer	None

INDEPENDENT DIRECTORS

The independent directors of the Company as of 30 April 2026 are Johanna Marie B. Belgira, Nathalie Ann F. Debuque and Lorna C. Selverio.

SIGNIFICANT EMPLOYEES

The Company has no employee who is not an executive officer but who is expected to make a significant contribution to the business.

FAMILY RELATIONSHIPS

Director and Chairman Ferjenel G. Biron is the father of Director Brandt Luke Q. Biron. Director Lemuel T. Fernandez is the spouse of Investor Relations Officer Toni Dinah Cheer Fernandez. The spouse of Director and Assistant Corporate Secretary Lusyl Gomez is the first cousin of Director and President Agnes Jean Villaflor.

Other than the foregoing, there are no other family relationships either by consanguinity or affinity up to the fourth civil degree between and among Directors, Executive Officers, or persons nominated.

INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS

A. **Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City (Complaint for Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-emption, and for Attorney'sFees) Dax Matthew M. Quijano et.al. v. ACE Medical Center Cebu Inc., Felix P. Nolasco, et.al.**

On 7 March 2018, several complainants (Dax Matthew M. Quijano, et.al.) through counsel filed a civil complaint against the Hospital and its Directors including Felix Nolasco praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff's Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase of capital approved by the Board on November 12, 2016. The Defendants (based in Cebu) have already filed their Answer to the Complaint but the Manila based Doctors which include Dr. Nolasco had not been served the summons. On 5 August 2020, a Motion to Dismiss the Complaint was filed for lack of interest of plaintiffs to prosecute the case. The case was scheduled for mediation on 14 July 2021. Since an agreement was not reached, another mediation was scheduled on 29 July 2021. No agreement was reached so it was sent back to court for judicial dispute resolution which was held on 9 February 2022. The JDR failed. The pre-trial conference which was previously scheduled on 13 April 2023 was cancelled and moved to 02 June 2023 at 10:45 am.

During the 13 August 2024 hearing, the Court informed the Parties that it needed time to evaluate the Motion for Partial Summary Judgement filed by complainants and reset the pre-trial conference on 16 October 2024 at 8:30 in the morning without prejudice to the resolution of the motion.

During the 16 October 2024 hearing, the Court informed the parties that it needs more time to resolve plaintiff's Motion for Partial Summary Judgement. The pre-trial conference was set on 05 February 2025 at 9:15 in the morning. On 05 February 2025, the Court set the pre-trial conference on 21 March 2025 at 9:15 in the morning without prejudice to the resolution of the Motion for Partial Summary Judgement.

On 21 March 2025, the pre-trial conference was reset on 23 May 2025 at 10:45 in the morning considering that plaintiffs' motion for partial summary judgment is still to be resolved by the court.

On 23 May 2025, an Order was issued by the Regional Trial Court Branch XI of Cebu City resetting the pre-trial conference to 25 July 2025 at 10:00 in the morning, considering that there is still a pending motion for partial summary judgment, however, the same was cancelled.

Thereafter, the next hearing was scheduled on November 24, 2025, at 9:15 a.m., but this was subsequently reset to June 21, 2026, at 8:00 a.m.

B. **Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City (Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-Emption, and/or Attorney's Fees) Ferdinand P. Kionisala vs. Allied Care Experts (ACE) Medical Center- Cebu, Inc., Felix P. Nolasco et.al.**

On 5 February 2018, complainant Ferdinand P. Kionisala filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff"s Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on 12 November 2016. The Cebu-based defendants had already filed their Answer to the Complaint and Dr. Kionisala has filed a Motion for Partial Summary Judgement, but the same was opposed by defendants on 2 May 2018. No ruling was made on such motion hence the case had not moved. The Defendants filed a Motion to Dismiss the case for failure of the plaintiff to prosecute for lack of interest. The case was scheduled for mediation on 16 June 2021. Since an agreement was not reached, the pre-trial on 13 August 2021 proceeded as scheduled.

On 5 November 2021, a hearing was held but no resolution was made. Another hearing was scheduled on 4 March 2022 but plaintiffs were unavailable. On 22 April 2022, another hearing was scheduled but plaintiff requested that his previous manifestation be addressed first. The hearing scheduled on 24 June 2022 was postponed.

The Court rendered on 09 August 2022 a partial summary judgement on plaintiff's prayer for issuance of certificates of stock leaving the other issues sought for trial on the merits. However, instead of presenting his evidence, plaintiff filed a motion to submit the case for decision based on legal issues through the filing of memorandum which is still pending resolution.

The Plaintiff submitted a motion to submit the case for decision based on legal issues, which was filed with the Court on October 24, 2022. The Defendant filed a comment on November 7, 2022. An order dated June 30, 2023, was received, in which the Court granted the Plaintiff's motion to submit the case for decision based on legal issues dated October 18, 2022. The Presiding Judge allowed both parties to file their respective memoranda, limited to the issue of the extent of the Plaintiff's preemptive right to purchase or subscribe to shares of stock in view of the Defendant Corporation's increase in capital stock, within 30 days from receipt of the said order.

The Defendant's counsel subsequently filed a Motion for Reconsideration seeking to set aside and deny the Plaintiff's motion to submit the case for decision based solely on the issue of whether the Plaintiff is entitled to the preemptive right to subscribe to one block of shares equivalent to 10 shares or only 3 shares, citing utter lack of merit. The Plaintiff's counsel filed an opposition to the Motion for Reconsideration.

The Defendant's Motion for Reconsideration of the Order dated June 30, 2023, which granted the Plaintiff's motion to submit the case for decision based on legal issues, remains pending resolution by the Court. As a matter of procedure, should the Court grant the Motion for Reconsideration, the case will proceed to pre-trial and trial. Otherwise, both parties will be directed to submit their respective memoranda in support of their respective claims and defenses, after which the case shall be deemed submitted for decision.

As of 30 April 2026, to the knowledge and information of the Company, except for the abovementioned Directors, none of the Company's other Directors or Executive Officers have been involved in any legal proceedings during the last five (5) years that are material to an evaluation of their ability or integrity to act as such.

F. CORPORATE GOVERNANCE

The Company endeavors to comply with the recommendations set forth in SEC Memorandum Circular No. 24 -Series of 2019. It is committed to a strong corporate governance with transparency and accountability as its hallmarks.

On January 27, 2019, during its first meeting after the issuance of the Permit to Offer Securities, the Board of Directors appointed its Compliance Officer as an initial step in ensuring that it will adhere to the highest standards of good governance. The Company submitted its Manual on Corporate Governance on 27 June 2019.

On 30 September 2020, the Company submitted its Revised Manual on Corporate Governance. It substantially adopted in its Manual on Corporate Governance all the recommendations under SEC Memorandum Circular No. 24, Series of 2019, otherwise known as the Code of Corporate Governance for Public Companies and Registered Issuers (CG Code for PCs and RIs).

To comply with the requirement that the Corporate Secretary must not be a member of the Board of Directors, the Board appointed a new Corporate Secretary during its Organizational meeting on 30 June 2023 to allow the Compliance Officer to focus on compliance matters.

The minor deviations from the recommendations of the CG Code for PCs and RI such as the Executive directors being more than non-executive directors and having three (3) Independent Directors instead of five (5) were necessitated by the fact that the company has just commenced operations and there is a need to tighten the purse that is achieved by having a lean manpower in preparation for pre-operation expenses.

To ensure good governance, the Company had its new CEO attend the Strategic Thinking for Board Directors and Leaders conducted by the Center for Global Practices. With the new CEO properly trained, the Board is scheduled to revisit its vision, strategic objectives, key policies, and procedures for the management of the company, as well as the mechanism for monitoring and evaluating Management's performance before it commences operation. The Board also makes certain of the presence and adequacy of internal control mechanisms for good governance.

The Company is taking further steps to strengthen adherence principles and practices of corporate governance by sending its Directors in various trainings and programs conducted by the Institute of Directors and Center for Global Best Practices. The Committee on Corporate Governance is also set to review its Revised Manual on Corporate Governance to ensure compliance with recent regulations and harmonize it with operational requirements.

The 2025 SEC Form 17–A shall be available at the above stated company website. Upon the written request of the stockholder, the Company undertakes to furnish said stockholder a copy of the said 2025 SEC Form 17-A free of charge, except for exhibits attached which shall be charged at cost. Any written request for a copy of SEC Form 17-A shall be addressed as follows:

Asia Pacific Medical Center-Iloilo Inc.
(Formerly:Allied Care Experts Medical Center-Iloilo, Inc).
Brgy. Ungka , Jaro Iloilo City 5000

Attention : The Corporate Secretary

ASIA PACIFIC MEDICAL CENTER ILOILO

ANNEX " H"

MATERIAL INFORMATION ON THE CURRENT STOCKHOLDERS
(as of 30 APRIL 2026)

No.	Name	Voting Shares	Percentage of Ownership
	NATURAL PERSONS/ INDIVIDUALS		
1	ABECIA, GREG	100	0.04%
2	BARRAMEDA, ROMULO S.	1,900	0.79%
3	BIRON, BRANDT LUKE Q.	43,050	17.94%
4	BIRON, FERJENEL G.	48,406	20.17%
5	COMUELO, JERUSHA A.	3,462	1.44%
6	CRUZ, MAITA C.	1,110	0.46%
7	DATOR, COSSETTE P.	100	0.04%
8	DAULO, SYLVA L.	3,050	1.27%
9	DE CASTRO, MARIA GLORIA	1,400	0.58%
10	DEBUQUE, MA. TERESA F	2,040	0.85%
11	DIANCO, FELIBERT O.	3,350	1.40%
12	DOMINGO, CARMELO JR.	3,400	1.42%
13	FERNANDEZ, LEMUEL T.	1,940	0.81%
14	GALLEGA-PEREZ, MA. GRACE	3,442	1.43%
15	GATMAYTAN, ISABELLA MARIA REGINA S.	50	.02%
16	GOMEZ, LUSYL M.	2,781	1.16%
17	GONZAGA, YOLANDA J.	100	0.04%
18	GONZALES, NOEL G.	3,410	1.42%
19	GONZALES, FLORINA	500	0.21%
20	GONZALES, PEARL JOY B.	100	0.04%
21	GUBATINA, MARIA GERALDINE L.	1,900	0.79%
22	HAYANO, WINDIE V.	2,000	0.83%
23	HOLIPAS, ISMAEL A. JR	100	0.04%
24	LABBAO, MARIEL C.	100	0.04%
25	LAO, ROSELLE D.	50	0.02%
26	LAVALLE, AMADO JR. M	3,668	1.53%
27	LAVILLA, FRANCINE MARIE D	300	0.12%
28	LAVILLA, FRANCIS G.	2,440	1.02%
29	LAVILLA, LOU VALERIE D	300	0.12%
30	LAVILLA, MERIDE D.	3,638	1.52%
31	LAVILLA, MERYLL FAITH	300	0.12%

32	MINERVA, IKE T.	3,400	1.42%
33	NOLASCO, EULENA P.	2,350	0.98%
34	NOLASCO, FELIX P.	2,350	0.98%
35	OCA-BIRON, MA. REGINA ISABELLE	21,210	8.84%
36	OCA, PEDRO MANUEL	630	0.26%
37	OCA, CONRAD	130	0.05%
38	ONG, MARY FLOR G.	3,362	1.40%
39	PATRIMONIO, DEMETRIO	1,900	0.79%
40	PRIETO, CEASAR	100	0.04%
41	RAMIREZ, RUBEN B.	5,950	2.48%
42	REGOZO, DANILO C.	3,668	1.53%
43	REQUINTO, MELVIN D.	50	0.02%
44	SALAZAR, MA. IRIS V.	415	0.17%
45	SAMORO, FREDILYN G.	6,768	2.82%
46	Heirs of Samoro, Ronnie : Fredilyn Samoro; Kim Karolyn Samoro; Karmela Marie Samoro; Katrina Belle Marie Samoro	3,462	1.44%
47	SAQUIAN, JEREMY M.	1,900	0.79%
48	SILVERIO, LORNA	500	0.21%
49	SERDEÑA, JONATHAN S.	100	0.04%
50	SOLAS, CRISPIN JR.	100	0.04%
51	SUPLICO, ROLEX T.	2,000	0.83%
52	SY, WILFREDO S. SR.	100	0.04%
53	TAN, HELEN	100	0.04%
54	TINGSON, PEDRO F. JR.	1,900	0.79%
55	TUPAS, RAUL	50	0.02%
56	VILLAFLOR, AGNES JEAN M.	2,758	1.15%
57	VILLAFLOR, TRISTAN TIMOTHY M.	500	.21%
58	VILLAFLOR, TRINA THERESE M	500	.21%
59	YAP, JERRY P.	120	0.05%
60	YAP, LAZARINA B.	100	0.04%
61	ZERRUDO, THELMA	50	0.02%
	CORPORATE STOCKHOLDERS		
1	F. GURREA CONSTRUCTION, INC.	630	.26%
2	INTERNATIONAL BUILDERS CORPORATION	1,200	0.50%
3	THE ROMAN CATHOLIC ARCHBISHOP OF JARO	200	0.08%
4	UNIVERSITY OF SAN AGUSTIN	1,400	0.58%
5	UNITAN CONSTRUCTION & DEVELOPMENT CORPORATION	100	0.04%
	All other investors with less than 50 shares	31,460	13.52%

N.B *with 50 shares or more

Annex "I"

The following document has been received:

Receiving: DONNA ENCARNADO
Receipt Date and Time: January 27, 2026 04:35:38 PM

Company Information

SEC Registration No.: CS201423954
Company Name: ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
Industry Classification: N85122
Company Type: Stock Corporation

Document Information

Document ID: OST10127202683890895
Document Type: Secretary's Certificate Meeting of Board Directors (Appointment)
Document Code: CS_CERT-ATTENDANCE
Period Covered: December 31, 2025
Submission Type: Annual
Remarks: None

Acceptance of this document is subject to review of forms and contents

COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2025 December 31
(Fiscal Year Ending-Month and Day)

Secretary's Certificate on the Attendance of Board of Directors
(FORM TYPE)

_____
(Period Ended Date)

_____
(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any)

ASIA PACIFIC
MEDICAL CENTER
ILOILO

REPUBLIC OF THE PHILIPPINES)
CITY OF ILOILO) S.S.

SECRETARY'S CERTIFICATE

I, **Therese Marie A. Gerafil**, a duly elected and qualified Corporate Secretary of Asia Pacific Medical Center-Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center- Iloilo Inc.), a corporation duly organized and existing under and by virtue of the law of the Philippines, DO HEREBY CERTIFY, that:

1. I am the duly elected and qualified Corporate Secretary of Asia Pacific Medical Center-Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center- Iloilo Inc.), a corporation duly organized and existing under the laws of the Philippines, with principal place of business at Brgy. Ungka, Jaro, Iloilo City, 5000 and as such, I have custody and possession of the corporate books and other records of the Corporation, including the minutes of the meetings of the Stockholders and the Board of Directors of the Corporation.

2. The Board of Directors of the Corporation held Thirteen (13) meetings during the year 2025, as follow:

Date	Type
January 19, 2025	Regular Board Meeting
February 16, 2025	Regular Board Meeting
March 16, 2025	Regular Board Meeting
April 27, 2025	Regular Board Meeting
May 18, 2025	Regular Board Meeting
June 18, 2025	Organizational Meeting
June 30, 2025	Regular Board Meeting
July 27, 2025	Regular Board Meeting
August 25, 2025	Regular Board Meeting
September 28, 2025	Regular Board Meeting
October 28, 2025	Regular Board Meeting

November 23, 2025	Regular Board Meeting
December 23, 2025	Regular Board Meeting

3. The attendees of the above-mentioned meetings are listed in Schedule 1 attached hereto.

4. I am issuing this certification to attest to the truth of the foregoing, to certify the completeness of and attendance in the meetings of the Board of Directors of the Corporation for the year 2025, for whatever other legal purposes it may serve.

JAN 09 2026

IN WITNESS WHEREOF, I hereunto set my hand on this _____ day of January 2026, at Iloilo City.

THERESE MARIE A. GERAFIL
Corporate Secretary

SUBSCRIBED AND SWORN TO before me this _____ of JAN 09 2026, 2026, affiant personally appeared and exhibited to me her IBP ID with Roll#88537.

Doc. No. 22;
Page No. 6;
Book No. VI;
Series of 2026.

ATTY. EDUARDO A. DUERO
NOTARY PUBLIC CITY AND PROVINCE OF ILOILO
LACSON BUILDING, CALASANZ STREET,
PLAZA LIBERTAD, ILOILO CITY
NOTARIAL COMMISSION REG. NO. 264
UNTIL DECEMBER 31, 2026
ROLL OF ATTORNEY NO. 67032
PTR NO. 9155035 / 01-05-2026 : ILOILO CITY
IBPR NO. INV 543924 / 05-21-2025 : ILOILO CITY
MCLE EXEMPTION NO. VIII-BEP 003807 / PASIG CITY

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

SUMMARY OF BODs ATTENDANCE FOR REGULAR AND ORGANIZATIONAL MEETING 2025

	APMCI BOARD MEETINGS	REG	REG	REG	REG	REG	ORG	REG	REG	REG	REG	REG	REG	REG	Total No. of Meetings Attended by Each Member	Percentage of No. of Meetings Attended By Each Member
		19 Jan	16 Feb	16 Mar	27 Apr	18 May	18 Jun	30 Jun	27 Jul	25 Aug	28 Sep	28 Oct	23 Nov.	23 Dec		
1	JOHANNA MARIE B. BERMUDO-BELGIRA	P	P	P	P	A	P	A	P	P	P	P	A	A	9	69.23%
2	FERJENEL G. BIRON	P	P	A	A	P	P	P	P	P	P	P	P	P	11	84.62%
3	BRANDT LUKE Q. BIRON						NEWLY ELECTED	A	A	P	P	A	A	A	3	37.50%
4	JERUSHA A. COMUELO	P	P	P	A	P	OUTGOING								4	80.00%
5	MA. TERESA F. DEBUQUE	P	P	P	A	A	OUTGOING								3	60.00%
6	NATHALIE ANN F. DEBUQUE						NEWLY ELECTED		P	P	P	P	P	P	6	75.00%
7	FELIBERT O. DIANCO	P	P	P	A	P	P	P	P	P	P	P	P	P	12	92.31%
8	LEMUEL T. FERNANDEZ	P	P	P	P	P	P	P	P	P	P	P	P	P	13	100.00%
9	LUSYL M. GOMEZ	A	P	A	P	P	P	P	A	P	P	A	A	P	8	61.54%
10	AMADO M. LAVALLE JR.	P	P	P	P	P	OUTGOING								5	100.00%
11	MERIDE D. LAVILLA	P	P	P	P	P	P	P	P	P	P	P	P	P	13	100.00%
12	FELIX P. NOLASCO	P	P	P	P	P	P	P	P	P	P	P	P	A	12	92.31%
13	MARY FLOR ONG	P	P	P	P	P	P	P	P	P	P	A	P	P	12	92.31%
14	DANILO C. REGOZO	P	P	P	P	P	P	P	P	P	P	P	P	P	13	100.00%
15	FREDILYN G. SAMORO	A	P	P	P	P	P	P	A	P	P	P	P	P	11	84.62%
16	LORNA C. SILVERIO						NEWLY ELECTED	P	A	A	P	A	A	P	4	50.00%
17	ROLEX T. SUPLICO	P	P	A	A	P	P	P	P	P	P	P	P	P	11	84.62%
18	AGNES JEAN B. VILLAFLOR	P	P	P	P	P	P	P	P	P	P	P	P	P	13	100.00%
Total No. of Members Present in Each Meeting		13	15	12	10	13	14	12	11	14	15	11	11	13		
Percentage of No. of Members Present in Each Meeting		86.66%	100%	80%	66.66%	86.66%	93.33%	80%	73.33%	93.33%	100%	73.33%	73.33%	86.66%		

ASIA PACIFIC
MEDICAL CENTER
ILOILO

REPUBLIC OF THE PHILIPPINES)
CITY OF ILOILO) S.S.

SECRETARY'S CERTIFICATE

I, **Therese Marie A. Gerafil**, duly elected and qualified Corporate Secretary of **Asia Pacific Medical Center - Iloilo, Inc.** (Formerly: Allied Care Experts (ACE) Medical Center - Iloilo, Inc.), a corporation duly organized and existing under and by virtue of the law of the Philippines, DO HEREBY CERTIFY, that:

1. I am the duly elected and qualified Corporate Secretary of Asia Pacific Medical Center-Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center- Iloilo Inc.), with principal place of business at Brgy. Ungka, Jaro, Iloilo City, 5000 and as such, I have custody and possession of the corporate books and other records of the Corporation, including the minutes of the meetings of the Stockholders and the Board of Directors of the Corporation.

2. The Board of Directors of the Corporation held seventeen (17) meetings from January 2025 to April 2026, as follows:

Date	Type
January 19, 2025	Regular Board Meeting
February 16, 2025	Regular Board Meeting
March 16, 2025	Regular Board Meeting
April 27, 2025	Regular Board Meeting
May 18, 2025	Regular Board Meeting
June 18, 2025	Organizational Meeting
June 30, 2025	Regular Board Meeting
July 27, 2025	Regular Board Meeting
August 25, 2025	Regular Board Meeting
September 28, 2025	Regular Board Meeting
October 28, 2025	Regular Board Meeting
November 23, 2025	Regular Board Meeting
December 23, 2025	Regular Board Meeting
January 25, 2026	Regular Board Meeting
March 1, 2026	Regular Board Meeting
April 7, 2026	Regular Board Meeting
April 30, 2026	Regular Board Meeting

3. The attendees of the above-mentioned meetings are listed in Schedule 1 attached hereto.

4. I am issuing this certification to attest to the truth of the foregoing, to certify the completeness of and attendance in the meetings of the Board of Directors of the Corporation for the period January 2025 to April 2026, and for whatever other legal purposes it may serve.

IN WITNESS WHEREOF, I hereunto set my hand on this _____ day of MAY 13 2026, at Iloilo City, Philippines.

THERESE MARIE A. GERAFIL
Corporate Secretary

SUBSCRIBED AND SWORN TO before me this _____ day of MAY 13 2026 2026, at Iloilo City, Philippines, affiant personally appeared and exhibited to me her IBP ID with Roll No. 88537.

Doc. No. 405;
Page No. 82;
Book No. 48;
Series of 2026.

ATTY. IGMEDIO S. PRADO JR.
NOTARY PUBLIC FOR THE CITY AND PROVINCE
OF ILOILO UNTIL DECEMBER 31, 2027
IBP NO. 587[illegible]/01/07/2026/PASIG CITY
PTR NO. 9155[illegible]/01/07/2026/ILOILO CITY
REG. NOT. NO. 103, ROLL NO. 25533
MCLE VIII UNTIL 4/14/2028/NO.0013688
TIN: 117-855-747
MEZZANINE FLOOR RED PLAZA BUILDING
ABAGA ST., ILOILO CITY (033) 3[illegible]

SUMMARY OF BODs ATTENDANCE FOR REGULAR AND ORGANIZATIONAL MEETING
JANUARY 2025 TO APRIL 2026

	APMCI BOARD MEETINGS	REG	REG	REG	REG	REG	ORG	REG	REG	REG	REG	REG	REG	REG	REG	REG	REG	REG	Total No. of Meetings Attended by Each Member	Percentage of No. of Meetings Attended By Each Member
		19 Jan	16 Feb	16 Mar	27 Apr	18 May	18 Jun	30 Jun	27 Jul	25 Aug	28 Sep	28 Oct	23 Nov.	23 Dec	25 Jan	1 Mar	7 Apr	30 April		
1	JOHANNA MARIE B. BERMUDO-BELGIRA	P	P	P	P	A	P	A	P	P	P	P	A	A	P	P	P	A	12	70.59%
2	FERJENEL G. BIRON	P	P	A	A	P	P	P	P	P	P	P	P	P	P	P	P	P	15	88.24%
3	BRANDT LUKE Q. BIRON						NEWLY ELECTED	A	A	P	P	A	A	A	P	P	P	P	7	58.33%
4	JERUSHA A. COMUELO	P	P	P	A	P	OUTGOING												4	80%
5	MA. TERESA F. DEBUQUE	P	P	P	A	A	OUTGOING												3	60%
6	NATHALIE ANN F. DEBUQUE						NEWLY ELECTED		P	P	P	P	P	P	A	P	P	P	9	90%
7	FELIBERT O. DIANCO	P	P	P	A	P	P	P	P	P	P	P	P	P	P	P	P	P	16	94.12%
8	LEMUEL T. FERNANDEZ	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	17	100%
9	LUSYL M. GOMEZ	A	P	A	P	P	P	P	A	P	P	A	A	P	P	P	P	P	12	70.59%
10	AMADO M. LAVALLE JR.	P	P	P	P	P	OUTGOING												5	100%
11	MERIDE D. LAVILLA	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	17	100%
12	FELIX P. NOLASCO	P	P	P	P	P	P	P	P	P	P	P	P	A	P	P	P	P	16	94.12%
13	MARY FLOR G. ONG	P	P	P	P	P	P	P	P	P	P	A	P	P	P	P	P	P	16	94.12%
14	DANILO C. REGOZO	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	17	100%
15	FREDILYN G. SAMORO	A	P	P	P	P	P	P	A	P	P	P	P	P	P	P	P	P	15	88.24%
16	LORNA C. SILVERIO						NEWLY ELECTED	P	A	A	P	A	A	P	P	A	P	P	7	58.33%
17	ROLEX T. SUPLICO	P	P	A	A	P	P	P	P	P	P	P	P	P	P	P	P	A	14	82.35%
18	AGNES JEAN M. VILLAFLOR	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	17	100%
	Total No. of Members Present in Each Meeting	13	15	12	10	13	15	12	11	14	15	11	11	12	14	14	15	13		
	Percentage of No. of Members Present in Each Meeting	86.66%	100%	80%	66.66%	86.66%	100%	80%	73.33%	93.33%	100%	73.33%	73.33%	86.66%	93.33%	93.33%	100%	86.66%		

ASIA PACIFIC MEDICAL CENTER ILOILO

ANNEX “J”

2026 BOARD APPRAISAL/PERFORMANCE REPORT

In line with corporate governance best practices and in accordance with the key mandate of the Board of Directors (BOD), Asia Pacific Medical Center – Iloilo, Inc. formulated a Board Performance Evaluation Criteria to enable the Board to periodically identify overall strengths and specific areas for improvements based on results of assessment, and to obtain important feedback and views from the members of the Board which will serve as one of the basis for the Company’s overall strategy, performance and or future directions or endeavors.

The 2025 Board of Directors were asked to evaluate how well the Board has performed for each criterion anchored on its Revised Manual on Corporate Governance such as Structure, Leadership Roles and Responsibilities, Internal Control, Code of Conduct and Other Governance Policies, Independence, Stewardship, Resources, Monitoring, Reporting and Disclosures and Shareholder Benefits and indicate rating using the scale of 1 to 5, (1- Poor, 2- Below Average, 3- Average, 4- Above Average and 5- Excellent). Below is the result of the Self-Assessment conducted by the 2025 BOD based on the aforementioned criteria.

BOARD SELF-ASSESSMENT	Rating
STRUCTURE	
1. The Board has a proper mix of directors with the appropriate skills, knowledge and experience to enable them to effectively participate in Board deliberations.	4.23
2. The Board has a process of selection that ensures an appropriate mix of directors and officers who can perform competently and professionally and add value to the Company.	4.08
3. The powers, roles, responsibilities and accountabilities between the Board and Management are clearly defined, segregated and understood.	4.15
4. The Board has the necessary committees in place to assist the Board in the performance of its duties and responsibilities.	4.62
5.The roles of the Chairman and the CEO are separate or, if not there are adequate checks and balances to help ensure that independent, outside views, perspective, and judgments are given proper hearing in the Board.	4.31
LEADERSHIP ROLES AND RESPONSIBILITIES	
6. The Board, together with the Management determines and periodically reviews the Company's purpose, vision, mission and strategic objectives and business plans and policies that guide and direct activities of the Company, and the means to attain the same.	4.46
7. The Board oversees management's implementation of sound strategic policies and guidelines on major capital expenditures, business strategies, operational budgets, plans and policies.	4.31
8. The Board regularly and periodically monitors the Company's corporate performance against such strategic objectives and business plans.	4.31

9. The Board provides oversight with regard to enterprise risk management and identifies key risk areas and key performance indicators and monitor these factors with due diligence.	4.23
10. The Board adopts and decides on Company's governance principles, model/framework, guideline and practices and oversees the implementation thereof.	4.38
11. The Board ensures that the Company complies with all relevant laws and regulations and endeavors to adopt accepted best business practices.	4.62
12. The Board approves objectives and policies for Company's social, community and environmental performance.	4.54
13. The Board exercises corporate powers in accordance with the principles of sound corporate governance, and secures the Company's long-term viability and success.	4.46
INTERNAL CONTROL	
14. The Board has a good understanding of Management's responsibilities in relation to internal control.	4.08
15. The Board ensures the continuing soundness, effectiveness and adequacy of the Company's internal control environment.	4.38
16. The Board ensures that the Company has an internal audit system that can reasonably assure that the Company's key organizational and operational controls are complied with.	4.31
17. The Board ensures that the Company has an independent audit mechanism for the proper audit and review of financial statements by independent auditors.	4.38
CODE OF CONDUCT AND OTHER CORPORATE GOVERNANCE POLICIES	
18. The Board adopts a system of check and balance within the Board and regularly reviews its system of checks and balances for effectiveness.	4.23
19. The Board understands and actively promotes the Company's principles and values.	4.38
20. There is a written Code of Business Conduct and Ethics (the "Code of Conduct") to be followed by the Board, CEO, officers and employees.	4.15
21. There is a formal system to monitor compliance with the Code of Conduct.	4.08
22. The Code of Conduct is communicated, understood and followed by the Board, CEO, officers and employees.	4.08
23. The Code of Conduct provides that there shall be no waiver of any provision of the Code of Conduct in favor of directors or officers, except when expressly granted by the Board and any such waiver must be promptly disclosed to the stockholders.	4.08
24. There is a formal channel established to allow employees to report unethical conduct.	4.23
25. The Board ensures it has and is communicating and implementing a formal conflict of interest policy and it contains guidelines and provisions prohibiting the Company whether directly or indirectly from granting loans to directors and officers.	4.15
26. There are appropriate policies and procedures governing related party transactions.	4.08
27. The Board ensures that the directors are, as required or necessary or upon request of such directors, trained on corporate governance leading practices and principles by competent and recognized experts in the field, which may include institutional training providers accredited or recognized by the Philippine SEC.	4.23
I**NDEPENDENCE**	
28. The Board thinks and acts independently of, and is not unduly influenced by, the CEO and Management.	3.92

29. The Board has a balance of executive and non-executive directors, including independent directors such that no individual or small group of individuals can dominate the Board's decision making.	4.00
STEWARDSHIP	
30. The Board ensures that the company has a delegation of authorities document(s) and system(s) governing approval and reporting limits and levels, including its own delegated authority levels to the Board Committees and the CEO.	4.23
31. The Board maintains close oversight and operations and financial aspects of the Company.	4.38
32. The Board approves strategic financial and non-financial objectives and policies and monitors the achievement thereof against approved targets/performance to ensure the efficiency and effectiveness of the Company.	4.38
33. The Board ensures the recruitment and retention of high potential and high performance key employees (through the CEO and Management).	4.23
34. The Board ensures that there is a professional development programs for employees and officers and provides for a succession plan for senior management that the Board reviews.	4.31
RESOURCES	
35. The Board members have access to Management and independent professional advice to enable them to discharge their duties.	4.31
36. The Corporate Secretary has the primary role of supporting the Board and Chairperson.	4.00
MONITORING - MEETINGS	
37. The Board schedules and holds regular meetings and convenes special meetings when required by business exigencies.	4.62
38. At least one independent director is always in attendance in all Board meetings.	4.62
39. The Board holds sessions with the non-management/non-executive and independent directors (excluding management/executive directors) at least once a year and as such other times as the Board may deem necessary or appropriate.	4.15
40. There is active solicitation of views and opinions of the members of the Board in the process of arriving at a decision.	4.15
41. The Board uses an annual calendar to plan meetings, address issues and align with planning and reporting cycles.	4.31
42. The Board meetings are duly minutes.	4.85
43. The minutes of Board meetings are clear and useful.	
44. The Board receives in a timely manner the right information it needs to fulfill its responsibilities.	4.38
MONITORING -PERFORMANCE ASSESSMENT	
45. The Board ensures that there are mechanisms to monitor its performance and that of its Committees and individual members.	4.23
46. The Board really knows how well it and its Committees are fulfilling their responsibilities and achieving their objectives.	4.15
47. The Board operates smoothly and effectively as a team.	4.31
48. The Board has its own succession and development plans which reflect the results of performance evaluations.	4.15
49. The Board has an effective ongoing development programs for directors and Board Committee members.	4.31
50. Overall, the Board and the Board Committee are contributing to the success of the Company.	4.38
REPORTING AND DISCLOSURES	
51. The Company has a clear policy on communicating or relating with its various shareholders	4.46

52. The Board regularly and timely reviews, approves and communicates the financial reports, key corporate activities and other material disclosures and statements of the Company to its stakeholders.	4.38
53. The Board asks probing and informed questions of management about the Company's results of operations and disclosures.	4.23
54. The Board promotes and ensures a culture of openness and transparency in the Company.	4.31
SHAREHOLDER BENEFITS	
55. The Board ensures that the Company has an existing mechanism which promotes stockholders' rights.	4.46
56. The Company has in place an investor relations program that will keep stockholders and investors informed of important developments in the Company.	4.62
57. The Board ensures that the Company implements steps to facilitate stockholders' participation in annual or special meetings of stockholders.	4.38
58. The Board ensures that the Company timely provides stockholders with relevant and timely information prior to such meetings.	4.46
59. The Board ensures transparency and fairness in the conduct of stockholders meetings.	4.38
60. The Chairman of the meeting of stockholders gives stockholders an opportunity to raise their concerns or questions relating to the items in the agenda of the meeting.	4.31

This is to certify that the ratings in this appraisal/performance report are true and correct results of the self-assessment made by the 2025 Board of Directors.

(SGD.) THERESE MARIE A. GERAFIL
Corporate Secretary

ASIA PACIFIC
MEDICAL CENTER
ILOILO

ANNEX "K"

BOARD COMPENSATION REPORT
(January 2025 to December 2025)

The Board's remuneration is supposed to be set at an optimum level to attract and retain competent directors who continuously and effectively deliver services as such. Directors are compensated for missed income opportunities in attending to the affairs of the Corporation. Considering the current financial condition of the Hospital, the salaries and per diems of the Directors for the year 2025 were not disbursed and were nooked as payable, considering the current financial condition of the Hospital, only Executive Directors/Officers received compensation.

.

Name of Director	Year	Reasonable Per Diem Received for the Year
Biron, Ferjenel G.	2025	820,000.00
Lavilla, Meride D.	2025	710,000.00
Regozo, Danilo C.	2025	360,000.00
Villaflor, Agnes Jean M.	2025	360,000.00
Gomez, Lusyl M.	2025	330,000.00
Fernandez, Lemuel T.	2025	360,000.00
Dianco, Felibert O.	2025	330,000.00
Nolasco, Felix P.	2025	330,000.00
Ong, Mary Flor G	2025	360,000.00
Samoro, Fredilyn G.	2025	360,000.00
Suplico, Rolex T.	2025	330,000.00
Belgira, Johanna Marie B.	2025	270,000.00
Lavalle Jr., Amado M.	January 2025- May 2025	150,000.00
Comuelo, Jerusha A	January 2025- May 2025	120,000.00
Debuque Ma. Teresa F.	January 2025- May 2025	90,000.00
Biron, Brandt Luke Q.	June 2025- December 2025	150,000.00
Debuque, Nathalie Ann F.	July 2025- December 2025	210,000.00
Silverio, Lorna C.	June 2025- December 2025	120,000.00

CRIS T. CORTES
Chief Finance Officer
Date: 5/25/24

MARY FLOR G. ONG
Treasurer
Date: 5/25/24

Brgy. Ungka, Jaro, Iloilo City, 500
(033) 339 999
info@apmc-iloilo.com
www.apmc-iloilo.com

ASIA PACIFIC
MEDICAL CENTER
ILOILO

ANNEX "K"

BOARD COMPENSATION REPORT
(January 2026 to April 2026)

The Board's remuneration is supposed to be set at an optimum level to attract and retain competent directors who continuously and effectively deliver services as such. Directors are compensated for missed income opportunities in attending to the affairs of the Corporation. Considering the current financial condition of the Hospital, the salaries and per diems of the Directors for the year 2026 were not disbursed and were nooked as payable, considering the current financial condition of the Hospital, only Executive Directors/Officers received compensation

Name of Director	Year	Reasonable Per Diem Received for the Year
Biron, Ferjenel G.	2026	400,000.00
Lavilla, Meride D.	2026	320,000.00
Regozo, Danilo C.	2026	120,000.00
Villaflor, Agnes Jean M.	2026	120,000.00
Gomez, Lusyl M.	2026	120,000.00
Fernandez, Lemuel T.	2026	120,000.00
Biron, Brandt Luke Q	2026	90,000.00
Dianco, Felibert O.	2026	120,000.00
Nolasco, Felix P.	2026	60,000.00
Ong, Mary Flor G	2026	120,000.00
Samoro, Fredilyn G.	2026	120,000.00
Suplico, Rolex T.	2026	90,000.00
Johanna Marie Belgira B.	2026	30,000.00
Debuque, Nathalie Ann F.	2026	120,000.00
Silverio, Lorna C.	2026	90,000.00

CRIS T. CORTES
Chief Finance Officer
Date: 05/25/26

MARY FLOR G. ONG
Treasurer
Date: 5/25/26

Brgy. Ungka, Jaro, Iloilo City, 500
(033) 339 999
info@apmc-iloilo.com
www.apmc-iloilo.com

ASIA PACIFIC
MEDICAL CENTER
ILOILO

ANNEX "L"

DISCLOSURE ON DIRECTORS' SELF DEALING AND RELATED PARTY TRANSACTIONS

Related Party relationships exist when one party has the ability to control directly or indirectly through one or more intermediaries, the other party, or exercises significant influence over the other party in making financial and operational decisions. Such relationships also exist between and/or among entities that are under common control with the reporting enterprise or between and/or among the reporting enterprise and its key management personnel, directors, or its shareholders. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

As of March 31, 2026, the following are the related party transactions involving the current directors of APMC Iloilo.

Name of Director	Company	Transaction	Amount in Php
Ferjenel G. Biron	Phil Pharmawealth Inc.	Cash Borrowed	Php 544,871,969.21
Ferjenel G. Biron	Endure Medical, Inc.	Importation and acquisition of various furniture & fixtures, and medical/hospital equipment for the company.	Php 194,816,096.28

CRIS T. CORTES
Chief Finance Officer
Date: 3/25/24

MARY FLOR G. ONG
Treasurer
Date: 3/25/24

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

Annex "M"

The following document has been received:

Receiving: DONNA ENCARNADO
Receipt Date and Time: May 19, 2026 08:23:55 PM

Company Information

SEC Registration No.: CS201423954
Company Name: ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
Industry Classification: N85122
Company Type: Stock Corporation

Document Information

Document ID: OST105192026811449370
Document Type: Quarterly Report
Document Code: SEC_Form_17-Q
Period Covered: March 31, 2026
Submission Type: Original Filing
Remarks: None

Acceptance of this document is subject to review of forms and contents

COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2025 December 31
(Fiscal Year Ending-Month and Day)

17-Q (1st Qtr)
(FORM TYPE)

March 31, 2026
(Period Ended Date)

_____
(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any

ASIA PACIFIC
MEDICAL CENTER
ILOILO

REPUBLIC OF THE PHILIPPINES)
CITY & PROVINCE OF ILOILO) S.S.

CERTIFICATION

I, **AGNES JEAN M. VILLAFLOR** of **Asia Pacific Medical Center – Iloilo, Inc. (formerly Allied Care Experts (ACE) Medical Center – Iloilo Inc.)**, with SEC registration number **CS201423954** with principal office at Barangay Ungka, Jaro, Iloilo City, 5000 on oath state:

1) That on behalf of Asia Pacific Medical Center – Iloilo, Inc. (formerly Allied Care Experts (ACE) Medical Center-Iloilo Inc.), I have caused this SEC Form **17-Q 1st Quarter** dated MAY 19 2026 to be prepared;
2) That I read and understood its contents which are true and correct of my own personal knowledge and/or based on true records;
3) That I comply with the requirements set forth in SEC Memorandum Circular No. 18 dated 09 October 2023 and SEC Notice dated 05 March 2025, for a complete and official submission of reports and/or documents through electronic mail and/or through the Electronic Filing and Submission Tool (eFAST) effective 28 March 2025; and
4) That I am fully aware that documents filed online which requires pre-evaluation and/or processing fee shall be considered complete and officially received only upon payment of a filing fee.

IN WITNESS WHEREOF, I hereunto affix my signature this MAY 19 2026, in Iloilo City.

AGNES JEAN M. VILLAFLOR
Affiant

SUBSCRIBED AND SWORN TO before me this MAY 19 2026 at Iloilo City, Philippines, affiant exhibiting her PRC ID #0070893.

ATTY. KRISTAL JOY S. ADORACION
NOTARY PUBLIC
CITY and PROVINCE OF ILOILO
Notarial Commission No. 245 / Valid until 12-31-2026
Roll of Attorneys No. 74[illegible] - 1/24/2025
IBP No. 535575 / 1-4-2026 / Iloilo City
PTR No. 5810238 / 1-5-2026 / Iloilo City
DB OSO Business Center, Blk 5, Lot 6, Bolilao,
Mandurriao, Iloilo City
MCLE Compliance (Signed the Roll of Attorney's January 6, 2023)

Doc. No. 408
Page No. 83
Book No. I
Series of 2026.

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended **31 MARCH 2026**

2. Commission identification number **CS201423954** 3. BIR Tax Identification No: **008-922-703**.

ASIA PACIFIC MEDICAL CENTER (APMC) – ILOILO, INC. (Formerly Allied Care Experts (ACE) Medical Center – Iloilo, Inc.

4. Exact name of issuer as specified in its charter

Iloilo City, Philippines

5. Province, country or other jurisdiction of incorporation or organization

6. Industry Classification Code: [ ] (SEC Use Only)

Brgy. Ungka , Jaro, Iloilo City **5000**

7. Address of issuer's principal office Postal Code

8. Issuer's telephone number, including area code: **(033) 3215748/09175234802**

9. **N.A.**

Former name, former address and former fiscal year, if changed since last report

10. Securities registered pursuant to Sections 8 and 12 of the Code, or Sections 4 and 8 of the RSA

Title of each Class	Number of Shares Outstanding	Amount of Debt
Founder Shares	600	
Common Shares	239,400	
Debt Outstanding		2,399,838,947

11. Are any or all of the securities listed on a Stock Exchange? Yes [ ] No [✓]

If yes, state the name of such Stock Exchange and the class/es of securities listed therein:

12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the Code and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period the registrant was required to file such reports)

Yes [✓] No [ ]

(b) has been subject to such filing requirements for the past ninety (90) days. Yes [✓] No [ ]

TABLE OF CONTENTS

	Page No.
Part I - Financial Information	3
Item 1 – Financial Statements	3
Item 2 – Management's Discussion and Analysis	3
Results of Operations	3
Plan of Operations	4
Statement of Financial Condition	6
Financial Soundness Indicator	8
Trends, Events and/or Uncertainties	9
Part II - Other Information	11
Signatures	12
Annex A – Financial Statement	

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

The Financial Statements (FS) of the Company as of and for the 3 months ended March 31, 2026 is incorporated herein. (see Annex A)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Management Discussions and Analysis (MD&A) or Plan of Operations

I. RESULTS OF OPERATIONS (March 31, 2026 vs. March 31, 2025)

			Horizontal Analysis		Vertical Analysis	
	31-March-26	31-March-25	Inc./(Dec.)	%	31-March-26	31-March-25
Net Revenue	P107,536,458	P82,148,885	25,387,573	30.90%	100.00%	100.00%
Direct Cost	(66,207,525)	(63,974,470)	2,233,055	-3.49%	61.57%	77.88%
Gross profit/(loss)	41,328,933	18,174,415	23,154,518	127.40%	38.43%	22.12%
Other income	2,776,785	816,308	1,960,477	240.16%	2.58%	0.99%
Gross income / (loss)	44,105,718	18,990,723	25,114,995	132.25%	41.01%	23.12%
General and admin expenses	(71,870,856)	(64,381,440)	7,489,416	-11.63%	66.83%	78.37%
Loss from operations	(27,765,138)	(45,390,717)	(17,625,579)	38.83%	25.82%	55.25%
Finance cost	(35,890,364)	(42,918,349)	(7,027,985)	16.38%	33.38%	52.24%
Net Income / (loss) for the period	**(P63,655,502)**	**(P88,309,066)**	**(P24,653,564)**	**27.92%**	**59.19%**	**107.50%**

REVENUE

During the third quarter ending March 31, 2026, Hospital generated Php107.54 million in revenue, net of discounts, representing a 30.90% increase from the previous year's Php82.15 million. This positive trend underscores the hospital's commitment to fostering patient relationships and continuously enhancing its products and services. Hospital's gross revenue of Php122.94 million includes the following services:

- Pharmacy: Php35.91 million (29.21%)
- Room accommodation: Php22.31 million (18.15%)
- Laboratory: Php19.04 million (15.49%)
- Imaging: Php10.96 million (8.91%)
- Central supply room: Php10.69 million (8.70%)
- Pulmonary: Php5.56 million (4.52%)
- Dialysis: Php4.91 million (4.00%)
- Other specialized healthcare services: Php13.56 million (11.03%)

DIRECT COST

Direct costs, directly attributable to patient care, experienced an increase due to factors such as the procurement of medications and supplies, the surge in patient volume, and the requirement for specialized equipment and personnel. For the third quarter concluded on March 31, 2026, Php66.21 million, comprising Php39.71 million in direct hospital supplies and Php26.50 million in direct overheads.

GENERAL AND ADMIN EXPENSES

This account consists of:

	For the 1st quarter periods March		Horizontal Analysis	
	2026	2025	Inc./(Dec.)	%
Salaries and Wages	P23,491,369	P25,710,653	(P2,219,284)	-8.63%
Utilities Expenses	12,563,082	7,829,492	4,733,590	60.46%
Depreciation	11,948,988	11,578,310	370,678	3.20%
Professional Fees	5,761,241	4,561,761	1,199,480	26.29%
SSS, PHIC and HDMF Contributions	3,852,257	4,121,398	(269,141)	-6.53%
Security Services	3,043,597	2,628,907	414,690	15.77%
Office Supplies	2,642,211	1,487,591	1,154,620	77.62%
Housekeeping Expense	1,898,531	2,870,819	(972,288)	-33.87%
Repairs and Maintenance Expenses	883,183	256,136	627,047	244.81%
Taxes and Licenses	643,111	1,620,623	(977,512)	-60.32%
Communication Expenses	393,281	174,399	218,882	125.51%
Training, Workshop, Seminar	277,750	112,694	165,056	146.46%
Transportation and Travel Expenses	112,756	350,658	(237,902)	-67.84%
Entertainment and Representation Expenses	111,836	45,849	65,987	143.92%
Board meetings and conferences	15,000	-	15,000	100.00%
Advertising Expenses	-	9,585	(9,585)	-100.00%
Miscellaneous Expenses	4,232,663	1,022,565	3,210,098	313.93%
TOTAL	**P71,870,856**	**P64,381,440**	**P7,489,416**	**11.63%**

General and administrative expenses for the 1st quarter ending March 31, 2026, amounted to Php71.87 million, a 11.63% increase from the previous year's Php64.38 million. This substantial increase reflects core business operations expenses, including salaries and wages (Php23.49 million), utilities (Php12.56 million), depreciation (Php11.94 million), professional consultancy fees (Php5.76 million), housekeeping and security services (Php4.94 million), taxes and license fees (Php0.64 million), and other expenses (Php 12.54 million). The significant increase in depreciation expenses is attributed to the building amounting to Php9.19 million as of March 31, 2026.

Other Income

Other income is mostly derived from interest income earned from bank; affiliation fee and other miscellaneous income amounted to Php2,174; and Php2.77 million, during the first quarter period ending March 31, 2026, respectively.

Finance Costs

This consists of interest expenses incurred on bank and related party loans. For the 1st quarter ended March 31, 2026, bank loans incurred Php18.98 million in interest, while related party loans incurred Php16.91 million.

Net Losses for the Period

Despite its financial deficit, the hospital encountered challenges during the first quarter of 2026. To sustain its operations, it requires an increase in patient admissions and collaborates with affiliated physicians for referrals and marketing initiatives. We remain optimistic about overcoming these obstacles and delivering exceptional hospital services.

II. PLAN OF OPERATION

Asia Pacific Medical Center–Iloilo, Inc. ("APMC Iloilo" or the "Hospital") incurred net losses during the last two (2) fiscal years. Management attributes such losses primarily to the Hospital's early-stage operating profile following inauguration, the fixed costs inherent in hospital operations, the gradual build-up of patient volumes, and the continuing expenditures necessary to support personnel, equipment, utilities, and other operational requirements.

Management notes that, based on industry experience and as observed by the Hospital's independent auditor, healthcare institutions of similar scale typically require approximately four (4) to five (5) years from inauguration to recover initial capital expenditures and attain more stable operating levels. In this regard, management believes that the Hospital's financial performance to date remains generally consistent with the expected development period of a newly established hospital facility.

During the current year, the Hospital recorded a 47% increase in gross revenues compared to the previous year. Management believes that this growth is aligned with internal projections and reflects continued improvement in patient volumes, service utilization, physician referrals, and market awareness within the City and Province of Iloilo. Although the Hospital has not yet attained profitability, management considers the current revenue growth trend to be a positive indicator of its ongoing operational development.

For the next twelve (12) months, the Hospital's plan of operation shall focus on: (i) increasing patient volumes and revenues, (ii) improving operating efficiency and expense management, (iii) strengthening liquidity and collections, and (iv) supporting operations and future growth through additional capitalization.

Management's principal operating objectives are to:

1. Increase patient volumes in major service lines, including inpatient, outpatient, emergency, surgery, women's health, pediatrics, diagnostics, laboratory, imaging, and ancillary services;
2. Improve utilization of existing facilities, equipment, and manpower;
3. strengthen referral relationships with physicians, clinics, and healthcare providers in Iloilo and nearby areas;
4. Improve billing, claims processing, and collection efforts, particularly for government healthcare programs, HMOs, corporate accounts, and self-pay patients;
5. Implement cost management measures, including tighter control over operating expenses, inventory, manpower, and non-essential expenditures; and
6. Preserve liquidity through internally generated cash flows, working capital management, and, when necessary, capital-raising or financing initiatives.

As part of its capital strengthening measures, management intends to recommend an increase in the Hospital's authorized capital stock, subject to approval by the Board of Directors and stockholders. The Hospital also plans to pursue a second round of public offering of its shares, subject to compliance with the requirements of the Securities and Exchange Commission and other applicable regulatory approvals.

Management believes that, if successfully implemented, these capital measures will provide additional resources to support operations, strengthen the Hospital's balance sheet, and fund priority investments. However, there can be no assurance that such capital-raising initiatives will be completed within the expected timeframe.

The Hospital likewise intends to continue prioritizing the development of its core revenue-generating departments while exercising prudent control over operating costs and limiting capital expenditures to those necessary for patient care, operational continuity, compliance, and selected service improvements. Currently, the Company employs approximately seven hundred fifty six (756) individuals. The decision to hire additional employees will be contingent upon the outcome of the upcoming hospital census.

Management recognizes that the execution of its plan of operation remains subject to various risks and uncertainties, including competitive conditions, cost inflation, staffing constraints, reimbursement and collection delays, regulatory developments, and broader economic conditions. While there can be no assurance that the Hospital will achieve profitability within the next twelve (12) months, management believes that its current revenue growth trend and planned capital measures provide a reasonable basis for the continuation of operations and the gradual improvement of financial performance.

The Company intends to purchase the following equipment to attract more patients:

1. Pet scan
2. Cath lab Machine
3. Mechanical Ventilators (High-End With Advanced Modes) -Avea (3IN1 Ventilator)
4. Cyber Ho Magneto System 152W Holmium: YAG Surgical Laser System
5. Hospital Waste Management Plant
6. Sonomammography
7. M822 Leica Microscope
8. Portable Ultrasound(Ge)
9. Mammo(Ui)2D
10. KW ON-Grid Rooftop Solar
11. Alcon Centurion Phacoemulsification Machine

12. 2D Echo Vivid T9 (GE)
13. Ultrasound LOGIQ P8 (GE)
14. Cardiac Rehab System
15. Polysomnography Machine (Sleep Machine)
16. NCV/EMG
17. EEG
18. Infusion Pump
19. Super Inductive System BTL-6000
20. Syringe Pump
21. Sewage Treatment Plant
22. Bone Densitometry
23. Treadmill (GE)
24. Biosafety Cabinet Class III
25. Calibration Tools
26. ECG Machine (GE)
27. Detecto Weighing Scale
28. Ortho Table
29. Fracture Bed

These are expected to enhance service capacity and support the Hospital's operational and revenue growth objectives, subject to funding availability.

III. STATEMENT OF FINANCIAL CONDITION (March 31, 2026 VS. December 31, 2025)

			Horizontal Analysis		Vertical Analysis		
ASSETS	31-March-26	31-Dec-25	Inc./(Dec.)	%	31-March-26	31-Dec-24	
CURRENT ASSETS							
Cash	P26,414,935	P23,296,041	3,118,894	13.39%	0.96%	0.86%	[I.II]
Receivables	192,816,543	165,796,569	27,019,974	16.30%	7.04%	6.11%	[I.II]
Advances to contractors and suppliers	89,868,430	72,449,059	17,419,371	24.04%	3.28%	2.67%	[I.II]
Medical and hospital supplies inventories	47,935,244	59,994,528	(12,059,284)	-20.10 %	1.75%	2.21%	[I.II]
Prepayments and other current assets	33,109,906	28,714,938	4,394,968	15.31%	1.21%	1.06%	[I.II]
TOTAL CURRENT ASSETS	**390,145,058**	**350,251,135**	**39,893,923**	**11.39%**	**14.24%**	**12.90%**	[I.II]
NON-CURRENT ASSETS							
Property and equipment (net)	**2,342,868,883**	**2,357,222,256**	**(14,353,373)**	**-0.61%**	**85.51%**	**86.84%**	[I.I]
Advances to related parties	**6,950,256**	**6,950,256**	**-**	**0.00%**	**0.25%**	**0.26%**	
TOTAL NON-CURRENT ASSETS	**2,349,819,139**	**2,364,172,512**	**(14,353,373)**	**-0.61%**	**85.76%**	**87.10%**	[I.I]
TOTAL ASSETS	**2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	[I]
LIABILITIES AND EQUITY							
CURRENT LIABILITIES							
Accounts payable and other liabilities	**717,399,179**	**689,539,570**	**27,859,609**	**4.04%**	**26.18%**	**25.40%**	[II]
Loans payable to individuals	**91,589,939**	**15,703,226**	**75,886,713**	**483.26 %**	**3.34%**	**0.58%**	[II]
Notes payable - current portion	**227,010,404**	**191,558,072**	**35,452,332**	**18.51%**	**8.29%**	**1.66%**	[II]
TOTAL CURRENT LIABILITIES	**1,035,999,522**	**896,800,868**	**139,198,654**	**15.52%**	**37.81%**	**27.64%**	
NON-CURRENT LIABILITIES							
Notes payable - net of current portion	757,790,363	954,351,037	(50,002,602)	-6.19%	27.66%	35.16%	[II]
Loans payable to related party	**544,871,969**	**544,871,969**	**-**	**0.00%**	**19.89%**	**20.07%**	[II]
Deferred tax liability	**61,177,093**	**61,177,093**	**-**	**0.00%**	**2.23%**	**2.25%**	[II]
TOTAL NON-CURRENT LIABILITIES	**1,363,839,425**	**1,560,400,099**	**(50,002,602)**	**-3.54%**	**49.78%**	**55.23%**	
TOTAL LIABILITIES	**2,399,838,947**	**2,310,642,895**	**89,196,052**	**3.86%**	**87.59%**	**82.87%**	[II]
EQUITY							
Share Capital (net)	**240,000,000**	**240,000,000**	**-**	**0.00%**	**8.76%**	**8.84%**	
Share Premium	**958,532,662**	**958,532,662**	**-**	**0.00%**	**34.98%**	**35.31%**	
Revaluation surplus	183,531,277	183,531,277	-	0.00%	6.70%	6.76%	
Retained Earnings/(Deficit)	(1,041,938,689)	(978,283,187)	(63,655,502)	6.51%	-38.03%	-36.04%	
TOTAL EQUITY	**340,125,250**	**403,780,752**	**(63,655,502)**	**-15.76 %**	**12.41%**	**17.13%**	[III]
TOTAL LIABILITIES AND EQUITY	**P2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	

Assets

[I]	**Assets**	As of the first quarter period ending March 31, 2026, the Company's assets have exhibited a consistent growth trajectory. This growth is primarily attributed to the strong performance of essential financial assets, including cash, receivables, and hospital supplies. These assets are necessary for ensuring patient care and optimizing operational efficiency. As of March 31, 2026, the Company's total assets were Php2.74 billion, with Php0.39 billion (14.24%) in current assets and Php2.34 billion (85.76%) in non-current assets.
[I.I]	**Non-Current Assets**	The Company's non-current assets consisted of the following: **Property and Equipment, Net of Depreciation** As of March 31, 2026, this account consists of the land with revalued carrying amount of Php273.00 million, Building - Php1,753.77 billion, medical equipment - Php238.97 million, hospital equipment - Php50.05 million, kitchen tools - Php15.22 million, hospital vehicles - P5.76 million, and office equipment - Php6.10 million. During the year, the Company had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026, by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. **Advances to Related Party** Advances to related parties have no movement as of March 31, 2026

[I.II]	**Current Assets**	**The current assets consist of the following:** **Cash and Cash Equivalents** The surge in cash and cash equivalents is attributable to collections from its revenue streams. The hospital consistently encounters substantial increments in patient volume and revenue generation. Despite commencing operations, it encountered challenges, including escalating patient admissions to sustain daily operations and relying on its affiliate physicians for referrals. Furthermore, the hospital engaged in marketing and promotional endeavors to attract potential patients. It remains optimistic about overcoming these challenges as it continues to provide hospital services to the public. **Medical and Hospital Supplies Inventories** As of March 31, 2026, the inventory account comprises general hospital maintenance supplies; medical and laboratory supplies; and drugs and medicines, amounting to Php21.53 million, Php19.26 million, and Php7.15 million, respectively. **Trade and Other Receivables** The hospital's trade and other receivables indicate a positive financial position, although cash payments have not yet been received. Several factors contribute to this delay, including the billing methods employed for patients, the payment processes of insurance companies, and the payment arrangements made by patients for their medical care. As of March 31, 2026, the hospital's trade and other receivables encompass funds from PHIC (Php72.92 million), HMOs (Php55.10 million), Government Institutions (Php44.23 million), and other sources (Php20.57 million). Refundable deposits, including Php5.00 million to MORE POWER Corporation, Php15,000 to Iloilo Medical Society for office rent, and Php20,000 for drug testing services from the Department of Health, have been reclassified to the other receivable, current assets account. These deposits are expected to be applied for or recovered as per the agreements and regulatory requirements. **Advances to contractors and suppliers** Advances to contractors and suppliers. Advances to contractors are recognized as a benefit for each project awarded and are liquidated through deduction, on a pro-rata basis, from the contractor's periodic progress billings. As a result of the building's completion, there was no material movement to this account as at March 31, 2026. Advances to suppliers increased by Php17.42 million (24.04%), representing down payments made to various hospital suppliers as at March 31, 2026. **Prepayments and other Current Assets** The account represents the unutilized cost of insurance amounted to Php0.82 million, Php24.34 million for the excess of input over output VAT and the carryover of input VAT from previous periods, and prepaid income tax of Php7.94 million, as at March 31, 2026.

[II]	**Liabilities**	**Accounts Payables and Other Liabilities** This account consists of the following: Accounts payable - contractors and suppliers amounting to Php368.59 million; Retention Payable amounting to Php40.56 million; Accrued Interest Payable Php172.20 million; and other payables amounting to Php136.05 million. **Loans Payable to Related Parties** These are loans extended by Phil Pharmawealth, Inc. (PPI) to the Company. As of December 31, 2024, the balance stands at P544.87 million. These loans were granted to help pay off company obligations. **Loans from Individuals** These are loans provided to the Company to help in the construction of the hospital building and sustain its operations. These are gradually liquidated whenever funds are available. As of March 31, 2026, the balance amounted to Php91.59 million. **Notes Payable (LBP)** In 2023, Landbank of the Philippines, approved the restructuring of the total outstanding balance of term loan 1, 3 and 4 in the amount of Php985,594,306 up to seven (7) years from date of effectivity with one (1) quarter grace period on principal and interest. In 2024, it approved Term Loan 6 and a Working Capital Line for P70 million and P30 million, respectively. As at March 31, 2026, the outstanding balance amounted to Php984.80 million and interest expense incurred amounted to Php18.98 million. **Deferred Tax Liabilities** This account represents the recognized deferred tax liability on revaluation resulted from the conducted land appraisal.
[III]	**Equity**	The Company's land was appraised in 2026 by Cubing Surveying, an SEC-accredited professional valuer. The appraisal report, issued on March 9, 2026, used the Sales Comparison Approach based on recent comparable property transactions. As of December 31, 2025, the revaluation resulted in a surplus of Php244,708,370. As of March 31, 2026, the total equity stood at Php340.13 million, a decrease of Php63.66 million (15.76%) resulting from the loss incurred during the quarter.

IV. FINANCIAL SOUNDNESS INDICATOR (March 31, 2026 VS December 31, 2025)

Key Performance Indicators

	Definition	31-March-26	31-Dec-25	Remarks
1. Liquidity				
Quick Asset Ratio	$\frac{\text{Cash + Receivables}}{\text{Current Liabilities}}$	0.21:1	0.21:1	During the first quarter of its operations in 2026, the hospital encountered an elevated level of trade and other receivables. This suggests that the hospital has generated revenue but has not yet received cash payments due to billing processes, insurance claims, or patient payment arrangements. Additionally, current liabilities have experienced significant increase. The rise in current liabilities can be attributed to the recognized current portion of the long-term bank loan and advances from the stockholders to be utilized for operational purposes. Consequently, strategies have been implemented to optimize cash collection, thereby enhancing the company's access to funds and facilitating its timely payment of debts.
Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	0.38:1	0.39:1	During the first quarter of its operations in 2026, the hospital experienced an increase in patient volume and revenue, which resulted in a decrease in its current asset ratio compared to the previous year. This reduction can be attributed to an increase in receivables and current liabilities. While the hospital has generated revenue, it has not yet received cash payments due to billing processes, insurance claims, or patient

				payment arrangements. Additionally, current liabilities have significantly increased. This rise in current liabilities can be attributed to the recognition of the current portion of the long-term bank loan and advances from stockholders intended for operational purposes. In response to these challenges, the hospital has implemented strategies to optimize cash collection, thereby improving its access to funds and ensuring timely payment of debts.
2. Solvency				
Debt to Equity Ratio	$\frac{\text{Long Term Debt}}{\text{Equity}}$	4.01:1	3.50:1	The rise in long-term debt is attributed to additional loans granted to the hospital, while the revenue generated from sales has not yet been sufficient to cover the expenses incurred in the monthly operations.
3. Profitability				
Net Profit Margin	$\frac{\text{Net Income}}{\text{Total Revenue}}$	0.00	0.00	While sales growth has been favorable, operational expenses have experienced an increase. Undeterred by these challenges, the hospital maintains optimism about surmounting them in the forthcoming years and providing exceptional healthcare services to our community.
Return on Equity	$\frac{\text{Net Income}}{\text{Stockholder's Equity}}$	0.00	0.00	Stockholders can expect to earn returns on their investment after the hospital generates net income.
4. Leverage				
Debt to Total Asset Ratio	$\frac{\text{Total Liabilities}}{\text{Total Asset}}$	0.88:1	0.85:1	There has been a slight increase in total liabilities compared to total assets. The hospital is still in debt to Land Bank for loans used for constructing the building and acquiring state-of-the-art medical equipment. The increase in liabilities also includes current liabilities.
Asset To Equity Ratio	$\frac{\text{Total Asset}}{\text{Equity}}$	8.06:1	6.72:1	This increase in the ratio indicates that a substantial portion of the hospital's assets, including the most recent medical equipment, the hospital's buildings, and its infrastructure, is being financed through loans and borrowing.
5. Interest Rate Coverage Ratio	$\frac{\text{Earnings Before Interests \& Taxes}}{\text{Interest Expense}}$	0.00	0.00	An increase in the Interest Coverage Ratio (ICR) can be attributed to the company's efforts in timely payments and effective debt management throughout the year.

Trends, Events or Uncertainties that have had or that are reasonably expected to affect revenues or income

As of March 31, 2026:

1. The company's improved quick asset and current ratios reflect enhanced liquidity, primarily due to increased collections from patient admissions and receivables from PhilHealth and other government agencies such as DSWD and PCSO. While the hospital remains operational, it continues to face initial challenges, including the need to boost patient admissions, reduce reliance on affiliate doctors for referrals, and strengthen marketing efforts to expand its patient base. Management remains optimistic that these issues will be addressed in the coming quarters through ongoing service enhancements and operational strategies. There are no seasonal aspects that had any material impact on the financial condition or results of operations of the Company.
2. There are no events or any default or acceleration of an obligation that will trigger direct or contingent financial obligation that is material to the Company.
3. There are no off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the Company with unconsolidated entities or other persons created during the period.
4. A complaint was filed against Allied Care Experts Medical Center-Valenzuela, Allied Care Experts Medical Center-Pateros, Allied Care Experts Medical Center-Baypointe, Allied Care Experts Medical Center–Quezon City, Allied Care Experts (ACE) Medical Center-Baliwag and Asia Pacific Medical Center-Iloilo (formerly Allied Care Experts Medical Center-Iloilo) before the Insurance Commission (IC) for engaging in pre-need activities without license. Ferdinand Kionisala declared that the benefits and privileges enjoyed by him or offered by any of the named respondents he impleaded in his complaint is not a pre-need contract, agreement, deed, nor plan contemplated under the law and that ACEMC-Cebu or any other respondent named (which include ACEMC-Iloilo) are not engaged in pre-need business, hence not required to secure a separate license therefor before the Insurance Commission. Kionisala filed a Motion for Reconsideration dated 25 November 2020 but was denied. Later on, he filed a special civil action for Certiorari under Rule 65 before the Court of Appeals alleging that the Insurance Commission acted with grave abuse of discretion amounting to lack or excess of jurisdiction. In his petition dated 04 February 2022, Mr. Kionisala prayed that the Court of Appeals set aside the letter dated 11 December 2018 and letter dated 29 November 2021, be nullified and set aside, and that the Insurance Commission be ordered to take appropriate action(s) against the private respondents for violating the Pre-Need Code of the Philippines.

   In a Resolution dated 26 July 2022, the Eighteenth (18th) Division of the Court of Appeals directed the petitioners to rectify the infirmity observed in the petition within an inextendible period of ten (10) days from notice, which is the submission of a mere plain photostatic copy of the assailed letter dated 11 December 2018. Petitioner submitted its compliance on 22 September 2022, copy of which was received by APMC Iloilo on 19 October 2022.

   On 01 September 2025, APMC Iloilo received a Resolution dated 05 March 2025, directing the parties to file their respective Comments on the petitioner’s Petition for Certiorari within an inextendible period of ten (10) days from notice. APMC Iloilo subsequently filed its Comment on 11 September 2025.

   As of 31 March 2026, to the knowledge and information of the Company, there are no other pending material legal proceedings that involve APMCI or any of its properties aside from the aforementioned case.

5. The company has no investment on foreign securities.
6. There were material commitments for capital expenditure during the period as disclosed in Note 11 of the financial statements.

PART II – OTHER INFORMATION

There are no additional material information to be disclosed which were not previously reported under SEC Form 17-C

SIGNATURES

Pursuant to the requirements of the Securities Regulation Code, the issuer has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AGNES JEAN M. VILLAFLOR
PRESIDENT
May 19, 2026

CRIS T. CORTES
CHIEF FINANCE OFFICER
May 19, 2026

Asia Pacific Medical Center – Iloilo, Inc.

(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

Unaudited Interim Financial Statements

As of and for the 1st quarter period ended March 31, 2026
(with comparative figures as at December 31, 2025 and for the 1st quarter period ended March 31, 2025)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

STATEMENTS OF FINANCIAL POSITION

AS OF MARCH 31, 2026 AND DECEMBER 31, 2025
(Amounts in Philippine Peso)

ASSETS	*Notes*	**2026 Unaudited**	2025 Audited
CURRENT ASSETS			
Cash	***4,6,26***	**P26,414,935**	P23,296,041
Receivables	***4,7,26***	**192,816,543**	165,796,569
Advances to contractors and suppliers	***4,8***	**89,868,430**	72,449,059
Medical and hospital supplies inventories	***4,9***	**47,935,244**	59,994,528
Prepayments and other current assets	***4,10***	**33,109,906**	28,714,938
		390,145,058	350,251,135
NON-CURRENT ASSETS			
Property and equipment (net)	***4,11***	**2,342,868,883**	2,357,222,256
Advances to related parties	***12,26***	**6,950,256**	6,950,256
		2,349,819,139	2,364,172,512
TOTAL ASSETS		**2,739,964,197**	2,714,423,647
LIABILITIES AND EQUITY			
CURRENT LIABILITIES			
Accounts payable and other liabilities	***4,13,26***	**717,399,179**	689,539,570
Loans payable to individuals	***14,26***	**91,589,939**	15,703,226
Notes payable - current portion	***15,26***	**227,010,404**	191,558,072
		1,035,999,522	896,800,868
NON-CURRENT LIABILITIES			
Notes payable - net of current portion	***15,16***	**757,790,363**	807,792,965
Loans payable to a related party	***12***	**544,871,969**	544,871,969
Deferred tax liability	***16,18***	**61,177,093**	61,177,093
		1,363,839,425	1,413,842,027
TOTAL LIABILITIES		**2,399,838,947**	2,310,642,895
EQUITY			
Share capital (net)	***4,17***	**240,000,000**	240,000,000
Share premium	***4,17***	**958,532,662**	958,532,662
Revaluation surplus	***16,18***	**183,531,277**	183,531,277
Deficit	***4,26***	**(1,041,938,689)**	(978,283,187)
TOTAL EQUITY		**340,125,250**	403,780,752
TOTAL LIABILITIES AND EQUITY		**P2,739,964,197**	P2,714,423,647

296

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS

FOR THE PERIODS ENDED MARCH 31, 2026 AND 2025

(Amounts in Philippine Peso)

	Notes	**2026**	2025
REVENUE	***4,19***	**P107,536,458**	P82,148,885
DIRECT COST	***4,20***	**66,207,525**	63,974,470
GROSS INCOME		**41,328,933**	18,174,415
OTHER INCOME	***4,6,21***	**2,776,785**	816,308
GROSS INCOME		**44,105,718**	18,990,723
GENERAL AND ADMINISTRATIVE EXPENSES	***4,22***	**71,870,856**	64,381,440
LOSS FROM OPERATIONS		**(27,765,138)**	(45,390,717)
FINANCE COSTS	***12,15***	**(35,890,364)**	(42,918,349)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(P63,655,502)**	(P88,309,066)

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

UNAUDITED STATEMENTS OF CHANGES IN EQUITY
AS OF MARCH 31, 2026
(Amounts in Philippine Peso)

	Share Capital (Note 16)	Share Premium (Note 16)	Revaluation Surplus (Note 17)	Deficit (Note 1)	Total
EQUITY					
As at January 1, 2024	P239,960,000	P953,896,162	P -	(P345,203,042)	P848,653,120
Proceeds from subscription receivable	-	3,476,500	-	-	3,476,500
Net loss for the period	-	-	-	(397,759,075)	(397,759,075)
As of December 31, 2024	239,960,000	957,372,662	-	(742,962,117)	454,370,545
Additional share capital	40,000	-		-	40,000
Share premium	-	1,560,000	-	-	1,560,000
Subscription receivable	-	(400,000)	-	-	(400,000)
Appraisal increase (Land)	-	-	183,531,277	-	183,531,277
Net loss for the year	-	-	-	(235,321,070)	(235,321,070)
As of December 31, 2025	**240,000,000**	**958,532,662**	**183,531,277**	**(978,283,187)**	**403,780,752**
Additional share capital	-	-	-	-	-
Share premium	-	-	-	-	-
Subscription receivable	-	-	-	-	-
Appraisal increase (Land)	-	-	-	-	-
Net loss for the year	-	-	-	**(63,655,502)**	**(63,655,502)**
As of March 31, 2026	**P240,000,000**	**P958,532,662**	**P183,531,277**	**(P1,041,938,689)**	**P340,125,250**

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

UNAUDITED STATEMENTS OF CHANGES IN EQUITY
FOR THE PERIODS ENDED MARCH 31, 2026, DECEMBER 31, 2025 and 2024

	Notes	**2026**	**2025**	2024
CASH FLOWS FROM OPERATING ACTIVITIES				
Net loss before income tax		**(P63,655,502)**	**(P235,321,070)**	(P397,759,075)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:				
Depreciation	***4,11***	**38,255,815**	**150,719,634**	148,272,068
Interest income	***4,6,21***	**(2,175)**	**(1,002)**	(2,106)
Unrealized foreign exchange gain/(loss)	***4,6,21***	**-**	**3,505**	(310,228)
Interest expense	***4,15***	**35,890,364**	**136,010,582**	(155,699,208)
Operating cashflows before changes in working capital		**10,488,502**	**51,411,649**	(405,498,549)
Changes in working capital components:				
Decrease (increase) in current assets:				
Receivable	***4,7,26***	**(27,019,974)**	**(83,366,406)**	(69,436,588)
Advances to contractors and suppliers	***8***	**(17,419,371)**	**(24,872,330)**	10,587,407
Medical and hospital inventories	***9***	**12,059,284**	**15,667,861**	(72,952,625)
Prepayments and other current assets		**(4,394,968)**	**(10,641,610)**	(14,036,648)
Increase (decrease) in current liabilities:				
Accounts payable and other liabilities		**3,427,087**	**160,075,552**	229,246,192
Net cash provided/(used in) operations		**(22,859,440)**	**108,274,716**	(322,090,811)
Income tax paid	***20***	**-**	**(1,260,617)**	(953,920)
Interest received	***6,19,21***	**2,175**	**1,002**	2,106
Net cash provided/(used in) operating activities		**(22,857,265)**	**107,015,101**	(323,042,625)

Balance forwarded

	Notes	As at period ended March 31 and December 31, 2026	2025	2024
CASH FLOWS FROM INVESTING ACTIVITIES				
Additions to construction-in-progress	*11*	-	-	1,900,987,351
Additions to property and equipment	*4,11*	**(23,902,442)**	**(24,572,572)**	(1,859,376,138)
Other non-current assets	13,27	-	-	(20,000)
Net cash provided/(used in) investing activities		**(23,902,442)**	**(24,572,572)**	41,611,213
CASH FLOWS FROM FINANCING ACTIVITIES				
Advances to related parties	*12,26*	-	32,079,869	-
Payments of loans payable to individuals	*14,26*	**(5,700,000)**	-	(4,639,474)
Proceeds from bank loans	*15*		30,000,000	-
Payments of principal on bank loans	*15,26*	**(14,550,270)**	(1,243,269)	(15,000,000)
Proceeds of loans payable to a related party	*15*		1,000,000	150,437,000
Additional share capital	*4, 17*		40,000	-
Advances from shareholders		**81,586,713**		
Proceeds from subscription receivable	*4,17*		1,160,000	3,476,500
Interest paid	*4,15*	**(11,457,842)**	(136,010,582)	155,699,208
Net cash provided/(used in) by financing activities		**49,878,601**	(72,973,983)	289,973,234
NET EFFECT OF EXCHANGE RATE	*4,6,21*	-	(3,505)	310,228
NET INCREASE/(DECREASE) IN CASH		**3,118,894**	9,465,042	8,832,050
CASH, beginning of the year		**23,296,041**	13,830,999	4,998,949
CASH, end of the year	*6*	**P26,414,935**	P23,296,041	P13,830,999

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.

NOTES TO FINANCIAL STATEMENTS
As of and for the years ended March 31, 2026, 2025 and 2024
(Amounts in Philippine Peso)

NOTE 1 - CORPORATE INFORMATION AND STATUS OF OPERATIONS

Corporate Information

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC. (the "Company") was incorporated as a domestic corporation under Philippine laws and was duly registered with the Securities and Exchange Commission (SEC) under registration no. CS201423954 on December 10, 2014.

The Company's primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and businesses such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinics, condo-hospitals, scientific research institutions and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional, medical or surgical services shall be performed by duly qualified and licensed physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The Company is a duly registered Board of Investment (BOI) - Accredited "New Operator of General Hospital" at Level 2 Category on a Non-Pioneering Status with Certificate of Registration No. 2023-065 in accordance with the provisions of the Omnibus Investment Code of 1987 (Executive Order No. 226) and pursuant to Title XIII of the Tax Code of 1997, as amended by Republic Act 11534, or the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.

The Certification entitles the Company to certain major incentives, to wit: (1) Income Tax Holiday (ITH) for six (6) years, Enhanced Deductions for five (5) years and (3) Duty exemptions for eleven (11) years. The Company should have started commercial operations in January 2023 (or within three (3) years from date of registration with the BOI) but availment shall in no case commence earlier than the date of registration with BOI.

The Company was granted by the Philippine Health Insurance Corporation of certificate of accreditation as a Level 2 Hospital (Accredited Beds: 100) which was granted on 6th day of January 2025 the certificate of which shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Philippine Hospital Association of certificate of membership as a Level 2 Hospital (Accredited Beds: 100) on 20th day of December 2024 and this certificate shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Department of Health, as a Level 2 Hospital (Accredited Beds: 100), with license number 06-0023-25-H2-2 and this license to operate shall be valid from January 1, 2025 to December 31, 2025.

On August 2, 2021, and in accordance with the approval of the appropriate regulatory authorities, including the Securities and Exchange Commission, the Company amended its corporate name from Allied Care Experts (ACE) Medical Center – Iloilo, Inc. to Asia Pacific Medical Center – Iloilo, Inc. The change in corporate name did not result in any change in the Company's legal personality, ownership structure, operations, or principal activities. Accordingly, all rights, obligations, contracts, and commitments previously entered into under the former corporate name remain valid and enforceable and are deemed to continue under the Company's new registered corporate name.

The registered office is located at Barangay Ungka, Jaro, Iloilo City, where the hospital construction site is located.

Status of Operations

The Company commenced full commercial operations of its multi-disciplinary medical facility in 2024. The hospital provides a comprehensive range of services, including in-patient and out-patient care, as well as emergency medical services. Since the start of operations, the respective revenue centers have been activated and progressively scaled to achieve full operational capacity and status.

The activation of these revenue centers reflects the hospital's transition from development to full service delivery, enabling the facility to generate revenues across its core medical disciplines. The commencement of operations in 2024 marked a significant milestone in the Company's strategy to expand its healthcare services and establish a sustainable platform for long-term growth.

The hospital healthcare system is a highly specialized and capital-intensive undertaking. Establishing a multi-disciplinary medical facility requires substantial and sustainable infrastructure investments, which typically take an average of five (5) to seven (7) years after incorporation to complete construction and inaugurate its business line services.

Given the peculiarities of the industry, it generally requires an additional four (4) to five (5) years after inauguration to recover initial capital expenditures and achieve full commercial operations. This extended timeline reflects the scale of investment, the complexity of healthcare infrastructure, and the gradual ramp-up of patient volumes and service utilization.

Against this backdrop, Management is encouraged by the Company's performance. The 47% increase in gross revenues during the current year is well aligned with its projections and demonstrates strong progress toward achieving full competitive status among hospitals in the area. This growth affirms the Company's trajectory toward recovering its initial investments, strengthening its market position, and establishing a sustainable platform for long-term expansion in the healthcare sector.

Management expects continued growth driven by:

- Increasing patient volumes as the hospital builds its reputation and expands its catchment area.
- Diversification of medical services, including specialized care units and advanced diagnostic facilities.

- Operational efficiencies from scaling up revenue centers and optimizing healthcare delivery.
- Competitive positioning within the region, supported by the hospital's modern infrastructure and comprehensive service offerings.

These factors are expected to support the Company's long-term objective of achieving sustainable profitability and securing a strong competitive presence in the healthcare industry.

Management remains confident that the hospital is well-positioned to deliver sustainable healthcare services and long-term value to stakeholders.

Authorization for Issuance of the Financial Statements

The financial statements of the Company as at and for the year ended December 31, 2025, including its comparative figures as at 2024 and 2023, were approved and authorized for issuance by the Board of Directors on April 7, 2026.

NOTE 2 - FINANCIAL REPORTING FRAMEWORK AND BASIS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS

Statement of Compliance

Basis of Preparation

The financial statements of the Company have been prepared in compliance with the Philippine Financial Reporting Standards (PFRS) Accounting Standards which are based on International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB). PFRS consist of PFRS, Philippine Accounting Standards (PAS), and Philippine Interpretations issued by the Financial and Sustainability Reporting Standards Council (FSRSC) and the Board of Accountancy (BOA) and adopted by the Securities and Exchange Commission (SEC).

Basis of Measurement

The financial statements have been prepared under the historical cost basis, unless otherwise stated.

Functional and Presentation Currency

These financial statements are presented in Philippine Peso (PhP), the currency of the primary economic environment in which the Company operates. All amounts are rounded to the nearest peso, except when otherwise indicated.

NOTE 3 - ADOPTION OF NEW AND REVISED ACCOUNTING STANDARDS AND INTERPRETATIONS

Adoption of New and Revised Accounting Standards Effective in 2025

The Company adopted all applicable accounting standards and interpretations as at December 31, 2025. The new and revised accounting standards and interpretations that have been published by

the International Accounting Standards Board (IASB) and approved by the Financial and Sustainability Reporting Standards Council (FSRSC) in the Philippines, that were assessed by the Management to be applicable to the Company's financial statements are as follows:

Adoption of Amended Standards Effective Beginning on or after January 1, 2025:

The accounting policies adopted are consistent with those of the previous financial year, except for the adoption of the following new and amended Standard which the Company adopted effective for annual period beginning January 1, 2025.

Unless otherwise indicated, the adoption of the new and amended standard did not have any material effect on the financial statements. Additional disclosures have been included in the notes to financial statements, as applicable.

- Amendments to PAS 21, *The Effects of Changes in Foreign Exchange Rates, Lack of Exchangeability* - The amendments specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking.

New and Amended PFRS and PIC Issuances in Issue but Not Yet Effective or Adopted

Unless otherwise indicated, the Company does not expect that the future adoption of the said pronouncements to have a significant impact on the financial statements.

The Company intends to adopt the following pronouncements when they become effective;

Effective beginning on or after January 1, 2026:

- Amendments to Illustrative Examples on PFRS 7, PFRS 18, PAS 1, PAS 8, PAS 26 and PAS 37, *Disclosures about Uncertainties in the Financial Statements*
- Amendments to PFRS 9 and PFRS 7, *Classification and Measurement of Financial Instruments*
- Amendments to PFRS 9 and PFRS 7, *Contracts Referencing Nature-dependent Electricity*
- Annual Improvements to PFRS Accounting Standards – Volume 11
  - Amendments to PFRS, 1, *Hedge Accounting by a First-time Adopter*
  - Amendments to PFRS 7, *Gain or Loss on Derecognition*
  - Amendments to PFRS 9, *Lease Derecognition of Lease Liabilities and Transaction Price*
  - Amendments to PFRS 10, *Determination of a 'De Facto Agent'*
  - Amendments to PAS 7, *Cost Method*

Effective beginning on or after January 1, 2027:

- PFRS 17, *Insurance Contracts* – The standard will replace PFRS 4, Insurance Contracts. It requires insurance liabilities to be measured at current fulfillment value and provides a more uniform measurement and presentation approach to achieve consistent, principle-based accounting for all insurance contracts. It also requires similar principles to be applied to reinsurance contracts held and investment contracts with discretionary participation features issued.

On February 14, 2025, the Financial and Sustainability Reporting Standards Council (FSRSC) has approved the amendment to PFRS 17, Date of Initial application. The amendment further defer the date of initial application of PFRS 17 by an additional two years, to annual periods beginning on or after January 1, 2027.

Under prevailing circumstances, the adoption of the forgoing new and amended PFRS is not expected to have any material effect on the financial statements of the Company. Additional disclosures were included in the financial statements, as applicable.

- PFRS 18, *Presentation and Disclosure in Financial Statements*
- PFRS 19, *Subsidiaries without Public Accountability*
- Amendments to PAS 21, *Translation to a Hyperinflationary Presentation Currency*

Deferred effectivity

- Amendments to PFRS 10, *Consolidated Financial Statements,* and PAS 28, *Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*.

NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING AND FINANCIAL REPORTING POLICIES

The significant accounting policies that have been used in the preparation of these financial statements are summarized below. These policies have been consistently applied to all years presented, unless otherwise stated.

Current versus Noncurrent Classification

The Company presents its assets and liabilities in the statements of financial position based on current/noncurrent classification.

An asset is current when it is:

- expected to be realized or intended to be sold or consumed in the normal operating cycle;
- held primarily for the purpose of trading;
- expected to be realized within twelve months after the reporting period; or
- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as noncurrent.

A liability is current when:

- it is expected to be settled in the normal operating cycle;
- it is held primarily for the purpose of trading;
- it is due to be settled within twelve months after the reporting period; or
- there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company also modifies classification of prior year amounts to conform to current year's presentation.

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability, takes place either:

- in the principal market for the asset or liability; or
- in the absence of a principal market, in the most advantageous market for the asset or liability, the principal or the most advantageous market must be accessible to the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use, or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Financial Instruments

A financial instrument is any contract that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial Recognition and Measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss (FVPL).

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. The Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

In order for a financial asset to be classified and measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss.

The Company's business model for managing financial assets refer to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Financial assets at amortized cost (debt instruments);
- Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instrument);
- Financial assets designated at fair value through OCI with no recycling of cumulative gains or losses upon derecognition (equity instruments); and
- Financial assets at fair value through profit or loss.

Financial assets at amortized cost (debt instruments)

Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.

The Company's financial assets at amortized cost includes cash (excluding cash on hand), receivables and advances to related parties as at reporting date (see Notes 6, 7 and 12).

Financial assets at fair value through OCI (debt instruments)

For debt instruments at fair value through OCI, interest income, foreign exchange revaluation, if any, and impairment losses or reversals are recognized in the statements of profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit and loss.

The Company does not have debt instruments designated at fair value through OCI as at reporting dates.

Financial assets designated at fair value through OCI (equity instruments)

Upon initial recognition, the Company can elect to classify irrevocably its equity instruments as equity instruments designated at fair value through OCI when they meet the definition of equity under IAS 32 – *Financial Instruments: Presentation* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statements of profit or loss when the right of payment has been established, except when the Company benefits from such proceeds as recovery of part of the cost of the financial assets, in which case, such gains are recovered in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Company does not have equity instruments designated at fair value through OCI as at reporting dates.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statements of financial position at fair value with net changes in fair value recognized in the statements of profit or loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognized as other income in the statements of profit or loss when the right of payment has been established.

The Company does not have financial assets at fair value through profit or loss as at reporting dates.

Derecognition

The financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's statements of financial position) when:

- the rights to receive cash flows from the asset have expired, or
- the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risk and rewards of the asset, or (b) the Company has

neither transferred nor retained substantially all the risk and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a 'pass-through' agreement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership. When it has neither transferred nor retained substantially all of the risk and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on the basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Reclassification

The Company reclassifies its financial assets when, and only when, it changes its business model for managing those financial assets. The reclassification is applied prospectively from the first day of the first reporting period following the change in the business model (reclassification date).

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVPL, any gain or loss arising from the difference between the previous amortized cost of the financial asset and fair value is recognized in profit or loss.

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVOCI, any gain or loss arising from a difference between the previous amortized cost of the financial asset and fair value is recognized in OCI.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at amortized cost, its fair value at the reclassification date becomes its new gross carrying amount.

For a financial asset reclassified out of the financial assets at FVOCI category to financial assets at amortized cost, any gain or loss previously recognized in OCI, and any difference between the new amortized cost and maturity amount, are amortized to profit or loss over the remaining life of the investment using the effective interest method. If the financial asset is subsequently impaired, any gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

In the case of a financial asset that does not have a fixed maturity, the gain or loss shall be recognized in profit or loss when the financial asset is sold or disposed. If the financial asset is subsequently impaired, any previous gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at FVOCI, its fair value at the reclassification date becomes its new gross carrying amount. Meanwhile, for a financial asset reclassified out of the financial assets at FVOCI category to financial assets at FVPL, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss as a reclassification adjustment at the reclassification date.

Impairment

The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been significant increase in credit risk since initial recognition, a loss is required for credit expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full or in part before taking into account any credit enhancements held by the Company. A financial asset is written off in full or in part when there is no reasonable expectation of recovering the contractual cash flows.

Write-off

Financial assets are written-off when the Company has no reasonable expectations of recovering the financial asset either in its entirety or a portion of it. This is the case when the Company determines that the borrower does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. A write-off constitutes a derecognition event.

Financial Liabilities

Initial Recognition and Measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognized initially at fair value and in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Subsequent Measurement

The measurement of financial liabilities depends on their classified into two categories:

- Financial liabilities at fair value through profit or loss; and
- Financial liabilities at amortized cost (loans and borrowings).

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss are designated upon initial recognition at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by PFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognized in profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in PFRS 9 are satisfied.

The Company has not designated any financial liability at fair value through profit or loss at the end of each reporting period.

Financial liabilities at amortized cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings and other payables are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as "Finance cost" in the statements of comprehensive loss.

The Company's financial liabilities include accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, notes payable and loans payable to a related party (see Notes 12,14, and 15).

Derecognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statements of comprehensive loss.

Fair Value Option

The Company may, at initial recognition, irrevocably designate a financial asset or liability that would otherwise have to be measured at amortized cost or fair value through other comprehensive loss to be measured at fair value through profit or loss if doing so would eliminate or significantly reduce an accounting mismatch or otherwise results in more relevant information.

Classification of Financial Instrument between Liability and Equity

A financial instrument is classified as liability if it provides for a contractual obligation to:

- Deliver cash or another financial asset to another entity;
- Exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavorable to the Company; or

- Satisfy the obligation other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of own equity shares.

If the Company does not have an unconditional right to avoid delivering cash or another financial asset to settle its contractual obligation, the obligation meets the definition of a financial liability.

Offsetting of Financial Instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

The Company assesses that it has currently enforceable right to offset if the right is not contingent on a future event and is legally enforceable in the event of insolvency or bankruptcy of the Company and all of the counterparties.

Cash

Cash in the statements of financial position comprise of cash in banks and on hand that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value.

Advances to Contractors and Suppliers

Advances represent deposits or down payments (ranging from 25% to 50%) paid to contractors, merchants or broker-agents for specific completion or delivery of contractual obligations or service undertakings, including acquisition of medical machineries or clinical apparatus or equipment and medicinal inventories or supplies. These advances which are already paid but not yet incurred will be recognized either as an asset or an expense upon completion or delivery of such obligations, undertakings or acquisitions.

Medical and Hospital Supplies Inventories

Medical and hospital supplies inventories are initially measured at cost. Cost includes all costs of purchases, cost of conversion and other costs incurred in bringing the medical inventories and hospital supplies to their present location and condition. Medical inventories and hospital supplies are subsequently measured at the lower of cost (net realizable value). Cost is determined using the first-in, first-out (FIFO) method. At each reporting date, medical inventories and hospital supplies are assessed for impairment. If medical inventories and hospital supplies is impaired, the impairment loss is recognized immediately in the statements of comprehensive loss.

Prepayments and Other Current Assets

Prepayments represent expenses not yet incurred but already paid in cash. Prepayments are initially recorded as assets and measured at the amount of cash paid. Subsequently, these are charged to profit or loss as they are consumed in operations or expire with the passage of time.

Other current assets represent assets of the Company which are expected to be realized or consumed within one year or within the Company's normal operating cycle whichever is longer. Other current assets are both measured initially and subsequently presented in the financial statements at cost.

Property and Equipment

Property and equipment are initially measured at cost. The cost of an item of property and equipment consists of:

- its purchases price, including import duties and non-refundable purchases taxes, after deducting trade discounts and rebates; and
- any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent expenditures relating to an item of property and medical and hospital equipment that have already been recognized are added to the carrying amount of the asset when it is probable that future economic benefits, in excess of the originally assessed standard of performance of the existing asset, will flow to the Company. All other subsequent expenditures are recognized as expenses in the period in which those are incurred.

At the end of each reporting period, items of property and equipment except land measured using the cost model are carried at cost less any subsequent accumulated depreciation and impairment losses. Land is carried at cost less any impairment in value. Land is not depreciated.

Land is carried at revalued amounts, being its fair value at the date of revaluation less any subsequent impairment losses. Revaluations are performed with sufficient regularity to ensure that the carrying amount does not differ materially from that which would be determined using fair value at the reporting date. Increases in the carrying amount of land arising from revaluation are recognized in equity under "Revaluation Surplus." Decreases that offset previous increases are charged against the surplus; other decreases are recognized in profit or loss. Land is not depreciated.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, if there is an indication of a significant change since the last reporting date. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

An item of property and equipment shall be derecognized upon disposal or when no future economic benefits are expected from its use or disposal. When assets are derecognized, their costs, accumulated depreciation and amortization and accumulated impairment losses are eliminated from the accounts. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in the statements of comprehensive loss.

Fully depreciated and fully amortized assets are retained by the Company as part of property and equipment until these are derecognized or until they are no longer in use.

Construction-in-progress

Construction-in-progress is stated at cost. This includes the costs related to the construction of the hospital building and installation of medical equipment, property development costs and other direct costs. Cost of borrowings and any additional costs incurred in relation to the project are recognized in this account. Construction-in-progress is not depreciated until such time that the relevant assets are completed and ready for its intended use.

The Company recognizes the effect of revisions in the total project cost estimates in the year in which these changes become known. Any impairment loss from the construction project is charged to operations during the period in which the loss is determined.

During the year, the Construction-in-progress was closed to Building account.

Impairment of Non-Financial Assets

At each reporting dates, the Company reviews the carrying amounts of its non-financial assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. When the asset does not generate cash flows that are independent from the other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of net realizable value and value-in-use. In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated1 than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately.

When an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior years. A reversal of an impairment loss is recognized as income.

Equity

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue cost.

Share capital

Share capital is recognized as issued when the stock is paid for or subscribed under a binding subscription agreement and is measured at par value.

Share premium

Share premium is the difference between the issue price and the par value of the stock and is known as securities premium. The shares are said to be issued at a premium when the issue price of the share is greater than its face value or par value.

Deficit

Deficit represents accumulated losses incurred by the Company. Deficit may also include effects of changes in accounting policy as may be required by the standard's transitional provision.

Other comprehensive income (loss)

Other comprehensive income (loss) is defined as comprising items of income and expense that is not recognized in profit or loss as required or permitted by other standards.

Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Revenue is measured by reference to the fair value of consideration received or receivable excluding discounts, returns and sales taxes. Revenue is recognized at a point in time or over a period of time.

Hospital services – Revenue from in-patient, out-patient, and emergency services is recognized when the services are rendered.

Sale of medicines and medical goods – Revenue is recognized at the point in time when control of the goods passes to the customer, generally upon delivery or sale at the hospital pharmacy.

Revenue recognition outside the Scope of PFRS 15

Interest Income

Interest income is recognized as it accrues, using the effective interest method under PFRS 9 – Financial Instruments. This approach reflects the effective yield on the related financial asset and allocates interest income over the relevant period in a manner that produces a constant periodic rate of return on the carrying amount of the asset.

Other Income

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

Costs and Expense Recognition

The Company presents expenses in the statement of income using the function of expense method. Direct costs represent expenses incurred that are specifically associated with the services rendered, while operating expenses include costs attributable to general, administrative, and other business activities. Expenses are recognized in profit or loss on accrual basis, meaning they are recorded when incurred and not when paid. Costs are matched with related income when association can be directly established, or allocated systematically when benefits are expected to arise over several periods. Expenditures that do not generate future economic benefits are recognized immediately in profit or loss.

Related Party Relationships and Transactions

Related party relationship exists when one party has the ability to control, directly, or indirectly through one or more intermediaries, the other party or exercises significant influence over the other party in making financial and operating decisions. Such relationships also exist between and/or among entities which are under common control with the reporting enterprise, or between, and/or among the reporting enterprise and its key management personnel, directors, or its shareholders. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

A related party transaction is a transfer of resources, services or obligations between related parties, regardless of whether a price is charged.

Foreign Currency Transactions

Transactions in currencies other than functional currency of the Company are recorded at the rates of exchange prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing at the end of the reporting period.

Employee Benefits

Employee benefits are all forms of consideration given by an entity in exchange for services rendered by its employees.

Short-term Benefits

Short-term employee benefits are those benefits expected to be settled wholly before twelve months after the end of the annual reporting period during which employee services are rendered, but do not include termination benefits. Short-term benefits given by the Company to its employees include salaries and wages, social security, health insurance and housing contributions, short-term compensated absences, bonuses and other non-monetary benefits. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

Retirement or Post-employment Benefits

The Company is subject to the provisions of Republic Act No. 7641 (known as the Retirement Law). This requires that in the absence of a retirement plan, an agreement providing benefits for retiring employees in the private sector, an employee upon reaching the age of 60 years or more, but not beyond 65 years, who has served at least 5 years in service, may retire and shall be entitled to a retirement pay equivalent to at least ½ month's salary for every year of service, fraction of at least 6 months being considered as 1 whole year. The current service cost is the present value of benefits, which accrue during the last year.

As at reporting date, the Company has not yet established a Retirement Benefits Plan for its employees since to date no employee is entitled to retirement benefits. The Company started commercial operation in December 2023.

Borrowing costs

Borrowing costs are generally recognized as expense in the year in which these costs are incurred. However, borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized. Capitalization of borrowing costs commences when the activities necessary to prepare the asset for intended use are in progress and expenditures and borrowing costs are being incurred. Borrowing costs are capitalized until the asset is available for their intended use. It includes interest expense, finance charges in respect of finance leases and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

Income Tax

Income tax expense represents the sum of the current tax expense and deferred tax expense.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the statements of comprehensive loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

Deferred tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax base used in the computations of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognized if the temporary difference arises from the initial recognition of goodwill.

The carrying amount of deferred tax assets is reviewed at each reporting dates and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Earnings (Loss) per Share

Basic earnings (loss) per share is calculated by dividing income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the year, after giving retroactive effect to any bonus issued/declared during the year, if any.

For the purpose of calculating diluted earnings per share, profit or loss for the year attributable to ordinary equity holders of the Company and the weighted average number of shares outstanding are adjusted for the effects of all dilutive potential ordinary shares.

Reclassification of Comparative amounts

In 2025, certain amounts in the comparative financial statements and notes disclosures have been reclassified to conform with current year's presentation.

Management believes that the foregoing reclassifications would reflect the true nature of the transactions and correct the classification, as well as conform to the prevailing standards, - which did not have any impact on prior year's statement of receipts and expenses and current standing (please refer to Note 13).

Summary of changes on liabilities arising from the reclassification are shown below:

Account	December 31, 2024 (Previously Stated)	Effect	December 31, 2024 (As reclassified)
ACCOUNTS PAYABLE AND OTHER LIABILITIES			
Accounts payable – contractors and suppliers[1)]	P 339,278,543	(68,409,287)	P 270,869,256
Accrued interest payable[2)]	95,515,462		95,515,462
Accounts payable – nontrade [4)]	33,513,950	35,497,050	69,011,000
Retention payable[3)]	42,061,657		42,061,657
Accrued expenses[5)]	13,359,749	3,904,654	17,264,403
Statutory liabilities[6)]	1,737,537		1,737,537
Other payables	3,997,120	29,007,583	33,004,703
TOTAL ACCOUNTS PAYABLE AND OTHER LIABILITIES	529,464,018	–	529,464,018

The reclassifications had no impact on current income tax and deferred tax, as the adjustments were limited to liability accounts only.

NOTE 5 - CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on the historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Judgments, estimates and assumptions are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The effects of any change in estimates are reflected in the financial statements as they become reasonably determinable.

Judgments in Applying the Company's Accounting Policies

In the process of applying the Company's accounting policies, management has made the following judgments, apart from those involving estimations, which have the most significant effect on the amounts recognized in the financial statements:

Business Model Assessment

Classification and measurement of financial assets depend on the results of the Solely Payments of Principal and Interest (SPPI) and the business model test. The Company determines the business model at a level that reflects how groups of financial assets are managed together to achieve a particular business objective. This assessment includes judgment reflecting all relevant evidence including how the performance of the assets is evaluated and their performance measured, the risks that affect the performance of the assets and how these are managed and how the managers of the assets are compensated. Monitoring is part of the Company's continuous assessment of whether the business model for which the remaining financial assets are held continues to be appropriate and if it is not appropriate, whether there has been a change in business model and so a prospective change to the classification of those assets.

Significant Increase of Credit Risk

Where the fair values of financial assets and financial liabilities recorded on the statement of financial position cannot be derived from active markets, they are determined using internal valuation techniques using generally accepted market valuation models. The input to these models is taken from observable markets where possible, but where this is not feasible, estimates are used in establishing fair values. These estimates may include considerations of liquidity, volatility and correlation.

Functional Currency

Based on the economic substance of the underlying circumstances relevant to the Company, the functional currency of the Company has been determined to be the Philippine Peso (₱). It is the currency that mainly influences the Company's operations.

Classification of Financial Instrument

The Company classifies a financial instrument, or its component parts, on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual agreement and the definitions of a financial asset, a financial liability or an equity instrument. The substance of a financial instrument, rather than its legal form, governs its classification in the statement of financial position.

Determination of Whether a Lease is a Finance or Operating Lease

The evaluation of whether an arrangement contains a lease is based on its substance. An arrangement is, or contains, a lease when the fulfillment of the arrangement depends on a specific asset or assets and the arrangement conveys the right to use the asset.

Recognition of Deferred Income Taxes

Significant judgment is required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain in the ordinary course of business. Recognition of deferred income taxes depends on management's assessment of the probability of available future taxable income against which the temporary difference can be applied.

Impairment of Non-Financial Assets

Property and equipment, inventories and intangible assets are periodically reviewed to determine any indications of impairment. Though the management believes that the assumptions used in the estimation of fair values are reasonable and appropriate, significant changes in these assumptions may materially affect the assessment of the recoverable amounts and any resulting impairment loss could have a material adverse effect in the results of operations.

Provisions and Contingencies

Judgment is exercised by management to distinguish between provisions and contingencies. Policies on recognition and disclosure of provision and disclosure of contingencies are discussed in Note 4, subheading "*Provisions and Contingencies*."

Estimates and Assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the financial reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year are discussed below:

Assessment for ECL on Other Financial Assets at Amortized Cost

The Company determines the allowance for ECL using general approach based on the probability-weighted estimate of the present value of all cash shortfalls over the expected life of financial assets at amortized cost. ECL is provided for credit losses that result from possible default events within the next 12-months unless there has been a significant increase in credit risk since initial recognition in which case ECL is provided based on lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not represent a significant risk in credit risk such as when non-payment was an administrative oversight rather than resulting from financial difficulty of the borrower.

The Company has assessed that the ECL on other financial assets at amortized cost is not material because the transactions with respect to these financial assets were entered into by the Company only with reputable banks and companies with good credit standing and relatively low risk of defaults. Accordingly, no provision for ECL on other financial assets at amortized cost was recognized as at December 31, 2025 and 2024.

The carrying amounts of other financial assets at amortized cost are as follows:

	2026	2025
Cash in banks*	**P25,635,281**	P22,446,473
Receivables	**192,816,543**	165,796,569
	P218,451,824	P188,243,042

**Excluding petty cash fund amounting to 779,654 as at March 31, 2026 and ₱849,568 in 2025.*

Assessment for Impairment of Non-financial Assets

The Company assesses impairment on non-financial assets whenever events or changes in circumstances indicate that the carrying amount of the assets or group of assets may not be recoverable. The relevant factors that the Company considers in deciding whether to perform an asset impairment review include, among others, the following:

- Significant underperformance of a business in relation to expectations;
- Significant negative industry or economic trends; and
- Significant changes or planned changes in the use of the assets.

Whenever the carrying amount of an asset exceeds its recoverable amount, an impairment loss is recognized. Recoverable amounts are estimated for individual assets or, if it is not possible, for the cash-generating unit to which the asset belongs.

The recoverable amount of the asset is the greater of the fair value less cost of disposal or value in use. The fair value less cost of disposal is the amount obtainable from the sale of an asset in an arm's-length transaction. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

No impairment loss on non-financial assets was recognized as at March 31, 2026 and 2025.

The carrying amounts of non-financial assets are as follows:

	2026	2025
Property and equipment (net)	**P2,342,868,883**	P2,357,222,256
Advances to suppliers	**63,387,374**	45,968,003
Medical and hospital supplies inventories	**47,935,244**	59,994,528
Advances to contractors	**26,481,056**	26,481,056
Prepayments and other current assets	**33,109,906**	28,714,938
Advances to related parties	**6,950,256**	6,950,256
	P2,520,732,719	P2,525,331,038

Estimating Useful Lives of Assets

The Company estimates the useful lives of property and equipment and intangible assets based on the period over which the assets are expected to be available for use. The estimated useful lives of property and equipment and intangible assets are reviewed periodically and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence and legal or other limits on the use of the assets. In addition, estimation of the useful lives of property and equipment and intangible assets is based on collective assessment of industry practice, internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in estimates brought about by changes in factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of property and equipment and intangible assets would increase recorded operating expenses and decrease non-current assets.

Depreciation is calculated on a straight-line basis over the following estimated useful lives of the assets:

Categories	Estimated Useful Life
Building	50 years
Building improvement	50 years
Office equipment	3 - 5 years
Medical equipment	5 years
Hospital equipment	5-10 years
IT equipment and software	5 years
Kitchen tools	3-5 years
Hospital vehicle	5 years

As at March 31, 2026 and 2025, the Company's property and equipment had carrying amounts of ₱2,342,868,883 and ₱2,357,222,256, respectively, as disclosed in Note 11, and includes land and revaluation of the land.

Revaluation of Land

Management exercises judgement in determining whether the revaluation model provides a more reliable measure of the land's value compared to the cost model. This includes assessing the frequency of revaluations, the appropriateness of valuation techniques, and the independence and qualifications of external valuers. Judgement is also applied in deciding whether market transactions used as comparables are sufficiently similar to the Company's land holdings.

The fair value of land is determined based on market evidence of recent transactions for comparable properties. Significant assumptions include:

- Comparable property selection and adjustments for location, size, and use;
- Market conditions prevailing at the valuation date; and
- The absence of restrictions or encumbrances affecting the land's marketability.

Because these assumptions involve estimation, actual outcomes may differ, and future revaluations could result in material changes to the carrying amount of land and the related revaluation surplus.

Asset impairment other than goodwill

The Company performs an impairment review when certain impairment indicators are present.

Determining the recoverable amount of property and equipment, which require the determination of future cash flows expected to be generated from the continued use and ultimate disposition of such assets, requires the Company to make estimates and assumptions that can materially affect the financial statements. Future events could cause the Company to conclude that property and equipment are impaired. Any resulting impairment loss could have a material adverse impact on the financial condition and results of operations.

The preparation of the estimated future cash flows involves significant judgment and estimations. While the Company believes that its assumptions are appropriate and reasonable, significant changes in the assumptions may materially affect the assessment of recoverable values and may lead to future additional impairment charges.

As at March 31, 2026 and 2025, Management believes that the recoverable amounts of the Company's property and equipment approximate its carrying amounts. Accordingly, no impairment loss was recognized in both years.

Deferred tax assets

The Company reviews the carrying amounts of deferred tax assets at each financial reporting date and reduces deferred tax assets to the extent that it is no longer probable that sufficient future taxable income will be available to allow all or part of the deferred tax assets to be utilized. The Company did not recognize net deferred tax assets as at March 31, 2026 and 2025.

Deferred tax assets with full valuation allowance as at March 31, 2026 and December 31, 2025, and December 31, 2024 amounted to ₱168,867,765, and ₱-, respectively (see Note 23).

NOTE 6 - CASH

This account consists of:

	2026	2025
Cash in banks	**P25,635,281**	P22,446,473
Petty cash fund and cash on hand	**779,654**	849,568
	P26,414,935	P23,296,041

Cash includes petty cash fund and cash on hand and in banks that are unrestricted and available for current operations. This is stated in the statements of financial position at face amount.

Cash in banks generally earn interest at the prevailing bank's deposit rates. Interest earned from bank accounts amounted to ₱2,175, ₱1,002, and ₱2,106 in 2026, 2025 and 2024, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

Unrealized foreign exchange gain (loss) resulting from translation of foreign currency-denominated cash in bank into Philippine peso amounted to ₱-, 3,505 and (₱310,228) in 2026, 2025 and 2024, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

NOTE 7 - RECEIVABLES

This account consists of:

	2026	2025
Accounts receivable government agencies[1)]	**P72,922,383**	P90,686,847
Due from HMO's[2)]	**55,096,172**	50,848,955
Advances to employees and officers[5)]	**5,072,138**	5,028,526
Deposits[4)]	**5,035,000**	5,035,000
Other receivables[3)]	**15,493,733**	14,197,241
	P192,816,543	P165,796,569

[1)]Accounts receivable pertains to financial assistance availed of by patients from the Department of Social Welfare and Development (DSWD), Philippine Health Insurance Corporation (PhilHealth) and Philippine Charity Sweepstakes Office (PCSO) and reimbursable to the company.

[2)]Due from HMO's pertains to reimbursements for hospital expenses and doctors' fees availed of by patients who are members of Health Maintenance Organization (HMOs).

[3)]Other receivables – represent promissory notes from local area patients which are collected in installments or staggered payments due within the year.

[4)] Deposits represent payments made by the Company to More Power Corporation, to Iloilo Medical Society, and to the Department of Health in connection with regulatory application requirements for the Company's drug testing services operations. These deposits are expected to be applied or recovered in accordance with the terms and conditions of the related agreements and regulatory requirements.

[5)]Advances to employees and officers represent advances that are deducted directly from payroll.

In determining the recoverability of receivables, the Company considers any change in the credit quality of the receivable from the date credit was initially granted up to the end of the reporting period. Considering that majority of the accounts are relatively guaranteed by accredited providers, the Company believes that no estimated credit loss is required for both years.

NOTE 8 - ADVANCES TO CONTRACTORS AND SUPPLIERS

This account consists of:

	2026	2025
Advances to contractors[1)]	**P26,481,056**	P26,481,056
Advances to suppliers[2)]	**63,387,374**	45,968,003
	P89,868,430	P72,449,059

[1)] Advances to contractors represent advances for each awarded project activity and are liquidated via deduction, on a pro-rata basis, from the contractor's periodic progress billings.

[2)] Advances to suppliers are downpayments made to suppliers of medical equipment and/or construction materials ordered. The amounts represent 15% - 50% of the total contract price of the items purchased.

NOTE 9 - MEDICAL AND HOSPITAL SUPPLIES INVENTORIES

This account consists of:

	2026	2025
General hospital maintenance supplies[2)]	**P23,432,295**	P20,137,406
Medical and laboratory supplies[1)]	**19,289,135**-	25,458,660
Drugs and medicines for sale[3)]	**5,213,814**	14,398,462
	P47,935,244	P59,994,528

[1)]Medical and laboratory supplies refer to a wide array of materials, in the form of test or culture tubes and vessels, consumables, reagents, medical media and sera, etc., which are used in medical chemistry and various laboratory tests.

[2)]General hospital maintenance supplies pertain to purchases of cleaning and sanitation supplies for the hospital upkeep and general housekeeping.

[3)]Drugs and medicines for sale are medicinal and therapeutic substances (in capsule, tablet or liquid forms) available at the Hospital's pharmacy which are intended for patient care and treatment.

NOTE 10 - PREPAYMENTS AND OTHER CURRENT OTHERS

This account consists of:

	2026	2025
Input tax	**P28,667,692**	P24,371,398
Prepaid income tax (Note 24)	**3,522,368**	3,522,368
Prepaid insurance	**821,174**	821,172
Prepaid taxes and licenses	**-**	-
	P33,011,234	P28,714,938

NOTE 11 - PROPERTY AND EQUIPMENT (net)

Reconciliation of property and equipment (net) as at March 31, 2026 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	**P273,000,000**	**P1,836,316,739**	**P107,908**	**P3,547,131**	**P378,891,712**	**P115,213,227**	**P14,238,019**	**P32,215,795**	**P10,478,200**	**P2,664,008,731**
Additions	**–**	**–**	**–**	**–**	**23,599,299**	**123,750**	**36,504**	**142,888**	**-**	**23,902,441**
At end of year	**273,000,000**	**1,836,316,739**	**107,908**	**3,547,131**	**402,491,011**	**115,336,977**	**14,274,523**	**32,358,683**	**10,478,200**	**2,687,911,172**
Accumulated depreciation:										
At beginning of year	**–**	**73,452,670**	**19,183**	**2,166,632**	**144,752,430**	**57,894,816**	**8,777,834**	**15,531,630**	**4,191,280**	**306,786,475**
Depreciation	**–**	**9,181,584**	**5,395**	**145,011**	**18,768,563**	**7,393,175**	**627,387**	**1,610,790**	**523,910**	**38,255,815**
At end of year	**–**	**82,634,254**	**24,578**	**2,311,643**	**163,520,993**	**65,287,991**	**9,405,221**	**17,142,420**	**4,715,190**	**345,042,290**
Appraisal increase (Note 17):										
At beginning of year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
Increase for the year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
At end of year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
Net carrying value,										
March 31, 2026	**P273,000,000**	**P1,753,682,485**	**P83,330**	**P1,235,488**	**P238,970,019**	**P50,048,986**	**P4,869,302**	**P15,216,263**	**P5,763,010**	**P2,342,868,883**

Reconciliation of property and equipment (net) as at December 31, 2025 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	P28,291,630	P1,836,316,739	P33,721	P3,427,143	P355,432,128	P114,697,074	P13,835,359	P32,215,795	P10,478,200	P2,394,727,789
Additions	-	-	74,187	119,988	23,459,584	516,153	402,660	-	-	24,572,572
At end of year	28,291,630	1,836,316,739	107,908	3,547,131	378,891,712	115,213,227	14,238,019	32,215,795	10,478,200	2,419,300,361
Accumulated depreciation:										
At beginning of year	–	36,726,335	3,934	1,576,267	70,413,534	29,905,788	6,256,872	9,088,471	2,095,640	156,066,841
Depreciation	–	36,726,335	15,249	590,365	74,338,896	27,989,028	2,520,962	6,443,159	2,095,640	150,719,634
At end of year	–	73,452,670	19,183	2,166,632	144,752,430	57,894,816	8,777,834	15,531,630	4,191,280	306,786,475
Appraisal increase (Note 17):										
At beginning of year	–	–	–	–	–	–	–	–	–	–
Increase for the year	244,708,370	–	–	–	–	–	–	–	–	244,708,370
At end of year	244,708,370	–	–	–	–	–	–	–	–	244,708,370
Net carrying value, December 31, 2025	P273,000,000	P1,762,864,069	P88,725	P1,380,499	P234,139,282	P57,318,411	P5,460,185	P16,684,165	P6,286,920	P2,357,222,256

No assets were used as collateral for any liability as of March 31, 2026 and 2025.

328

Depreciation on medical and hospital equipment shall commence when it is available for use – when it is in the location and condition necessary to be capable of operating in the manner intended by the Management. The depreciation expense of medical and hospital equipment amounting to ₱70,343,235 and ₱102,327,924 in 2026 and 2025 was charged to cost of services (see Note 20).

The Company has a total contract commitment to purchase medical equipment totaling ₱454,370,959 as at December 31, 2023. Advances to ACE hospitals, Endure Medical, Inc. and TIPP Digital Solutions Inc. amounting to ₱6,950,256and ₱39,030,125 in 2026 and 2025, respectively (Note 12) was recognized in the books as it represents advance payment for such medical equipment.

The land covered by TCT No. 095-2015000546 and TCT No. 095-2015000547 represent the area located at Barangay Sambag, Jaro District, Iloilo City, Panay Island, where the Company constructed a multidisciplinary special medical facility (hospital) (Note 12) and is the subject of a real estate mortgage as disclosed in Note 15.

During the year, the Company has had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026 by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. The valuation was determined as of March 31, 2026.

As a result of the appraisal conducted by an independent appraiser, the carrying amount of land increased by ₱244,708,370, which was recognized in equity under Revaluation Surplus in accordance with the applicable financial reporting framework. Accordingly, the land is carried at its revalued amount or fair market value of ₱273,000,000 as of March 31, 2026 (see Notes 11, 16 and 18).

Management has reviewed the carrying values of property and equipment as at March 31, 2026 and 2025, for any impairment. Based on the results of its evaluation, there are no indications that these assets are impaired.

NOTE 12 - RELATED PARTY TRANSACTIONS

In the normal course of business, the Company transacts with companies/individuals, which are considered related parties. The following transactions were carried out with related parties as at March 31, 2026 and 2025:

Advances to related parties:

Category	Outstanding Balance 2024	Amount of Transactions 2025	Outstanding Balance 2025	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Receivable – others (various ACE hospitals – note 7)	P47,472	P -	P47,472	P -	**P47,472**	Non-interest bearing, to be collected in cash	Unsecured, unguaranteed, not impaired
Endure Medical, Inc. (note 7)	32,079,869	-	32,079,869	**(32,079,869)**	–	Non-interest bearing, to be collected in cash (a)	Unsecured, unguaranteed, not impaired
TIPP Digital Solutions Inc.	6,902,784	-	6,902,784	–	**6,902,784**	Non-interest bearing, to be collected in cash (b)	Unsecured, unguaranteed, not impaired

	P39,030,125	P-	P39,030,125	**(P32,079,869)**	**P6,950,256**

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions **2025**	Outstanding Balance **2025**	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable - Endure Medical, Inc.	63,768,359	**(3,091,827)**	**60,676,532**	**(60,676,532)**	**-**	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans payable to a related party	543,871,969	**1,000,000**	**544,871,969**	**(544,871,969)**	**-**	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	607,640,328	**(2,091,827)**	**605,548,501**	**(605,548,501)**	**-**		

Accounts payable – Endure Medical, Inc. is included under accounts payable – contractors and suppliers amounting to ₱194,816,096, ₱60,676,532, and ₱63,768,359 as of March 31, 2026, 2025, and 2024, respectively (see Note 13).

(a) Advances to a related party - Endure Medical, Inc.

The Company engaged the services of an indentor (Endure Medical, Inc.) which has relatively significant influence over the key management personnel of the Company. The Indentor facilitates the importation and acquisition of medical and hospital equipment, furniture and fixtures for the hospital building under construction (see Note 11).

The foregoing is classified as a related party transaction(s) (pursuant to the condition set forth in PAS 24), wherein the key management personnel of Endure Medical, Inc. has significant influence over the Company and its key officer.

(b) Advances to a related party - TIPP Digital Solutions Inc.

The account represents a 15% downpayment made for the acquisition of Healthcare Management Information System.

(c) Loans payable to a related party

The account represents an unsecured interest-bearing loan from Phil Pharmawealth, Inc., which has relatively significant influence over a key management personnel of the Company. The loan was incurred for payment of interest with Land Bank of the Philippines (LBP). The loan bears an interest rate ranging from 6.50%-8.50% per annum. Interest incurred for the years ended March 31, 2026, 2025 and 2024 and is reflected in the statements of comprehensive loss amounted to ₱-, ₱72,419,241, and ₱56,927,769, respectively. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Key Management Personnel Compensation

Key management compensation amounted to ₱1,446,667, ₱5,895,813, and ₱7,571,693 for the years ended March 31, 2026, 2025, and 2024, respectively. These amounts are incorporated in the salaries and allowances account in the financial statements.

NOTE 13 - ACCOUNTS PAYABLE AND OTHER LIABILITIES

This account consists of:

	2026	2025
Accounts payable – contractors and suppliers[1)]	**₱368,589,593**	₱308,165,389
Accrued interest payable[2)]	**172,201,043**	160,840,676
Accounts payable – nontrade [3)]	**39,500,737**	110,346,682
Retention payable[4)]	**40,558,089**	40,795,308
Accrued expenses[5)]	**1,359,755**	6,725,263
Statutory liabilities[6)]	**3,168,705**	2,999,859
Other payables[7)]	**92,021,257**	59,666,393
	₱717,399,179	₱689,539,570

[1)] Accounts payable – contractors and suppliers represent unpaid billings of the contractors and balances of equipment already installed in the construction building as of reporting date. This payable also included the related party of Endure Medical, Inc. (see note 12). This account is non-interest bearing, unsecured and non-collateral.

[2)] Accrued interest payable refers to interest expense incurred on loans from bank.

[3)] Accounts payable – nontrade pertains to unsettled fees to medical practitioners, legal, and other consultancy fees. It also includes obligations to housekeeping supplies and construction, which is a significant portion of the account.

[4)] Retention payable refers to the amount withheld by the Company from the contractor's periodic progress billings as provided for in their respective contract. This shall be released to the contractor, net of deductions, if any, upon full completion and turnover of the project and final acceptance by the Company.

[5)] Accrued expenses are normally settled within one year from financial reporting date.

[6)] Statutory liabilities pertain to tax withheld from payment to suppliers, employees' compensation and statutory contributions to SSS, PHIC and HDMF.

[7)] Other payables represent liabilities to suppliers and other parties for which no specific account classification has been designated. This account also includes payables pertaining to reimbursements, patient refunds, advances from officers and employees, and replenishment of the petty cash fund, which are non-interest bearing, non-collateralized, and payable on demand.

NOTE 14 - LOANS PAYABLE TO INDIVIDUALS

This account constitutes non-interest bearing, non-collateral and demandable obligations to shareholders which was primarily used by the Company to support the preliminary financing aspect of the construction of the hospital structure amounting to P91,589,939 and P15,703,226 as of March 31, 2026 and 2025.

NOTE 15 - NOTES PAYABLE

Movement of notes payable as at December 31 is as follows:

	2026	2025
Beginning	**999,351,037**	970,594,306
Availment	**-**	48,756,731
Payment	**-**	(20,000,000)
	999,351,037	999,351,037

Notes payable are presented in the financial statements as follows:

	2026	2025
Current	**191,558,072**	191,558,072
Non-current	**807,792,965**	807,792,965
	999,351,037	999,351,037

The Landbank of the Philippines – Iloilo Branch (LBP – Iloilo) extended to the Company several term loans equivalent to a credit line facility totaling **₱1.060 BILLION** to finance the construction of hospital structure and the acquisition of various medical equipment and fixtures.

The foregoing credit line facility consists of a term loan 1 the availment of which was granted on 2015 amounting to **₱465 MILLION** allotted to finance the construction of hospital building. However, term loan 2 availment amounting to **₱35 MILLION** was eventually cancelled or withdrawn. Subsequently, the bank approved on July 31, 2019, term loan 3 in the amount of **₱195 MILLION** for hospital structure and term loan 4 amounting to **₱400 MILLION** allotted for the acquisition of medical equipment and fixtures.

The loan is available in several drawdowns, payable ranging from 8 years to 10 years in ladderized quarterly amortizations, including grace periods ranging from 1 year to 4 years on principal amortization, with an interest rate of 5% to 6.63% per annum payable quarterly in arrears from date of loan release.

As discussed in Note 11, the loan is collaterized and secured by a Real Estate Mortgage (REM) on both parcels of land owned by the Company, including present and future improvements thereon and Chattel Mortgage on various medical equipment, furniture, and fixtures.

On November 29, 2023, Land Bank of the Philippines approved the restructuring of the total outstanding balance of Term Loans 1, 3, and 4 amounting to ₱985,594,306. The restructuring extended the repayment period up to seven (7) years from the date of effectivity, with a one (1) quarter grace period on both principal and interest.

In 2024, the Bank further approved Term Loan 6 and a Working Capital Line amounting to ₱70 million and ₱30 million, respectively.

As of March 31, 2026 and 2025, the Company's total outstanding loans and borrowings amounted to ₱999,351,037 and ₱999,351,037, respectively. Correspondingly, interest expense recognized in profit or loss for the years then ended amounted to ₱- in 2026 and ₱72,419,241 in 2025. Due to the restructuring arrangement, the finance costs related to these loans cannot be specifically allocated to the hospital building and medical equipment and fixtures.

Since the hospital structure is already in the state of its intended use (operational), the related borrowing costs (finance costs) are no longer allocated, yet rather - charged to and absorbed by operations. Hence, the total finance cost for the years 2026, 2025 and 2024 were presented as follows:

	2026	2025	2024
A. Construction in Progress			
a.) Construction of hospital building	**P -**	**P -**	**P -**
b.) Medical equipment and fixtures	**-**	**-**	**-**
Sub-total	**-**	**-**	**-**
B. Operations	**35,890,364**	**136,010,583**	155,699,208
Total	**P35,890,364**	**P136,010,583**	P155,699,208

NOTE 16 - DEFERRED TAX LIABILITY

Deferred tax liability is measured at the tax rate applied in which the liability is recognized based on the tax regulation rate enacted by the end of the reporting period. It is computed and determined by the product or equivalent of the 25% tax regulation rate as applied to the total revaluation surplus amounting to nil and P61,177,093 as of March 31, 2026 and 2025 (see Note 11).

Deferred tax liability resulting from the revaluation of land amounted to Php61,177,093 as at March 31, 2026, and December 31, 2025.

NOTE 17 - SHARE CAPITAL

Details of the Company's share capital as at March 31, 2026 are as follows:

	No. of Shares	**Amount**
Authorized share capital – ₱1,000 par value		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total authorized share capital	**240,000**	**240,000,000**
Subscribed share capital:		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total subscribed share capital	**240,000**	**240,000,000**

Paid-up share capital:

Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total paid-up share capital	**240,000**	**240,000,000**

Details of the Company's share capital as at December 31, 2025 are as follows:

	No. of Shares	Amount
Authorized share capital – ₱1,000 par value		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total authorized share capital	240,000	240,000,000
Subscribed share capital:		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total subscribed share capital	240,000	240,000,000
Paid-up share capital:		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total paid-up share capital	240,000	240,000,000

In 2018, the Company filed a Registration Statement covering the proposed Initial Public Offering (IPO) of its 36,000 common shares. Said registration statement was approved on December 27, 2019, in accordance with the provisions of the SEC's Securities Regulation Code (see Note 1).

As of date, pursuant to SEC's approval, the Company issued a total of **THIRTY-SIX THOUSAND (36,000)** common shares. The related share premium after deducting transaction costs associated with the issuance of shares amounted to ₱957,372,662. The common share offer price amounted to ₱250,000 up to ₱400,000 per block [one (1) block = ten (10) common shares].

Founder shares have the exclusive right to vote and be voted upon as directors for five (5) years from the date of SEC registration. Thereafter, the holders of Founder's shares shall have the same rights and privileges as holders of common shares.

NOTE 18 - REVALUATION SURPLUS

The Company's revaluation surplus amounting to ₱183,531,277 is the difference between the market value of ₱273,000,000 and the land's initial cost as at December 31, 2025. The valuation of its parcels of land was performed by independent appraisers and reflected in its report of March 2026 covering December 31, 2025. The fair value was determined by reference to market transactions on an arm's length term at the date of valuation (see Notes 11 and 16).

The value of the parcels of land was arrived at using a combination of cost and market (or direct sales comparison) approach. Cost approach is based on the principle of substitution, which holds that an informed buyer would not pay more for a given property than the cost of an equally desirable alternative. Market data approach is an appraisal technique in which the market value estimate is predicted based upon prices paid in actual market transactions and current listings, the former fixing the lower limit of value in a static or advancing market (pricewise) and fixing the higher limit of value in a declining market; and the latter fixing the higher limit in any market.

NOTE 19 - REVENUES

Revenues for the year ended are as follows:

	2026	2025	2024
Sale of services	**121,082,143**	514,069,665	349,859,649
Sale of goods	**1,857,509**	5,847,025	2,952,362
	122,939,652	519,916,690	352,812,011
Less: Sales discount on services	**15,392,795**	(67,672,300)	(43,380,347)
Sales discount on goods	**10,399**	(46,026)	(1,221,433)
Sales return and allowances	**-**	(32,698)	(300,205)
	(15,403,194)	(67,751,024)	(44,901,985)
Net Revenues	**107,536,458**	452,165,666	307,910,026

Sale of services pertains to billings for patient care services, including doctors' appointments and consultancies, surgical procedures, medical chemistry and laboratory analyses and ancillary services.

Sale of goods refers to the sale of medications and medical supplies provided to patients during their stay or confinement or as part of their treatment plan.

Discounts and allowances – are cost of provision for free services at certain times, discounts or returns to underprivileged patients, senior citizens and employees.

An analysis in the timing of revenue recognition is as follows:

	2026	2025	2024
Revenue recognized over the period of time	**P107,536,458**	P452,165,666	P307,910,026

NOTE 20 - DIRECT COSTS

This account consists of the following:

	2026	2025	2024
Cost of hospital services:			
Hospital supplies	**P94,488,993**	P136,033,287	P102,251,913
Depreciation	**70,343,235**	102,327,924	99,889,654
Salaries and wages	**16,209,273**	21,140,534	37,167,173
Professional fees	**-**	-	27,184,394
Utilities	**-**	-	2,274,166
	P181,041,501	P259,501,745	P268,767,300

Direct costs are explicit expenditures with specific identification to the corresponding cost centers of hospital services.

NOTE 21 - OTHER INCOME

Details of account consist of:

	2026	2025	2024
Interest income (Note 6)	**P2,175**	P1,002	P2,106
Unrealized foreign exchange gain (Note 6)	**-**	3,505	(310,228)
Other income	**2,774,610**	10,310,474	1,490,856
	P2,776,785	P10,314,981	P1,182,734

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

NOTE 22 - GENERAL AND ADMINISTRATIVE EXPENSES

Details of accounts consist of:

	Notes	**2026**	2025	2024
Salaries and allowances		**P23,491,369**	P111,313,162	P87,491,420
Utilities		**12,563,082**	54,800,309	51,738,090
Depreciation	***11***	**11,948,988**	48,391,711	48,382,414
Professional and legal fees		**5,761,241**	25,287,779	33,272,069
SSS, PHIC and HDMF contributions		**3,852,257**	13,743,882	14,586,982
Security services		**3,043,597**	12,334,776	8,684,813
Office supplies		**2,642,211**	7,827,951	8,509,166
Housekeeping		**1,898,531**	9,322,573	8,415,291
Repairs and maintenance		**883,183**	4,239,547	901,410
Taxes and licenses		**643,111**	5,802,631	6,926,145
Communication		**393,281**	1,110,669	811,393
Trainings and seminars		**277,750**	255,299	954,891
Transportation and travel		**112,756**	1,002,276	1,190,229
Entertainment and representation		**111,836**	313,229	292,075
Board meetings and conferences		**15,000**	341,050	4,862,485
Insurance		**-**	2,465,225	2,305,495
Advertising		**-**	104,984	749,906
Rental		**-**	18,947	44,211
Miscellaneous		**4,232,663**	3,613,389	2,266,842
		P71,870,856	P302,289,389	P282,385,327

NOTE 23 - INCOME TAX

Computation of income tax due (RCIT or MCIT, whichever is higher) is as follows:

I. Regular Corporate Income tax (RCIT)	2026	2025	2024
Loss before income tax	**(P63,655,502)**	(P235,321,070)	(P397,759,075)
Add (deduct) reconciling items:			
Interest expense arbitrage	**-**	251	526
Unrealized forex gain (Notes 6 and 21)	**-**	(3,505)	310,228
Interest income subjected to final tax (Notes 6,21)	**(2,175)**	(1,002)	(2,106)
Taxable loss	**(63,657,677)**	(235,325,326)	(397,450,427)
Tax rate	**25%**	25%	25%
Tax Assets	**(P15,914,419)**	(P58,831,332)	(P99,362,607)

In accordance with its registration with the Board of Investment (BOI), the Company is granted an Income Tax Holiday (ITH) for a period of six (6) years, effective from December 8, 2023 to December 8, 2029.

During this incentive period, the Company's registered activities are exempt from the Regular Corporate Income Tax (RCIT) and the Minimum Corporate Income Tax (MCIT) of 2% on gross income. This tax incentive is subject to the Company's continued compliance with the terms and conditions as set forth in its registration agreement and the requirements of the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act (see Note 1).

II. Tax Due (RCIT or MCIT whichever is higher)	2026	2025	2024
RCIT or MCIT	**P -**	P -	P -
Less: Tax credits or payments			
Prior years excess tax credits	**(3,522,368)**	(953,920)	-
Quarterly income tax payments (1st-3rd quarter)	-	-	-
Creditable withholding tax (1st - 3rd quarter)	**(213,008)**	(2,126,309)	-
Creditable withholding tax (4th quarter)	**-**	(442,139)	(953,920)
Prepaid Income Tax (Note 10)	**(P3,735,376)**	(P3,522,368)	(P953,920)

III. Net Operating Loss Carry-Over (NOLCO)

Revenue Regulation 25-2020, implementing Section 4 of the Bayanihan to Recover as One or Bayanihan 2 Act, particularly on the NOLCO of companies wherein The Bureau of Internal Revenue (BIR) has extended to five years the carry-over period for net operating losses incurred by businesses in 2020 and 2021 (due to the impact of the coronavirus pandemic).

Year Incurred	Expiration date	Beginning balance	Additions	Expired	Claimed	Ending Balance
NOLCO						
2020	2025	P43,425,573	P -	(P43,425,573)	P -	P -
2021	2026	34,889,728	-	-	-	34,889,728
		P78,315,301	**P -**	(P43,425,573)	**P -**	P34,889,728

On June 30, 2022 the NOLCO carry over period was reverted back to three years. Thus, as at December 31, 2025, NOLCO that can be claimed as deduction from future taxable income are as follows:

Year Incurred	Expiration date	Beginning balance	Additions	Expired	Claimed	Ending Balance
NOLCO						
2022	2025	P34,889,728	P52,339,339	(P52,339,339)	P -	P34,889,728
2023	2026	-	147,365,993	-	-	182,255,721
2024	2027	-	397,450,427	-	-	579,706,148
2025	2028	-	235,325,326	-	-	815,031,474
2026	**2029**	**-**	**63,655,502**	**-**	**-**	**878,686,976**
		P34,889,728	**P896,136,587**	**(P52,339,339)**	**P -**	**P878,686,976**

IV. Deferred Tax Assets

The significant components of the Company's deferred tax assets are as follows:

	2026	2025	2024
NOLCO	P878,686,976	P815,031,474	P675,471,060
Tax rate	25%	25%	25%
	219,671,744	203,757,869	168,867,765
MCIT	**-**	–	–
	219,671,744	203,757,869	168,867,765
Valuation allowance (Note 5)	(219,671,744)	(203,757,869)	(168,867,765)
Deferred tax asset (other noncurrent assets)	**P -**	P -	P -

The Company provides full valuation allowance on its deferred tax assets from NOLCO since management believes that the Company will not be able to generate future taxable income in which such can be applied. The deferred tax asset of the Company arising from net operating loss carry over (NOLCO) prior to 2021 can be charged against future taxable income of the next three (3) years. On the other hand, deferred tax assets arising from NOLCO for the years 2020 and 2021 can be charged against future taxable income of the next five (5) taxable years.

NOTE 24 - LEASES

The Company has adopted PFRS 16. However, the Company does not have lease arrangements for its building, as the property is owned by the Company and recognized as part of property and equipment.

As of the reporting date, the Company has no significant lease contracts that would require recognition of right-of-use assets and lease liabilities. Accordingly, the impact of PFRS 16 on the financial statements is not material.

NOTE 25 - BASIC LOSS PER SHARE

Basic loss per share is computed as follows:

	2026	2025	2024
Loss attributable to ordinary shares	**(P63,655,502)**	(P235,321,070)	(P397,759,075)
Divide by: Weighted average number of ordinary shares outstanding	**240,000**	240,000	239,960
Basic loss per share	**(P265.23)**	(P980.50)	(P1,657.61)

There are no potential dilutive ordinary shares outstanding as at March 31, 2026, 2025 and 2024.

NOTE 26 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Financial Risk

The Company's financial risk management policies seek to minimize potential adverse effects of financial risk such as credit risk, liquidity risk, and interest rate risk to its financial assets and financial liabilities.

The Company's principal financial assets and financial liabilities consist of cash (excluding petty cash fund), receivable - others, other non-current assets payable (excluding deferred tax assets), accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, loans payable to a related party and notes payable which arise from operations.

The Company's Board of Directors reviews and approves the policies for managing each of these risks and these are summarized below:

Credit risk

Credit risk is the risk that the third party will default on its obligation to the Company and cause the Company to incur financial loss. The Company's business policy aims to limit the amount of credit exposure to any individual client and financial institution. The Company has credit management policies in place to ensure that contracts are entered into with clients who have sufficient financial capacity and good credit history.

The Company's financial assets at amortized cost are composed of cash (excluding petty cash fund), receivable – others, advances to related parties and other assets under the noncurrent assets (excluding deferred tax assets). The Company limits its exposure to credit risk by investing its cash only with banks that have good credit standing and reputation in the local and international banking industry. These instruments are graded in the top category by an acceptable credit rating agency and, therefore, are considered to be low credit risk investments.

Receivable - others and other assets under the non-current assets are being monitored on a regular basis to ensure timely execution of necessary intervention efforts to minimize credit losses.

It is the Company's policy to measure ECL on the above instruments on a 12-month basis. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not represent significant credit risk such as when non-payment arising from administrative oversight rather than resulting from financial difficulty of the borrower.

The table below presents the summary of the Company's exposure to credit risk and shows the credit quality of the assets by indicating whether the assets are subjected to 12-month ECL or lifetime ECL. Assets that are credit-impaired are separately presented.

As at March 31, 2026

	Financial assets at amortized cost			
	12-month ECL	**Lifetime ECL – not credit impaired**	**Lifetime ECL – credit impaired**	**Total**
Cash in banks*	**₱25,635,281**	–	–	**₱25,635,281**
Receivables	**192,816,543**	–	–	**192,816,543**
	₱218,451,824	–	–	**₱218,451,824**

**Excluding petty cash fund amounting to ₱779,654 as at March 31, 2026.*

As at December 31, 2025

	Financial assets at amortized cost			
	12-month ECL	Lifetime ECL – not credit impaired	Lifetime ECL – credit impaired	Total
Cash in banks*	₱22,446,473	–	–	₱22,446,473
Receivables	165,796,569	–	–	165,796,569
	₱188,243,042	–	–	₱188,243,042

**Excluding petty cash fund amounting to ₱849,568 as at December 31, 2025.*

Interest Rate Risk

Interest rate risk refers to the possibility that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate.

The primary source of the Company's interest rate risk relates to its cash in banks, notes payable and loans payable to a related party (Notes 6, 14 and 15).

Cash in banks are subject to prevailing market interest rates. Considering that such financial assets have short-term maturities, the Company does not foresee any cash flow and fair value interest rate risks to have a significant impact on the Company's operations.

Likewise, notes payable and loans payable to a related party are subject to prevailing market interest rates. As such, these are subject to fluctuations in market interest rates for a given period.

The Company has no established policy in managing interest rate risk. Any favorable or unfavorable effect of the fluctuations on the interest rates are absorbed by the Company. The effect of such is presented in the Company's financial performance.

Liquidity Risk

In the management of liquidity, the Company monitors and maintains a level of cash deemed adequate by the management to finance the Company's operations and mitigate the effects of fluctuations in cash flows.

The table below summarizes the maturity profile of the Company's financial assets and liabilities based on contractual and undiscounted payments:

As at March 31, 2026

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Assets:					
Cash*	₱25,635,281	P –	P –	P –	₱25,635,281
Receivable - others	192,816,543	–	–	–	192,816,543
Advances to related parties	6,950,256	–	–	–	6,950,256
	₱225,402,080	P –	P –	P –	₱225,402,080

**Excluding petty cash fund and cash on hand amounting to ₱779,654 March 31, 2026.*

Financial Liabilities:					
Accounts payable and other liabilities***	27,690,762	686,539,712	-	-	P714,230,474
Loans payable to individuals	-	-	91,589,939	-	91,589,939
Loans payable to a related party	-	-	544,871,969	-	544,871,969
Notes payable	-	-	984,800,767	-	984,800,767
	P27,690,762	P686,539,712	P1,621,262,675	P -	P2,335,493,149

****Excluding government liabilities amounting to ₱3,168,705 as at March 31, 2026S*

As at December 31, 2025

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Assets:					
Cash*	P22,446,473	P -	P -	P -	P22,446,473
Receivable - others	165,796,569	-	-	-	165,796,569
Advances to related parties	6,950,256				6,950,256
	P195,193,298	P -	P -	P -	P195,193,298

**Excluding petty cash fund and cash on hand amounting to ₱849,568 December 31, 2025.*

Financial Liabilities:					
Accounts payable and other liabilities***	P308,520,389	P378,019,323	P -	P -	P686,539,712
Loans payable to individuals	-	15,703,226	-	-	15,703,226
Loans payable to a related party	-	-	544,871,969	-	544,871,969
Notes payable	191,558,072	-	807,792,965	-	999,351,037
	P500,078,461	P393,722,549	P1,352,664,934	P -	P2,246,465,944

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

The carrying amounts and estimated fair values of the Company's financial assets and financial liabilities are presented below:

	As at March 31, 2026		As at December 31, 2025	
	Carrying Amounts	**Fair Values**	Carrying Amounts	Fair Values
Financial Assets:				
Cash*	**P25,635,281**	**P25,635,281**	P22,446,473	P22,446,473
Receivable – others	**192,816,543**	**192,816,543**	165,796,569	165,796,569
Advances to related parties	**6,950,256**	**6,950,256**	6,950,256	6,950,256
	P225,402,080	**P225,402,080**	P195,193,298	P195,193,298

Excluding petty cash fund and cash on hand amounting to **₱779,654 and ₱849,568 as at March 31, 2026 and 2025.*

Financial Liabilities:				
Accounts payable and other liabilities***	**P714,230,474**	**P714,230,474**	P686,539,712	P686,539,712
Loans payable to individuals	**91,589,939**	**91,589,939**	15,703,226	15,703,226
Loans payable to a related party	**544,871,969**	**544,871,969**	544,871,969	544,871,969
Notes payable	**984,800,767**	**984,800,767**	999,351,037	999,351,037
	P2,335,493,149	**P2,335,493,149**	P2,246,465,944	P2,246,465,944

****Excluding government liabilities amounting to ₱3,168,705 and ₱2,999,859 as at March 31, 2026 and 2025, respectively.*

Assumption Used to Estimate Fair Values

The carrying amounts of cash, receivable - others, accounts payable and other liabilities, loans payable to individuals, and loans payable to a related party approximate their fair values as at reporting dates due to the short-term nature of the transactions.

The carrying amount of notes payable approximates its fair value due to pre-determined contractual cash flow arrangements based on an applicable and regular re-priceable Philippine Dealing System Treasury (PDST) floating rate covering the term of the loan, as provided by the financial lending institution.

The fair value of refundable deposits cannot be measured reliably since there was no comparable market data and inputs for the sources of fair value such as discounted cash flows analysis. However, Management believes that their carrying amounts approximate their fair value.

Fair Value Hierarchy

The Company uses the following hierarchy for determining the fair value of financial assets and liabilities:

- Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- Level 3 - Inputs are unobservable for the asset or liability

The table below summarizes the classification of the Company’s financial assets and liabilities based on the fair value measurement hierarchy:

	As at March 31, 2026		
	Quoted Prices in Active Markets (Level 1)	**Significant Observable Inputs (Level 2)**	**Significant Un-observable Inputs (Level 3)**
Financial Assets:			
Cash*	**P -**	**P25,635,281**	**P -**
Receivable – others	**-**	**192,816,543**	**-**
	P -	**P218,451,824**	**P -**

**Excluding petty cash fund and cash on hand amounting to ₱779,654 as at March 31, 2026.*

Financial Liabilities:			
Accounts payable and other liabilities***	P –	**714,230,474**	P –
Loans payable to individuals	–	**91,589,939**	–
Loans payable to a related party	–	**544,871,969**	–
Notes payable	–	**984,800,767**	–
	P –	**2,335,493,149**	P –

****Excluding government liabilities amounting to ₱3,168,705 as at March 31, 2026.*

	As at December 31, 2025		
	Quoted Prices in Active Markets (Level 1)	Significant Observable Inputs (Level 2)	Significant Un-observable Inputs (Level 3)
Financial Assets:			
Cash*	P -	P22,446,473	**P -**
Receivable – others	-	165,796,569	**-**
	P -	P188,243,042	**P -**

**Excluding petty cash fund and cash on hand amounting to ₱849,568 as at December 31, 2025.*

Financial Liabilities:			
Accounts payable and other liabilities***	P -	P686,539,712	P -
Loans payable to individuals	-	15,703,226	-
Loans payable to a related party	-	544,871,969	-
Notes payable	-	999,351,037	-
	P -	P2,246,465,944	P -

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

There were no reclassifications made between the different fair value hierarchy level as at December 31, 2025 and 2024.

CAPITAL MANAGEMENT

The primary objective of the Company's capital management is to ensure that it maintains healthy capital ratios in order to support its business, pay existing obligations and maximize shareholders value.

The Company manages capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust capital, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes during the years ended March 31, 2026 and 2025.

The following table pertains to the account balances the Company considers as its core economic capital:

	2026	2025
Share capital	**₱240,000,000**	P240,000,000
Share premium	**958,532,662**	958,532,662
Revaluation surplus	**183,531,277**	183,531,277
Deficit	**(978,283,186)**	(978,283,187)
	₱403,780,753	P403,780,752

The loan agreement with Landbank (Note 16) provides certain restrictions and requirements with respect to, among others, maintenance of financial ratios (debt-to-equity ratio of 80:20), percentage of ownership of specific shareholders, creation of property encumbrances and additional guarantees for the incurrence of additional long-term indebtedness.

As of reporting dates, all covenants and requirements are complied with except for the required financial ratio wherein the financial institution was made aware of since the Company has not yet started commercial operations.

FINANCIAL RATIOS

The following were the financial ratios of the Company for the years ended March 31, 2026, and 2025:

Particulars	**2026**	2025
Current ratio	**0.38**	0.39
Solvency ratio	**1.14**	1.17
Debt to-equity	**4.01**	5.72
Asset to equity	**8.06**	6.72
Return on equity	**(0.17)**	(0.55)
Return on assets	**(0.02)**	(0.090)

Computation of the above financial ratios are as follows:

- Current ratio = Current assets divided by current liabilities
- Solvency ratio = Total assets divided by total liabilities
- Debt-to-equity = Total liabilities divided by total equity
- Asset-to-equity = Total assets divided by total equity
- Return on equity = Net income divided by average total equity for the periods indicated
- Return on assets = Net income divided by average total assets for the periods indicated

SUPPLEMENTARY INFORMATION REQUIRED BY REVENUE REGULATION (RR)

The following information is presented for purposes of filing with the BIR and is not a required part of the basic financial statements.

Revenue Regulations (RR) 15-2010

On November 25, 2010, the Bureau of Internal Revenue (BIR) issued Revenue Regulations (RR) 15-2010, which requires certain information on taxes, duties, and license fees paid or accrued during the taxable year to be disclosed as part of the notes to financial statements. This

supplemental information, which is an addition to the disclos*u*res mandated under PFRS Accounting Standards is presented as follows:

Output Value-Added Tax

Details of the Company's output VAT declared consist of:

	2026
Exempt sales	**P96,883,812**
Vatable sales	**730,514**
VAT rate	**12%**
	P87,662

Input Value-Added Tax

Details of the Company's Input VAT claimed consist of:

	2026
At beginning of year	**P -**
Current purchases and payments for:	
Domestic purchase of capital goods not exceeding 1M	-
Domestic purchase of capital goods exceeding 1M	-
Domestic purchase of goods other than capital goods	**19,470,079**
Domestic purchases of services	**16,083,359**
At end of year	**P35,553,438**

Computation of Net VAT payable is as follows:

	2026
Output VAT payable	**P87,662**
Less: Input VAT claimed	**(28,580,030)**
Excess Input VAT for the year	**(28,667,692)**
Less: Payments made during the year	-
Input VAT Carry-over (Note 10)	**(P28,667,692)**

Documentary Stamp Tax

Documentary stamp tax paid by the Company during the year amounted to ₱85,993 for the additional availment of notes payable.

Taxes and licenses

Details of the Company's other local and national taxes for the year are as follows:

	2026
Real Property Tax	**P390,814**
Business Permit Fee	**142,152**
Documentary Stamp Tax	**85,993**
Community Tax Certificate	**10,500**
Others	**13,652**
	P643,111

Withholding Taxes

Withholding taxes paid by the Company for the year are as follows:

	2026
Compensation withholding tax	**₱109,807.80**
Expanded withholding tax	**995,626.10**
	₱1,105,433.90

Deficiency Tax Assessment and Tax Cases

The Company has no deficiency tax assessments or any tax cases, litigation, and/or prosecution in court or bodies outside the Bureau of Internal Revenue as of December 31, 2025.

RR 19-2020 and RR 34-2020

In 2020, the Bureau of Internal Revenue (BIR) issued the foregoing Revenue Regulations for the effective implementation of Philippine Accounting Standard No. 24 (PAS 24) governing the guidelines and procedures for "transfer pricing documentations" involving related party transactions thru the submission of BIR Form No. 1709 and the supporting documents, as an attachment to the financial statements to be filed with the BIR.

The Company reported net operating losses for the current taxable year and the immediately preceding two (2) consecutive taxable years, hence, meets the criteria provided by these Revenue Regulations, and accordingly, required to submit BIR Form 1709.

* * *

SCHEDULES

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.

(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

As at March 31, 2026

Schedule A. Financial Assets

Name of issuing entity and association of each issue	Number of shares or principal amount of bonds and notes	Amount shown in the statements of financial position	Value based on market quotation at the end of reporting period	Income received and accrued
Cash*	N/A	**P25,635,281**	N/A	**P2,175**
Receivable – others	N/A	**192,816,543**	N/A	**-**
Other non-current assets	N/A	**-**	N/A	**-**
		P218,451,824		**P2,175**

**Excluding petty cash fund amounting to ₱779,654 as at March 31, 2026*

Schedule B. Amounts Receivable from Directors, Officers, Employees, Related Parties, and Principal Stockholders

Name and designation of Debtor	Balance at Beginning of Period	Additions	Amounts Collected	Amounts Written Off	Current	Not Current	Balance at End of 1st Quarter Period
TIPP Digital Solutions Inc.	P6,902,784	P -	P -	P -	P6,902,784	-	P6,902,784
Receivable – others (various ACE Hospitals)	47,472	-	-	-	47,472	-	47,472
	P6,950,256	**P -**	**P -**	**P -**	**P6,950,256**	**P -**	**P6,950,256**

Schedule C. Amounts Receivable from Related Parties which are eliminated during Consolidation of Financial Statements

Name and designation of Debtor	Balance at Beginning of Period	Additions	Amounts Collected	Amounts Written Off	Current	Not Current	Balance at End of Year
- Not Applicable -							

Schedule D. Long –Term Debt

Title of issue and type of Obligation	Amount authorized by indenture	Amount shown under caption "Current portion of long-term debt" in related statement of financial position	Amount shown under caption "Long-term debt" in related statement of financial position
Non-interest-bearing Notes Payable	P984,800,767	P227,010,404	P757,790,363 *(payable in 27 quarterly installments for 7 year from the date of effectivity with one (1) quarter grace period on principal and interest beginning October 31, 2023 to October 31, 2030 with a current interest rate of 7.5% per annum)*

Schedule E. Indebtedness to Related Parties (Long –Term Loans from Related Companies)

Name of Related Party	Balance at beginning of Period	Balance at end of Period
Phil Pharmawealth, Inc.	P544,871,969	P544,871,969
Endure Medical, Inc.	60,676,532	194,816,096
	P605,548,501	P739,688,065

Schedule F. Guarantees of Securities of Other Issuers

Name of issuing entity of securities guaranteed by the Company for which this statement is filed	Title of issue of each class of securities guaranteed	Total amount guaranteed and outstanding	Amount owned by person for which statement is filed	Nature of guarantee
- Not Applicable -				

Schedule G. Capital Stock

Title of issue	Number of shares authorized	Number of shares issued and outstanding as shown under related statement of financial position caption	Number of shares reserved for options, warrants, conversion and other rights	Number of shares held by related parties	Directors, officers and employees	Others
Founder's Shares	600	600	-	-	-	-
Common Shares	239,400	239,400	-	-	-	-
	240,000	**240,000**	**-**	**-**	**-**	**-**

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

Statement of Accumulated Deficit
As at March 31, 2026

Accumulated Deficit, beginning of quarter	**P978,283,187**
Net loss incurred for the quarter	**63,655,502**
Accumulated Deficit, ending of quarter	**P1,041,938,689**

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

MAP OF THE RELATIONSHIPS BETWEEN AND AMONG THE COMPANIES IN THE GROUP, ITS ULTIMATE PARENT COMPANY AND CO-SUBSIDIARIES
As at March 31, 2026

-Not Applicable-
EXPLANATION ON NON-APPLICABILITY OF CONGLOMERATE MAP

Asia-Pacific Medical Center-Iloilo, Inc., Asia Pacific Medical Center-Bacolod, Inc., and Asia Pacific Medical Center - Aklan, Inc. are not affiliate companies nor sister companies because they do not operate under one parent company. They are related only because the Chairman of the three companies, Dr. Ferjenel G. Biron, is one and the same person and they have interlocking directors and shareholders and common officers as follows:

Name of Stockholder	Percentage of Ownership and Position in APMC Iloilo	Percentage of Ownership and Position in APMC Bacolod	Percentage of Ownership and Position in APMC Aklan
Biron, Ferjenel G.	20.17%/ Chairman	3.99%/ Chairman	4.67%/Chairman
Biron, Bryant Paul Q.	8.81% (8.81% as Trustor under VTA)[1]	1.54% (1.54% as Trustor under VTA)	1.92% (1.92% as Trustor under VTA)
Biron, Brandt Luke Q.	9.12% (8.81% as Trustee under VTA/Director	3.08% (1.54% as Trustee under VTA)	8.98% (1.92% as Trustee under VTA)
Biron, Braeden John Q.	8.81% (8.81% as Trustor under VTA[2])	1.54% (1.54% as Trustor under VTA)	1.92% (1.92% as Trustor under VTA)
Oca-Biron, Ma. Regina Isabelle	.02% (8.81% as Trustee under VTA)	1.54% as Trustee under VTA	1.92% as Trustee under VTA
Barrameda, Romulo Jr. S.	1.44%	1.56%/Independent Director	None
Comuelo, Jerusha A.	1.44%	0.73%	1.56%/ Independent Director
Depalac, Jonas A.	0.0042%	1.54%	None
Domingo, Joan B.	0.0042%	1.54%	None
Lavalle, Amado Jr. M.	1.53%	2.27%	1.56%
Lavilla, Meride D.	2.91% (1.52 % Direct + 1.38% Indirect)/ Vice Chairman	9.63%/ Director	3.12%/ Director

[1] Biron, Brandt Luke Q. (8.81% as Trustees under VTA)

[2] Oca-Biron, Ma. Regina Isabelle (8.81% as Trustees under VTA)

Minerva, Ike T.	1.42%	2.20%	1.56%
Ong, Mary Flor G.	1.40%/Treasurer	0.73%	None
Perez, Ma. Grace G.	1.43%	0.73%	None
Regozo, Danilo C.	1.53%/ Executive Vice President	2.72%/ Executive Vice President	1.56%/ Director
Samoro, Fredilyn G.	4.26% (2.82% Direct + 1.44% Indirect) /Director	None	1.56%
Villaflor, Agnes Jean M.	1.15%/ President	0.73%	1.56%

(Percentage of Shares as of March 31, 2026)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

SCHEDULE OF FINANCIAL SOUNDNESS INDICATORS

As of March 31, 2026
(with comparative figures as of December 31, 2025)

Financial KPI	Definition	31-Mar-26	31-Dec-25
1. Liquidity			
Quick Asset Ratio	$\frac{\text{Cash + Receivables}}{\text{Current Liabilities}}$	0.21 : 1	0.21 : 1
Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	0.38 : 1	0.39 : 1
2. Solvency			
Debt to Equity Ratio	$\frac{\text{Long Term Debt}}{\text{Equity}}$	4.01:1	3.50 : 1
3. Profitability			
Net Profit Margin	$\frac{\text{Net Income}}{\text{Total Revenue}}$	0.00	0.00
Return on Equity	$\frac{\text{Net Income}}{\text{Stockholder's Equity}}$	0.00	0.00
4. Leverage			
Debt to Total Asset Ratio	$\frac{\text{Total Liabilities}}{\text{Total Asset}}$	0.88:1	0.85 : 1
Asset To Equity Ratio	$\frac{\text{Total Asset}}{\text{Equity}}$	8.06:1	6.72 : 1
5. Interest Rate Coverage Ratio	$\frac{\text{Earnings Before Interests \& Taxes}}{\text{Interest Expense}}$	0.00	0.00

ASIA PACIFIC
MEDICAL CENTER
ILOILO

We hereby certify that the information set forth in this report for the quarter ended 31 March 2026is complete and correct.

That the Board of Directors reviews and approves the interim financial statements, including the schedules attached thereto.

That the interim financial statement of the company will be filed and subject to audit by the independent auditor appointed by the stockholders.

AGNES JEAN M. VILLAFLOR
President

MARY FLOR G. ONG
Corporate Treasurer

CRIS T. CORTES
Chief Finance Officer

COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2026 December 31
(Fiscal Year Ending-Month and Day)

17-C
(FORM TYPE)

_____
(Period Ended Date)

_____
(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any)

REPUBLIC OF THE PHILIPPINES)
City of Iloilo) S.S.

Certification

I, **THERESE MARIE A. GERAFIL**, Corporate Secretary of **Asia Pacific Medical Center – Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center-Iloilo Inc.)**, with SEC registration number **CS201423954** with principal office at **Barangay Ungka, Jaro, Iloilo City**, on oath state:

1) That on behalf of **Asia Pacific Medical Center – Iloilo, Inc., (Formerly: Allied Care Experts (ACE) Medical Center-Iloilo Inc.)**, I have caused this **17 - C** dated 26 **May 2026** to be prepared;

2) That I read and understood its contents which are true and correct of my own personal knowledge and/or based on true records;

3) That the company Asia Pacific Medical Center – Iloilo, Inc. (formerly Allied Care Experts (ACE) Medical Center-Iloilo Inc.), will comply with the requirements set forth in SEC Memorandum Circular No. 18 dated October 9, 2023 and SEC Notice dated 05 March 2025, for a complete and official submission of reports and/or documents through electronic mail and through the Electronic Filing and Submission Tool (eFAST) effective 28 March 2025; and

4) That I am fully aware that documents filed online which requires pre-evaluation and/or processing fee shall be considered complete and officially received only upon payment of a filing fee.

IN WITNESS WHEREOF, I have hereunto set my hand this 26 MAY 2026 at Iloilo City.

THERESE MARIE A. GERAFIL
Corporate Secretary

SUBSCRIBED AND SWORN TO before me this _____ day of 26 MAY 2026 2026 at Iloilo City; Affiant exhibiting her IBP ID with Roll of Attorneys No. 88537 and avowed the truthfulness of the foregoing declarations.

ATTY. ELAINE L. SEGURA
Notary Public, City and Province of Iloilo
Commission No. 140 valid until December 31, 2027
Gayanilo Gonzaga Jungco and Chavez Law Office
LM Casa Street, Iloilo City
Attorney's Roll No. 95369 / 01/24/2025
PTR No. 9229381 / 03/11/2026 / Iloilo City
IBP No. INV 598636 / 02/04/2026
Email Address: el_segura@outlook.com
Contact No. 09171739164

Doc. No. 18
Page No. 4
Book No. 1
Series of 2026.

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-C

CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER

1. 26 May 2026
   Date of Report

2. SEC Identification Number CS201423954 3. BIR Tax Identification No. 008-922-703

4. ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
   Exact name of issuer as specified in its charter

5. Iloilo City, Philippines
   Province, country or other jurisdiction of incorporation

6. (SEC Use Only)
   Industry Classification Code:

7. Brgy. Ungka, Jaro, Iloilo City
   Address of principal office

   5000
   Postal Code

8. (033) 3215748/09175234802
   Issuer's telephone number, including area code

9. Not Applicable
   Former name or former address, if changed since last report

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Founder	600
Common	239,400
Amount of Debt	1,823,309,661.40

11. Indicate the item numbers reported herein: **Item 9 (b)**

Please be advised that the following items were approved by the Board of Directors of Asia Pacific Medical Center (APMC) - Iloilo, Inc., acting by majority vote through a referendum held on **26 May 2026.**

Item 9 (b) Amendment of the SEC Form 17-Q (1st Quarter of 2026) as of 31 March 2026

Amendment of SEC Form 17-Q Quarterly Financial Report for the 1st Quarter of 2026 through the attachment of the approved and correct Interim Financial Statement as of 31 March 2026 as Annex A to the previously filed SEC Form 17-Q for the same period reflecting the following changes from the previous attachment.

Specifically, Note 12 of the Interim Financial Statemnent was amended to reflect the correct amount of transactions and outstanding balance of Accounts Payable as of 31 March 2026.

Submitted Table for Advances from related parties:

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions **2025**	Outstanding Balance **2025**	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable - Endure Medical, Inc.	63,768,359	**(3,091,827)**	**60,676,532**	**(60,676,532)**	-	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans payable to a related party	543,871,969	**1,000,000**	**544,871,969**	**(544,871,969)**	-	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	607,640,328	**(2,091,827)**	**605,548,501**	**(605,548,501)**	-		

Approved Table for Advances from related parties:

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions 2025	Outstanding Balance 2025	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable – Endure Medical, Inc.	P63,768,359	(P3,091,827)	P60,676,532	**P134,139,564**	**P194,816,096**	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans Payable to a related party	543,871,969	1,000,000	544,871,969	-	**544,871,969**	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	P607,640,328	(P2,091,827)	P605,548,501	**P134,139,564**	**P739,688,065**		

Attached herewith as **Annex "A"** is the Secretary's Certificate on the Referendum approving the amended SEC Form 17-QA (1st Quarter of 2026) as of 31 March 2026 (attached herein as **Annex "B"**).

SIGNATURES

Pursuant to the requirements of the Securities Regulation Code, the issuer has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO INC.)
Issuer

26 May 2026
Date

THERESE MARIE A. GERAFIL
Corporate Secretary

Annex "A"

REPUBLIC OF THE PHILIPPINES)
City of Iloilo) S.S.

SECRETARY'S CERTIFICATE

I, **Therese Marie A. Gerafil,** of legal age, Filipino, with office address at 9th Floor, Asia Pacific Medical Center- Iloilo, Brgy. Ungka Jaro, Iloilo City, after having been duly sworn to in accordance with law, do hereby depose, state, and certify that:

I am the duly elected Corporate Secretary of **Asia Pacific Medical Center-Iloilo Inc. (formerly: Allied Care Experts Medical Center-Iloilo, Inc.)** ("Corporation"), a corporation duly organized and existing under the laws of the Republic of the Philippines, with principal address at Brgy. Ungka, Jaro, Iloilo City;

At a referendum of the Board of Directors held on **26 May 2026**, by a majority vote, the following resolution was approved and is now in full force and effect, to wit:

Resolution No. 2026-05-12 (r)

WHEREAS, it was reported to the Board of Directors that the Interim Financial Statements attached in the Company's SEC Form 17-Q for the First Quarter of 2026 submitted to the Securities and Exchange Commission (SEC) Markets and Securities Regulation Department (MSRD), contained errors particularly in Note 12, regarding the presented amount of transactions and outstanding balance of Accounts Payable as of 31 March 2026;

WHEREAS, the Board resolved to have the correct Interim Financial Statements attached to the SEC Form 17-Q for First Quarter of 2026;

RESOLVED, AS IT IS HEREBY RESOLVED, to amend the SEC Form 17-Q for the First Quarter of 2026 through the attachment of the correct Interim Financial Statements reflecting the following data:

Submitted Table for Advances from related parties:

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions **2025**	Outstanding Balance **2025**	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable - Endure Medical, Inc.	63,768,359	**(3,091,827)**	**60,676,532**	**(60,676,532)**	-	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans payable to a related party	543,871,969	**1,000,000**	**544,871,969**	**(544,871,969)**	-	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	607,640,328	**(2,091,827)**	**605,548,501**	**(605,548,501)**	-		

Approved Table for Advances from related parties:

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions 2025	Outstanding Balance 2025	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable – Endure Medical, Inc.	P63,768,359	(P3,091,827)	P60,676,532	**P134,139,564**	**P194,816,096**	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans Payable to a related party	543,871,969	1,000,000	544,871,969	-	**544,871,969**	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaired
	P607,640,328	(P2,091,827)	P605,548,501	**P134,139,564**	**P739,688,065**		

RESOLVED FURTHER, that the President, Corporate Treasurer and Chief Finance Officer of the Corporation be authorized to refile the amended SEC Form 17-Q (First Quarter of 2026) with the Securities and Exchange Commission (SEC);

RESOLVED FINALLY, that the Corporate Secretary of the Corporation be authorized to file the SEC Form 17-C reporting the reissuance of the said amended 1st Quarter Interim Financial Statements with the SEC.

The foregoing resolution has not been amended, superseded, or repealed as of the date hereof.

IN WITNESS WHEREOF, I hereunto affix my signature this _____day of MAY 26 2026, in Iloilo City, Philippines.

THERESE MARIE A. GERAFIL
Corporate Secretary

SUBSCRIBED AND SWORN TO before me this 26 MAY 2026 day of May 2026 at Iloilo City; affiant exhibiting her IBP ID with Roll of Attorneys No. 88537.

ATTY. ELAINE L. SEGURA
Notary Public, City and Province of Iloilo
Commission No. 140, valid until December 31, 2027
Gayanilo Gonzaga Jungco and Chavez Law Office
J.M. Basa Street, Iloilo City
Attorney's Roll No. 95369 / 01/24/2025
PTR No. 9329891 / 03/11/2026 / Iloilo City
IBP No. INV 598636 / 02/04/2026
Email Address: el_segura@outlook.com
Contact No. 09171739164

Doc. No. 29
Page No. 7
Book No. I
Series of 2026.

COVER SHEET

SEC Number **CS201423954**
File Number _____

ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
(Formerly: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-ILOILO, INC.)**
(Company's Full Name)

Brgy. Ungka, Jaro, Iloilo City 5000
(Company's Address)

Tel # 321-57-48/0917-523-4802
(Company's Telephone Number)

2026 DECEMBER 31
(Fiscal Year Ending-Month and Day)

17-Q (1st Qtr)
(FORM TYPE)

March 31, 2026
(Period Ended Date)

SEC FORM 17-Q-A-1
(Amendment Designation, if Applicable)

Issuer of Securities
(Secondary License Type, if any

ASIA PACIFIC
MEDICAL CENTER
ILOILO

REPUBLIC OF THE PHILIPPINES)
CITY & PROVINCE OF ILOILO) S.S.

CERTIFICATION

I, **AGNES JEAN M. VILLAFLOR** of **Asia Pacific Medical Center – Iloilo, Inc. (formerly Allied Care Experts (ACE) Medical Center – Iloilo Inc.)**, with SEC registration number **CS201423954** with principal office at Barangay Ungka, Jaro, Iloilo City, 5000 on oath state:

1) That on behalf of Asia Pacific Medical Center – Iloilo, Inc. (formerly Allied Care Experts (ACE) Medical Center-Iloilo Inc.), I have caused this SEC Form **17-Q 1st Quarter** dated MAY 19 2026 to be prepared;
2) That I read and understood its contents which are true and correct of my own personal knowledge and/or based on true records;
3) That I comply with the requirements set forth in SEC Memorandum Circular No. 18 dated 09 October 2023 and SEC Notice dated 05 March 2025, for a complete and official submission of reports and/or documents through electronic mail and/or through the Electronic Filing and Submission Tool (eFAST) effective 28 March 2025; and
4) That I am fully aware that documents filed online which requires pre-evaluation and/or processing fee shall be considered complete and officially received only upon payment of a filing fee.

IN WITNESS WHEREOF, I hereunto affix my signature this MAY 19 2026, in Iloilo City.

AGNES JEAN M. VILLAFLOR
Affiant

SUBSCRIBED AND SWORN TO before me this MAY 19 2026 at Iloilo City, Philippines, affiant exhibiting her PRC ID #0070893.

ATTY. KRISTAL JOY S. ADORACION
NOTARY PUBLIC
CITY and PROVINCE OF ILOILO
Notarial Commission No. 248 / Valid until 12-31-2026
Roll of Attorneys No. 54[illegible] / 1/24/2025
IBP No. 535575 / 1-5-2026 / Iloilo City
PTR No. 5816035 / 1-5-2026 / Iloilo City
DB GSO Business Center, Blk 5, Lot 6, Dollias,
Mandurriao, Iloilo City
MCLE Compliance (Signed the Roll of Attorney's January 5, 2022)

Doc. No. 408
Page No. 83
Book No. I
Series of 2026.

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended **31 MARCH 2026**

2. Commission identification number **CS201423954** 3. BIR Tax Identification No: **008-922-703**.

ASIA PACIFIC MEDICAL CENTER (APMC) – ILOILO, INC. (Formerly Allied Care Experts (ACE) Medical Center – Iloilo, Inc.

4. Exact name of issuer as specified in its charter

Iloilo City, Philippines

5. Province, country or other jurisdiction of incorporation or organization

6. Industry Classification Code: [ ] (SEC Use Only)

Brgy. Ungka , Jaro, Iloilo City **5000**

7. Address of issuer's principal office Postal Code

8. Issuer's telephone number, including area code: **(033) 3215748/09175234802**

9. **N.A.**

Former name, former address and former fiscal year, if changed since last report

10. Securities registered pursuant to Sections 8 and 12 of the Code, or Sections 4 and 8 of the RSA

Title of each Class	Number of Shares Outstanding	Amount of Debt
Founder Shares	600	
Common Shares	239,400	
Debt Outstanding		2,399,838,947

11. Are any or all of the securities listed on a Stock Exchange? Yes [ ] No [✓]

If yes, state the name of such Stock Exchange and the class/es of securities listed therein:

12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the Code and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period the registrant was required to file such reports)

Yes [✓] No [ ]

(b) has been subject to such filing requirements for the past ninety (90) days. Yes [✓] No [ ]

TABLE OF CONTENTS

	Page No.
Part I - Financial Information	
Item 1 – Financial Statements	3
Item 2 – Management's Discussion and Analysis	3
Results of Operations	3
Plan of Operations	3
Statement of Financial Condition	4
Financial Soundness Indicator	6
Trends, Events and/or Uncertainties	8
	9
Part II - Other Information	
Signatures	11
Annex A – Financial Statement	12
Schedules	
Schedule A. *Financial Assets*	64
Schedule B. *Amounts Receivable from Directors, Officers, Employees, Related Parties and Principal Stockholders*	64
Schedule C. *Amounts Receivable from Related Parties which are eliminated during Consolidation of Financial Statements*	64
Schedule D. *Long-Term Debt*	64
Schedule E. *Indebtedness to Related Parties*	64
Schedule F. *Guarantees of Securities of Other Issues*	65
Schedule G. *Capital Stock*	65
Map of the Relationships Between and Among the Companies in the Group, its Ultimate Parent Company and Co-Subsidiaries	67
Schedule of Financial Soundness Indicators	68

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

The Financial Statements (FS) of the Company as of and for the 3 months ended March 31, 2026 is incorporated herein. (see Annex A)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Management Discussions and Analysis (MD&A) or Plan of Operations

I. RESULTS OF OPERATIONS (March 31, 2026 vs. March 31, 2025)

			Horizontal Analysis		Vertical Analysis	
	31-March-26	31-March-25	Inc./(Dec.)	%	31-March-26	31-March-25
Net Revenue	P107,536,458	P82,148,885	25,387,573	30.90%	100.00%	100.00%
Direct Cost	(66,207,525)	(63,974,470)	2,233,055	-3.49%	61.57%	77.88%
Gross profit/(loss)	41,328,933	18,174,415	23,154,518	127.40%	38.43%	22.12%
Other income	2,776,785	816,308	1,960,477	240.16%	2.58%	0.99%
Gross income / (loss)	44,105,718	18,990,723	25,114,995	132.25%	41.01%	23.12%
General and admin expenses	(71,870,856)	(64,381,440)	7,489,416	-11.63%	66.83%	78.37%
Loss from operations	(27,765,138)	(45,390,717)	(17,625,579)	38.83%	25.82%	55.25%
Finance cost	(35,890,364)	(42,918,349)	(7,027,985)	16.38%	33.38%	52.24%
Net Income / (loss) for the period	**(P63,655,502)**	**(P88,309,066)**	**(P24,653,564)**	**27.92%**	**59.19%**	**107.50%**

REVENUE

During the third quarter ending March 31, 2026, Hospital generated Php107.54 million in revenue, net of discounts, representing a 30.90% increase from the previous year's Php82.15 million. This positive trend underscores the hospital's commitment to fostering patient relationships and continuously enhancing its products and services. Hospital's gross revenue of Php122.94 million includes the following services:

- Pharmacy: Php35.91 million (29.21%)
- Room accommodation: Php22.31 million (18.15%)
- Laboratory: Php19.04 million (15.49%)
- Imaging: Php10.96 million (8.91%)
- Central supply room: Php10.69 million (8.70%)
- Pulmonary: Php5.56 million (4.52%)
- Dialysis: Php4.91 million (4.00%)
- Other specialized healthcare services: Php13.56 million (11.03%)

DIRECT COST

Direct costs, directly attributable to patient care, experienced an increase due to factors such as the procurement of medications and supplies, the surge in patient volume, and the requirement for specialized equipment and personnel. For the third quarter concluded on March 31, 2026, Php66.21 million, comprising Php39.71 million in direct hospital supplies and Php26.50 million in direct overheads.

GENERAL AND ADMIN EXPENSES

This account consists of:

	For the 1st quarter periods March		Horizontal Analysis	
	2026	2025	Inc./(Dec.)	%
Salaries and Wages	P23,491,369	P25,710,653	(P2,219,284)	-8.63%
Utilities Expenses	12,563,082	7,829,492	4,733,590	60.46%
Depreciation	11,948,988	11,578,310	370,678	3.20%
Professional Fees	5,761,241	4,561,761	1,199,480	26.29%
SSS, PHIC and HDMF Contributions	3,852,257	4,121,398	(269,141)	-6.53%
Security Services	3,043,597	2,628,907	414,690	15.77%
Office Supplies	2,642,211	1,487,591	1,154,620	77.62%
Housekeeping Expense	1,898,531	2,870,819	(972,288)	-33.87%
Repairs and Maintenance Expenses	883,183	256,136	627,047	244.81%
Taxes and Licenses	643,111	1,620,623	(977,512)	-60.32%
Communication Expenses	393,281	174,399	218,882	125.51%
Training, Workshop, Seminar	277,750	112,694	165,056	146.46%
Transportation and Travel Expenses	112,756	350,658	(237,902)	-67.84%
Entertainment and Representation Expenses	111,836	45,849	65,987	143.92%
Board meetings and conferences	15,000	-	15,000	100.00%
Advertising Expenses	-	9,585	(9,585)	-100.00%
Miscellaneous Expenses	4,232,663	1,022,565	3,210,098	313.93%
TOTAL	**P71,870,856**	**P64,381,440**	**P7,489,416**	**11.63%**

General and administrative expenses for the 1st quarter ending March 31, 2026, amounted to Php71.87 million, a 11.63% increase from the previous year's Php64.38 million. This substantial increase reflects core business operations expenses, including salaries and wages (Php23.49 million), utilities (Php12.56 million), depreciation (Php11.94 million), professional consultancy fees (Php5.76 million), housekeeping and security services (Php4.94 million), taxes and license fees (Php0.64 million), and other expenses (Php 12.54 million). The significant increase in depreciation expenses is attributed to the building amounting to Php9.19 million as of March 31, 2026.

Other Income

Other income is mostly derived from interest income earned from bank; affiliation fee and other miscellaneous income amounted to Php2,174; and Php2.77 million, during the first quarter period ending March 31, 2026, respectively.

Finance Costs

This consists of interest expenses incurred on bank and related party loans. For the 1st quarter ended March 31, 2026, bank loans incurred Php18.98 million in interest, while related party loans incurred Php16.91 million.

Net Losses for the Period

Despite its financial deficit, the hospital encountered challenges during the first quarter of 2026. To sustain its operations, it requires an increase in patient admissions and collaborates with affiliated physicians for referrals and marketing initiatives. We remain optimistic about overcoming these obstacles and delivering exceptional hospital services.

II. PLAN OF OPERATION

Asia Pacific Medical Center–Iloilo, Inc. ("APMC Iloilo" or the "Hospital") incurred net losses during the last two (2) fiscal years. Management attributes such losses primarily to the Hospital's early-stage operating profile following inauguration, the fixed costs inherent in hospital operations, the gradual build-up of patient volumes, and the continuing expenditures necessary to support personnel, equipment, utilities, and other operational requirements.

Management notes that, based on industry experience and as observed by the Hospital's independent auditor, healthcare institutions of similar scale typically require approximately four (4) to five (5) years from inauguration to recover initial capital expenditures and attain more stable operating levels. In this regard, management believes that the Hospital's financial performance to date remains generally consistent with the expected development period of a newly established hospital facility.

During the current year, the Hospital recorded a 47% increase in gross revenues compared to the previous year. Management believes that this growth is aligned with internal projections and reflects continued improvement in patient volumes, service utilization, physician referrals, and market awareness within the City and Province of Iloilo. Although the Hospital has not yet attained profitability, management considers the current revenue growth trend to be a positive indicator of its ongoing operational development.

For the next twelve (12) months, the Hospital's plan of operation shall focus on: (i) increasing patient volumes and revenues, (ii) improving operating efficiency and expense management, (iii) strengthening liquidity and collections, and (iv) supporting operations and future growth through additional capitalization.

Management's principal operating objectives are to:

1. Increase patient volumes in major service lines, including inpatient, outpatient, emergency, surgery, women's health, pediatrics, diagnostics, laboratory, imaging, and ancillary services;
2. Improve utilization of existing facilities, equipment, and manpower;
3. strengthen referral relationships with physicians, clinics, and healthcare providers in Iloilo and nearby areas;
4. Improve billing, claims processing, and collection efforts, particularly for government healthcare programs, HMOs, corporate accounts, and self-pay patients;
5. Implement cost management measures, including tighter control over operating expenses, inventory, manpower, and non-essential expenditures; and
6. Preserve liquidity through internally generated cash flows, working capital management, and, when necessary, capital-raising or financing initiatives.

As part of its capital strengthening measures, management intends to recommend an increase in the Hospital's authorized capital stock, subject to approval by the Board of Directors and stockholders. The Hospital also plans to pursue a second round of public offering of its shares, subject to compliance with the requirements of the Securities and Exchange Commission and other applicable regulatory approvals.

Management believes that, if successfully implemented, these capital measures will provide additional resources to support operations, strengthen the Hospital's balance sheet, and fund priority investments. However, there can be no assurance that such capital-raising initiatives will be completed within the expected timeframe.

The Hospital likewise intends to continue prioritizing the development of its core revenue-generating departments while exercising prudent control over operating costs and limiting capital expenditures to those necessary for patient care, operational continuity, compliance, and selected service improvements. Currently, the Company employs approximately seven hundred fifty six (756) individuals. The decision to hire additional employees will be contingent upon the outcome of the upcoming hospital census.

Management recognizes that the execution of its plan of operation remains subject to various risks and uncertainties, including competitive conditions, cost inflation, staffing constraints, reimbursement and collection delays, regulatory developments, and broader economic conditions. While there can be no assurance that the Hospital will achieve profitability within the next twelve (12) months, management believes that its current revenue growth trend and planned capital measures provide a reasonable basis for the continuation of operations and the gradual improvement of financial performance.

The Company intends to purchase the following equipment to attract more patients:

1. Pet scan
2. Cath lab Machine
3. Mechanical Ventilators (High-End With Advanced Modes) -Avea (3IN1 Ventilator)
4. Cyber Ho Magneto System 152W Holmium: YAG Surgical Laser System
5. Hospital Waste Management Plant
6. Sonomammography
7. M822 Leica Microscope
8. Portable Ultrasound(Ge)
9. Mammo(Ui)2D
10. KW ON-Grid Rooftop Solar
11. Alcon Centurion Phacoemulsification Machine

12. 2D Echo Vivid T9 (GE)
13. Ultrasound LOGIQ P8 (GE)
14. Cardiac Rehab System
15. Polysomnography Machine (Sleep Machine)
16. NCV/EMG
17. EEG
18. Infusion Pump
19. Super Inductive System BTL-6000
20. Syringe Pump
21. Sewage Treatment Plant
22. Bone Densitometry
23. Treadmill (GE)
24. Biosafety Cabinet Class III
25. Calibration Tools
26. ECG Machine (GE)
27. Detecto Weighing Scale
28. Ortho Table
29. Fracture Bed

These are expected to enhance service capacity and support the Hospital's operational and revenue growth objectives, subject to funding availability.

III. STATEMENT OF FINANCIAL CONDITION (March 31, 2026 VS. December 31, 2025)

			Horizontal Analysis		Vertical Analysis		
ASSETS	31-March-26	31-Dec-25	Inc./(Dec.)	%	31-March-26	31-Dec-24	
CURRENT ASSETS							
Cash	P26,414,935	P23,296,041	3,118,894	13.39%	0.96%	0.86%	[I.II]
Receivables	192,816,543	165,796,569	27,019,974	16.30%	7.04%	6.11%	[I.II]
Advances to contractors and suppliers	89,868,430	72,449,059	17,419,371	24.04%	3.28%	2.67%	[I.II]
Medical and hospital supplies inventories	47,935,244	59,994,528	(12,059,284)	-20.10 %	1.75%	2.21%	[I.II]
Prepayments and other current assets	33,109,906	28,714,938	4,394,968	15.31%	1.21%	1.06%	[I.II]
TOTAL CURRENT ASSETS	**390,145,058**	**350,251,135**	**39,893,923**	**11.39%**	**14.24%**	**12.90%**	[I.II]
NON-CURRENT ASSETS							
Property and equipment (net)	**2,342,868,883**	**2,357,222,256**	**(14,353,373)**	**-0.61%**	**85.51%**	**86.84%**	[I.I]
Advances to related parties	**6,950,256**	**6,950,256**	**-**	**0.00%**	**0.25%**	**0.26%**	
TOTAL NON-CURRENT ASSETS	**2,349,819,139**	**2,364,172,512**	**(14,353,373)**	**-0.61%**	**85.76%**	**87.10%**	[I.I]
TOTAL ASSETS	**2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	[I]
LIABILITIES AND EQUITY							
CURRENT LIABILITIES							
Accounts payable and other liabilities	**717,399,179**	**689,539,570**	**27,859,609**	**4.04%**	**26.18%**	**25.40%**	[II]
Loans payable to individuals	**91,589,939**	**15,703,226**	**75,886,713**	**483.26 %**	**3.34%**	**0.58%**	[II]
Notes payable - current portion	**227,010,404**	**191,558,072**	**35,452,332**	**18.51%**	**8.29%**	**1.66%**	[II]
TOTAL CURRENT LIABILITIES	**1,035,999,522**	**896,800,868**	**139,198,654**	**15.52%**	**37.81%**	**27.64%**	
NON-CURRENT LIABILITIES							
Notes payable - net of current portion	757,790,363	954,351,037	(50,002,602)	-6.19%	27.66%	35.16%	[II]
Loans payable to related party	**544,871,969**	**544,871,969**	**-**	**0.00%**	**19.89%**	**20.07%**	[II]
Deferred tax liability	**61,177,093**	**61,177,093**	**-**	**0.00%**	**2.23%**	**2.25%**	[II]
TOTAL NON-CURRENT LIABILITIES	**1,363,839,425**	**1,560,400,099**	**(50,002,602)**	**-3.54%**	**49.78%**	**55.23%**	
TOTAL LIABILITIES	**2,399,838,947**	**2,310,642,895**	**89,196,052**	**3.86%**	**87.59%**	**82.87%**	[II]
EQUITY							
Share Capital (net)	**240,000,000**	**240,000,000**	**-**	**0.00%**	**8.76%**	**8.84%**	
Share Premium	**958,532,662**	**958,532,662**	**-**	**0.00%**	**34.98%**	**35.31%**	
Revaluation surplus	183,531,277	183,531,277	-	0.00%	6.70%	6.76%	
Retained Earnings/(Deficit)	(1,041,938,689)	(978,283,187)	(63,655,502)	6.51%	-38.03%	-36.04%	
TOTAL EQUITY	**340,125,250**	**403,780,752**	**(63,655,502)**	**-15.76 %**	**12.41%**	**17.13%**	[III]
TOTAL LIABILITIES AND EQUITY	**P2,739,964,197**	**2,714,423,647**	**25,540,550**	**0.94%**	**100.00%**	**100.00%**	

Assets

[I]	**Assets**	As of the first quarter period ending March 31, 2026, the Company's assets have exhibited a consistent growth trajectory. This growth is primarily attributed to the strong performance of essential financial assets, including cash, receivables, and hospital supplies. These assets are necessary for ensuring patient care and optimizing operational efficiency. As of March 31, 2026, the Company's total assets were Php2.74 billion, with Php0.39 billion (14.24%) in current assets and Php2.34 billion (85.76%) in non-current assets.
[I.I]	**Non-Current Assets**	The Company's non-current assets consisted of the following: **Property and Equipment, Net of Depreciation** As of March 31, 2026, this account consists of the land with revalued carrying amount of Php273.00 million, Building - Php1,753.77 billion, medical equipment - Php238.97 million, hospital equipment - Php50.05 million, kitchen tools - Php15.22 million, hospital vehicles - P5.76 million, and office equipment - Php6.10 million. During the year, the Company had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026, by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. **Advances to Related Party** Advances to related parties have no movement as of March 31, 2026

[I.II]	**Current Assets**	**The current assets consist of the following:** **Cash and Cash Equivalents** The surge in cash and cash equivalents is attributable to collections from its revenue streams. The hospital consistently encounters substantial increments in patient volume and revenue generation. Despite commencing operations, it encountered challenges, including escalating patient admissions to sustain daily operations and relying on its affiliate physicians for referrals. Furthermore, the hospital engaged in marketing and promotional endeavors to attract potential patients. It remains optimistic about overcoming these challenges as it continues to provide hospital services to the public. **Medical and Hospital Supplies Inventories** As of March 31, 2026, the inventory account comprises general hospital maintenance supplies; medical and laboratory supplies; and drugs and medicines, amounting to Php21.53 million, Php19.26 million, and Php7.15 million, respectively. **Trade and Other Receivables** The hospital's trade and other receivables indicate a positive financial position, although cash payments have not yet been received. Several factors contribute to this delay, including the billing methods employed for patients, the payment processes of insurance companies, and the payment arrangements made by patients for their medical care. As of March 31, 2026, the hospital's trade and other receivables encompass funds from PHIC (Php72.92 million), HMOs (Php55.10 million), Government Institutions (Php44.23 million), and other sources (Php20.57 million). Refundable deposits, including Php5.00 million to MORE POWER Corporation, Php15,000 to Iloilo Medical Society for office rent, and Php20,000 for drug testing services from the Department of Health, have been reclassified to the other receivable, current assets account. These deposits are expected to be applied for or recovered as per the agreements and regulatory requirements. **Advances to contractors and suppliers** Advances to contractors and suppliers. Advances to contractors are recognized as a benefit for each project awarded and are liquidated through deduction, on a pro-rata basis, from the contractor's periodic progress billings. As a result of the building's completion, there was no material movement to this account as at March 31, 2026. Advances to suppliers increased by Php17.42 million (24.04%), representing down payments made to various hospital suppliers as at March 31, 2026. **Prepayments and other Current Assets** The account represents the unutilized cost of insurance amounted to Php0.82 million, Php24.34 million for the excess of input over output VAT and the carryover of input VAT from previous periods, and prepaid income tax of Php7.94 million, as at March 31, 2026.

[II]	**Liabilities**	**Accounts Payables and Other Liabilities** This account consists of the following: Accounts payable - contractors and suppliers amounting to Php368.59 million; Retention Payable amounting to Php40.56 million; Accrued Interest Payable Php172.20 million; and other payables amounting to Php136.05 million. **Loans Payable to Related Parties** These are loans extended by Phil Pharmawealth, Inc. (PPI) to the Company. As of December 31, 2024, the balance stands at P544.87 million. These loans were granted to help pay off company obligations. **Loans from Individuals** These are loans provided to the Company to help in the construction of the hospital building and sustain its operations. These are gradually liquidated whenever funds are available. As of March 31, 2026, the balance amounted to Php91.59 million. **Notes Payable (LBP)** In 2023, Landbank of the Philippines, approved the restructuring of the total outstanding balance of term loan 1, 3 and 4 in the amount of Php985,594,306 up to seven (7) years from date of effectivity with one (1) quarter grace period on principal and interest. In 2024, it approved Term Loan 6 and a Working Capital Line for P70 million and P30 million, respectively. As at March 31, 2026, the outstanding balance amounted to Php984.80 million and interest expense incurred amounted to Php18.98 million. **Deferred Tax Liabilities** This account represents the recognized deferred tax liability on revaluation resulted from the conducted land appraisal.
[III]	**Equity**	The Company's land was appraised in 2026 by Cubing Surveying, an SEC-accredited professional valuer. The appraisal report, issued on March 9, 2026, used the Sales Comparison Approach based on recent comparable property transactions. As of December 31, 2025, the revaluation resulted in a surplus of Php244,708,370. As of March 31, 2026, the total equity stood at Php340.13 million, a decrease of Php63.66 million (15.76%) resulting from the loss incurred during the quarter.

IV. FINANCIAL SOUNDNESS INDICATOR (March 31, 2026 VS December 31, 2025)

Key Performance Indicators

	Definition	31-March-26	31-Dec-25	Remarks
1. Liquidity				
Quick Asset Ratio	$\frac{\text{Cash + Receivables}}{\text{Current Liabilities}}$	0.21:1	0.21:1	During the first quarter of its operations in 2026, the hospital encountered an elevated level of trade and other receivables. This suggests that the hospital has generated revenue but has not yet received cash payments due to billing processes, insurance claims, or patient payment arrangements. Additionally, current liabilities have experienced significant increase. The rise in current liabilities can be attributed to the recognized current portion of the long-term bank loan and advances from the stockholders to be utilized for operational purposes. Consequently, strategies have been implemented to optimize cash collection, thereby enhancing the company's access to funds and facilitating its timely payment of debts.
Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	0.38:1	0.39:1	During the first quarter of its operations in 2026, the hospital experienced an increase in patient volume and revenue, which resulted in a decrease in its current asset ratio compared to the previous year. This reduction can be attributed to an increase in receivables and current liabilities. While the hospital has generated revenue, it has not yet received cash payments due to billing processes, insurance claims, or patient

				payment arrangements. Additionally, current liabilities have significantly increased. This rise in current liabilities can be attributed to the recognition of the current portion of the long-term bank loan and advances from stockholders intended for operational purposes. In response to these challenges, the hospital has implemented strategies to optimize cash collection, thereby improving its access to funds and ensuring timely payment of debts.
2. Solvency				
Debt to Equity Ratio	Long Term Debt / Equity	4.01:1	3.50:1	The rise in long-term debt is attributed to additional loans granted to the hospital, while the revenue generated from sales has not yet been sufficient to cover the expenses incurred in the monthly operations.
3. Profitability				
Net Profit Margin	Net Income / Total Revenue	0.00	0.00	While sales growth has been favorable, operational expenses have experienced an increase. Undeterred by these challenges, the hospital maintains optimism about surmounting them in the forthcoming years and providing exceptional healthcare services to our community.
Return on Equity	Net Income / Stockholder's Equity	0.00	0.00	Stockholders can expect to earn returns on their investment after the hospital generates net income.
4. Leverage				
Debt to Total Asset Ratio	Total Liabilities / Total Asset	0.88:1	0.85:1	There has been a slight increase in total liabilities compared to total assets. The hospital is still in debt to Land Bank for loans used for constructing the building and acquiring state-of-the-art medical equipment. The increase in liabilities also includes current liabilities.
Asset To Equity Ratio	Total Asset / Equity	8.06:1	6.72:1	This increase in the ratio indicates that a substantial portion of the hospital's assets, including the most recent medical equipment, the hospital's buildings, and its infrastructure, is being financed through loans and borrowing.
5. Interest Rate Coverage Ratio	Earnings Before Interests & Taxes / Interest Expense	0.00	0.00	An increase in the Interest Coverage Ratio (ICR) can be attributed to the company's efforts in timely payments and effective debt management throughout the year.

Trends, Events or Uncertainties that have had or that are reasonably expected to affect revenues or income

As of March 31, 2026:

1. The company's improved quick asset and current ratios reflect enhanced liquidity, primarily due to increased collections from patient admissions and receivables from PhilHealth and other government agencies such as DSWD and PCSO. While the hospital remains operational, it continues to face initial challenges, including the need to boost patient admissions, reduce reliance on affiliate doctors for referrals, and strengthen marketing efforts to expand its patient base. Management remains optimistic that these issues will be addressed in the coming quarters through ongoing service enhancements and operational strategies. There are no seasonal aspects that had any material impact on the financial condition or results of operations of the Company.
2. There are no events or any default or acceleration of an obligation that will trigger direct or contingent financial obligation that is material to the Company.
3. There are no off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the Company with unconsolidated entities or other persons created during the period.
4. A complaint was filed against Allied Care Experts Medical Center-Valenzuela, Allied Care Experts Medical Center-Pateros, Allied Care Experts Medical Center-Baypointe, Allied Care Experts Medical Center–Quezon City, Allied Care Experts (ACE) Medical Center-Baliwag and Asia Pacific Medical Center-Iloilo (formerly Allied Care Experts Medical Center-Iloilo) before the Insurance Commission (IC) for engaging in pre-need activities without license. Ferdinand Kionisala declared that the benefits and privileges enjoyed by him or offered by any of the named respondents he impleaded in his complaint is not a pre-need contract, agreement, deed, nor plan contemplated under the law and that ACEMC-Cebu or any other respondent named (which include ACEMC-Iloilo) are not engaged in pre-need business, hence not required to secure a separate license therefor before the Insurance Commission. Kionisala filed a Motion for Reconsideration dated 25 November 2020 but was denied. Later on, he filed a special civil action for Certiorari under Rule 65 before the Court of Appeals alleging that the Insurance Commission acted with grave abuse of discretion amounting to lack or excess of jurisdiction. In his petition dated 04 February 2022, Mr. Kionisala prayed that the Court of Appeals set aside the letter dated 11 December 2018 and letter dated 29 November 2021, be nullified and set aside, and that the Insurance Commission be ordered to take appropriate action(s) against the private respondents for violating the Pre-Need Code of the Philippines.

   In a Resolution dated 26 July 2022, the Eighteenth (18th) Division of the Court of Appeals directed the petitioners to rectify the infirmity observed in the petition within an inextendible period of ten (10) days from notice, which is the submission of a mere plain photostatic copy of the assailed letter dated 11 December 2018. Petitioner submitted its compliance on 22 September 2022, copy of which was received by APMC Iloilo on 19 October 2022.

   On 01 September 2025, APMC Iloilo received a Resolution dated 05 March 2025, directing the parties to file their respective Comments on the petitioner’s Petition for Certiorari within an inextendible period of ten (10) days from notice. APMC Iloilo subsequently filed its Comment on 11 September 2025.

   As of 31 March 2026, to the knowledge and information of the Company, there are no other pending material legal proceedings that involve APMCI or any of its properties aside from the aforementioned case.

5. The company has no investment on foreign securities.
6. There were material commitments for capital expenditure during the period as disclosed in Note 11 of the financial statements.

PART II – OTHER INFORMATION

There are no additional material information to be disclosed which were not previously reported under SEC Form 17-C

SIGNATURES

Pursuant to the requirements of the Securities Regulation Code, the issuer has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AGNES JEAN M. VILLAFLOR
PRESIDENT
May 19, 2026

CRIS T. CORTES
CHIEF FINANCE OFFICER
May 19, 2026

ANNEX A

Asia Pacific Medical Center – Iloilo, Inc.

(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

Unaudited Interim Financial Statements

As of and for the 1st quarter period ended March 31, 2026
(with comparative figures as at December 31, 2025 and for the 1st quarter period ended March 31, 2025)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

STATEMENTS OF FINANCIAL POSITION

AS OF MARCH 31, 2026 AND DECEMBER 31, 2025
(Amounts in Philippine Peso)

ASSETS	*Notes*	**2026 Unaudited**	2025 Audited
CURRENT ASSETS			
Cash	***4,6,26***	**P26,414,935**	P23,296,041
Receivables	***4,7,26***	**192,816,543**	165,796,569
Advances to contractors and suppliers	***4,8***	**89,868,430**	72,449,059
Medical and hospital supplies inventories	***4,9***	**47,935,244**	59,994,528
Prepayments and other current assets	***4,10***	**33,109,906**	28,714,938
		390,145,058	350,251,135
NON-CURRENT ASSETS			
Property and equipment (net)	***4,11***	**2,342,868,883**	2,357,222,256
Advances to related parties	***12,26***	**6,950,256**	6,950,256
		2,349,819,139	2,364,172,512
TOTAL ASSETS		**2,739,964,197**	2,714,423,647
LIABILITIES AND EQUITY			
CURRENT LIABILITIES			
Accounts payable and other liabilities	***4,13,26***	**717,399,179**	689,539,570
Loans payable to individuals	***14,26***	**91,589,939**	15,703,226
Notes payable - current portion	***15,26***	**227,010,404**	191,558,072
		1,035,999,522	896,800,868
NON-CURRENT LIABILITIES			
Notes payable - net of current portion	***15,16***	**757,790,363**	807,792,965
Loans payable to a related party	***12***	**544,871,969**	544,871,969
Deferred tax liability	***16,18***	**61,177,093**	61,177,093
		1,363,839,425	1,413,842,027
TOTAL LIABILITIES		**2,399,838,947**	2,310,642,895
EQUITY			
Share capital (net)	***4,17***	**240,000,000**	240,000,000
Share premium	***4,17***	**958,532,662**	958,532,662
Revaluation surplus	***16,18***	**183,531,277**	183,531,277
Deficit	***4,26***	**(1,041,938,689)**	(978,283,187)
TOTAL EQUITY		**340,125,250**	403,780,752
TOTAL LIABILITIES AND EQUITY		**P2,739,964,197**	P2,714,423,647

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)
UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE PERIODS ENDED MARCH 31, 2026 AND 2025
(Amounts in Philippine Peso)

	Notes	**2026**	2025
REVENUE	***4,19***	**P107,536,458**	P82,148,885
DIRECT COST	***4,20***	**66,207,525**	63,974,470
GROSS INCOME		**41,328,933**	18,174,415
OTHER INCOME	***4,6,21***	**2,776,785**	816,308
GROSS INCOME		**44,105,718**	18,990,723
GENERAL AND ADMINISTRATIVE EXPENSES	***4,22***	**71,870,856**	64,381,440
LOSS FROM OPERATIONS		**(27,765,138)**	(45,390,717)
FINANCE COSTS	***12,15***	**(35,890,364)**	(42,918,349)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(P63,655,502)**	(P88,309,066)

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

UNAUDITED STATEMENTS OF CHANGES IN EQUITY
AS OF MARCH 31, 2026
(Amounts in Philippine Peso)

	Share Capital (Note 16)	Share Premium (Note 16)	Revaluation Surplus (Note 17)	Deficit (Note 1)	Total
EQUITY					
As at January 1, 2024	P239,960,000	P953,896,162	P -	(P345,203,042)	P848,653,120
Proceeds from subscription receivable	-	3,476,500	-	-	3,476,500
Net loss for the period	-	-	-	(397,759,075)	(397,759,075)
As of December 31, 2024	239,960,000	957,372,662	-	(742,962,117)	454,370,545
Additional share capital	40,000	-		-	40,000
Share premium	-	1,560,000	-	-	1,560,000
Subscription receivable	-	(400,000)	-	-	(400,000)
Appraisal increase (Land)	-	-	183,531,277	-	183,531,277
Net loss for the year	-	-	-	(235,321,070)	(235,321,070)
As of December 31, 2025	**240,000,000**	**958,532,662**	**183,531,277**	**(978,283,187)**	**403,780,752**
Additional share capital	-	-	-	-	-
Share premium	-	-	-	-	-
Subscription receivable	-	-	-	-	-
Appraisal increase (Land)	-	-	-	-	-
Net loss for the year	-	-	-	**(63,655,502)**	**(63,655,502)**
As of March 31, 2026	**P240,000,000**	**P958,532,662**	**P183,531,277**	**(P1,041,938,689)**	**P340,125,250**

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center - Iloilo Inc.)

UNAUDITED STATEMENTS OF CHANGES IN EQUITY
FOR THE PERIODS ENDED MARCH 31, 2026, DECEMBER 31, 2025 and 2024

	Notes	**2026**	**2025**	2024
CASH FLOWS FROM OPERATING ACTIVITIES				
Net loss before income tax		**(P63,655,502)**	**(P235,321,070)**	(P397,759,075)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:				
Depreciation	***4,11***	**38,255,815**	**150,719,634**	148,272,068
Interest income	***4,6,21***	**(2,175)**	**(1,002)**	(2,106)
Unrealized foreign exchange gain/(loss)	***4,6,21***	**-**	**3,505**	(310,228)
Interest expense	***4,15***	**35,890,364**	**136,010,582**	(155,699,208)
Operating cashflows before changes in working capital		**10,488,502**	**51,411,649**	(405,498,549)
Changes in working capital components:				
Decrease (increase) in current assets:				
Receivable	***4,7,26***	**(27,019,974)**	**(83,366,406)**	(69,436,588)
Advances to contractors and suppliers	***8***	**(17,419,371)**	**(24,872,330)**	10,587,407
Medical and hospital inventories	***9***	**12,059,284**	**15,667,861**	(72,952,625)
Prepayments and other current assets		**(4,394,968)**	**(10,641,610)**	(14,036,648)
Increase (decrease) in current liabilities:				
Accounts payable and other liabilities		**3,427,087**	**160,075,552**	229,246,192
Net cash provided/(used in) operations		**(22,859,440)**	**108,274,716**	(322,090,811)
Income tax paid	***20***	**-**	**(1,260,617)**	(953,920)
Interest received	***6,19,21***	**2,175**	**1,002**	2,106
Net cash provided/(used in) operating activities		**(22,857,265)**	**107,015,101**	(323,042,625)

Balance forwarded

		As at period ended March 31 and December 31,		
	Notes	*2026*	2025	2024
CASH FLOWS FROM INVESTING ACTIVITIES				
Additions to construction-in-progress	***11***	**-**	**-**	1,900,987,351
Additions to property and equipment	***4,11***	**(23,902,442)**	**(24,572,572)**	(1,859,376,138)
Other non-current assets	13,27	**-**	**-**	(20,000)
Net cash provided/(used in) investing activities		**(23,902,442)**	**(24,572,572)**	41,611,213
CASH FLOWS FROM FINANCING ACTIVITIES				
Advances to related parties	***12,26***	**-**	32,079,869	-
Payments of loans payable to individuals	***14,26***	**(5,700,000)**	-	(4,639,474)
Proceeds from bank loans	***15***		30,000,000	-
Payments of principal on bank loans	***15,26***	**(14,550,270)**	(1,243,269)	(15,000,000)
Proceeds of loans payable to a related party	***15***		1,000,000	150,437,000
Additional share capital	***4, 17***		40,000	-
Advances from shareholders		**81,586,713**		
Proceeds from subscription receivable	***4,17***		1,160,000	3,476,500
Interest paid	***4,15***	**(11,457,842)**	(136,010,582)	155,699,208
Net cash provided/(used in) by financing activities		**49,878,601**	(72,973,983)	289,973,234
NET EFFECT OF EXCHANGE RATE	***4,6,21***	**-**	(3,505)	310,228
NET INCREASE/(DECREASE) IN CASH		**3,118,894**	9,465,042	8,832,050
CASH, beginning of the year		**23,296,041**	13,830,999	4,998,949
CASH, end of the year	***6***	**P26,414,935**	P23,296,041	P13,830,999

(The accompanying Notes to Financial Statements is an integral part of these Financial Statements)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.

NOTES TO FINANCIAL STATEMENTS
As of and for the years ended March 31, 2026, 2025 and 2024
(Amounts in Philippine Peso)

NOTE 1 - CORPORATE INFORMATION AND STATUS OF OPERATIONS

Corporate Information

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC. (the "Company") was incorporated as a domestic corporation under Philippine laws and was duly registered with the Securities and Exchange Commission (SEC) under registration no. CS201423954 on December 10, 2014.

The Company's primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and businesses such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinics, condo-hospitals, scientific research institutions and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional, medical or surgical services shall be performed by duly qualified and licensed physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The Company is a duly registered Board of Investment (BOI) - Accredited "New Operator of General Hospital" at Level 2 Category on a Non-Pioneering Status with Certificate of Registration No. 2023-065 in accordance with the provisions of the Omnibus Investment Code of 1987 (Executive Order No. 226) and pursuant to Title XIII of the Tax Code of 1997, as amended by Republic Act 11534, or the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.

The Certification entitles the Company to certain major incentives, to wit: (1) Income Tax Holiday (ITH) for six (6) years, Enhanced Deductions for five (5) years and (3) Duty exemptions for eleven (11) years. The Company should have started commercial operations in January 2023 (or within three (3) years from date of registration with the BOI) but availment shall in no case commence earlier than the date of registration with BOI.

The Company was granted by the Philippine Health Insurance Corporation of certificate of accreditation as a Level 2 Hospital (Accredited Beds: 100) which was granted on 6th day of January 2025 the certificate of which shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Philippine Hospital Association of certificate of membership as a Level 2 Hospital (Accredited Beds: 100) on 20th day of December 2024 and this certificate shall be valid from January 1, 2025 to December 31, 2025.

The Company was granted by the Department of Health, as a Level 2 Hospital (Accredited Beds: 100), with license number 06-0023-25-H2-2 and this license to operate shall be valid from January 1, 2025 to December 31, 2025.

On August 2, 2021, and in accordance with the approval of the appropriate regulatory authorities, including the Securities and Exchange Commission, the Company amended its corporate name from Allied Care Experts (ACE) Medical Center – Iloilo, Inc. to Asia Pacific Medical Center – Iloilo, Inc. The change in corporate name did not result in any change in the Company's legal personality, ownership structure, operations, or principal activities. Accordingly, all rights, obligations, contracts, and commitments previously entered into under the former corporate name remain valid and enforceable and are deemed to continue under the Company's new registered corporate name.

The registered office is located at Barangay Ungka, Jaro, Iloilo City, where the hospital construction site is located.

Status of Operations

The Company commenced full commercial operations of its multi-disciplinary medical facility in 2024. The hospital provides a comprehensive range of services, including in-patient and out-patient care, as well as emergency medical services. Since the start of operations, the respective revenue centers have been activated and progressively scaled to achieve full operational capacity and status.

The activation of these revenue centers reflects the hospital's transition from development to full service delivery, enabling the facility to generate revenues across its core medical disciplines. The commencement of operations in 2024 marked a significant milestone in the Company's strategy to expand its healthcare services and establish a sustainable platform for long-term growth.

The hospital healthcare system is a highly specialized and capital-intensive undertaking. Establishing a multi-disciplinary medical facility requires substantial and sustainable infrastructure investments, which typically take an average of five (5) to seven (7) years after incorporation to complete construction and inaugurate its business line services.

Given the peculiarities of the industry, it generally requires an additional four (4) to five (5) years after inauguration to recover initial capital expenditures and achieve full commercial operations. This extended timeline reflects the scale of investment, the complexity of healthcare infrastructure, and the gradual ramp-up of patient volumes and service utilization.

Against this backdrop, Management is encouraged by the Company's performance. The 47% increase in gross revenues during the current year is well aligned with its projections and demonstrates strong progress toward achieving full competitive status among hospitals in the area. This growth affirms the Company's trajectory toward recovering its initial investments, strengthening its market position, and establishing a sustainable platform for long-term expansion in the healthcare sector.

Management expects continued growth driven by:

- Increasing patient volumes as the hospital builds its reputation and expands its catchment area.
- Diversification of medical services, including specialized care units and advanced diagnostic facilities.

- Operational efficiencies from scaling up revenue centers and optimizing healthcare delivery.
- Competitive positioning within the region, supported by the hospital's modern infrastructure and comprehensive service offerings.

These factors are expected to support the Company's long-term objective of achieving sustainable profitability and securing a strong competitive presence in the healthcare industry.

Management remains confident that the hospital is well-positioned to deliver sustainable healthcare services and long-term value to stakeholders.

Authorization for Issuance of the Financial Statements

The financial statements of the Company as at and for the year ended December 31, 2025, including its comparative figures as at 2024 and 2023, were approved and authorized for issuance by the Board of Directors on May 11, 2026.

NOTE 2 - FINANCIAL REPORTING FRAMEWORK AND BASIS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS

Statement of Compliance

Basis of Preparation

The financial statements of the Company have been prepared in compliance with the Philippine Financial Reporting Standards (PFRS) Accounting Standards which are based on International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB). PFRS consist of PFRS, Philippine Accounting Standards (PAS), and Philippine Interpretations issued by the Financial and Sustainability Reporting Standards Council (FSRSC) and the Board of Accountancy (BOA) and adopted by the Securities and Exchange Commission (SEC).

Basis of Measurement

The financial statements have been prepared under the historical cost basis, unless otherwise stated.

Functional and Presentation Currency

These financial statements are presented in Philippine Peso (PhP), the currency of the primary economic environment in which the Company operates. All amounts are rounded to the nearest peso, except when otherwise indicated.

NOTE 3 - ADOPTION OF NEW AND REVISED ACCOUNTING STANDARDS AND INTERPRETATIONS

Adoption of New and Revised Accounting Standards Effective in 2025

The Company adopted all applicable accounting standards and interpretations as at December 31, 2025. The new and revised accounting standards and interpretations that have been published by

the International Accounting Standards Board (IASB) and approved by the Financial and Sustainability Reporting Standards Council (FSRSC) in the Philippines, that were assessed by the Management to be applicable to the Company's financial statements are as follows:

Adoption of Amended Standards Effective Beginning on or after January 1, 2025:

The accounting policies adopted are consistent with those of the previous financial year, except for the adoption of the following new and amended Standard which the Company adopted effective for annual period beginning January 1, 2025.

Unless otherwise indicated, the adoption of the new and amended standard did not have any material effect on the financial statements. Additional disclosures have been included in the notes to financial statements, as applicable.

- Amendments to PAS 21, *The Effects of Changes in Foreign Exchange Rates, Lack of Exchangeability* - The amendments specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking.

New and Amended PFRS and PIC Issuances in Issue but Not Yet Effective or Adopted

Unless otherwise indicated, the Company does not expect that the future adoption of the said pronouncements to have a significant impact on the financial statements.

The Company intends to adopt the following pronouncements when they become effective;

Effective beginning on or after January 1, 2026:

- Amendments to Illustrative Examples on PFRS 7, PFRS 18, PAS 1, PAS 8, PAS 26 and PAS 37, *Disclosures about Uncertainties in the Financial Statements*
- Amendments to PFRS 9 and PFRS 7, *Classification and Measurement of Financial Instruments*
- Amendments to PFRS 9 and PFRS 7, *Contracts Referencing Nature-dependent Electricity*
- Annual Improvements to PFRS Accounting Standards – Volume 11
  - Amendments to PFRS, 1, *Hedge Accounting by a First-time Adopter*
  - Amendments to PFRS 7, *Gain or Loss on Derecognition*
  - Amendments to PFRS 9, *Lease Derecognition of Lease Liabilities and Transaction Price*
  - Amendments to PFRS 10, *Determination of a 'De Facto Agent'*
  - Amendments to PAS 7, *Cost Method*

Effective beginning on or after January 1, 2027:

- PFRS 17, *Insurance Contracts* – The standard will replace PFRS 4, Insurance Contracts. It requires insurance liabilities to be measured at current fulfillment value and provides a more uniform measurement and presentation approach to achieve consistent, principle-based accounting for all insurance contracts. It also requires similar principles to be applied to reinsurance contracts held and investment contracts with discretionary participation features issued.

On February 14, 2025, the Financial and Sustainability Reporting Standards Council (FSRSC) has approved the amendment to PFRS 17, Date of Initial application. The amendment further defer the date of initial application of PFRS 17 by an additional two years, to annual periods beginning on or after January 1, 2027.

Under prevailing circumstances, the adoption of the forgoing new and amended PFRS is not expected to have any material effect on the financial statements of the Company. Additional disclosures were included in the financial statements, as applicable.

- PFRS 18, *Presentation and Disclosure in Financial Statements*
- PFRS 19, *Subsidiaries without Public Accountability*
- Amendments to PAS 21, *Translation to a Hyperinflationary Presentation Currency*

Deferred effectivity

- Amendments to PFRS 10, *Consolidated Financial Statements,* and PAS 28, *Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*.

NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING AND FINANCIAL REPORTING POLICIES

The significant accounting policies that have been used in the preparation of these financial statements are summarized below. These policies have been consistently applied to all years presented, unless otherwise stated.

Current versus Noncurrent Classification

The Company presents its assets and liabilities in the statements of financial position based on current/noncurrent classification.

An asset is current when it is:

- expected to be realized or intended to be sold or consumed in the normal operating cycle;
- held primarily for the purpose of trading;
- expected to be realized within twelve months after the reporting period; or
- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as noncurrent.

A liability is current when:

- it is expected to be settled in the normal operating cycle;
- it is held primarily for the purpose of trading;
- it is due to be settled within twelve months after the reporting period; or
- there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company also modifies classification of prior year amounts to conform to current year's presentation.

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability, takes place either:

- in the principal market for the asset or liability; or
- in the absence of a principal market, in the most advantageous market for the asset or liability, the principal or the most advantageous market must be accessible to the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use, or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Financial Instruments

A financial instrument is any contract that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial Recognition and Measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss (FVPL).

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. The Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

In order for a financial asset to be classified and measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss.

The Company's business model for managing financial assets refer to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Financial assets at amortized cost (debt instruments);
- Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instrument);
- Financial assets designated at fair value through OCI with no recycling of cumulative gains or losses upon derecognition (equity instruments); and
- Financial assets at fair value through profit or loss.

Financial assets at amortized cost (debt instruments)

Financial assets at amortized cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.

The Company's financial assets at amortized cost includes cash (excluding cash on hand), receivables and advances to related parties as at reporting date (see Notes 6, 7 and 12).

Financial assets at fair value through OCI (debt instruments)

For debt instruments at fair value through OCI, interest income, foreign exchange revaluation, if any, and impairment losses or reversals are recognized in the statements of profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit and loss.

The Company does not have debt instruments designated at fair value through OCI as at reporting dates.

Financial assets designated at fair value through OCI (equity instruments)

Upon initial recognition, the Company can elect to classify irrevocably its equity instruments as equity instruments designated at fair value through OCI when they meet the definition of equity under IAS 32 – *Financial Instruments: Presentation* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statements of profit or loss when the right of payment has been established, except when the Company benefits from such proceeds as recovery of part of the cost of the financial assets, in which case, such gains are recovered in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Company does not have equity instruments designated at fair value through OCI as at reporting dates.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statements of financial position at fair value with net changes in fair value recognized in the statements of profit or loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognized as other income in the statements of profit or loss when the right of payment has been established.

The Company does not have financial assets at fair value through profit or loss as at reporting dates.

Derecognition

The financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's statements of financial position) when:

- the rights to receive cash flows from the asset have expired, or
- the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risk and rewards of the asset, or (b) the Company has

neither transferred nor retained substantially all the risk and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a 'pass-through' agreement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership. When it has neither transferred nor retained substantially all of the risk and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on the basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Reclassification

The Company reclassifies its financial assets when, and only when, it changes its business model for managing those financial assets. The reclassification is applied prospectively from the first day of the first reporting period following the change in the business model (reclassification date).

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVPL, any gain or loss arising from the difference between the previous amortized cost of the financial asset and fair value is recognized in profit or loss.

For a financial asset reclassified out of the financial assets at amortized cost category to financial assets at FVOCI, any gain or loss arising from a difference between the previous amortized cost of the financial asset and fair value is recognized in OCI.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at amortized cost, its fair value at the reclassification date becomes its new gross carrying amount.

For a financial asset reclassified out of the financial assets at FVOCI category to financial assets at amortized cost, any gain or loss previously recognized in OCI, and any difference between the new amortized cost and maturity amount, are amortized to profit or loss over the remaining life of the investment using the effective interest method. If the financial asset is subsequently impaired, any gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

In the case of a financial asset that does not have a fixed maturity, the gain or loss shall be recognized in profit or loss when the financial asset is sold or disposed. If the financial asset is subsequently impaired, any previous gain or loss that has been recognized in OCI is reclassified from equity to profit or loss.

For a financial asset reclassified out of the financial assets at FVPL category to financial assets at FVOCI, its fair value at the reclassification date becomes its new gross carrying amount. Meanwhile, for a financial asset reclassified out of the financial assets at FVOCI category to financial assets at FVPL, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss as a reclassification adjustment at the reclassification date.

Impairment

The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been significant increase in credit risk since initial recognition, a loss is required for credit expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full or in part before taking into account any credit enhancements held by the Company. A financial asset is written off in full or in part when there is no reasonable expectation of recovering the contractual cash flows.

Write-off

Financial assets are written-off when the Company has no reasonable expectations of recovering the financial asset either in its entirety or a portion of it. This is the case when the Company determines that the borrower does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. A write-off constitutes a derecognition event.

Financial Liabilities

Initial Recognition and Measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognized initially at fair value and in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Subsequent Measurement

The measurement of financial liabilities depends on their classified into two categories:

- Financial liabilities at fair value through profit or loss; and
- Financial liabilities at amortized cost (loans and borrowings).

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss are designated upon initial recognition at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by PFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognized in profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in PFRS 9 are satisfied.

The Company has not designated any financial liability at fair value through profit or loss at the end of each reporting period.

Financial liabilities at amortized cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings and other payables are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as "Finance cost" in the statements of comprehensive loss.

The Company's financial liabilities include accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, notes payable and loans payable to a related party (see Notes 12,14, and 15).
Derecognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statements of comprehensive loss.

Fair Value Option

The Company may, at initial recognition, irrevocably designate a financial asset or liability that would otherwise have to be measured at amortized cost or fair value through other comprehensive loss to be measured at fair value through profit or loss if doing so would eliminate or significantly reduce an accounting mismatch or otherwise results in more relevant information.

Classification of Financial Instrument between Liability and Equity

A financial instrument is classified as liability if it provides for a contractual obligation to:

- Deliver cash or another financial asset to another entity;
- Exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavorable to the Company; or

- Satisfy the obligation other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of own equity shares.

If the Company does not have an unconditional right to avoid delivering cash or another financial asset to settle its contractual obligation, the obligation meets the definition of a financial liability.

Offsetting of Financial Instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

The Company assesses that it has currently enforceable right to offset if the right is not contingent on a future event and is legally enforceable in the event of insolvency or bankruptcy of the Company and all of the counterparties.

Cash

Cash in the statements of financial position comprise of cash in banks and on hand that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value.

Advances to Contractors and Suppliers

Advances represent deposits or down payments (ranging from 25% to 50%) paid to contractors, merchants or broker-agents for specific completion or delivery of contractual obligations or service undertakings, including acquisition of medical machineries or clinical apparatus or equipment and medicinal inventories or supplies. These advances which are already paid but not yet incurred will be recognized either as an asset or an expense upon completion or delivery of such obligations, undertakings or acquisitions.

Medical and Hospital Supplies Inventories

Medical and hospital supplies inventories are initially measured at cost. Cost includes all costs of purchases, cost of conversion and other costs incurred in bringing the medical inventories and hospital supplies to their present location and condition. Medical inventories and hospital supplies are subsequently measured at the lower of cost (net realizable value). Cost is determined using the first-in, first-out (FIFO) method. At each reporting date, medical inventories and hospital supplies are assessed for impairment. If medical inventories and hospital supplies is impaired, the impairment loss is recognized immediately in the statements of comprehensive loss.

Prepayments and Other Current Assets

Prepayments represent expenses not yet incurred but already paid in cash. Prepayments are initially recorded as assets and measured at the amount of cash paid. Subsequently, these are charged to profit or loss as they are consumed in operations or expire with the passage of time.

Other current assets represent assets of the Company which are expected to be realized or consumed within one year or within the Company's normal operating cycle whichever is longer. Other current assets are both measured initially and subsequently presented in the financial statements at cost.

Property and Equipment

Property and equipment are initially measured at cost. The cost of an item of property and equipment consists of:

- its purchases price, including import duties and non-refundable purchases taxes, after deducting trade discounts and rebates; and
- any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent expenditures relating to an item of property and medical and hospital equipment that have already been recognized are added to the carrying amount of the asset when it is probable that future economic benefits, in excess of the originally assessed standard of performance of the existing asset, will flow to the Company. All other subsequent expenditures are recognized as expenses in the period in which those are incurred.

At the end of each reporting period, items of property and equipment except land measured using the cost model are carried at cost less any subsequent accumulated depreciation and impairment losses. Land is carried at cost less any impairment in value. Land is not depreciated.

Land is carried at revalued amounts, being its fair value at the date of revaluation less any subsequent impairment losses. Revaluations are performed with sufficient regularity to ensure that the carrying amount does not differ materially from that which would be determined using fair value at the reporting date. Increases in the carrying amount of land arising from revaluation are recognized in equity under "Revaluation Surplus." Decreases that offset previous increases are charged against the surplus; other decreases are recognized in profit or loss. Land is not depreciated.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, if there is an indication of a significant change since the last reporting date. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

An item of property and equipment shall be derecognized upon disposal or when no future economic benefits are expected from its use or disposal. When assets are derecognized, their costs, accumulated depreciation and amortization and accumulated impairment losses are eliminated from the accounts. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in the statements of comprehensive loss.

Fully depreciated and fully amortized assets are retained by the Company as part of property and equipment until these are derecognized or until they are no longer in use.

Construction-in-progress

Construction-in-progress is stated at cost. This includes the costs related to the construction of the hospital building and installation of medical equipment, property development costs and other direct costs. Cost of borrowings and any additional costs incurred in relation to the project are recognized in this account. Construction-in-progress is not depreciated until such time that the relevant assets are completed and ready for its intended use.

The Company recognizes the effect of revisions in the total project cost estimates in the year in which these changes become known. Any impairment loss from the construction project is charged to operations during the period in which the loss is determined.

During the year, the Construction-in-progress was closed to Building account.

Impairment of Non-Financial Assets

At each reporting dates, the Company reviews the carrying amounts of its non-financial assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. When the asset does not generate cash flows that are independent from the other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of net realizable value and value-in-use. In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated1 than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognized as an expense immediately.

When an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior years. A reversal of an impairment loss is recognized as income.

Equity

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue cost.

Share capital

Share capital is recognized as issued when the stock is paid for or subscribed under a binding subscription agreement and is measured at par value.

Share premium

Share premium is the difference between the issue price and the par value of the stock and is known as securities premium. The shares are said to be issued at a premium when the issue price of the share is greater than its face value or par value.

Deficit

Deficit represents accumulated losses incurred by the Company. Deficit may also include effects of changes in accounting policy as may be required by the standard's transitional provision.

Other comprehensive income (loss)

Other comprehensive income (loss) is defined as comprising items of income and expense that is not recognized in profit or loss as required or permitted by other standards.

Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Revenue is measured by reference to the fair value of consideration received or receivable excluding discounts, returns and sales taxes. Revenue is recognized at a point in time or over a period of time.

Hospital services – Revenue from in-patient, out-patient, and emergency services is recognized when the services are rendered.

Sale of medicines and medical goods – Revenue is recognized at the point in time when control of the goods passes to the customer, generally upon delivery or sale at the hospital pharmacy.

Revenue recognition outside the Scope of PFRS 15

Interest Income

Interest income is recognized as it accrues, using the effective interest method under PFRS 9 – Financial Instruments. This approach reflects the effective yield on the related financial asset and allocates interest income over the relevant period in a manner that produces a constant periodic rate of return on the carrying amount of the asset.

Other Income

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

Costs and Expense Recognition

The Company presents expenses in the statement of income using the function of expense method. Direct costs represent expenses incurred that are specifically associated with the services rendered, while operating expenses include costs attributable to general, administrative, and other business activities. Expenses are recognized in profit or loss on accrual basis, meaning they are recorded when incurred and not when paid. Costs are matched with related income when association can be directly established, or allocated systematically when benefits are expected to arise over several periods. Expenditures that do not generate future economic benefits are recognized immediately in profit or loss.

Related Party Relationships and Transactions

Related party relationship exists when one party has the ability to control, directly, or indirectly through one or more intermediaries, the other party or exercises significant influence over the other party in making financial and operating decisions. Such relationships also exist between and/or among entities which are under common control with the reporting enterprise, or between, and/or among the reporting enterprise and its key management personnel, directors, or its shareholders. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

A related party transaction is a transfer of resources, services or obligations between related parties, regardless of whether a price is charged.

Foreign Currency Transactions

Transactions in currencies other than functional currency of the Company are recorded at the rates of exchange prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing at the end of the reporting period.

Employee Benefits

Employee benefits are all forms of consideration given by an entity in exchange for services rendered by its employees.

Short-term Benefits

Short-term employee benefits are those benefits expected to be settled wholly before twelve months after the end of the annual reporting period during which employee services are rendered, but do not include termination benefits. Short-term benefits given by the Company to its employees include salaries and wages, social security, health insurance and housing contributions, short-term compensated absences, bonuses and other non-monetary benefits. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

Retirement or Post-employment Benefits

The Company is subject to the provisions of Republic Act No. 7641 (known as the Retirement Law). This requires that in the absence of a retirement plan, an agreement providing benefits for retiring employees in the private sector, an employee upon reaching the age of 60 years or more, but not beyond 65 years, who has served at least 5 years in service, may retire and shall be entitled to a retirement pay equivalent to at least ½ month's salary for every year of service, fraction of at least 6 months being considered as 1 whole year. The current service cost is the present value of benefits, which accrue during the last year.

As at reporting date, the Company has not yet established a Retirement Benefits Plan for its employees since to date no employee is entitled to retirement benefits. The Company started commercial operation in December 2023.

Borrowing costs

Borrowing costs are generally recognized as expense in the year in which these costs are incurred. However, borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized. Capitalization of borrowing costs commences when the activities necessary to prepare the asset for intended use are in progress and expenditures and borrowing costs are being incurred. Borrowing costs are capitalized until the asset is available for their intended use. It includes interest expense, finance charges in respect of finance leases and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

Income Tax

Income tax expense represents the sum of the current tax expense and deferred tax expense.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the statements of comprehensive loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

Deferred tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax base used in the computations of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognized if the temporary difference arises from the initial recognition of goodwill.

The carrying amount of deferred tax assets is reviewed at each reporting dates and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Earnings (Loss) per Share

Basic earnings (loss) per share is calculated by dividing income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the year, after giving retroactive effect to any bonus issued/declared during the year, if any.

For the purpose of calculating diluted earnings per share, profit or loss for the year attributable to ordinary equity holders of the Company and the weighted average number of shares outstanding are adjusted for the effects of all dilutive potential ordinary shares.

Reclassification of Comparative amounts

In 2025, certain amounts in the comparative financial statements and notes disclosures have been reclassified to conform with current year's presentation.

Management believes that the foregoing reclassifications would reflect the true nature of the transactions and correct the classification, as well as conform to the prevailing standards, - which did not have any impact on prior year's statement of receipts and expenses and current standing (please refer to Note 13).

Summary of changes on liabilities arising from the reclassification are shown below:

Account	December 31, 2024 (Previously Stated)	Effect	December 31, 2024 (As reclassified)
ACCOUNTS PAYABLE AND OTHER LIABILITIES			
Accounts payable – contractors and suppliers[1)]	P 339,278,543	(68,409,287)	P 270,869,256
Accrued interest payable[2)]	95,515,462		95,515,462
Accounts payable – nontrade [4)]	33,513,950	35,497,050	69,011,000
Retention payable[3)]	42,061,657		42,061,657
Accrued expenses[5)]	13,359,749	3,904,654	17,264,403
Statutory liabilities[6)]	1,737,537		1,737,537
Other payables	3,997,120	29,007,583	33,004,703
TOTAL ACCOUNTS PAYABLE AND OTHER LIABILITIES	529,464,018	–	529,464,018

The reclassifications had no impact on current income tax and deferred tax, as the adjustments were limited to liability accounts only.

NOTE 5 - CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on the historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Judgments, estimates and assumptions are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The effects of any change in estimates are reflected in the financial statements as they become reasonably determinable.

Judgments in Applying the Company's Accounting Policies

In the process of applying the Company's accounting policies, management has made the following judgments, apart from those involving estimations, which have the most significant effect on the amounts recognized in the financial statements:

Business Model Assessment

Classification and measurement of financial assets depend on the results of the Solely Payments of Principal and Interest (SPPI) and the business model test. The Company determines the business model at a level that reflects how groups of financial assets are managed together to achieve a particular business objective. This assessment includes judgment reflecting all relevant evidence including how the performance of the assets is evaluated and their performance measured, the risks that affect the performance of the assets and how these are managed and how the managers of the assets are compensated. Monitoring is part of the Company's continuous assessment of whether the business model for which the remaining financial assets are held continues to be appropriate and if it is not appropriate, whether there has been a change in business model and so a prospective change to the classification of those assets.

Significant Increase of Credit Risk

Where the fair values of financial assets and financial liabilities recorded on the statement of financial position cannot be derived from active markets, they are determined using internal valuation techniques using generally accepted market valuation models. The input to these models is taken from observable markets where possible, but where this is not feasible, estimates are used in establishing fair values. These estimates may include considerations of liquidity, volatility and correlation.

Functional Currency

Based on the economic substance of the underlying circumstances relevant to the Company, the functional currency of the Company has been determined to be the Philippine Peso (₱). It is the currency that mainly influences the Company's operations.

Classification of Financial Instrument

The Company classifies a financial instrument, or its component parts, on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual agreement and the definitions of a financial asset, a financial liability or an equity instrument. The substance of a financial instrument, rather than its legal form, governs its classification in the statement of financial position.

Determination of Whether a Lease is a Finance or Operating Lease

The evaluation of whether an arrangement contains a lease is based on its substance. An arrangement is, or contains, a lease when the fulfillment of the arrangement depends on a specific asset or assets and the arrangement conveys the right to use the asset.

Recognition of Deferred Income Taxes

Significant judgment is required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain in the ordinary course of business. Recognition of deferred income taxes depends on management's assessment of the probability of available future taxable income against which the temporary difference can be applied.

Impairment of Non-Financial Assets

Property and equipment, inventories and intangible assets are periodically reviewed to determine any indications of impairment. Though the management believes that the assumptions used in the estimation of fair values are reasonable and appropriate, significant changes in these assumptions may materially affect the assessment of the recoverable amounts and any resulting impairment loss could have a material adverse effect in the results of operations.

Provisions and Contingencies

Judgment is exercised by management to distinguish between provisions and contingencies. Policies on recognition and disclosure of provision and disclosure of contingencies are discussed in Note 4, subheading "*Provisions and Contingencies*."

Estimates and Assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the financial reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year are discussed below:

Assessment for ECL on Other Financial Assets at Amortized Cost

The Company determines the allowance for ECL using general approach based on the probability-weighted estimate of the present value of all cash shortfalls over the expected life of financial assets at amortized cost. ECL is provided for credit losses that result from possible default events within the next 12-months unless there has been a significant increase in credit risk since initial recognition in which case ECL is provided based on lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not represent a significant risk in credit risk such as when non-payment was an administrative oversight rather than resulting from financial difficulty of the borrower.

The Company has assessed that the ECL on other financial assets at amortized cost is not material because the transactions with respect to these financial assets were entered into by the Company only with reputable banks and companies with good credit standing and relatively low risk of defaults. Accordingly, no provision for ECL on other financial assets at amortized cost was recognized as at December 31, 2025 and 2024.

The carrying amounts of other financial assets at amortized cost are as follows:

	2026	2025
Cash in banks*	**P25,635,281**	P22,446,473
Receivables	**192,816,543**	165,796,569
	P218,451,824	P188,243,042

**Excluding petty cash fund amounting to 779,654 as at March 31, 2026 and ₱849,568 in 2025.*

Assessment for Impairment of Non-financial Assets

The Company assesses impairment on non-financial assets whenever events or changes in circumstances indicate that the carrying amount of the assets or group of assets may not be recoverable. The relevant factors that the Company considers in deciding whether to perform an asset impairment review include, among others, the following:

- Significant underperformance of a business in relation to expectations;
- Significant negative industry or economic trends; and
- Significant changes or planned changes in the use of the assets.

Whenever the carrying amount of an asset exceeds its recoverable amount, an impairment loss is recognized. Recoverable amounts are estimated for individual assets or, if it is not possible, for the cash-generating unit to which the asset belongs.

The recoverable amount of the asset is the greater of the fair value less cost of disposal or value in use. The fair value less cost of disposal is the amount obtainable from the sale of an asset in an arm's-length transaction. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

No impairment loss on non-financial assets was recognized as at March 31, 2026 and 2025.

The carrying amounts of non-financial assets are as follows:

	2026	2025
Property and equipment (net)	**P2,342,868,883**	P2,357,222,256
Advances to suppliers	**63,387,374**	45,968,003
Medical and hospital supplies inventories	**47,935,244**	59,994,528
Advances to contractors	**26,481,056**	26,481,056
Prepayments and other current assets	**33,109,906**	28,714,938
Advances to related parties	**6,950,256**	6,950,256
	P2,520,732,719	P2,525,331,038

Estimating Useful Lives of Assets

The Company estimates the useful lives of property and equipment and intangible assets based on the period over which the assets are expected to be available for use. The estimated useful lives of property and equipment and intangible assets are reviewed periodically and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence and legal or other limits on the use of the assets. In addition, estimation of the useful lives of property and equipment and intangible assets is based on collective assessment of industry practice, internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in estimates brought about by changes in factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of property and equipment and intangible assets would increase recorded operating expenses and decrease non-current assets.

Depreciation is calculated on a straight-line basis over the following estimated useful lives of the assets:

Categories	Estimated Useful Life
Building	50 years
Building improvement	50 years
Office equipment	3 - 5 years
Medical equipment	5 years
Hospital equipment	5-10 years
IT equipment and software	5 years
Kitchen tools	3-5 years
Hospital vehicle	5 years

As at March 31, 2026 and 2025, the Company's property and equipment had carrying amounts of ₱2,342,868,883 and ₱2,357,222,256, respectively, as disclosed in Note 11, and includes land and revaluation of the land.

Revaluation of Land

Management exercises judgement in determining whether the revaluation model provides a more reliable measure of the land's value compared to the cost model. This includes assessing the frequency of revaluations, the appropriateness of valuation techniques, and the independence and qualifications of external valuers. Judgement is also applied in deciding whether market transactions used as comparables are sufficiently similar to the Company's land holdings.

The fair value of land is determined based on market evidence of recent transactions for comparable properties. Significant assumptions include:

- Comparable property selection and adjustments for location, size, and use;
- Market conditions prevailing at the valuation date; and
- The absence of restrictions or encumbrances affecting the land's marketability.

Because these assumptions involve estimation, actual outcomes may differ, and future revaluations could result in material changes to the carrying amount of land and the related revaluation surplus.

Asset impairment other than goodwill

The Company performs an impairment review when certain impairment indicators are present.

Determining the recoverable amount of property and equipment, which require the determination of future cash flows expected to be generated from the continued use and ultimate disposition of such assets, requires the Company to make estimates and assumptions that can materially affect the financial statements. Future events could cause the Company to conclude that property and equipment are impaired. Any resulting impairment loss could have a material adverse impact on the financial condition and results of operations.

The preparation of the estimated future cash flows involves significant judgment and estimations. While the Company believes that its assumptions are appropriate and reasonable, significant changes in the assumptions may materially affect the assessment of recoverable values and may lead to future additional impairment charges.

As at March 31, 2026 and 2025, Management believes that the recoverable amounts of the Company's property and equipment approximate its carrying amounts. Accordingly, no impairment loss was recognized in both years.

Deferred tax assets

The Company reviews the carrying amounts of deferred tax assets at each financial reporting date and reduces deferred tax assets to the extent that it is no longer probable that sufficient future taxable income will be available to allow all or part of the deferred tax assets to be utilized. The Company did not recognize net deferred tax assets as at March 31, 2026 and 2025.

Deferred tax assets with full valuation allowance as at March 31, 2026 and December 31, 2025, and December 31, 2024 amounted to ₱168,867,765, and ₱-, respectively (see Note 23).

NOTE 6 - CASH

This account consists of:

	2026	2025
Cash in banks	**P25,635,281**	P22,446,473
Petty cash fund and cash on hand	**779,654**	849,568
	P26,414,935	P23,296,041

Cash includes petty cash fund and cash on hand and in banks that are unrestricted and available for current operations. This is stated in the statements of financial position at face amount.

Cash in banks generally earn interest at the prevailing bank's deposit rates. Interest earned from bank accounts amounted to ₱2,175, ₱1,002, and ₱2,106 in 2026, 2025 and 2024, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

Unrealized foreign exchange gain (loss) resulting from translation of foreign currency-denominated cash in bank into Philippine peso amounted to ₱-, 3,505 and (₱310,228) in 2026, 2025 and 2024, respectively, and is presented as part of "other income" in the statements of comprehensive loss (see Note 22).

NOTE 7 - RECEIVABLES

This account consists of:

	2026	2025
Accounts receivable government agencies[1)]	**P72,922,383**	P90,686,847
Due from HMO's[2)]	**55,096,172**	50,848,955
Advances to employees and officers[5)]	**5,072,138**	5,028,526
Deposits[4)]	**5,035,000**	5,035,000
Other receivables[3)]	**15,493,733**	14,197,241
	P192,816,543	P165,796,569

[1)]Accounts receivable pertains to financial assistance availed of by patients from the Department of Social Welfare and Development (DSWD), Philippine Health Insurance Corporation (PhilHealth) and Philippine Charity Sweepstakes Office (PCSO) and reimbursable to the company.

[2)]Due from HMO's pertains to reimbursements for hospital expenses and doctors' fees availed of by patients who are members of Health Maintenance Organization (HMOs).

[3)]Other receivables – represent promissory notes from local area patients which are collected in installments or staggered payments due within the year.

[4)] Deposits represent payments made by the Company to More Power Corporation, to Iloilo Medical Society, and to the Department of Health in connection with regulatory application requirements for the Company's drug testing services operations. These deposits are expected to be applied or recovered in accordance with the terms and conditions of the related agreements and regulatory requirements.

[5)]Advances to employees and officers represent advances that are deducted directly from payroll.

In determining the recoverability of receivables, the Company considers any change in the credit quality of the receivable from the date credit was initially granted up to the end of the reporting period. Considering that majority of the accounts are relatively guaranteed by accredited providers, the Company believes that no estimated credit loss is required for both years.

NOTE 8 - ADVANCES TO CONTRACTORS AND SUPPLIERS

This account consists of:

	2026	2025
Advances to contractors[1)]	**P26,481,056**	P26,481,056
Advances to suppliers[2)]	**63,387,374**	45,968,003
	P89,868,430	P72,449,059

[1)] Advances to contractors represent advances for each awarded project activity and are liquidated via deduction, on a pro-rata basis, from the contractor's periodic progress billings.

[2)] Advances to suppliers are downpayments made to suppliers of medical equipment and/or construction materials ordered. The amounts represent 15% - 50% of the total contract price of the items purchased.

NOTE 9 - MEDICAL AND HOSPITAL SUPPLIES INVENTORIES

This account consists of:

	2026	2025
General hospital maintenance supplies[2)]	**P23,432,295**	P20,137,406
Medical and laboratory supplies[1)]	**19,289,135**-	25,458,660
Drugs and medicines for sale[3)]	**5,213,814**	14,398,462
	P47,935,244	P59,994,528

[1)]Medical and laboratory supplies refer to a wide array of materials, in the form of test or culture tubes and vessels, consumables, reagents, medical media and sera, etc., which are used in medical chemistry and various laboratory tests.

[2)]General hospital maintenance supplies pertain to purchases of cleaning and sanitation supplies for the hospital upkeep and general housekeeping.

[3)]Drugs and medicines for sale are medicinal and therapeutic substances (in capsule, tablet or liquid forms) available at the Hospital's pharmacy which are intended for patient care and treatment.

NOTE 10 - PREPAYMENTS AND OTHER CURRENT OTHERS

This account consists of:

	2026	2025
Input tax	**P28,667,692**	P24,371,398
Prepaid income tax (Note 24)	**3,522,368**	3,522,368
Prepaid insurance	**821,174**	821,172
Prepaid taxes and licenses	**-**	-
	P33,011,234	P28,714,938

NOTE 11 - PROPERTY AND EQUIPMENT (net)

Reconciliation of property and equipment (net) as at March 31, 2026 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	**P273,000,000**	**P1,836,316,739**	**P107,908**	**P3,547,131**	**P378,891,712**	**P115,213,227**	**P14,238,019**	**P32,215,795**	**P10,478,200**	**P2,664,008,731**
Additions	**–**	**–**	**–**	**–**	**23,599,299**	**123,750**	**36,504**	**142,888**	**-**	**23,902,441**
At end of year	**273,000,000**	**1,836,316,739**	**107,908**	**3,547,131**	**402,491,011**	**115,336,977**	**14,274,523**	**32,358,683**	**10,478,200**	**2,687,911,172**
Accumulated depreciation:										
At beginning of year	**–**	**73,452,670**	**19,183**	**2,166,632**	**144,752,430**	**57,894,816**	**8,777,834**	**15,531,630**	**4,191,280**	**306,786,475**
Depreciation	**–**	**9,181,584**	**5,395**	**145,011**	**18,768,563**	**7,393,175**	**627,387**	**1,610,790**	**523,910**	**38,255,815**
At end of year	**–**	**82,634,254**	**24,578**	**2,311,643**	**163,520,993**	**65,287,991**	**9,405,221**	**17,142,420**	**4,715,190**	**345,042,290**
Appraisal increase (Note 17):										
At beginning of year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
Increase for the year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
At end of year	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
Net carrying value,										
March 31, 2026	**P273,000,000**	**P1,753,682,485**	**P83,330**	**P1,235,488**	**P238,970,019**	**P50,048,986**	**P4,869,302**	**P15,216,263**	**P5,763,010**	**P2,342,868,883**

Reconciliation of property and equipment (net) as at December 31, 2025 is as follows:

	Land	Building	Building Improvement	Office Equipment	Medical Equipment	Hospital Equipment	IT Equipment & Software	Kitchen Tools	Hospital Vehicle	Total
Cost:										
At beginning of year	P28,291,630	P1,836,316,739	P33,721	P3,427,143	P355,432,128	P114,697,074	P13,835,359	P32,215,795	P10,478,200	P2,394,727,789
Additions	-	-	74,187	119,988	23,459,584	516,153	402,660	-	-	24,572,572
At end of year	28,291,630	1,836,316,739	107,908	3,547,131	378,891,712	115,213,227	14,238,019	32,215,795	10,478,200	2,419,300,361
Accumulated depreciation:										
At beginning of year	–	36,726,335	3,934	1,576,267	70,413,534	29,905,788	6,256,872	9,088,471	2,095,640	156,066,841
Depreciation	–	36,726,335	15,249	590,365	74,338,896	27,989,028	2,520,962	6,443,159	2,095,640	150,719,634
At end of year	–	73,452,670	19,183	2,166,632	144,752,430	57,894,816	8,777,834	15,531,630	4,191,280	306,786,475
Appraisal increase (Note 17):										
At beginning of year	–	–	–	–	–	–	–	–	–	–
Increase for the year	244,708,370	–	–	–	–	–	–	–	–	244,708,370
At end of year	244,708,370	–	–	–	–	–	–	–	–	244,708,370
Net carrying value, December 31, 2025	P273,000,000	P1,762,864,069	P88,725	P1,380,499	P234,139,282	P57,318,411	P5,460,185	P16,684,165	P6,286,920	P2,357,222,256

No assets were used as collateral for any liability as of March 31, 2026 and 2025.

Depreciation on medical and hospital equipment shall commence when it is available for use – when it is in the location and condition necessary to be capable of operating in the manner intended by the Management. The depreciation expense of medical and hospital equipment amounting to ₱70,343,235 and ₱102,327,924 in 2026 and 2025 was charged to cost of services (see Note 20).

The Company has a total contract commitment to purchase medical equipment totaling ₱454,370,959 as at December 31, 2023. Advances to ACE hospitals, Endure Medical, Inc. and TIPP Digital Solutions Inc. amounting to ₱6,950,256and ₱39,030,125 in 2026 and 2025, respectively (Note 12) was recognized in the books as it represents advance payment for such medical equipment.

The land covered by TCT No. 095-2015000546 and TCT No. 095-2015000547 represent the area located at Barangay Sambag, Jaro District, Iloilo City, Panay Island, where the Company constructed a multidisciplinary special medical facility (hospital) (Note 12) and is the subject of a real estate mortgage as disclosed in Note 15.

During the year, the Company has had its land appraised. The property was inspected on February 8, 2026, and the appraisal report was issued on March 9, 2026 by Cubing Surveying, an independent professional valuer accredited with the Securities and Exchange Commission (SEC). The valuation was performed using the Sales Comparison Approach, which relies on market evidence of recent transactions for comparable properties in the same area. The valuation was determined as of March 31, 2026.

As a result of the appraisal conducted by an independent appraiser, the carrying amount of land increased by ₱244,708,370, which was recognized in equity under Revaluation Surplus in accordance with the applicable financial reporting framework. Accordingly, the land is carried at its revalued amount or fair market value of ₱273,000,000 as of March 31, 2026 (see Notes 11, 16 and 18).

Management has reviewed the carrying values of property and equipment as at March 31, 2026 and 2025, for any impairment. Based on the results of its evaluation, there are no indications that these assets are impaired.

NOTE 12 - RELATED PARTY TRANSACTIONS

In the normal course of business, the Company transacts with companies/individuals, which are considered related parties. The following transactions were carried out with related parties as at March 31, 2026 and 2025:

Advances to related parties:

Category	Outstanding Balance 2024	Amount of Transactions 2025	Outstanding Balance 2025	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Receivable – others (various ACE hospitals – note 7)	P47,472	P -	P47,472	P -	**P47,472**	Non-interest bearing, to be collected in cash	Unsecured, unguaranteed, not impaired
Endure Medical, Inc. (note 7)	32,079,869	-	32,079,869	**(32,079,869)**	–	Non-interest bearing, to be collected in cash (a)	Unsecured, unguaranteed, not impaired
TIPP Digital Solutions Inc.	6,902,784	-	6,902,784	–	**6,902,784**	Non-interest bearing, to be collected in cash (b)	Unsecured, unguaranteed, not impaired

	P39,030,125	P-	P39,030,125	**(P32,079,869)**	**P6,950,256**		

Advances from related parties:

Category	Outstanding Balance 2024	Amount of Transactions 2025	Outstanding Balance 2025	**Amount of Transactions 2026**	**Outstanding Balance 2026**	Terms	Conditions
Accounts Payable – Endure Medical, Inc.	P63,768,359	(P3,091,827)	P60,676,532	**P134,139,564**	**P194,816,096**	Non-interest bearing, to be paid in cash	Unsecured, unguaranteed, not impaired
Loans Payable to a related party	543,871,969	1,000,000	544,871,969	**-**	**544,871,969**	Interest bearing, to be paid in cash (c)	Unsecured, unguaranteed, not impaured
	P607,640,328	(P2,091,827)	P605,548,501	**P134,139,564**	**P739,688,065**		

Accounts payable – Endure Medical, Inc. is included under accounts payable – contractors and suppliers amounting to ₱194,816,096, ₱60,676,532, and ₱63,768,359 as of March 31, 2026, December 31, 2025, and 2024, respectively (see Note 13).

(a) Advances to a related party - Endure Medical, Inc.

The Company engaged the services of an indentor (Endure Medical, Inc.) which has relatively significant influence over the key management personnel of the Company. The Indentor facilitates the importation and acquisition of medical and hospital equipment, furniture and fixtures for the hospital building under construction (see Note 11).

The foregoing is classified as a related party transaction(s) (pursuant to the condition set forth in PAS 24), wherein the key management personnel of Endure Medical, Inc. has significant influence over the Company and its key officer.

(b) Advances to a related party - TIPP Digital Solutions Inc.

The account represents a 15% downpayment made for the acquisition of Healthcare Management Information System.

(c) Loans payable to a related party

The account represents an unsecured interest-bearing loan from Phil Pharmawealth, Inc., which has relatively significant influence over a key management personnel of the Company. The loan was incurred for payment of interest with Land Bank of the Philippines (LBP). The loan bears an interest rate ranging from 6.50%-8.50% per annum. Interest incurred for the years ended March 31, 2026, 2025 and 2024 and is reflected in the statements of comprehensive loss amounted to ₱-, ₱72,419,241, and ₱56,927,769, respectively. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Key Management Personnel Compensation

Key management compensation amounted to ₱1,446,667, ₱5,895,813, and ₱7,571,693 for the years ended March 31, 2026, 2025, and 2024, respectively. These amounts are incorporated in the salaries and allowances account in the financial statements.

NOTE 13 - ACCOUNTS PAYABLE AND OTHER LIABILITIES

This account consists of:

	2026	2025
Accounts payable – contractors and suppliers[1)]	**₱368,589,593**	₱308,165,389
Accrued interest payable[2)]	**172,201,043**	160,840,676
Accounts payable – nontrade [3)]	**39,500,737**	110,346,682
Retention payable[4)]	**40,558,089**	40,795,308
Accrued expenses[5)]	**1,359,755**	6,725,263
Statutory liabilities[6)]	**3,168,705**	2,999,859
Other payables[7)]	**92,021,257**	59,666,393
	₱717,399,179	₱689,539,570

[1)] Accounts payable – contractors and suppliers represent unpaid billings of the contractors and balances of equipment already installed in the construction building as of reporting date. This payable also included the related party of Endure Medical, Inc. (see note 12). This account is non-interest bearing, unsecured and non-collateral.

[2)] Accrued interest payable refers to interest expense incurred on loans from bank.

[3)] Accounts payable – nontrade pertains to unsettled fees to medical practitioners, legal, and other consultancy fees. It also includes obligations to housekeeping supplies and construction, which is a significant portion of the account.

[4)] Retention payable refers to the amount withheld by the Company from the contractor's periodic progress billings as provided for in their respective contract. This shall be released to the contractor, net of deductions, if any, upon full completion and turnover of the project and final acceptance by the Company.

[5)] Accrued expenses are normally settled within one year from financial reporting date.

[6)] Statutory liabilities pertain to tax withheld from payment to suppliers, employees' compensation and statutory contributions to SSS, PHIC and HDMF.

[7)] Other payables represent liabilities to suppliers and other parties for which no specific account classification has been designated. This account also includes payables pertaining to reimbursements, patient refunds, advances from officers and employees, and replenishment of the petty cash fund, which are non-interest bearing, non-collateralized, and payable on demand.

NOTE 14 - LOANS PAYABLE TO INDIVIDUALS

This account constitutes non-interest bearing, non-collateral and demandable obligations to shareholders which was primarily used by the Company to support the preliminary financing aspect of the construction of the hospital structure amounting to P91,589,939 and P15,703,226 as of March 31, 2026 and 2025.

NOTE 15 - NOTES PAYABLE

Movement of notes payable as at December 31 is as follows:

	2026	2025
Beginning	**999,351,037**	970,594,306
Availment	**-**	48,756,731
Payment	**-**	(20,000,000)
	999,351,037	999,351,037

Notes payable are presented in the financial statements as follows:

	2026	2025
Current	**191,558,072**	191,558,072
Non-current	**807,792,965**	807,792,965
	999,351,037	999,351,037

The Landbank of the Philippines – Iloilo Branch (LBP – Iloilo) extended to the Company several term loans equivalent to a credit line facility totaling **₱1.060 BILLION** to finance the construction of hospital structure and the acquisition of various medical equipment and fixtures.

The foregoing credit line facility consists of a term loan 1 the availment of which was granted on 2015 amounting to **₱465 MILLION** allotted to finance the construction of hospital building. However, term loan 2 availment amounting to **₱35 MILLION** was eventually cancelled or withdrawn. Subsequently, the bank approved on July 31, 2019, term loan 3 in the amount of **₱195 MILLION** for hospital structure and term loan 4 amounting to **₱400 MILLION** allotted for the acquisition of medical equipment and fixtures.

The loan is available in several drawdowns, payable ranging from 8 years to 10 years in ladderized quarterly amortizations, including grace periods ranging from 1 year to 4 years on principal amortization, with an interest rate of 5% to 6.63% per annum payable quarterly in arrears from date of loan release.

As discussed in Note 11, the loan is collaterized and secured by a Real Estate Mortgage (REM) on both parcels of land owned by the Company, including present and future improvements thereon and Chattel Mortgage on various medical equipment, furniture, and fixtures.

On November 29, 2023, Land Bank of the Philippines approved the restructuring of the total outstanding balance of Term Loans 1, 3, and 4 amounting to ₱985,594,306. The restructuring extended the repayment period up to seven (7) years from the date of effectivity, with a one (1) quarter grace period on both principal and interest.

In 2024, the Bank further approved Term Loan 6 and a Working Capital Line amounting to ₱70 million and ₱30 million, respectively.

As of March 31, 2026 and 2025, the Company's total outstanding loans and borrowings amounted to ₱999,351,037 and ₱999,351,037, respectively. Correspondingly, interest expense recognized in profit or loss for the years then ended amounted to ₱- in 2026 and ₱72,419,241 in 2025. Due to the restructuring arrangement, the finance costs related to these loans cannot be specifically allocated to the hospital building and medical equipment and fixtures.

Since the hospital structure is already in the state of its intended use (operational), the related borrowing costs (finance costs) are no longer allocated, yet rather - charged to and absorbed by operations. Hence, the total finance cost for the years 2026, 2025 and 2024 were presented as follows:

	2026	2025	2024
A. Construction in Progress			
a.) Construction of hospital building	**P -**	**P -**	**P -**
b.) Medical equipment and fixtures	**-**	**-**	**-**
Sub-total	**-**	**-**	**-**
B. Operations	**35,890,364**	**136,010,583**	155,699,208
Total	**P35,890,364**	**P136,010,583**	P155,699,208

NOTE 16 - DEFERRED TAX LIABILITY

Deferred tax liability is measured at the tax rate applied in which the liability is recognized based on the tax regulation rate enacted by the end of the reporting period. It is computed and determined by the product or equivalent of the 25% tax regulation rate as applied to the total revaluation surplus amounting to nil and P61,177,093 as of March 31, 2026 and 2025 (see Note 11).

Deferred tax liability resulting from the revaluation of land amounted to Php61,177,093 as at March 31, 2026, and December 31, 2025.

NOTE 17 - SHARE CAPITAL

Details of the Company's share capital as at March 31, 2026 are as follows:

	No. of Shares	**Amount**
Authorized share capital – ₱1,000 par value		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total authorized share capital	**240,000**	**240,000,000**
Subscribed share capital:		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total subscribed share capital	**240,000**	**240,000,000**
Paid-up share capital:		
Founder shares	**600**	**600,000**
Common shares	**239,400**	**239,400,000**
Total paid-up share capital	**240,000**	**240,000,000**

Details of the Company's share capital as at December 31, 2025 are as follows:

	No. of Shares	Amount
Authorized share capital – ₱1,000 par value		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total authorized share capital	240,000	240,000,000
Subscribed share capital:		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total subscribed share capital	240,000	240,000,000
Paid-up share capital:		
Founder shares	600	600,000
Common shares	239,400	239,400,000
Total paid-up share capital	240,000	240,000,000

In 2018, the Company filed a Registration Statement covering the proposed Initial Public Offering (IPO) of its 36,000 common shares. Said registration statement was approved on December 27, 2019, in accordance with the provisions of the SEC's Securities Regulation Code (see Note 1).

As of date, pursuant to SEC's approval, the Company issued a total of **THIRTY-SIX THOUSAND (36,000)** common shares. The related share premium after deducting transaction costs associated with the issuance of shares amounted to ₱957,372,662. The common share offer price amounted to ₱250,000 up to ₱400,000 per block [one (1) block = ten (10) common shares].

Founder shares have the exclusive right to vote and be voted upon as directors for five (5) years from the date of SEC registration. Thereafter, the holders of Founder's shares shall have the same rights and privileges as holders of common shares.

NOTE 18 - REVALUATION SURPLUS

The Company's revaluation surplus amounting to ₱183,531,277 is the difference between the market value of ₱273,000,000 and the land's initial cost as at December 31, 2025. The valuation of its parcels of land was performed by independent appraisers and reflected in its report of March 2026 covering December 31, 2025. The fair value was determined by reference to market transactions on an arm's length term at the date of valuation (see Notes 11 and 16).

The value of the parcels of land was arrived at using a combination of cost and market (or direct sales comparison) approach. Cost approach is based on the principle of substitution, which holds that an informed buyer would not pay more for a given property than the cost of an equally desirable alternative. Market data approach is an appraisal technique in which the market value estimate is predicted based upon prices paid in actual market transactions and current listings, the former fixing the lower limit of value in a static or advancing market (pricewise) and fixing the higher limit of value in a declining market; and the latter fixing the higher limit in any market.

NOTE 19 - REVENUES

Revenues for the year ended are as follows:

	2026	2025	2024
Sale of services	**121,082,143**	514,069,665	349,859,649
Sale of goods	**1,857,509**	5,847,025	2,952,362
	122,939,652	519,916,690	352,812,011
Less: Sales discount on services	**15,392,795**	(67,672,300)	(43,380,347)
Sales discount on goods	**10,399**	(46,026)	(1,221,433)
Sales return and allowances	**-**	(32,698)	(300,205)
	(15,403,194)	(67,751,024)	(44,901,985)
Net Revenues	**107,536,458**	452,165,666	307,910,026

Sale of services pertains to billings for patient care services, including doctors' appointments and consultancies, surgical procedures, medical chemistry and laboratory analyses and ancillary services.

Sale of goods refers to the sale of medications and medical supplies provided to patients during their stay or confinement or as part of their treatment plan.

Discounts and allowances – are cost of provision for free services at certain times, discounts or returns to underprivileged patients, senior citizens and employees.

An analysis in the timing of revenue recognition is as follows:

	2026	2025	2024
Revenue recognized over the period of time	**P107,536,458**	P452,165,666	P307,910,026

NOTE 20 - DIRECT COSTS

This account consists of the following:

	2026	2025	2024
Cost of hospital services:			
Hospital supplies	**P94,488,993**	P136,033,287	P102,251,913
Depreciation	**70,343,235**	102,327,924	99,889,654
Salaries and wages	**16,209,273**	21,140,534	37,167,173
Professional fees	**-**	-	27,184,394
Utilities	**-**	-	2,274,166
	P181,041,501	P259,501,745	P268,767,300

Direct costs are explicit expenditures with specific identification to the corresponding cost centers of hospital services.

NOTE 21 - OTHER INCOME

Details of account consist of:

	2026	2025	2024
Interest income (Note 6)	**P2,175**	P1,002	P2,106
Unrealized foreign exchange gain (Note 6)	**-**	3,505	(310,228)
Other income	**2,774,610**	10,310,474	1,490,856
	P2,776,785	P10,314,981	P1,182,734

Other income pertains to revenues generated from ancillary services and related fees, including charges for medical certificates, send-out services, ambulance services, Clinical Use of Support Areas (CUSA), and privilege-to-practice fees.

NOTE 22 - GENERAL AND ADMINISTRATIVE EXPENSES

Details of accounts consist of:

	Notes	**2026**	2025	2024
Salaries and allowances		**P23,491,369**	P111,313,162	P87,491,420
Utilities		**12,563,082**	54,800,309	51,738,090
Depreciation	***11***	**11,948,988**	48,391,711	48,382,414
Professional and legal fees		**5,761,241**	25,287,779	33,272,069
SSS, PHIC and HDMF contributions		**3,852,257**	13,743,882	14,586,982
Security services		**3,043,597**	12,334,776	8,684,813
Office supplies		**2,642,211**	7,827,951	8,509,166
Housekeeping		**1,898,531**	9,322,573	8,415,291
Repairs and maintenance		**883,183**	4,239,547	901,410
Taxes and licenses		**643,111**	5,802,631	6,926,145
Communication		**393,281**	1,110,669	811,393
Trainings and seminars		**277,750**	255,299	954,891
Transportation and travel		**112,756**	1,002,276	1,190,229
Entertainment and representation		**111,836**	313,229	292,075
Board meetings and conferences		**15,000**	341,050	4,862,485
Insurance		**-**	2,465,225	2,305,495
Advertising		**-**	104,984	749,906
Rental		**-**	18,947	44,211
Miscellaneous		**4,232,663**	3,613,389	2,266,842
		P71,870,856	P302,289,389	P282,385,327

NOTE 23 - INCOME TAX

Computation of income tax due (RCIT or MCIT, whichever is higher) is as follows:

I. Regular Corporate Income tax (RCIT)	2026	2025	2024
Loss before income tax	**(P63,655,502)**	(P235,321,070)	(P397,759,075)
Add (deduct) reconciling items:			
Interest expense arbitrage	**-**	251	526
Unrealized forex gain (Notes 6 and 21)	**-**	(3,505)	310,228
Interest income subjected to final tax (Notes 6,21)	**(2,175)**	(1,002)	(2,106)
Taxable loss	**(63,657,677)**	(235,325,326)	(397,450,427)
Tax rate	**25%**	25%	25%
Tax Assets	**(P15,914,419)**	(P58,831,332)	(P99,362,607)

In accordance with its registration with the Board of Investment (BOI), the Company is granted an Income Tax Holiday (ITH) for a period of six (6) years, effective from December 8, 2023 to December 8, 2029.

During this incentive period, the Company's registered activities are exempt from the Regular Corporate Income Tax (RCIT) and the Minimum Corporate Income Tax (MCIT) of 2% on gross income. This tax incentive is subject to the Company's continued compliance with the terms and conditions as set forth in its registration agreement and the requirements of the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act (see Note 1).

II. Tax Due (RCIT or MCIT whichever is higher)	2026	2025	2024
RCIT or MCIT	**P -**	P -	P -
Less: Tax credits or payments			
Prior years excess tax credits	**(3,522,368)**	(953,920)	-
Quarterly income tax payments (1st-3rd quarter)	-	-	-
Creditable withholding tax (1st - 3rd quarter)	**(213,008)**	(2,126,309)	-
Creditable withholding tax (4th quarter)	**-**	(442,139)	(953,920)
Prepaid Income Tax (Note 10)	**(P3,735,376)**	(P3,522,368)	(P953,920)

III. Net Operating Loss Carry-Over (NOLCO)

Revenue Regulation 25-2020, implementing Section 4 of the Bayanihan to Recover as One or Bayanihan 2 Act, particularly on the NOLCO of companies wherein The Bureau of Internal Revenue (BIR) has extended to five years the carry-over period for net operating losses incurred by businesses in 2020 and 2021 (due to the impact of the coronavirus pandemic).

Year Incurred	Expiration date	Beginning balance	Additions	Expired	Claimed	Ending Balance
NOLCO						
2020	2025	P43,425,573	P -	(P43,425,573)	P -	P -
2021	2026	34,889,728	-	-	-	34,889,728
		P78,315,301	**P -**	(P43,425,573)	**P -**	P34,889,728

On June 30, 2022 the NOLCO carry over period was reverted back to three years. Thus, as at December 31, 2025, NOLCO that can be claimed as deduction from future taxable income are as follows:

Year Incurred	Expiration date	Beginning balance	Additions	Expired	Claimed	Ending Balance
NOLCO						
2022	2025	P34,889,728	P52,339,339	(P52,339,339)	P -	P34,889,728
2023	2026	-	147,365,993	-	-	182,255,721
2024	2027	-	397,450,427	-	-	579,706,148
2025	2028	-	235,325,326	-	-	815,031,474
2026	**2029**	**-**	**63,655,502**	**-**	**-**	**878,686,976**
		P34,889,728	**P896,136,587**	**(P52,339,339)**	**P -**	**P878,686,976**

IV. Deferred Tax Assets

The significant components of the Company's deferred tax assets are as follows:

	2026	2025	2024
NOLCO	P878,686,976	P815,031,474	P675,471,060
Tax rate	25%	25%	25%
	219,671,744	203,757,869	168,867,765
MCIT	-	–	–
	219,671,744	203,757,869	168,867,765
Valuation allowance (Note 5)	(219,671,744)	(203,757,869)	(168,867,765)
Deferred tax asset (other noncurrent assets)	**P -**	P -	P -

The Company provides full valuation allowance on its deferred tax assets from NOLCO since management believes that the Company will not be able to generate future taxable income in which such can be applied. The deferred tax asset of the Company arising from net operating loss carry over (NOLCO) prior to 2021 can be charged against future taxable income of the next three (3) years. On the other hand, deferred tax assets arising from NOLCO for the years 2020 and 2021 can be charged against future taxable income of the next five (5) taxable years.

NOTE 24 - LEASES

The Company has adopted PFRS 16. However, the Company does not have lease arrangements for its building, as the property is owned by the Company and recognized as part of property and equipment.

As of the reporting date, the Company has no significant lease contracts that would require recognition of right-of-use assets and lease liabilities. Accordingly, the impact of PFRS 16 on the financial statements is not material.

NOTE 25 - BASIC LOSS PER SHARE

Basic loss per share is computed as follows:

	2026	2025	2024
Loss attributable to ordinary shares	**(P63,655,502)**	(P235,321,070)	(P397,759,075)
Divide by: Weighted average number of ordinary shares outstanding	**240,000**	240,000	239,960
Basic loss per share	**(P265.23)**	(P980.50)	(P1,657.61)

There are no potential dilutive ordinary shares outstanding as at March 31, 2026, 2025 and 2024.

NOTE 26 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Financial Risk

The Company's financial risk management policies seek to minimize potential adverse effects of financial risk such as credit risk, liquidity risk, and interest rate risk to its financial assets and financial liabilities.

The Company's principal financial assets and financial liabilities consist of cash (excluding petty cash fund), receivable - others, other non-current assets payable (excluding deferred tax assets), accounts payable and other liabilities (excluding government liabilities), loans payable to individuals, loans payable to a related party and notes payable which arise from operations.

The Company's Board of Directors reviews and approves the policies for managing each of these risks and these are summarized below:

Credit risk

Credit risk is the risk that the third party will default on its obligation to the Company and cause the Company to incur financial loss. The Company's business policy aims to limit the amount of credit exposure to any individual client and financial institution. The Company has credit management policies in place to ensure that contracts are entered into with clients who have sufficient financial capacity and good credit history.

The Company's financial assets at amortized cost are composed of cash (excluding petty cash fund), receivable – others, advances to related parties and other assets under the noncurrent assets (excluding deferred tax assets). The Company limits its exposure to credit risk by investing its cash only with banks that have good credit standing and reputation in the local and international banking industry. These instruments are graded in the top category by an acceptable credit rating agency and, therefore, are considered to be low credit risk investments.

Receivable - others and other assets under the non-current assets are being monitored on a regular basis to ensure timely execution of necessary intervention efforts to minimize credit losses.

It is the Company's policy to measure ECL on the above instruments on a 12-month basis. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL.

When determining if there has been a significant increase in credit risk, the Company considers reasonable and supportable information that is available without undue cost or effort and that is relevant for the particular financial instrument being assessed such as, but not limited to, the following factors:

- Actual or expected external and internal credit rating downgrade;
- Existing or forecasted adverse changes in business, financial or economic conditions; and
- Actual or expected significant adverse changes in the operating results of the borrower.

The Company also considers financial assets that are more than 30 days past due to be the latest point at which lifetime ECL should be recognized unless it can demonstrate that this does not

represent significant credit risk such as when non-payment arising from administrative oversight rather than resulting from financial difficulty of the borrower.

The table below presents the summary of the Company's exposure to credit risk and shows the credit quality of the assets by indicating whether the assets are subjected to 12-month ECL or lifetime ECL. Assets that are credit-impaired are separately presented.

	As at March 31, 2026			
	Financial assets at amortized cost			
	12-month ECL	**Lifetime ECL – not credit impaired**	**Lifetime ECL – credit impaired**	**Total**
Cash in banks*	**₱25,635,281**	–	–	**₱25,635,281**
Receivables	**192,816,543**	–	–	**192,816,543**
	₱218,451,824	–	–	**₱218,451,824**

**Excluding petty cash fund amounting to ₱779,654 as at March 31, 2026.*

	As at December 31, 2025			
	Financial assets at amortized cost			
	12-month ECL	Lifetime ECL – not credit impaired	Lifetime ECL – credit impaired	Total
Cash in banks*	₱22,446,473	–	–	₱22,446,473
Receivables	165,796,569	–	–	165,796,569
	₱188,243,042	–	–	₱188,243,042

**Excluding petty cash fund amounting to ₱849,568 as at December 31, 2025.*

Interest Rate Risk

Interest rate risk refers to the possibility that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate.

The primary source of the Company's interest rate risk relates to its cash in banks, notes payable and loans payable to a related party (Notes 6, 14 and 15).

Cash in banks are subject to prevailing market interest rates. Considering that such financial assets have short-term maturities, the Company does not foresee any cash flow and fair value interest rate risks to have a significant impact on the Company's operations.

Likewise, notes payable and loans payable to a related party are subject to prevailing market interest rates. As such, these are subject to fluctuations in market interest rates for a given period.

The Company has no established policy in managing interest rate risk. Any favorable or unfavorable effect of the fluctuations on the interest rates are absorbed by the Company. The effect of such is presented in the Company's financial performance.

Liquidity Risk

In the management of liquidity, the Company monitors and maintains a level of cash deemed adequate by the management to finance the Company's operations and mitigate the effects of fluctuations in cash flows.

The table below summarizes the maturity profile of the Company's financial assets and liabilities based on contractual and undiscounted payments:

As at March 31, 2026

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Assets:					
Cash*	₱25,635,281	P –	P –	P –	₱25,635,281
Receivable - others	192,816,543	–	–	–	192,816,543
Advances to related parties	6,950,256	–	–	–	6,950,256
	₱225,402,080	P –	P –	P –	₱225,402,080

**Excluding petty cash fund and cash on hand amounting to ₱779,654 March 31, 2026.*

Financial Liabilities:					
Accounts payable and other liabilities***	27,690,762	686,539,712	-	-	P714,230,474
Loans payable to individuals	-	-	91,589,939	-	91,589,939
Loans payable to a related party	-	-	544,871,969	-	544,871,969
Notes payable	-	-	984,800,767	-	984,800,767
	P27,690,762	P686,539,712	P1,621,262,675	P -	P2,335,493,149

****Excluding government liabilities amounting to ₱3,168,705 as at March 31, 2026S*

As at December 31, 2025

	On Demand	Within 1 year	More than 1 year but less than 5 years	More than 5 years	Total
Financial Assets:					
Cash*	P22,446,473	P -	P -	P -	P22,446,473
Receivable - others	165,796,569	-	-	-	165,796,569
Advances to related parties	6,950,256				6,950,256
	P195,193,298	P -	P -	P -	P195,193,298

**Excluding petty cash fund and cash on hand amounting to ₱849,568 December 31, 2025.*

Financial Liabilities:					
Accounts payable and other liabilities***	P308,520,389	P378,019,323	P -	P -	P686,539,712
Loans payable to individuals	-	15,703,226	-	-	15,703,226
Loans payable to a related party	-	-	544,871,969	-	544,871,969
Notes payable	191,558,072	-	807,792,965	-	999,351,037
	P500,078,461	P393,722,549	P1,352,664,934	P -	P2,246,465,944

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

The carrying amounts and estimated fair values of the Company's financial assets and financial liabilities are presented below:

	As at March 31, 2026		As at December 31, 2025	
	Carrying Amounts	**Fair Values**	Carrying Amounts	Fair Values
Financial Assets:				
Cash*	**P25,635,281**	**P25,635,281**	P22,446,473	P22,446,473
Receivable – others	**192,816,543**	**192,816,543**	165,796,569	165,796,569
Advances to related parties	**6,950,256**	**6,950,256**	6,950,256	6,950,256
	P225,402,080	**P225,402,080**	P195,193,298	P195,193,298

Excluding petty cash fund and cash on hand amounting to **₱779,654 and ₱849,568 as at March 31, 2026 and 2025.*

Financial Liabilities:				
Accounts payable and other liabilities***	**P714,230,474**	**P714,230,474**	P686,539,712	P686,539,712
Loans payable to individuals	**91,589,939**	**91,589,939**	15,703,226	15,703,226
Loans payable to a related party	**544,871,969**	**544,871,969**	544,871,969	544,871,969
Notes payable	**984,800,767**	**984,800,767**	999,351,037	999,351,037
	P2,335,493,149	**P2,335,493,149**	P2,246,465,944	P2,246,465,944

****Excluding government liabilities amounting to ₱3,168,705 and ₱2,999,859 as at March 31, 2026 and 2025, respectively.*

Assumption Used to Estimate Fair Values

The carrying amounts of cash, receivable - others, accounts payable and other liabilities, loans payable to individuals, and loans payable to a related party approximate their fair values as at reporting dates due to the short-term nature of the transactions.

The carrying amount of notes payable approximates its fair value due to pre-determined contractual cash flow arrangements based on an applicable and regular re-priceable Philippine Dealing System Treasury (PDST) floating rate covering the term of the loan, as provided by the financial lending institution.

The fair value of refundable deposits cannot be measured reliably since there was no comparable market data and inputs for the sources of fair value such as discounted cash flows analysis. However, Management believes that their carrying amounts approximate their fair value.

Fair Value Hierarchy

The Company uses the following hierarchy for determining the fair value of financial assets and liabilities:

- Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- Level 3 - Inputs are unobservable for the asset or liability

The table below summarizes the classification of the Company’s financial assets and liabilities based on the fair value measurement hierarchy:

	As at March 31, 2026

	Quoted Prices in Active Markets (Level 1)	Significant Observable Inputs (Level 2)	Significant Un-observable Inputs (Level 3)
Financial Assets:			
Cash*	**P -**	**P25,635,281**	**P -**
Receivable – others	**-**	**192,816,543**	**-**
	P -	**P218,451,824**	**P -**

**Excluding petty cash fund and cash on hand amounting to ₱779,654 as at March 31, 2026.*

Financial Liabilities:			
Accounts payable and other liabilities***	P –	**714,230,474**	P –
Loans payable to individuals	–	**91,589,939**	–
Loans payable to a related party	–	**544,871,969**	–
Notes payable	–	**984,800,767**	–
	P –	**2,335,493,149**	P –

****Excluding government liabilities amounting to ₱3,168,705 as at March 31, 2026.*

	As at December 31, 2025		
	Quoted Prices in Active Markets (Level 1)	Significant Observable Inputs (Level 2)	Significant Un-observable Inputs (Level 3)
Financial Assets:			
Cash*	P -	P22,446,473	**P -**
Receivable – others	**-**	165,796,569	**-**
	P -	P188,243,042	**P -**

**Excluding petty cash fund and cash on hand amounting to ₱849,568 as at December 31, 2025.*

Financial Liabilities:			
Accounts payable and other liabilities***	P -	P686,539,712	P -
Loans payable to individuals	-	15,703,226	-
Loans payable to a related party	-	544,871,969	-
Notes payable	-	999,351,037	-
	P -	P2,246,465,944	P -

****Excluding government liabilities amounting to ₱2,999,859 as at December 31, 2025.*

There were no reclassifications made between the different fair value hierarchy level as at December 31, 2025 and 2024.

CAPITAL MANAGEMENT

The primary objective of the Company's capital management is to ensure that it maintains healthy capital ratios in order to support its business, pay existing obligations and maximize shareholders value.

The Company manages capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust capital, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes during the years ended March 31, 2026 and 2025.

The following table pertains to the account balances the Company considers as its core economic capital:

	2026	2025
Share capital	**₱240,000,000**	P240,000,000
Share premium	**958,532,662**	958,532,662
Revaluation surplus	**183,531,277**	183,531,277
Deficit	**(978,283,186)**	(978,283,187)
	₱403,780,753	P403,780,752

The loan agreement with Landbank (Note 16) provides certain restrictions and requirements with respect to, among others, maintenance of financial ratios (debt-to-equity ratio of 80:20), percentage of ownership of specific shareholders, creation of property encumbrances and additional guarantees for the incurrence of additional long-term indebtedness.

As of reporting dates, all covenants and requirements are complied with except for the required financial ratio wherein the financial institution was made aware of since the Company has not yet started commercial operations.

FINANCIAL RATIOS

The following were the financial ratios of the Company for the years ended March 31, 2026, and 2025:

Particulars	**2026**	2025
Current ratio	**0.38**	0.39
Solvency ratio	**1.14**	1.17
Debt to-equity	**4.01**	5.72
Asset to equity	**8.06**	6.72
Return on equity	**(0.17)**	(0.55)
Return on assets	**(0.02)**	(0.090)

Computation of the above financial ratios are as follows:

- Current ratio = Current assets divided by current liabilities
- Solvency ratio = Total assets divided by total liabilities
- Debt-to-equity = Total liabilities divided by total equity
- Asset-to-equity = Total assets divided by total equity
- Return on equity = Net income divided by average total equity for the periods indicated
- Return on assets = Net income divided by average total assets for the periods indicated

SUPPLEMENTARY INFORMATION REQUIRED BY REVENUE REGULATION (RR)

The following information is presented for purposes of filing with the BIR and is not a required part of the basic financial statements.

Revenue Regulations (RR) 15-2010

On November 25, 2010, the Bureau of Internal Revenue (BIR) issued Revenue Regulations (RR) 15-2010, which requires certain information on taxes, duties, and license fees paid or accrued during the taxable year to be disclosed as part of the notes to financial statements. This

supplemental information, which is an addition to the disclos*u*res mandated under PFRS Accounting Standards is presented as follows:

Output Value-Added Tax

Details of the Company's output VAT declared consist of:

	2026
Exempt sales	**P96,883,812**
Vatable sales	**730,514**
VAT rate	**12%**
	P87,662

Input Value-Added Tax

Details of the Company's Input VAT claimed consist of:

	2026
At beginning of year	**P -**
Current purchases and payments for:	
Domestic purchase of capital goods not exceeding 1M	-
Domestic purchase of capital goods exceeding 1M	-
Domestic purchase of goods other than capital goods	**19,470,079**
Domestic purchases of services	**16,083,359**
At end of year	**P35,553,438**

Computation of Net VAT payable is as follows:

	2026
Output VAT payable	**P87,662**
Less: Input VAT claimed	**(28,580,030)**
Excess Input VAT for the year	**(28,667,692)**
Less: Payments made during the year	-
Input VAT Carry-over (Note 10)	**(P28,667,692)**

Documentary Stamp Tax

Documentary stamp tax paid by the Company during the year amounted to ₱85,993 for the additional availment of notes payable.

Taxes and licenses

Details of the Company's other local and national taxes for the year are as follows:

	2026
Real Property Tax	**P390,814**
Business Permit Fee	**142,152**
Documentary Stamp Tax	**85,993**
Community Tax Certificate	**10,500**
Others	**13,652**
	P643,111

Withholding Taxes

Withholding taxes paid by the Company for the year are as follows:

	2026
Compensation withholding tax	**₱109,807.80**
Expanded withholding tax	**995,626.10**
	₱1,105,433.90

Deficiency Tax Assessment and Tax Cases

The Company has no deficiency tax assessments or any tax cases, litigation, and/or prosecution in court or bodies outside the Bureau of Internal Revenue as of December 31, 2025.

RR 19-2020 and RR 34-2020

In 2020, the Bureau of Internal Revenue (BIR) issued the foregoing Revenue Regulations for the effective implementation of Philippine Accounting Standard No. 24 (PAS 24) governing the guidelines and procedures for "transfer pricing documentations" involving related party transactions thru the submission of BIR Form No. 1709 and the supporting documents, as an attachment to the financial statements to be filed with the BIR.

The Company reported net operating losses for the current taxable year and the immediately preceding two (2) consecutive taxable years, hence, meets the criteria provided by these Revenue Regulations, and accordingly, required to submit BIR Form 1709.

* * *

SCHEDULES

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.

(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

As at March 31, 2026

Schedule A. Financial Assets

Name of issuing entity and association of each issue	Number of shares or principal amount of bonds and notes	Amount shown in the statements of financial position	Value based on market quotation at the end of reporting period	Income received and accrued
Cash*	N/A	**P25,635,281**	N/A	**P2,175**
Receivable – others	N/A	**192,816,543**	N/A	**-**
Other non-current assets	N/A	**-**	N/A	**-**
		P218,451,824		**P2,175**

**Excluding petty cash fund amounting to ₱779,654 as at March 31, 2026*

Schedule B. Amounts Receivable from Directors, Officers, Employees, Related Parties, and Principal Stockholders

Name and designation of Debtor	Balance at Beginning of Period	Additions	Amounts Collected	Amounts Written Off	Current	Not Current	Balance at End of 1st Quarter Period
TIPP Digital Solutions Inc.	P6,902,784	P -	P -	P -	P6,902,784	-	P6,902,784
Receivable – others (various ACE Hospitals)	47,472	-	-	-	47,472	-	47,472
	P6,950,256	**P -**	**P -**	**P -**	**P6,950,256**	**P -**	**P6,950,256**

Schedule C. Amounts Receivable from Related Parties which are eliminated during Consolidation of Financial Statements

Name and designation of Debtor	Balance at Beginning of Period	Additions	Amounts Collected	Amounts Written Off	Current	Not Current	Balance at End of Year
- Not Applicable -							

Schedule D. Long –Term Debt

Title of issue and type of Obligation	Amount authorized by indenture	Amount shown under caption "Current portion of long-term debt" in related statement of financial position	Amount shown under caption "Long-term debt" in related statement of financial position
Non-interest-bearing Notes Payable	P984,800,767	P227,010,404	P757,790,363 *(payable in 27 quarterly installments for 7 year from the date of effectivity with one (1) quarter grace period on principal and interest beginning October 31, 2023 to October 31, 2030 with a current interest rate of 7.5% per annum)*

Schedule E. Indebtedness to Related Parties (Long –Term Loans from Related Companies)

Name of Related Party	Balance at beginning of Period	Balance at end of Period
Phil Pharmawealth, Inc.	P544,871,969	P544,871,969
Endure Medical, Inc.	60,676,532	194,816,096
	P605,548,501	P739,688,065

Schedule F. Guarantees of Securities of Other Issuers

Name of issuing entity of securities guaranteed by the Company for which this statement is filed	Title of issue of each class of securities guaranteed	Total amount guaranteed and outstanding	Amount owned by person for which statement is filed	Nature of guarantee
- Not Applicable -				

Schedule G. Capital Stock

Title of issue	Number of shares authorized	Number of shares issued and outstanding as shown under related statement of financial position caption	Number of shares reserved for options, warrants, conversion and other rights	Number of shares held by related parties	Directors, officers and employees	Others
Founder's Shares	600	600	-	-	-	-
Common Shares	239,400	239,400	-	-	-	-
	240,000	**240,000**	**-**	**-**	**-**	**-**

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

Statement of Accumulated Deficit
As at March 31, 2026

Accumulated Deficit, beginning of quarter	**P978,283,187**
Net loss incurred for the quarter	**63,655,502**
Accumulated Deficit, ending of quarter	**P1,041,938,689**

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

MAP OF THE RELATIONSHIPS BETWEEN AND AMONG THE COMPANIES IN THE GROUP, ITS ULTIMATE PARENT COMPANY AND CO-SUBSIDIARIES
As at March 31, 2026

-Not Applicable-
EXPLANATION ON NON-APPLICABILITY OF CONGLOMERATE MAP

Asia-Pacific Medical Center-Iloilo, Inc., Asia Pacific Medical Center-Bacolod, Inc., and Asia Pacific Medical Center - Aklan, Inc. are not affiliate companies nor sister companies because they do not operate under one parent company. They are related only because the Chairman of the three companies, Dr. Ferjenel G. Biron, is one and the same person and they have interlocking directors and shareholders and common officers as follows:

Name of Stockholder	Percentage of Ownership and Position in APMC Iloilo	Percentage of Ownership and Position in APMC Bacolod	Percentage of Ownership and Position in APMC Aklan
Biron, Ferjenel G.	20.17%/ Chairman	3.99%/ Chairman	4.67%/Chairman
Biron, Bryant Paul Q.	8.81% (8.81% as Trustor under VTA)[1]	1.54% (1.54% as Trustor under VTA)	1.92% (1.92% as Trustor under VTA)
Biron, Brandt Luke Q.	9.12% (8.81% as Trustee under VTA/Director	3.08% (1.54% as Trustee under VTA)	8.98% (1.92% as Trustee under VTA)
Biron, Braeden John Q.	8.81% (8.81% as Trustor under VTA[2])	1.54% (1.54% as Trustor under VTA)	1.92% (1.92% as Trustor under VTA)
Oca-Biron, Ma. Regina Isabelle	.02% (8.81% as Trustee under VTA)	1.54% as Trustee under VTA	1.92% as Trustee under VTA
Barrameda, Romulo Jr. S.	1.44%	1.56%/Independent Director	None
Comuelo, Jerusha A.	1.44%	0.73%	1.56%/ Independent Director
Depalac, Jonas A.	0.0042%	1.54%	None
Domingo, Joan B.	0.0042%	1.54%	None
Lavalle, Amado Jr. M.	1.53%	2.27%	1.56%
Lavilla, Meride D.	2.91% (1.52 % Direct + 1.38% Indirect)/ Vice Chairman	9.63%/ Director	3.12%/ Director

[1] Biron, Brandt Luke Q. (8.81% as Trustees under VTA)

[2] Oca-Biron, Ma. Regina Isabelle (8.81% as Trustees under VTA)

Minerva, Ike T.	1.42%	2.20%	1.56%
Ong, Mary Flor G.	1.40%/Treasurer	0.73%	None
Perez, Ma. Grace G.	1.43%	0.73%	None
Regozo, Danilo C.	1.53%/ Executive Vice President	2.72%/ Executive Vice President	1.56%/ Director
Samoro, Fredilyn G.	4.26% (2.82% Direct + 1.44% Indirect) /Director	None	1.56%
Villaflor, Agnes Jean M.	1.15%/ President	0.73%	1.56%

(Percentage of Shares as of March 31, 2026)

ASIA PACIFIC MEDICAL CENTER – ILOILO, INC.
(Formerly: Allied Care Experts (ACE) Medical Center – Iloilo Inc.)

SCHEDULE OF FINANCIAL SOUNDNESS INDICATORS

As of March 31, 2026
(with comparative figures as of December 31, 2025)

Financial KPI	Definition	31-Mar-26	31-Dec-25
1. Liquidity			
Quick Asset Ratio	$\frac{\text{Cash + Receivables}}{\text{Current Liabilities}}$	0.21 : 1	0.21 : 1
Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	0.38 : 1	0.39 : 1
2. Solvency			
Debt to Equity Ratio	$\frac{\text{Long Term Debt}}{\text{Equity}}$	4.01:1	3.50 : 1
3. Profitability			
Net Profit Margin	$\frac{\text{Net Income}}{\text{Total Revenue}}$	0.00	0.00
Return on Equity	$\frac{\text{Net Income}}{\text{Stockholder's Equity}}$	0.00	0.00
4. Leverage			
Debt to Total Asset Ratio	$\frac{\text{Total Liabilities}}{\text{Total Asset}}$	0.88:1	0.85 : 1
Asset To Equity Ratio	$\frac{\text{Total Asset}}{\text{Equity}}$	8.06:1	6.72 : 1
5. Interest Rate Coverage Ratio	$\frac{\text{Earnings Before Interests \& Taxes}}{\text{Interest Expense}}$	0.00	0.00

ASIA PACIFIC
MEDICAL CENTER
ILOILO

We hereby certify that the information set forth in this report for the quarter ended 31 March 2026 is complete and correct.

That the Board of Directors reviews and approves the interim financial statements, including the schedules attached thereto.

AGNES JEAN M. VILLAFLOR
President

MARY FLOR G. ONG
Corporate Treasurer

CRIS T. CORTES
Chief Finance Officer

ASIA PACIFIC
MEDICAL CENTER
ILOILO

Annex "N"

REPUBLIC OF THE PHILIPPINES)
CITY OF ILOILO) S.S.

SECRETARY'S CERTIFICATE

I, **THERESE MARIE A. GERAFIL**, of legal age, Filipino, in my capacity as the duly elected, qualified, and incumbent Corporate Secretary of **Asia Pacific Medical Center – Iloilo, Inc. (Formerly: Allied Care Experts (ACE) Medical Center-Iloilo Inc.)** (the "Company"), a corporation duly organized and existing under and by virtue of the laws of the Philippines, with SEC registration number CS201423954 and principal office at Barangay Ungka, Jaro, Iloilo City, hereby attest and declare under penalty of perjury that:

1. On behalf of the Company, I have caused this Preliminary Information Statement ("SEC Form 20-ISA") dated 26 **May 2026** to be prepared and I am duly authorized by the Board of Directors of the Company to file this SEC Form 20-ISA with the Securities and Exchange Commission (the "Commission");

2. I read and understood its contents and all matters set forth in this SEC Form 20-ISA have been made in good faith, duly verified by me and to the best of my knowledge and belief are true and correct;

3. Certain directors of the Company are presently engaged in government service. **Dr. Ferjenel G. Biron** serves as Deputy Speaker in the House of Representatives; **Dr. Agnes Jean M. Villaflor** is engaged as a Medical Specialist III at West Visayas State University Medical Center; **Atty. T. Rolex Suplico** is currently an Iloilo Provincial Board Member; **Mr. Lemuel T. Fernandez** serves as Chief Political Officer at the House of Representatives; **Independent Directors Atty. Johanna Marie B. Bermudo-Belgira** is the Municipal Legal Officer of the Local Government Unit (LGU) of Barotac Nuevo, Iloilo and **Nathalie Ann F. Debuque** is the incumbent Vice Governor of the Province of Iloilo.

3. All information in this SEC Form 20-ISA are being submitted in compliance with the rules and regulations of the Commission, the collection, processing, storage and sharing of said information being necessary to carry out the functions of public authority for the performance of the constitutionality and statutorily mandated functions of the Commission as a regulatory agency;

4. The company will comply with the requirements set forth in SEC Memorandum Circular No. 18 dated October 9, 2023 and SEC Notice dated 05 March 2025, for a complete and official submission of reports and/or documents through electronic mail and through the Electronic Filing and Submission Tool (eFAST) effective 28 March 2025; and

5. I am fully aware that documents filed online which require pre-evaluation and/or processing fee shall be considered complete and officially received only upon payment of a filing fee.

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

IN WITNESS WHEREOF, I have hereunto set my hand this 26 MAY 2026 at Iloilo City, Philippines.

THERESE MARIE A. GERAFIL
Corporate Secretary

SUBSCRIBED AND SWORN TO before me this _____ day of 26 MAY 2026 2026 at Iloilo City; Affiant exhibiting her IBP ID with Roll of Attorneys No. 88537 as her competent evidence of identity.

ATTY. ERWIN L. SEGURA
Notary Public, City and Province of Iloilo
Commission No. 140, valid until December 31, 2027
Gayanilo Gonzaga Jungco and Chavez Law Office
J.M. Basa Street, Iloilo City
Attorney's Roll No. 95369 / 01/24/2025
PTR No. 9329381 / 03/11/2026 / Iloilo City
IBP No. INV 598636 / 02/04/2026
Email Address: el_segura@outlook.com
Contact No. 09171739164

Doc. No. 29
Page No. 7
Book No. 1
Series of 2026.

Brgy. Ungka, Jaro, Iloilo City, 5000
(033) 339 9991
info@apmc-iloilo.com
www.apmc-iloilo.com

SEC Main Office
The SEC Headquarters
7907 Makati Avenue, Salcedo Village, Barangay Bel-Air, Makati City , 1209

electronic Official Receipt

Transaction Details

eOR Number	20260515-PM-0076609-99
Transaction Number	613507163579
Payment Date	May 15, 2026 03:41 PM
Payment Scheme	master-card
Status	COMPLETED
Payment Status	PAYMENT_SUCCESS

Payment Assessment Details

PAF No.	20260515-15077085
PAF Date	2026-05-15 11:53:52
Payor Name	ASIA PACIFIC MEDICAL CENTER - ILOILO, INC.
Payor Address	ILOILO CITY

#	Nature of Collection	Account Code	Amount
1	Information Statement - Registrant	4020199099(678)	7,500.00
2	Legal Research Fee (A0823)	2020105000(131)	75.00
		TOTAL	**7,575.00**

Total amount indicated herein does not include the convenience/service fee of the selected payment channel.